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SUMMARY
In this thesis the influence of genetic factors on the 
apolipoprotein B metabolism in humans was investigated. 
The phenotype of the apolipoprotein E polymorphism was 
determined for normolipidaemic subjects (n = 1600). The 
metabolism of apolipoprotein B in fifteen subjects, 
homozygous for apoE3, apoE4 or apoE2, was examined by VLDL- 
turnover studies, using trace-labelled VLDL]_ (Sf 60-400) 
and VLDL2 (Sf 20-60). Results were used for computer 
modelling of the apoB metabolism, which enabled 
quantitative comparisons between the three study groups. 
In apoE2/2 subjects, clearance of VLDL]_ and VLDL2 as well 
as transfer from IDL into LDL was found to be delayed and 
in apoE4/4 subjects the LDL-FCR was reduced as compared 
to apoE3/3 normolipidaemics. These observations explain 
the correlation between apoE phenotypes and plasma 
cholesterol levels, which had been observed previously by 
others and were confirmed in the present study.
The Xbal restriction site polymorphism of the apoB 
gene was analysed in nineteen hypercholesterolaemic 
patients and correlated with fractional catabolic rates for 
LDL as defined by LDL-turnover studies. The X2 allele was 
found to be linked with a decreased LDL-FCR, in line with 
previous reports of a correlation between X2X2 genotype and 
increased plasma cholesterol concentrations.
xiii
In addition to these studies of common genetic 
determinants of apoB metabolism, five patients with rare 
inherited disorders of lipoprotein metabolism were 
investigated. These conditions were homozygous familial 
hypercholesterolaemia, lipoprotein lipase deficiency and 
hepatic lipase deficiency. VLDL-turnovers in these 
subjects revealed the significance of the LDL-receptor and 
the two lipolytic enzymes for apolipoprotein B metabolism.
Finally, some conclusions were drawn about metabolic 
heterogeneity within the VLDL subfraction and about apoB 
synthesis.
11. INTRODUCTION
It has been known for more than 80 years that 
cholesterol is an important constituent of degenerative 
lesions of the arterial wall (1). As early as 1913 Russian 
and German investigators concluded from experiments, in 
which they fed egg yolk to rabbits, that dietary 
cholesterol was the cause of the ' development of 
atherosclerotic lesions in these animals (2). Thus the 
link between cholesterol intake and atherosclerotic disease 
has been established for some time, but more detailed 
studies of plasma lipid metabolism became possible only 
after the invention of high performance centrifuges, which 
are still the main tool for investigation in this field. 
Gofman and co-workers in 1950 were the first to describe in 
plasma the presence of distinct lipoprotein particles, 
which were characterised by their flotation properties in a 
centrifugal field (3).
1.1 Lipoproteins in Plasma
The principle structure of lipoproteins is depicted 
in Fig. 1. Hydrophobic lipids, like cholesteryl esters and 
triglycerides, form the core material of lipoproteins. 
This is surrounded by a closely packed 20-22 % wide 
monolayer of polar lipids, comprising free cholesterol and 
phospholipids (4). Specific proteins, so-called
OH
Model of a human plasma lipoprotein. 
(Reproduced from: HB Brewer; Klin.
Wochenschr. (1981), 59, 1027).
2apolipoproteins, because of their orientation are able to 
both stabilise the lipoprotein and interact with key 
enzymes and receptors in plasma and on cells.
Table 1 illustrates the spectrum of human plasma 
lipoproteins: chylomicrons are triglyceride-rich particles
with the lowest density, followed by very low density 
lipoprotein (VLDL), intermediate density lipoprotein (IDL) 
and low density lipoprotein (LDL) which together form the 
group of apolipoprotein B-100 containing lipoproteins. 
Chylomicrons are secreted by the intestine following 
absorption of dietary fat whereas VLDL is secreted by the 
liver. IDL and LDL are derived from VLDL through 
delipidation within or close to the plasma compartment 
(see paragraph 1.3.2).
In normolipidaemic plasma roughly two-thirds of 
total plasma cholesterol is associated with LDL, a 
lipoprotein whose concentration correlates strongly with 
the risk for coronary heart disease. A variant of LDL, 
called Lp(a), is detectable in plasma in variable amounts 
in the density interval between LDL and HDL2 (5, 6). Lp(a) 
is an LDL, with another apoprotein, apo (a), coupled 
covalently to apoB probably via a disulphide bond.
HDL2 and HDL3 which differ by their size and 
apolipoprotein composition are distinct from the other 
lipoproteins in as much as they do not contain apo­
lipoprotein B (7). In contrast to apoB containing
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3lipoproteins, the mass of cholesterol transported in HDL is 
negatively correlated to coronary heart disease.
Finally, two lipoproteins - ft-VLDL and HDLq - are 
commonly referred to in the literature. They are usually 
not present in significant amounts in normolipidaemic 
plasma. Both lipoproteins were discovered in animals 
after cholesterol feeding (8). In man, ft-VLDL accumulates 
in familial dysbetalipoproteinaemia. Its potential signi­
ficance for atherogenesis will be discussed later 
(paragraph 1.4.4). HDLq or HDL]_, which is a subfraction of 
HDL-with-apoE as described by Weisgraber (9), may play a 
role in reverse cholesterol transport (see paragraph 
1.3.3).
1.2. Apolipoproteins
The functions of apolipoproteins are (i) to 
stabilise the structure of lipoproteins, (ii) to act as 
specific activators or inhibitors of enzymes, which react 
with the lipid components and (iii) to bind to specific 
cell surface receptors which play a key role in lipoprotein 
metabolism.
Details characterising the structure and function of 
apolipoproteins are summarised in Table 2.
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41.2.1. Apolipoproteins AI, All, AIV
Apolipoprotein AI is the main apolipoprotein of HDL. 
In adults it is mainly synthesised in the intestine (10) 
and secreted into the lymph either as a constituent 
of chylomicrons or as a component of intestinal HDL 
precursors. Another potential source of apoAI is the liver, 
where it is secreted possibly as part of nascent HDL (7, 
322). LCAT, an essential enzyme for HDL metabolism, 
requires apoAI as a cofactor (11). The second major
protein of HDL is apolipoprotein All. It is more abundant 
in HDL3 than in HDL2 , the former having a molar ratio of 
All to AI of 1:3 versus 1:4 in the latter (7). In HDL2 
some apoAI'I is linked to apolipoprotein E by a disulphide 
bond (12). Both, apoAI and apoAII, have specific binding 
sites for phospholipids primarily in their amphipathic 
alpha-helical regions and are thereby important for the 
structural stability of HDL (14, 15). Recent findings by 
Oram (16, 17) and Schmitz (18) suggest that macrophages and 
fibroblasts express a protein which binds apoAI and apoAII 
but not apoE and possibly plays an important role in HDL- 
cell interactions as a cell-surface receptor, facilitating 
cholesterol mobilisation.
ApoAIV is an apolipoprotein synthesised in 
intestinal cells. It was first described as a constituent 
of chylomicrons in a chyluric patient (19). Its specific 
function is unknown.
51.2.2. Apolipoprotein B
Apolipoprotein B-100 is one of the largest monomeric 
proteins known. Its molecular weight is 514 kD. It is 
synthesised in the liver and incorporated into lipoproteins 
(VLDL) in the smooth endoplasmatic reticulum (20). Over 
more than two decades the primary structure of apoB-100 
defied all efforts of elucidation due to the insolubility 
of this protein in aqueous buffers and its unusually 
large size. Only recently has the amino acid sequence 
been predicted by sequence analysis . of corresponding 
cDNA (21, 22). The protein consists of 4536 amino acids 
which adopt a secondary structure, with a high lipid 
binding potential mainly via amphipathic B-sheet 
structures (2 0 ).
Apolipoprotein B-100 is a ligand for the LDL- 
receptor (B/E-receptor) which is expressed on cell surfaces 
throughout the body and provides the main catabolic route 
for apoB-100 containing lipoproteins (23). The other 
apolipoprotein which binds to the B/E-receptor is 
apolipoprotein E. The receptor binding domain of this 
latter protein has been identified as a basic amino acid 
sequence between residues 12 6 and 218 by testing apoE 
derived proteolytic peptides for their receptor-binding 
ability in-vitro (24). By analogy the basic sequences of 
apoB-100 between residues 3147-3157 and 3359-3367 have been 
suggested as receptor binding domains (21). This binding
6region comprises three arginine and five lysine residues. 
By chemical modifications, such as covalent binding 
of cyclohexanedione to arginine residues or reductive 
methylation of lysine residues, the ability of apolipo­
protein B to bind to the LDL-receptor can be abolished both 
in-vitro and in-vivo, confirming a crucial role of these 
basic amino acids for ligand-receptor interaction (25-27). 
The significance of apolipoprotein B mutations is discussed 
in paragraph 1 .6 .2 .
A second apolipoprotein B isoform which is distinct 
from apoB-100 was isolated from chylomicrons (28). 
Chylomicrons are formed in the intestine following 
absorption of dietary fat. Apolipoprotein B associated 
with these particles differs from apolipoprotein B derived 
from VLDL when compared by SDS-electrophoresis: intestinal 
apoB having an apparent molecular weight of only 48% of 
hepatic apoB. The centile terminology for apoB isoforms, 
ie apoB-100 for apoB from the liver and apoB-48 for apoB 
from chylomicrons, was suggested by Kane (28). Recent work 
from Chen et a l . and from Powell et al. has unravelled the 
unique molecular mechanism by which these two apoB 
lipoproteins are produced from the same gene (29, 30). In 
the intestine the apoB gene is transcribed into large 
mRNA as in hepatocytes. However immediately following 
transcription this mRNA is subjected to specific editing 
exchanging one cytosine into uracil in the codon CAA 
encoding for Gin 2153 which results in a UAA stop codon.
7Thus the amino acid sequence apoB-48 is terminated after 
amino acid 2152 and hence corresponds to the amino-terminal 
half of apoB-100. As noted above, the receptor-binding 
domain of apoB-100 is situated in the carboxy-terminal half 
of the molecule which explains why apoB-48 does not 
interact with the B/E-receptor.
1.2.3. Apolipoprotein (a)
Lp(a) was mentioned previously as an LDL-like 
lipoprotein, characterised by the presence of an additional 
apolipoprotein called apo(a). Apo(a) is synthesised by the 
liver (31). Its structure has been determined recently, 
again by use of cDNA analyses. It is very similar to human 
plasminogen and contains two types of plasminogen-like 
kringle domains, one of which is present in up to 37 
repeats (32, 33). Despite this structural homology, apo(a) 
does not have any protease activity and its binding 
capacity for fibrin in-vitro is low. However, recent 
findings from two laboratories suggest that Lp(a) 
interacts with endothelial plasminogen receptors (307) 
and interferes with endothelial cell-mediated plasmin 
generation (308). This may result in impaired thrombolysis 
and thereby explain the role of Lp(a) as a risk factor 
for cardiovascular disease (35, 36, 314) . On the other 
hand, apo(a) has been isolated not only from Lp (a) but also 
from chylomicron remnants which in-vitro caused lipid
accumulation ir\ macrophages (280), providing additional 
scope for speculation about its involvement in 
atherogenesis.
Utermann et al . recently reported a size-polymorphism 
for apo(a), based on the number of kringle 4 repeats, which 
is controlled by several alleles for the apo(a) locus. 
Lp(a) phenotype and plasma Lp(a) concentration were found 
to be strongly correlated. The skewed curve for Lp(a) 
concentrations observed in population studies can be 
explained as a result of different gene frequencies for 
different Lp(a) isoforms (34). Published data on whether 
Lp(a) binds to the LDL-receptor are inconsistent, but most 
evidence points at Lp(a) being a less suitable ligand for 
the receptor than LDL (312,313).
1.2.4. Apolipoprotein Cl, CII, CIII
Apolipoprotein C is the collective term for three 
smaller apolipoproteins (apoCI, apoCII and apoCIII) found 
mainly in chylomicrons, VLDL and HDL. ApoCII and ApoCIII 
appear to have opposing effects on the activity of 
lipoprotein lipase, the key enzyme in the metabolism of 
triglyceride-rich lipoproteins such as chylomicrons and 
VLDL. If apoCII is absent or defective a clinical syndrome 
similar to primary lipoprotein lipase deficiency (Type I 
HLP) results, with massive accumulation of chylomicrons 
and VLDL (37, 38). On the other hand an equally rare
9condition with a genetic deficiency of apoCIII is marked 
by low triglyceride levels and accelerated VLDL
degradation (39). In addition to these findings in 
inherited disorders an inverse correlation between the 
apoCII/CIII ratio and VLDL-triglyceride levels has been 
observed in hypertriglyceridaemic subjects, suggesting a 
strong influence of these apoproteins on lipoprotein lipase 
activity (40).
A further function of apoCIII may be the regulation 
of receptor mediated uptake of chylomicron remnants in 
the liver by steric interference with the apoE binding 
site (41).
1.2.5. Apolipoprotein E
Apolipoprotein E is a 34 kD glycoprotein first 
described as the "arginine-rich protein" due to its 
unusually high arginine content of about 10 mmol per 
100 mmol protein (42). It is detectable in cell extracts 
from a number of different tissues including liver, adrenal 
gland, kidney, macrophages, skin and astrocytic glia (43- 
45). ApoE attached to lipoproteins seems to originate from 
the liver (31). In plasma it is mainly associated with 
VLDL, IDL, a subfraction of LDL and of HDL and with 
chylomicron remnants. The nucleotide sequence and 
structure of the apolipoprotein E gene has been analysed 
and the gene has been located on chromosome 11 (107, 328) .
10
Phenotypic heterogeneity of apolipoprotein E 
was first discovered by Utermann (46), using isoelectric 
focussing electrophoresis to show the presence of three 
distinct protein bands. The molecular nature of this 
polymorphism was deduced from amino acid sequencing of the 
three apoE isoforms, which by agreement then were referred 
to as apoE2, apoE3 and apoE4 (47). ApoE3, by far the most 
common apoE isoform, has cysteine in position 112 and 
arginine in position 158 of the amino acid sequence. ApoE2 
is derived from this by an arginine/cysteine interchange at
position 158 (Arg 158  ►Cys) and apoE4 is the result of a
cysteine/arginine interchange at position 112 (Cysll2 -- ►
Arg) (48-50) .
ApoE is a ligand for the B/E-receptor as described 
previously. Its receptor-binding domain is thought to be 
in the region of the above mentioned mutations. In-vitro 
studies of the functionality of apoE isoforms have shown 
that apoE3 and apoE4 bind effectively to the B/E-receptor, 
while apoE2 binding affinity is reduced to about 2% of the 
normal value (51). Since arginine residues are essential 
for the receptor-ligand interaction the impaired apoE2 
binding to the B/E-receptor can be explained by the 
mutation in position 158 which results in the loss of a 
positively charged arginine residue from the receptor- 
binding domain. Further evidence for the significance of a 
positive charge in this location was obtained from 
experiments showing that cysteamine treatment of apoE2
11
which converts cysteine into a positively charged lysine 
analogue, normalised receptor-binding completely (52). 
Functional apolipoprotein E, ie apoE3 and apoE4 binds not 
only to the B/E receptor but also to a second hepatic 
receptor, the apoE- or remnant-receptor. This putative 
receptor protein has been isolated recently from liver cell 
membranes (53).
Mutations other than the major isoforms apoE2, apoE3 
and apoE4 have been described. They are rarer and show a 
variable degree of impaired receptor-binding. Examples are
apoE2 (Arg 145  ►Cys), apoE2 (Cys 146 -- ► Gin), apoE2
(Arg 136 ---► Ser) , apoE3 (Cys 112  ►Arg, Arg 142 -- ► Cys)
apoE3 (Ala 99  ►Thr, Ala 152 -- ► Pro) , apoEl (Gly 127 — ►
Asp, Arg 15  ►Cys) (54-59) . Other naturally occurring
mutants have been identified but not sequenced yet (145- 
146). The significance of basic amino acids in positions 
136, 140, 143 and 150 for receptor-binding was further
demonstrated by site specific mutagenesis experiments, 
where these residues were replaced by neutral amino acids. 
The engineered variants all displayed defective binding 
pointing at the importance of ionic interactions in this 
process (329).
In addition to the genetically determined 
heterogeneity in apoE further variation in structure is 
caused by post translational modification, mainly covalent 
coupling of one or two sialic acid molecules to the 
protein (254) .
12
For a review of apolipoprotein structure and function 
see reference (50).
1.3 Pathways of Plasma Lipoprotein Metabolism
The major routes of lipoprotein metabolism are shown 
in Fig. 2. They interconnect in a complex fashion. 
However, three metabolic pathways can be distinguished: 
chylomicron metabolism
metabolism of lipoproteins containing apoB-100 
HDL metabolism.
Each of these will be discussed in this section but 
the main emphasis will be on apolipoprotein B-100 
metabolism. A fourth issue, illustrated in Fig. 2, has to 
do with the interaction between peripheral cells, in 
particular the cellular components of the arterial wall, 
and plasma lipoproteins. This is crucial for the 
development of arteriosclerotic disease and will be 
discussed in paragraph 1.5. Receptors and enzymes which 
play an important role in lipoprotein metabolism are listed 
in Table 3.
1.3.1 Chylomicron metabolism
Following intraintestinal hydrolysis, dietary fat is 
absorbed by enterocytes in the small intestine as L-
monoglycerides, fatty acids and free cholesterol.
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Intracellularly, triglycerides and - to a lesser extent - 
cholesteryl esters are formed by re-esterification and 
these are packaged with apoB-48 to form chylomicrons, and 
secreted into lymph. From there chylomicrons enter the 
bloodstream, via the thoracic duct, where they undergo 
prompt changes. As a result of exchange with other 
lipoproteins, notably HDL, chylomicrons acquire apoC and 
apoE and lose most of their apoA (60); secondly, the 
triglyceride-rich core of chylomicrons is degraded rapidly 
by the action of lipoprotein lipase situated in the 
capillary bed of skeletal muscle and adipose tissue. As 
the core shrinks during hydrolysis, parts of the outer 
shell detach from the particle and form so-called surface 
remnants consisting of phospholipids, apoA and possibly 
some apoC. Surface remnants are considered by some 
investigators as a main source of HDL precursors (61).
The core unit of chylomicrons is transformed by 
lipoprotein lipase into particles, which are relatively 
cholesteryl ester-rich, triglyceride depleted and contain 
apoB-48 and apoE. These chylomicron remnants are 
catabolised in the liver by receptor mediated endocytosis, 
probably through a specific apoE binding remnant receptor. 
The amino acid sequence of a putative receptor protein has 
been published recently (53). Although, prior to this 
publication, the precise nature of this receptor was a 
matter of some controversy (62, 63), the existence of an 
apoE-specific pathway for chylomicron clearance,
14
independent from the LDL-receptor, was deduced from the 
observation that in homozygous familial hypercholest- 
erolaemia, a condition with grossly impaired LDL-receptor 
function, chylomicron clearance is normal (64, 65). On the 
other hand, chylomicron clearance in subjects homozygous 
for apoE2 is markedly delayed (6 6, 67) . Because of this 
evidence the concept of an independent apoE receptor is at 
present accepted by most investigators. However in-vitro 
experiments have demonstrated that chylomicron remnants can 
be internalised by human macrophages via the LDL-receptor 
indicating that the apoE-receptor is not an exclusive route 
of catabolism (6 8).
1.3.2. Metabolism of apoB-100 containing lipoprotein
The spectrum of apoB-100 containing lipoproteins in 
plasma is illustrated by Fig. 3. They cover a density 
interval from 0.950-1.063 kg/1 with corresponding Svedberg 
flotation coefficients of Sf 0-400 at d = 1.063 kg/1. 
ApoB-100 containing lipoproteins are synthesised by 
the liver and secreted into the plasma compartment as 
VLDL particles (20, 69). Whether or not the liver 
can synthesise LDL directly is a matter of current debate 
(70-72). As indicated already in Table 1 the least dense 
particles - VLDL^ - are triglyceride-rich with a low 
content of cholesterol and protein, the latter comprising 
apoC and apoE in addition to apoB-100. With increasing
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density the lipoproteins become triglyceride-depleted and 
enriched in cholesterol, cholesteryl ester and protein. By
loss of apoC and apoE the composition of the protein
component alters so that apoB becomes dominant, and 
accounts for almost all of the protein associated with LDL. 
This spectrum of lipoproteins represents a delipidation 
cascade in which the less dense Sf 60-400 VLDL is 
hydrolysed to form denser VLDL (Sf 20-60), then IDL (Sf 12- 
20) and finally LDL (Sf 0-12) as an end-product of the 
process.
The two lipolytic enzymes catalysing lipid 
hydrolysis are lipoprotein lipase and hepatic lipase. In- 
vitro studies suggest that their action is complementary 
inasmuch as lipoprotein lipase reacts preferentially 
with larger, triglyceride-rich particles while the ideal 
substrate for hepatic lipase seems to be denser
lipoproteins of the IDL range (73). During VLDL 
delipidation surface remnants are formed in a fashion 
analogous to what has been described for chylomicron
hydrolysis. These surface remnants are believed to be 
either HDL precursors or contribute to the HDL3 to HDL2 
conversion (74). Concomitant with the loss of
triglycerides, denser apoB-100 containing particles acquire 
cholesteryl esters which in LDL account for about 40% of 
the total mass. Cholesteryl esters are transferred from 
HDL to LDL precursors by cholesteryl ester transfer protein 
(CETP), partly in exchange for core triglyceride (75, 76).
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A principal route of LDL catabolism is mediated by 
the LDL-receptor which was discovered by Goldstein and 
Brown in 1974 (77, 78). As mentioned earlier apoB and apoE 
are the specific binding proteins for this receptor with 
apoE showing an even higher binding affinity as compared to 
apoB (79, 80). Virtually all tissues express the LDL- 
receptor thus enabling cells to meet their cholesterol 
requirement at least in part by receptor mediated 
endocytosis. Cell culture experiments have shown that 
receptor-expression is regulated according to the LDL 
concentration in the medium, a mechanism by which 
cholesterol overloading via LDL-receptor mediated uptake is 
prevented (23, 81). From cholesterol feeding experiments 
in rabbits it became clear that the same principle applies 
to in-vivo conditions: as exogenous cholesterol supplies
to the liver increased, the number of hepatic LDL-receptors 
were down regulated (82). Similarly in humans receptor 
dependent LDL catabolism was up-regulated when cholesterol 
was removed from hepatocytes by a drug interfering with 
the enterohepatic recirculation (83, 84) .
Apart from LDL-receptor dependent degradation, LDL 
is catabolised by alternative routes. These are, on the 
one hand, other high affinity receptors of the 
reticuloendothelial system, such as the macrophage receptor 
for acetylated LDL, collectively referred to as the 
scavenger pathway (85-87). On the other hand non-specific, 
low affinity mechanisms like adsorptive endocytosis may
17
contribute significantly to LDL degradation. In 
normolipidaemic humans the relative contributions of LDL- 
receptor dependent and independent catabolism have been 
quantified by turnover studies using native and chemically 
modified LDL (27). About 50% of the LDL catabolism 
(0.19 pools/day out of a total FCR of 0.37/day) were 
attributable to LDL-receptor mediated degradation (27).
Studies investigating tissue-specific LDL degrad­
ation in various animals showed that approximately 50% of 
the total degradation takes place in the liver. This 
finding applies for receptor dependent and receptor 
independent LDL catabolism (8 8, 89). Following intra­
cellular uptake, LDL is degraded in lysosomal vesicles. 
Hepatocytes are the only cells in the body with a 
capability of disposing of sterols. These are excreted via 
bile either as cholesterol or - after oxidative degradation 
- as bile salts.
The nature of most of the working principles in 
apoB-100 metabolism, like lipase-protein interactions, 
lipid exchange mechanisms or receptor mediated catabolism, 
could be worked out by in-vitro experiments. This 
approach, however, is not appropriate for developing a more 
detailed understanding of the quantitative aspects which 
govern the precursor-product relationship of the VLDL to 
LDL transformation. Only by employing in-vivo studies 
using radiolabelled lipoproteins as tracers did it become
18
possible to investigate the metabolic fate and inter­
relations of distinct lipoprotein subfractions. The first 
experiments with trace-labelled VLDL in man demonstrated 
that radioactivity initially present in Sf 10-200 "VLDL” 
was rapidly transferred to the Sf 3-9 LDL density 
interval (90). Later with appreciation of the protein 
heterogeneity in VLDL, apoB was specifically examined 
and found to be the moiety that was conserved in this 
process in that all LDL apoB in the plasma could be 
attributed to the delipidation of VLDL (91). Sigurdsson 
et al. initially quantified this conversion and found 
that in normals not only did all LDL (d = 1.006-1.063 g/ml) 
come from VLDL but in addition all of the VLDL was 
catabolised to LDL (92). This rather strict precursor- 
product relationship was later shown to be not altogether 
correct in that while the majority of VLDL apoB did appear 
in the 1.006-1.019 kg/1 density range (ie IDL), in normals 
a smaller proportion of this ultimately became LDL (93). 
The transient intermediate, IDL, is short lived and of low 
concentration in most subjects but can be substantially 
elevated in certain dyslipoproteinaemias. Further 
investigation of the VLDL-IDL-LDL metabolic cascade has 
revealed that there are multiple sites of entry and exit 
which can only be quantified using computer-based 
multicompartmental modelling techniques. These not only 
permit the calculation of apoprotein flux rates but also 
allow for the testing of quantitative hypothesis regarding
19
the physiology of the VLDL to LDL conversion (94, 95). An 
up-to-date concept of apoB metabolism in the plasma 
compartment will be discussed in section 4 .5 .
1.3.3 HDL metabolism
HDL metabolism is relatively poorly understood, 
partly because the synthesis and removal of these particles 
from plasma do not follow easily discernible metabolic 
routes. Three sources of HDL precursors have been 
suggested (7): as mentioned in previous paragraphs on
chylomicron and apoB-100 metabolism, surface remnants 
generated during hydrolysis of triglyceride-rich particles 
are considered to be HDL precursors. Secondly, hepatic and 
intestinal cells may secrete directly discoidal "nascent" 
HDL and thirdly, phospholipid-apoprotein self-association 
may occur. Whatever the origin of HDL precursors, the 
discoidal shape of these complexes has to be converted 
into a spherical lipoprotein in order to form mature HDL3 . 
This process is catalysed by lecithin:cholesteryl acyl 
transferase (LCAT), an enzyme which esterifies cholesterol 
by acyl transfer from lecithin (96). Further surface 
remnant assimilation and LCAT —  mediated cholesterol 
esterification converts HDL3 into HDL2 (74). The core 
diameter of HDL2 is about 50% larger than that of HDL3 (60 
versus 40 K) and its cholesteryl ester content is increased 
accordingly. Furthermore, on a cholesterol-rich diet an
20
even bigger HDL particle, HDL]_ or HDLq , containing apoE 
but no apoAI, is generated, possibly by the same
mechanism (97). On the other hand, in-vitro studies with
cholesterol-loaded macrophages suggest that cholesterol, 
which is mobilised from these cells by interaction with 
HDL3 , plays a significant role in the formation of large, 
cholesterol-enriched HDL^ (45,98). A similar mechanism has 
been shown to operate in-vivo in rabbits. After injection 
of a large dose of native or chemically modified LDL the 
HDL2/HDL3 ratio increased indicating that cholesterol
deposited in peripheral tissues had been taken up by HDL3 
which in the process was converted into HDL2 (99).
The HDL receptor, currently under investigation by 
several groups of researchers, seems to be involved in the 
mobilisation of intracellular cholesterol. At present, two 
competing concepts suggest that cholesterol is transferred 
into HDL either by receptor mediated translocation from 
intracellular pools (1 00, 1 01) or via a receptor mediated 
retroendocytosis pathway (18). At present it is not clear
which mechanism is more important.
In light of the fact that almost half of the LDL 
degradation takes place in tissues which cannot break down 
or excrete sterols, a mechanism of cholesterol mobilisation 
from peripheral tissues, referred to as "reverse 
cholesterol transport", is of great importance. HDL]_, 
which usually is detectable only in low concentrations in 
human plasma, binds avidly to the B/E-receptor and is
21
probably catabolised by this route (1 0 2, 80). HDL2 
exchanges, via CETP, cholesteryl esters and triglycerides 
with triglyceride-rich apoB-containing lipoproteins (103). 
Subsequently, triglycerides are hydrolysed, primarily, by 
hepatic lipase and HDL3 is finally regenerated (104-105, 
340) .
1.4. Genetic Disorders Affecting Apolipoprotein B Metab­
olism
Understanding of lipoprotein metabolism has 
been enhanced by the study of human diseases which 
are associated with disturbances of plasma lipoprotein 
concentrations or compositions. In this section the 
following genetically determined disorders of lipoprotein 
metabolism are discussed:
Familial hyperchylomicronaemia (Type I HLP)
Familial hepatic lipase deficiency
Familial hypercholesterolaemia (Type II HLP)
Familial dysbetalipoproteinaemia (Type III HLP)
Familial hypertriglyceridaemia (Type IV HLP)
Familial combined hyperlipidaemia.
1.4.1. Familial hyperchylomicronaemia
Familial hyperchylomicronaemia is a rare autosomal 
recessive disorder with a frequency estimated to be less
22
than one in a million. In the classical form of this 
disorder, patients have very low or absent lipoprotein 
lipase activity measurable in plasma after heparin 
injection, resulting in excessive hypertriglyceridaemia 
(106). While lacking enzyme activity, most patients have 
at least some enzyme mass, as detected by an immunosorbent 
test, consistent with structural mutations of the 
lipoprotein lipase gene, which is located on chromosome 
8 (107, 108).
Typically, lipoprotein lipase deficiency is 
diagnosed in early childhood. Patients show failure to 
thrive, repeated attacks of abdominal pain, pancreatitis, 
splenomegaly and eruptive xanthomata. Their plasma is 
lactescent even after prolonged fasting due to delayed 
clearance of triglyceride-rich lipoproteins, both 
chylomicrons and large VLDL (109) . Triglyceride levels in 
plasma often are as high as 50 mmol/1, caused by a marked 
increase of chylomicrons and large VLDL. In contrast, 
levels of VLDL (Sf 20-60) were described as normal to only 
moderately elevated (106). LDL as well as HDL levels are 
low, probably due to reduced availability of LDL and HDL 
precursors (108). Patients with lipoprotein lipase 
deficiency are not at risk for coronary heart disease, 
however pancreatitis which often occurs with triglyceride 
levels above 10 mmol/1 is a serious complication. Therapy 
is a virtually fat-free diet, which can result in almost 
normal lipoprotein values.
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As mentioned earlier, apoCII is an obligatory cofactor 
for lipoprotein lipase. In the absence of apoCII a 
phenotype indistinguishable from lipoprotein lipase 
deficiency develops (110-114). Several kindreds affected 
by this very rare condition have been analysed revealing a 
number of structural or regulatory mutations of the apoCII 
gene (115, 116) . Another cause of functional lipoprotein 
lipase deficiency was observed in three related subjects 
in England (117). In this family lipoprotein lipase is 
blocked by an autologous plasma protein which was inherited 
as an autosomal dominant trait through four generations. 
Details about the VLDL metabolism in one of these patients 
are reported in section 3.4.
1.4.2. Familial hepatic lipase deficiency
Hepatic lipase deficiency is another extremely rare 
disease with only five patients described so far in the 
literature (118-120) . The lipoprotein profile of these 
subjects is characterised by an increase of IDL and VLDL 
remnants (ft-VLDL), very low levels of LDL and an HDL 
fraction which consists of HDL2 almost exclusively. VLDL 
levels vary widely between normal and markedly elevated. 
The triglyceride moieties of LDL and HDL are increased. 
Although the lipoprotein spectrum is clearly distorted, 
total cholesterol values are almost normal and at least two 
patients do not need lipid-lowering therapy. There is no
24
There is no evidence that hepatic lipase deficiency 
increases the risk of coronary heart disease. A study of 
the apolipoprotein B metabolism in one patient from 
Sweden (119) is reported in section 3.5.
1.4.3. Familial hypercholesterolaemia
Familial hypercholesterolaemia is a common inherited 
lipoprotein disorder with a gene frequency of about 1 in 
500. It is caused by a defective gene encoding for the 
LDL-receptor (121, 122). The condition is inherited in an 
autosomal codominant fashion and therefore occurs in 
heterozygous and homozygous form (123) . LDL-cholesterol 
levels in heterozygotes are usually two to three-fold 
increased as compared to normal subjects of the same age, 
with hypercholesterolaemia starting in early childhood. 
Clinically, patients show tendon xanthomas and arcus 
corneae and they are prone to premature cardiovascular 
disease. LDL levels in homozygous patients, who number 
about one in a million, are much higher, up to 20 mmol/1 . 
Here the concentrations of LDL precursors, ie IDL and even 
VLDL2 , are often increased as well. The symptoms of severe 
coronary heart disease develop in most cases before the 
age of 20 years (122) . The clinical course of familial 
hypercholesterolaemia both in its heterozygous and
homozygous form, varies significantly, which is thought to 
result, in part, from the heterogeneity of mutations
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affecting the structure of the receptor protein. Another
factor, which may modify the course of disease is the
concentration of Lp(a), which was found to be significantly 
higher in heterozygous FH patients with symptoms of 
coronary heart disease as compared to asymptomatic
heterozygous subjects (318) .
Mutations of the LDL-receptor may cause either no 
expression of the receptor at all (receptor-negative), or 
defects in the receptor function may occur, such as
insufficient LDL-binding or impaired LDL internalisation 
into cells (122). At the genomic level more than twenty 
different mutations have been identified in different 
kindreds (124, 125). This is why most patients with the 
"homozygous" form of the disease are genetically compound 
heterozygotes. Because of this heterogeneity of the 
receptor defect it is impractical to diagnose familial 
hypercholesterolaemia by use of a single DNA gene probe or 
an individual restriction fragment length polymorphism 
(RFLP) (126). Only in genetically isolated small
populations, like French Canadians, Afrikaner South 
Africans or Maronite Lebanese, familial FH is commonly 
linked with a single specific DNA mutation (127-129).
Metabolic studies have shown that increased levels 
of LDL in this condition primarily arise from delayed LDL 
clearance but in some patients oversynthesis of LDL also 
seems to contribute to the expanded plasma LDL pool (130, 
131) with some LDL being derived through a VLDL independent
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pathway (70, 132). Details of the apolipoprotein B meta­
bolism in two patients with homozygous FH will be presented 
in section 3.6.
While lipid-lowering drug therapy is usually quite 
successful in heterozygous patients (133), homozygotes 
respond only poorly to diet and drug treatment and 
therefore require much harsher therapeutic interventions 
such as additional plasma exchange or LDL-apheresis (134— 
136) .
1.4.4 Familial dysbetalipoproteinaemia
Patients with this disorder accumulate in , their 
plasma remnant particles of both chylomicrons and VLDL, 
collectively termed L-VLDL (137, 138) . These particles are 
buoyant at a density smaller than 1.006 kg/1 by 
ultracentrifugation but in contrast to VLDL they show im­
mobility, like LDL, on agarose gel electrophoresis (139). 
Compared to VLDL, L-VLDL is cholesteryl ester-enriched at 
the expense of triglycerides (140) . The apolipoprotein 
composition shows a decrease of apoC paralleled by an 
increase of apoE which accounts for their diminished 
electrophoretic mobility (141) .
The delayed clearance of these remnant particles 
is probably due to the inheritance of apoE isoforms which 
do not bind normally to apoE specific cell-surface 
receptors (142, 143, 379). Most cases are homozygous for
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apoE2 (Arg 158 — > Cys) but rarely heterozygotes for the 
apoE2 allele are also affected (144) . In addition a number 
of other rare apoE mutants with impaired receptor-binding 
affinity have been isolated from subjects with familial 
dysbetalipoproteinaemia (54-57, 146) , some patients being 
only heterozygous for the defective allele. Familial apoE 
deficiency, a syndrome with only trace amounts of apoE 
in plasma, is also expressed phenotypically as dysbeta­
lipoproteinaemia (147). Some degree of dysbetalipo­
proteinaemia without hyperlipidaemia is typical for 
normolipidaemic apoE2/2 homozygotes (142, 254).
Familial dysbetalipoproteinaemia occurs in about 1- 
2 in 10,000 subjects. Since apoE2 homozygosity is much more 
common than this, a second factor has to .be postulated for 
the manifestation of the disease. This may be, for 
instance, another genetically determined hyperlipidaemia 
(148, 149) or a cause of secondary hyperlipidaemia such as 
diabetes or hypothyroidism (138). The fact that women are 
less often affected and that they are on average ten years 
older than men at the time of diagnosis suggests that 
oestrogen has an influence on the phenotypic expression of 
the disorder (150) . Further evidence for genetic factors 
being involved in the manifestation of dysbetalipo­
proteinaemia come from two RFLPs which have been described 
in association with the condition: one for the apoB gene
(Xbal) and one for the apoE-CI-CII gene cluster (Hpal),
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the latter unassociated with normolipidaemic apoE2 
homozygosity (151, 152).
A comparative metabolic study with labelled apoE 
from patients and from normal controls confirmed that 
defective apoE metabolism is probably responsible for 
the lipoprotein abnormalities (153). Turnover studies with 
trace-labelled VLDL revealed a decreased fractional 
catabolic rate for VLDL and a reduced transfer from IDL 
to LDL, both explaining an accumulation of VLDL 
remnants (155, 274). Accordingly, labelled large trigly­
ceride-rich lipoproteins of hepatic and intestinal origin 
(Sf > 60) containing apoB-100 or apoB-48 showed a delayed 
clearance following reinjection and no appreciable transfer 
into denser lipoproteins (67) .
Typical clinical signs for dysbetalipoproteinaemia 
are xanthomata which may occur either as tuberous xanthoma 
of the skin or as linear yellow discolourations along 
palmar and interdigital creases (138). Cholesterol levels 
are usually in the range of 10-15 mmol/1 and triglycerides 
5-15 mmol/1. These lipid levels in combination with a 
VLDL-cholesterol/total triglyceride ratio of greater than 
0.7 (mmol/mmol) and an apoE2/2_ phenotype establish the 
diagnosis. Patients have a significantly increased risk 
for cardiovascular disease. This may be related to 
in-vitro observations showing that ft-VLDL is taken up 
avidly by macrophages which are eventually transformed into 
foam cells (156). The process which is mediated through
29 *k;
apolipoprotein E (156, 379) was thought to involve a 
specific fi-VLDL-receptor, but from recent studies it seems 
more likely now that ft-VLDL is internalised by the LDL- 
receptor (157). It is, however, not clear how the 
regulation of receptor-expression is circumvented which 
usually prevents cholesterol accumulation through the LDL- 
receptor pathway. Different rates of cellular uptake for 
LDL and B-VLDL observed with macrophages from a particular 
homozygous patient with familial hypercholesterolaemia 
(158) may be explained by the specific mutation within the 
receptor gene in this case, affecting selectively the 
binding affinity for LDL but not for ft-VLDL (159, 160) .
In dysbetalipoproteinemia therapeutic response to 
treatment usually is very good. Treatment starts with 
rectifying possible precipitating factors such as 
causes for secondary hyperlipidaemia. Lipid-lowering drugs 
may be considered in second line. Bezafibrate lowers 
plasma VLDL mainly by reducing VLDL synthesis without 
normalising the perturbed VLDL composition (161). In 
contrast, oestrogen (162) and lovastatin (163) both lower 
total cholesterol and triglyceride and normalise VLDL 
composition, probably by enhanced clearance of ft-VLDL. 
These drugs are known to up-regulate hepatic lipoprotein 
receptors. By this they help to overcome the inefficient 
interaction between apoE2-containing lipoproteins and 
receptors. The exception to this rule are seemingly 
patients with apoE deficiency who failed to respond
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appropriately to oestrogen therapy (147). This observation 
indicates the need for some apoE, however defective, to 
mediate VLDL remnant removal.
1.4.5. Familial hypertriglyceridaemia
Familial hypertriglyceridaemia has to be diagnosed 
in subjects with hypertriglyceridaemia due to elevated VLDL 
levels and a family history of the same lipid disorder but 
no other hyperlipidaemias (for differentiation from 
familial combined hyperlipidaemia see following paragraph) 
(164). It is probably not a single nosologic entity and 
until now could not be linked to one or more clearly 
defined, genetic defects. Most patients with increased 
VLDL levels do not suffer from familial hyper­
triglyceridaemia but from secondary hyperlipidaemias, due 
to carbohydrate-enriched diet, alcohol intake or diabetes. 
Another more frequent disorder is familial combined 
hyperlipidaemia which may phenotypically present as 
hypertriglyceridaemia. Particle distribution within the 
VLDL range is skewed towards larger triglyceride-enriched 
particles in familial hypertriglyceridaemia as compared to 
normals (165).
Early metabolic studies in hypertriglyceridaemic 
subjects have shown that these individuals synthesise three 
times as much VLDL apoB as required for LDL synthesis 
(166). Therefore, the VLDL to LDL delipidation cascade
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must allow for direct catabolism of LDL precursors at 
multiple sites along its length. The regulation of direct 
catabolism versus further delipidation is not well 
understood. One possible mechanism, suggested by in-vitro 
studies, is that if a VLDL particle has a prolonged 
residence in the plasma it may acquire too much cholesteryl 
ester in its core to permit it to shrink to the size of 
LDL (7 6). In support of this view, it has been shown that 
VLDL subfractions from normal subjects may be hydrolysed in 
the test-tube to LDL-like particles (167). Large VLDL from 
hypertriglyceridaemics on the other hand seems to be unable 
to be lipolysed sufficiently to form LDL in-vitro. In-vivo 
this would constitute a fraction of VLDL that fails to 
transit the delipidation cascade (168). Kinetic studies by 
Chait (169) and by Kissebah (170) investigated in parallel 
the metabolism of VLDL-apoB and VLDL-triglyceride in 
familial hypertriglyceridaemia as compared to normals. 
They found that the increase of triglyceride turnover was 
disproportionately greater than the increase of apoB 
suggesting that familial hypertriglyceridaemia may be due 
to hepatic oversynthesis of triglyceride which is then 
secreted as triglyceride-rich VLDL. In addition VLDL 
clearance was delayed, possibly because of saturation of 
lipoprotein lipase capacity (171). In a VLDL-turnover 
study by Packard et al . (154) large VLDL (Sf 100-400) and
small VLDL (Sf 20-60) was used as metabolic tracers. It 
was shown that only the catabolism of the former was
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delayed whereas the latter was converted to LDL at a normal 
rate. The reason for hepatic oversynthesis of large VLDL 
in this condition is unknown at present.
The risk for coronary heart disease does not seem 
to be significantly increased in familial hypertrigly­
ceridaemia as long as other risk factors are absent (164, 
321). On the other hand 5% of survivors of myocardial 
infarction were found to have familial hypertrigly­
ceridaemia in contrast to a prevalence in the general 
population of less than 0.5% (173). Therapy should focus 
first of all on dietary changes with carbohydrates 
providing no more than 40 cal%. Only if high triglyceride 
levels persist lipid-lowering agents, such as nicotinic 
acid, may be given. Bezafibrate seems unsuitable, in 
particular in cases with border-line hypercholesterolaemia, 
as it lowers VLDL levels through enhanced delipidation and 
thereby may even increase LDL levels (172).
1.4.6. Familial combined hyperlipidaemia
Familial combined hyperlipidaemia was first 
described by several authors in 1973 following genetic 
analysis of lipid levels in ' families of myocardial 
infarction survivors (173, 174, 175). It is probably the 
most common inherited lipoprotein disorder. 10% to 30% of 
patients who had suffered a heart attack had raised levels 
of plasma cholesterol or triglyceride or a combination of
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both and, in addition, a family history with the same 
spectrum of phenotypically different hyperlipidaemias. 
Lipoprotein levels are usually moderately elevated and 
pedigree studies have pointed at an autosomal dominant 
pattern of inheritance (176) . In contrast to familial 
hypercholesterolaemia, hyperlipidaemia is not expressed in 
childhood and tendon xanthomata are rare. VLDL particles 
in familial combined hyperlipidaemia are smaller than 
normal but of normal composition (165). Metabolic studies 
have demonstrated an oversynthesis of VLDL-apoB (169, 93) 
and - in hypercholesterolaemic patients - also an 
oversynthesis of LDL-apoB, without appreciable direct LDL 
production (93). Therefore, the primary defect seems to be 
hepatic VLDL-apoB oversynthesis. Whether the condition 
phenotypically emerges more as hypertriglyceridaemia or as 
hypercholesterolaemia seems to depend on the efficiency 
of VLDL to LDL conversion. This view is supported by the 
inverse correlation between VLDL-apoB and LDL-apoB found in 
familial combined hyperlipidaemia (165). Obesity, showing 
a reduced VLDL to LDL transfer (177), may for example cause 
hypertriglyceridaemia in these circumstances. The reason 
for apoB oversynthesis is unknown.
Hyperapobetalipoproteinaemia as described by Sniderman 
et al . (179) is a condition positively correlated to
cardiovascular disease and is marked by a relative increase 
of LDL-apoB without increased LDL-cholesterol levels. In 
this disorder too, LDL synthesis was found to be increased
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secondary to increased VLDL synthesis (180) . Hyperapobeta­
lipoproteinaemia, however,does not follow a dominant 
pattern of inheritance. The relationship between this 
condition and familial combined hyperlipidaemia is not
clear at present, but at least some overlap seems likely.
Treatment for both follows the principles outLined for 
heterozygous familial hypercholesterolaemia and for 
familial hypertriglycerid-aemia.
1.5 Lipoproteins and Atherosclerosis
The link between plasma lipoproteins and in 
particular between apoB containing lipoproteins and 
cardiovascular disease has been mentioned repeatedly
throughout the previous paragraphs. In the following 
more evidence for this correlation will be presented 
as derived from epidemiological studies during the last 
twenty years. In addition biochemical and cell-biological 
observations linking plasma lipoproteins with
atherosclerotic changes of the vessel wall will be 
discussed.
1.5.1. Population studies and intervention trials
The positive correlation between plasma cholesterol 
and the prevalence of coronary heart disease was
demonstrated by a number of population studies including
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the Framingham Heart Study (181), the Pooling Project (182) 
and the Seven Countries Study (183). The best data come 
from the Multiple Risk Factor Intervention Trial (MRFIT) 
where 356,222 men, aged 35-57 years, were screened and 
followed up for six years (184) . The number of deaths
caused by coronary heart disease in relation to plasma
cholesterol concentration is plotted in Fig. 4 (185). The 
correlation is continuous and dose-related in an 
exponential manner throughout the whole range of plasma 
cholesterol (186, 187). There is no threshold cholesterol 
level below which coronary heart disease is independent 
from the plasma cholesterol concentration. On the basis of 
quintile analysis it was estimated that nearly half ,of all
observed deaths from coronary heart disease were
attributable to serum cholesterol levels greater than
4.7 mmol/1 (186). Detailed analysis of the Framingham data 
have shown that the same graded correlation between plasma 
cholesterol and risk of cardiovascular disease exists in 
the presence of other risk factors, notably cigarette 
smoking, diastolic hypertension or diabetes (188). 
Conversely, observations from Japan demonstrate that 
smoking combined with low plasma cholesterol does not 
result in increased incidence rates for coronary heart 
disease (183). Furthermore, data from Framingham provided 
supportive evidence for opposing correlations between LDL- 
cholesterol and HDL-cholesterol with regard to CHD 
risk (189) . Based on twelve years follow-up data,
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individuals in the top quintile of HDL-cholesterol were 
found to have half the risk as compared with subjects in 
the lowest quintile (190). Autopsy studies have confirmed 
that serum cholesterol levels as well as high blood 
pressure are quantitatively related to the extent of 
atherosclerotic lesions (191).
Another line of evidence for a causal link between 
elevated plasma cholesterol levels and coronary heart 
disease comes from intervention trials where cholesterol 
levels were decreased with the aim of reducing coronary 
heart disease incidence. In the Lipid Research Clinics 
Coronary Primary Prevention Trial (LRC-CPPT) a 19% lower 
incidence of coronary heart disease was accomplished , by a 
mean fall of 12% in LDL-cholesterol in men treated with 
cholestyramine as compared to placebo controls (192). In 
another placebo-controlled trial, the Helsinki Heart Study, 
a 10% decrease in LDL-cholesterol and a 10% increase in 
HDL-cholesterol were achieved by treatment with gemfibrozil 
(600 mg/day). This caused the cumulative rate of cardiac 
morbidity after five years to fall by 34% in the treatment 
group (193). However, due to an unexplained increase in 
non-cardiovascular mortality (ie death mainly by accidents 
or violence but not by cancer) both studies failed to 
produce a significant decrease of total mortality in the 
treatment group (193, 194). The Multiple Risk Factor 
Intervention Trial (MRFIT) with 12,866 high-risk men 
participating, also did not show a difference in death
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rates between special intervention group and usual-care 
group, possibly because the beneficial effects of reduced 
cigarette smoking and dietetically lowered cholesterol were 
outweighed by an unfavourable response to antihypertensive 
drug therapy in a subgroup of hypertensive patients with 
arrhythmias. Statistical analysis was further complicated 
by the fact that risk factor levels declined not only in 
the intervention group but also, to a lesser extent, in the 
usual-care group (184) . In the Oslo Study, an earlier, 
smaller intervention trial, the CHD incidence rate was 
lowered by 47%. Intervention included dietary advice and 
encouragement to stop smoking but no antihypertensive 
treatment. Plasma cholesterol levels were decreased in the 
intervention group by 13% as compared to controls (316).
A more rigorous regimen of treatment with lipid- 
lowering drugs (Colestipol 30 g/day and Niacin 3-12 g/day) 
was applied in a placebo-controlled angiographic trial, 
the Cholesterol Lowering Atherosclerosis Study (CLAS), 
resulting in a 43% reduction of LDL-cholesterol and a 
simultaneous 37% increase of HDL-cholesterol. Participants 
were 162 non-smoking men with previous coronary bypass 
surgery. Coronary angiograms from before and after two
years of treatment showed that deterioration in overall 
coronary status was significantly less in drug-treated 
subjects and that regression of atherosclerotic lesions 
occurred in 16.2% of treated subjects versus 2.4% in 
controls (195).
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In conclusion, despite the problems of 
interpretation with the largest study mentioned above, 
evidence for a causal link between high plasma cholesterol 
and increased risk for cardiovascular disease is very 
strong.
1.5.2. Lipoprotein interactions with the arterial wall
Recent progress in cell biological research has now 
unveiled some of the mechanisms which are important for the 
interaction between plasma lipoproteins and the cells of 
the arterial wall (196). Henricksen et a l . observed in 
1981 that LDL, after incubation with arterial endothelial 
cells, is taken up more rapidly by macrophages than native 
LDL (197). Similar to acetylated LDL or ft-VLDL but in 
contrast to native LDL, endothelial cell-modified LDL can 
transform marcophages into foam cells. Cells other than 
endothelial cells such as smooth muscle cells or 
macrophages can modify LDL in the same way (198, 199). The 
cell-induced modification is primarily a peroxidation of 
polyunsaturated fatty acids cleaved from phospholipids 
(200). Short-chain aldehydes, generated during the 
process, react covalently with lysine residues of 
apolipoprotein B, modifying the protein in a way similar to 
in-vitro acetylation (201, 202). Interestingly, the uptake 
of acetylated LDL by macrophages can be competitively 
inhibited to about 80% by biologically modified LDL,
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meaning that both lipoproteins are binding to the same 
receptor. Thus, in-vivo oxidatively modified LDL seems to 
be a natural ligand for the acetylated LDL-receptor. As 
acetylated LDL is a far less effective competitor for the 
uptake of biologically modified LDL, the existence of a 
second scavenger receptor has been concluded (203). 
Oxidised LDL is antigenic, so antibodies could be raised 
against it, which were used to detect modified LDL by 
immunohistological methods in atherosclerotic lesions. 
Furthermore, autoantibodies against modified LDL can be 
demonstrated in human sera, providing evidence that 
biological LDL modification does occur in-vivo (204).
These observations form the basis for a model of 
atherogenesis, which was suggested first by Steinberg 
(205). It tries to explain the formation of fatty streaks, 
which are the earliest distinct lesions in the atherogenic 
process, starting from elevated LDL levels in plasma. LDL 
is transferred by endocytosis from plasma into the 
subendothelial space where it is oxidatively modified by 
appropriate cell contact and internalised by macrophages 
which by cholesteryl ester accumulation develop into foam 
cells. Biologically modified LDL is chemotactic for 
circulating monocytes but inhibits the mobility of resident 
macrophages, thus recruiting monocytes from the blood 
stream and accumulating macrophages in the subendothelial 
space (20 6). Morphologic studies have confirmed monocyte 
adhesion and foam cell accumulation as early events in the
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process of fatty streak formation (207). Activated 
macrophages release growth factors which in turn recruit 
smooth muscle cells from the media and stimulate
their growth (208). Moreover oxidatively modified LDL
is cytotoxic and may damage, for instance, endothelial
cells (198). Endothelial denudation, which again has been 
described by scanning electron microscopy in early 
atherosclerotic lesions, provides a focal point for
platelet aggregation and facilitates further influx of 
plasma proteins (207). This model of fatty streak
formation does not rule out other mechanisms to act 
simultaneously, for example, accumulation of chylomicron 
remanants (209) aggravated by cytotoxicity of lipolytic
surface remnants (210). On the other hand, it brings
together two often competing theories of atherogenesis 
"lipid infiltration" versus "response to injury" -
presenting them as complementary aspects of one process.
The progression of fatty streaks into fibrous 
plaques and eventually into necrotic lesions goes along 
with a continuation of the above outlined process (273). 
While foam cell formation continues at the luminal side of 
the vessel wall, foam cells at the bottom of the lesion 
start to die, possibly through intracellular precipitation 
of free cholesterol (211). In advanced lesions the content 
of free cholesterol, partly precipitated as crystals, is 
markedly higher than in fatty streaks (212). The
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cholesteryl ester profile (cholesteryl oleate versus
linoleate) of advanced lesions resembles more LDL than
fatty streaks (213), suggesting that most of the 
cholesteryl esters stored in foam cells are hydrolysed when 
cells die, while LDL-proteoglycan interactions may account 
for at least some of the cholesteryl esters trapped in che 
lipid core of necrotic plaques (214, 215).
As evidenced by the results of CLAS (195), which 
were outlined earlier in this section, regression of
atherosclerotic lesions can occur, if favourable conditions 
are provided. The role of HDL as a vehicle of reverse
cholesterol transport has been addressed in paragraph
1.3.3. In-vitro studies (45, 98) have shown that in the
presence of cholesterol acceptors, such as HDL3 ,
cholesteryl esters can be mobilised from foam cells.
Animal experiments with rhesus monkeys suggest that 
regression of coronary lesions occurs uniformly if the
total cholesterol/HDL-cholesterol ratio is smaller than
2.8 (216) .
1.6. Factors Determining Plasma Cholesterol Levels
In contrast to most other plasma constituents, 
cholesterol levels are not regulated within narrow limits 
but vary greatly. This variation can be seen between 
individuals but also within one person. As with most 
biological variables influences can be either environmental
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or genetic and probably most importantly a combination of 
both.
1.6.1. Influence of environmental factors on plasma
cholesterol concentration
Since World War II cardiovascular disease has been 
the major cause of death in Western Societies. The LDL- 
cholesterol levels typical of a polulation with a high CHD 
rate are about five times higher than the minimum thought 
to be required to deliver cholesterol to body cells via the 
LDL-receptor (23). In contrast, societies with almost no 
CHD mortality have mean cholesterol levels nearer to this 
biochemically defined ideal level. Cross-cultural 
comparisons, such as the Seven Countries Study, demonstrate 
that the amount and the composition of dietary fat in the 
habitual diets on the one hand and the mean serum
cholesterol levels and CHD rates on the other hand are 
strongly correlated (183). This points to diet as an 
important reason for high plasma cholesterol levels and for 
high CHD mortality in industrialised countries.
Anthropologists have developed some ideas of the 
composition of a "palaeolithic" diet which probably
prevailed through almost all of man's two million years of 
evolutionary history (217). Interestingly, the total
dietary energy in form of fat was only half of the
current American diet (21% versus 42%) and the
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polyunsaturated:saturated fat ratio was more than three 
times higher (1.41 versus 0.44), whereas cholesterol intake
was very similar. In the light of these observations the
current diet in "Western" countries seems unphysiological, 
resulting in lipoprotein levels which exceed by far natural 
requirements. Incidence rates for CHD are not static and 
in some countries, most notably in the USA, CHD rates are 
declining steadily after they had reached a peak in the 
early 1960s (218-220). These changes coincide with a
trend towards lower mean cholesterol levels among US
adults (2 2 1 ), a reduced per capita consumption of unskimmed 
dairy products, eggs and animal fats and with a marked 
increase in use of vegetable fats and oils (222).v _ Since 
1963 smoking has also declined significantly in North 
America. Major changes in lifestyle, some of which have 
had beneficial effects on plasma cholesterol, seem to have 
contributed to a significant decline of CHD mortality by 
more than 30% within three decades (218). A study from the 
Netherlands showed that as little as one fish meal per week 
(30 g per day) has a measurable effect in reducing the 
twenty year mortality from CHD (223). In this particular 
study lipoprotein levels were not measured. Not all 
dietary effects on CHD morbidity are caused by changes in 
lipoprotein metabolism (224) but from the observations 
outlined above it can be concluded that diet as an 
environmental factor has an important influence on plasma
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lipoprotein levels and - mainly as a result of this - on 
the incidence rate of CHD.
1.6.2. Genetic determinants of plasma cholesterol concen­
trations
On the other hand, there is clear evidence for 
genetic influence on plasma cholesterol levels which has 
been estimated by family and by population studies to 
account for 50% to 60% of the total individual 
variance (225, 226). A comparative study of Japanese 
living in Japan, in Hawaii and in North America has shown 
that along with assimilation to "Western" diet and 
lifestyle both cholesterol levels and CHD rate 
increased (227). However, the CHD incidence of Japanese 
living in California was, in spite of similar environmental 
influences, only half the rate observed in Caucasian North 
Americans.
One of the most striking examples for genetically 
defined hyperlipoproteinaemia is familial hypercholesterol­
aemia, which is discussed in paragraph 1.4.3. However, 
while it is one of the most common inherited metabolic 
disorders it accounts for only 5% of myocardial infarctions 
under the age of 60 years (173). Although the effect of a 
defective receptor gene is very significant for an affected 
individual, the impact on cholesterol level variation in 
the population is only modest, because the defective gene
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frequency of 1 in 500 is low with regard to the population 
as a whole. As the impact of a genetic trait on
interindividual variation within a population is defined by 
the product of gene effect and gene frequency, common 
mutations exerting a relatively small effect on cholesterol
concentrations may account for quite a large percentage of
interindividual differences.
It has been proposed that there is a genetic
contribution to LDL-receptor binding activity in 
normolipidaemic subjects. Receptor . dependent LDL 
degradation by mononuclear cells or fibroblasts obtained 
from normolipidaemic monozygotic and dizygotic twins 
demonstrated a markedly bigger within-pair variation for 
the latter (228, 229) . Plasma cholesterol levels did not 
vary accordingly, but the response to dietary cholesterol 
was found to be inversely linked to the LDL-receptor 
activity in-vitro (230) . A number of RFLPs for the 
receptor gene have now been reported and it remains to be 
seen whether some of them correlate with hyperlipidaemia or 
CHD (107) .
Variation of the apoB gene is another obvious 
possibility for genetic determination of apoB containing 
lipoprotein concentrations. Grundy et a l . reported a 
turnover study in which the metabolism of autologous LDL 
and LDL from a normal donor were directly compared in 
moderately hypercholesterolaemic subjects (231). In five 
individuals, autologous LDL was cleared at a markedly lower
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rate than control LDL. Fibroblast studies confirmed a 
reduced LDL-receptor binding affinity for LDL from one of 
these subjects (232) and subsequent sequencing of the 
receptor-binding domain revealed an Arg to Gin interchange 
in position 3500 of the amino acid sequence of 
apolipoprotein B (233). This mutant, now termed familial 
defective apolipoprotein B-100, has been found in several 
unrelated families where it also seems to be associated 
with moderate hypercholesterolaemia (234, 235).
Two other mutations of the apoB gene, originally
defined as RFLPs for MspI and for EcoRI in the 3' end
of the gene, are now identified as Arg 3611 — ► Gin and
Glu 4154 -- ► Cys amino acid substitutions respectively
(236, 237). Both mutations have been linked to significant
variations in serum cholesterol levels and CHD risk (238-
240). However, none of these correlations are sufficiently 
strong to be found consistently in all sample groups 
studied (240, 241).
In 62 subjects studied a Thr -- ► lie substitution at
apoB amino acid residue 71 was associated with an apoB 
polymorphism defined by high or low binding affinity to the 
monoclonal antibody MB19 (242). In heterozygotes for this 
polymorphism (MB19+/M19-) this antibody was used to 
identify an allele specific difference in the expression of 
the apoB gene. This was found to be an autosomal 
dominantly inherited trait (243) . The mechanisms of 
unequal apoB expression are unknown at present.
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Finally, many workers have investigated an apoB gene 
polymorphism defined by an Xbal-RFLP. The two alleles 
differ due to a C to T interchange in the third position of 
Codon 2488 of the apoB gene which creates a cutting site 
for Xbal but is silent with regard to the amino acid 
sequence of apoB (245). Thus the mutation in itself does 
not change the apoB structure, but it seems to be in 
linkage disequilibrium with other, functionally significant 
mutations. Several studies show an association between 
serum cholesterol levels and the Xbal-RFLP (151, 246-248) . 
Moreover, this polymorphism is closely linked to the x/y 
alleles of the antigenic group (Ag) system, an antigenic 
apoB polymorphism discovered by antisera from multiply 
transfused patients (237, 249). The Ag x/y antigen in turn 
has also been linked with different plasma cholesterol 
levels (250) . Other Ag-antigens have been characterised by 
specific RFLPs and are listed in Table 4 (275-279). Not 
all studies have confirmed an association between the Xbal 
polymorphism and plasma cholesterol levels and unless a 
functionally relevant mutation in close linkage to the Xbal 
cutting site is found, the significance of this 
polymorphism is difficult to evaluate (241, 251, 252) . 
This applies also to association studies of the Xbal 
polymorphism with regard to CHD, which have produced 
conflicting results (238, 241).
The best defined genetic factor determining 
variation of apoB lipoprotein concentrations within the
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normal range is the apolipoprotein E polymorphism (253). 
The molecular basis of the apolipoprotein E polymorphism is 
explained in paragraph 1.2.4. The three apoE isoforms, 
apoE2, apoE3 and apoE4 commonly found in the population, 
are the gene products of three different alleles, e2 / e3 
and 6 4 , for the apoE locus (254). Inheritance is 
codominant resulting in three homozygous and three 
heterozygous phenotypes which can be distinguished by 
isoelectric focussing: apoE2/2, apoE3/3, apoE4/4 and
apoE2/3, apoE3/4 and apoE2/4 respectively.
Gene frequencies observed in six Caucasian 
populations showed no statistically significant 
differences. The e3 gene is by far the most common, 
accounting for an apoE3/3 phenotype in 60-65% of the 
individuals studied in each group (255)• Comparisons 
between Caucasian and Asian populations demonstrated a 
higher e3 frequency in Asians but no other consistent 
differences (256). Within the group of Caucasian 
populations Finns had a significantly higher 64 frequency 
and a lower e2 frequency as compared to all other groups 
(257).
Utermann was the first to observe that the majority 
of apoE2/2 homozygotes, not affected by familial 
dyslipoproteinaemia, still had an increased VLDL- 
cholesterol/triglyceride ratio but their LDL-cholesterol 
levels were lower than the population mean (142) . 
Population studies which were carried out in various
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countries have confirmed that apoE2/2 subjects have 
significantly lower LDL-cholesterol levels than apoE3/3 
subjects. In contrast, apoE4/4 homozygotes have higher 
LDL-cholesterol levels and those of heterozygotes (apoE2/3, 
apoE3/4) fall between the values for the respective 
homozygotes. However, the impact of the e2 and e4 alleles 
on the LDL-cholesterol concentration is unequal. On 
average, the cholesterol reduction associated with e2 is 
more than two times the cholesterol increase linked with 
e4 (255) . In addition, the cholesterol increase in apoE4/4 
subjects is more variable with reports ranging from 
almost no difference to an increase of up to 12%. With 
regard to apolipoproteins the same correlations described 
for LDL-cholesterol were found for apolipoprotein B-100. 
Correlations for plasma apoE concentrations are inverse in 
that apoE2/2 subjects have the highest levels , apoE3/3 are 
intermediate and apoE4/4 levels are lowest (258, 259) .
It has been mentioned previously that in-vitro apoE2 
binding to the LDL-receptor is reduced to less than 2% of 
the binding observed with apoE3 and apoE4 which in cell 
binding assays are indistinguishable. In contrast, in-vivo 
studies in humans with trace-labelled apoE have 
demonstrated a more rapid catabolism of apoE4 as compared 
to apoE3 while the apoE2 clearance was delayed as 
expected (153, 260) . These results are in line with the 
above mentioned correlations between apoE phenotype and 
apoE plasma concentrations. How different apoE isoforms
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interfere with apoB metabolism is not yet entirely clear 
and will be discussed in section 4 .2 .
As apolipoprotein B levels are influenced by the 
apoE polymorphism, it is of obvious interest to see whether 
the apoE phenotype correlates with disorders of lipoprotein 
metabolism or with the risk for coronary heart disease. In 
hypertriglyceridaemia, notably in familial hypertri- 
glyceridaemia, the e2 allele is more frequent (261, 262)
and in hypercholesterolaemia the frequency of the e4 allele 
is increased in comparison with the population at 
large (261, 263). In severe hypertriglyceridaemia (Type V 
hyperlipidaemia with triglyceride >10 mmol/1 and fasting 
chylomicronaemia) the e4 allele frequency was found in two 
studies to be 2.5 to 3.5-fold increased (264, 265).
Only two (266, 267) out of several studies (266- 
271) have shown a higher frequency for the 64 allele 
in CHD patients. In two studies the mean age at the time 
of the first infarction was lower in apoE4/3 than in 
apoE3/2 subjects (266, 269). Another hint for a potential 
atherosclerotic risk associated with apoE4 is given by the 
high frequency of the 64 allele in the Finnish population, 
which coincides with high plasma cholesterol levels and 
a high incidence rate for CHD (257) . Finally, a lower 
overall frequency for the apoE4 phenotype has been reported 
in healthy octogenarians and can be taken as an indication 
for a relatively increased mortality associated with the e4 
gene (272). A possible reason for the lack of a stronger
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negative correlation between the e2 allele and CHD is the 
prolonged plasma residence time for VLDL- and chylomicron 
remnants, which may counteract the benefit from low LDL 
concentrations (209, 343). Taken together this evidence 
supports the view that apoE isoforms influence the risk 
for CHD although this effect is rather small. About 7% 
of the inter-individual total variation in cholesterol 
concentrations is associated with the apoE polymorphism, 
whereas less than 3% of the variation in CHD risk may be
ascribed to this gene locus (253, 255).
1.7. What Is The Purpose of This Study?
This thesis sets out to contribute to the
understanding of how genetically determined factors
interact with the metabolism of apolipoprotein B, the most 
important single risk factor for coronary heart disease. 
Two common genetic determinants of apoB metabolism, the 
apoE polymorphism and the Xbal apoB gene polymorphism were 
examined with regard to their impact on apoB metabolism in 
humans. The tools of investigation were turnover studies, 
either covering the whole of the apoB metabolism in plasma 
(ie VLDL-turnovers) or assessing the metabolism of LDL, the 
prevailing apoB containing lipoprotein in normolipidaemics 
as well as in most hyperlipidaemias. Apolipoprotein B 
metabolism was also studied in three genetically determined 
disorders of apolipoprotein B metabolism. These were
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familial hyperchylomicronaemia, familial hepatic lipase 
deficiency and familial hypercholesterolaemia. All of them 
are biochemically well characterised and provide unique 
opportunities to learn more about the significance of 
specific defects for apolipoprotein B metabolism as a 
whole. All metabolic studies were analysed on the basis of 
a metabolic model for apoB metabolism. This allowed 
testing of the validity of the model and led to suggestions 
for further developments.
2. METHODS
2.1. Apolipoprotein E Preparation by Preparative Gel 
Electrophoresis
Apolipoprotein E was prepared by a modified version 
of the method of Meunier et al. (284).
2.1.1. Preparation of samples
(a) Preparation of VLDL
250 ml of plasma were obtained by plasmapheresis
from a subject with plasma triglyceride concentration > 1.5
mmol/1. Total VLDL (d < 1.006 kg/1) was prepared by 
ultracentrifugation in a Beckman Ti60 rotor for 16 h at
36,000 rpm, 10°C. The supernatant VLDL (10-15 ml) was 
collected and dialysed against 0.01% EDTA, pH 7.4 at 4°C.
(b) Preparation of apo-VLDL
VLDL was delipidated at -20°C with ten volumes of 
ethanol:ether (3:1) twice and finally with ether once. The 
moist protein pellet was resolubilised in 6-12 ml of 
either:
(i) 0.1 M Tris, 3% SDS, 1% DTT, pH 6.7
(ii) 0.1 M Tris, 3% SDS, pH 8.2
Resolubilisation took place overnight at room temperature 
with gentle shaking.
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Samples resolubilised in buffer (i) were used for 
apolipoprotein E preparation. The protein solution was 
heated in a boiling water bath for 3-5 min and subsequently
glycerol was added to a final concentration of 20%. 20 ul
BPB solution were added as a colour marker. This
apolipoprotein preparation was aliquotted (2 ml) and could 
be stored at -20°C for several weeks.
(c) Dansylation of apo-VLDL
Samples resolubilised in buffer (ii) were used to 
produce dansylated apoproteins, which were used as markers 
on preparative electrophoretic gels (285). 2 ml of the
protein solution were mixed thoroughly with 40 ul of
10% dansyl chloride in acetone. This was incubated in a 
boiling water bath for 2 min. Then 0.02 g of DTT were 
added and the sample boiled for another 1 min. Thereafter, 
it was dialysed against 200 ml 0.1 M Tris, 3% SDS, 1% DTT, 
pH 6.7. Finally glycerol was added up to a final 
concentration of 10%. Aliquots of 250 ul were stored at 
-20°C for up to several months.
2.1.2. Preparative gel electrophoresis
The separation of VLDL apolipoproteins was carried 
out on a vertical acrylamide slab gel (14 cm x 14 cm x 
0.3 cm). The stacking gel was 1 cm high and had a 
concentration of 3.5% acrylamide in 0.06 M Tris, 0.1% 
SDS, pH 6.7. The separation gel concentration was 14%
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(w/v) acrylamide in 0.5 M Tris, 0.1% SDS, pH 9.1. Both 
gels contained bisacrylamide in a concentration 2 .5% 
(w/w) of the acrylamide concentration. Polymerisation of 
gels was initiated by addition of 0 .2% (w/v) ammonium
persulfate and 0.03% (v/v) TEMED.
The running buffer was 49 mM Tris, 380 mM glycine, 
0.1% SDS, pH 8.3. VLDL apolipoprotein preparation (2 ml) 
were applied on the stacking gel in a large central trough. 
As marker for VLDL apolipoproteins 100 pi of dansylated 
apo-VLDL were placed in each of the two lateral slots. For 
initial determination of molecular weight a 50 /al aliquot 
from a protein calibration kit was added to the apo-VLDL 
marker. Electrophoresis was performed at 100 V with a 
40 mA current for the first 1.5 h and at 200 V, 80 mA for 
another 3 h.
Dansylated lipoproteins were visualised under UV 
light ( = 254 nm). The fluorescent bands, which had been
identified as apoE by molecular weight calibration, were 
located at both margins of the separation gel (Fig. 5). A 
horizontal strip of gel containing apoE bands at both ends 
was excised under UV light control and put on top of a 
vertical agarose slab gel held by a bottom layer of a 3.0% 
acrylamide plug gel. Concentration of agarose (low 
standard -mr; Biorad) was 0.8% in 0.24 M Tris, 0.1% SDS, 
pH 6.7. The same buffer was used for the plug gel.
Fig. 5:
Apo B
Apo E
Apo; C
Preparative SDS-gel electrophoresis after 
separation of VLDL apolipoproteins. ApoB, apoE 
and apoC are visualised in UV light by 
dansylation. A central gel section containing 
apoE has been removed for apoE preparation.
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2.1.3. Preparation of apolipoprotein E
Protein was transferred from the acrylamide. gel to 
the agarose gel by a 2 h electrophoresis at 70 mA. The 
protein was detectable in the agarose gel as a refringent 
band which was sliced out and placed in an ultracentrifuge 
tube. After centrifugation in a Beckman Ti60 rotor at
40,000 rpm for 20 min, apoE was recovered in 1-2 ml of 
supernatant.
The apoE solution was lyophilised and successively 
extracted twice with 20% TCA and once with acetone in order 
to remove SDS and salt (28). The precipitated protein was 
resolubilised in saline or in sample buffer for IEF.
2.1.4. Preparation of ^-^^I-labelled apolipoprotein E
(a) Preparation of TMU-soluble apo-VLDL
VLDL was prepared as described above. 2 ml VLDL 
were warmed up to 37°C and mixed with an equal volume of 
TMU. After another 30 min at 37°C the sample was 
centrifuged (3000 rpm, 20 min) and the fluid phase 
containing non-apoB lipoproteins recovered. The solid apoB 
pellicle was discarded (286). Protein was precipitated 
from the water/TMU phase by incubation with five volumes 
of chloroform:methanol (1:1) for 4 h at 4°C with gentle 
rocking. After centrifugation protein was washed with ether 
and resolubilised in 0.5 ml saline (0.9% NaCl in water).
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Protein concentration was determined by the optical density 
at 280 n m .
(b) Radioiodination of TMU-soluble apo-VLDL
2 ml resolubilised protein were mixed with 0.5 ml 
1 M glycine, pH 10, and 2 mCi 125j . Finally IC1 (25 nm/jil) 
was added at a molar ratio of 1:1 with regard to protein 
(molecular weight of protein assumed as 29 nM equivalent 
to 1 mg) . During addition of IC1 the _ reagent mixture 
was gently shaken to enhance an even distribution (287). 
Iodination was followed by an overnight dialysis against 
0.1 M Tris, pH 6.7, for removal of free 125jodine. The 
solution of labelled proteins was then made 3% for SDS and 
1% for DTT, boiled for 3 min in a water bath and finally 
made 10% for glycerol.
This sample was applied on a preparative SDS- 
acrylamide gel as described above. Protein bands could be 
detected with a Geiger-Muller tube, with maximal counts in 
regions where dansylated apo-VLDL bands could be visualised 
under UV light.
ApoE preparation from the acrylamide gel was 
identical with the procedure described for unlabelled 
protein.
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2.2. Production of a Monoclonal Antibody Against Apolipo- 
protein E
2.2.1. Immunisation of mice
300 jig apoE solubilised in 600 jil saline were mixed 
thoroughly with 180 jil complete Freund's adjuvant until a 
creamy homogenous suspension was obtained. Ten mice were 
each injected intraperitoneally with 200 i^l containing 
20 pg apoE. After two weeks a booster injection, with 
incomplete Freund's adjuvant was applied. Dosage and route 
of injection were identical to the first injection.
Two weeks later the animals were anaesthetised with 
ether and 1-2 blood spots from the tail vein were collected 
on filter paper for antibody-binding tests. Three days 
before splenectomy for cell fusion (see 2.3.) a third apoE 
injection (20 jig) without adjuvant was administered into 
the tail vein.
2.2.2. Antibody-binding tests
Specific antibodies in murine plasma or cell culture 
medium were determined by a solid phase antibody-binding 
test (288) .
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(a) Solid phase anti-mouse y-immunoglobulin
This was prepared using carbonyldiimidazole 
activated Sepharose-CL 4B as described by Chapman et al . 
(289, 290) .
(b) Antibody-binding test from blood spot
A 6 mm disc was punched from the filter paper dried 
bloodspot and incubated overnight in 300 P1 PBS, 10% sheep 
serum. Plasma was eluted at an estimated dilution of 
1:150. Further dilutions of 1:450 and 1:1350 were prepared 
in the same buffer. Aliquots (100 pil) were taken in 
duplicate for each dilution and 200 pi PBS containing 125j_ 
apoE (about 20,000 cpm) were added. Samples were mixed 
thoroughly and incubated at room temperature overnight. 
Then 200 P1 solid phase anti-mouse y -immunoglobulin was 
added and incubated on an orbital shaker for another 1 h. 
After three washes with saline plus 0.2% Tween 20 
radioactivity in the Sepharose pellet was determined and 
expressed as percentage of initial radioactivity. Non­
specific binding of 125I-apoE was determined in controls 
containing saline instead of plasma.
(c) Antibody-binding and displacement test from cell
culture medium
Cell culture supernatant was diluted 1:3, 1:9 and 
1:27 with PBS. Sheep serum was added to a final 
concentration of 6 .6%. Aliquots (100 pi) were incubated 
with 50 pi 1 25I-apoE (20,000 cpm) and either (a) 50 pi 
saline or (b) 50 pi unlabelled apoE at a concentration of
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50 ^ jg/ml. After overnight incubation the same procedure 
was followed as described in the previous paragraph. 
Samples (a) provided results for antibody-binding whereas 
samples (b) accounted for antibody displacement by excess 
of unlabelled apoE. The former is given as percentage of 
the initially added radioactivity. The latter is the 
difference between specific binding with and without excess 
apoE, expressed as percentage of the binding without 
unlabelled apoE.
2.2.3. Fusion protocol for myeloma-lymphocyte hybrid cells
Murine myeloma cells and spleen lymphocytes obtained 
after apoE immunisation were fused to form hybridoma cells 
following a modified protocol from Fazekas et al . (291).
Two independent cell fusions with lymphocytes obtained from 
the same animal were performed in parallel.
(a) Myeloma cells
Myeloma cells (X63-Ag8-653) were grown up in 25 cm2 
flasks, then transferred into 75 cm2 flasks until about 
100 x 106 cells were obtained. Cells were collected, 
centrifuged (800 rpm, 10 min) and washed twice with RPMI- 
1640 and finally suspended in 10 ml RPMI-1640.
(b) Spleen lymphocytes
The spleen of an immunised mouse was dissected under 
aseptic conditions and placed in a Petri dish containing 
10 ml RPMI-1640. By teasing the organ a cell suspension
was prepared, which was allowed to settle a few minutes in a 
test tube. The cell suspension was centrifuged (800 rpm, 
10 min) and cells were resuspended in 10 ml RPMI-1640.
(c) Preparation of murine peritoneal macrophages
Three mice were killed by exposure to ether vapour.
The abdominal skin was dissected and 5 ml RPMI-1640 
were injected intraperitoneally. After gentle massage of 
the abdomen RPMI-1640 was withdrawn slowly. Peritoneal 
washings from three mice were pooled and centrifuged 
(800 rpm, 10 min). Cells were diluted in 100 ml 
hybridisation medium (see below) or RPMI-1640 to 
approximately 30,000 cells/ml.
(d) Fusion protocol
(i) Hybridisation medium: 20% FCS, 2 mM L-glutamine 
100 U/ml penicillin, 100 ug/ml streptomycin, 2.5 pg/ml 
fungizone, 2X HAT.
(ii) Polyethylene glycol solution: 5 ml RPMI-1640 
were added to 10 g PEG-1500 and heated in a 50°C water bath 
until all PEG was dissolved. 0.1 M NaOH was added to 
adjust to pH 7.0. Total volume was made up to 20 ml with 
pre-warmed RPMI-1640 to give a final PEG concentration of 
50%. Sterilisation was performed by membrane filtration or 
autoclav (15 min).
(e) Fusion procedure
5 ml aliquots of suspensions of myeloma cells and 
lymphocytes were mixed and centrifuged. The supernatant 
was removed quantitatively and the cell pellet was placed
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in a water bath at 37°C. 0.8 ml PEG solution was added
dropwise over 1 min (approximately 1 drop/3 sec) under 
constant shaking. 1 ml of pre-warmed RPMI-1640 was added 
in the same way followed by another 9 ml RPMI-1640 over 
5 min. Cells were centrifuged and resuspended in 120 ml 
pre-warmed hybridisation medium containing macrophages 
(approximately 30,000 cells/ml). This cell suspension was 
distributed on five 96-well plates with 200 ^ul aliquots per 
well by means of a multiwell transfer device (Transplate). 
Plates were sealed with transparent adhesive tape and 
incubated at 37°C for 10-14 days.
2.2.4. Screening and cloning of hybridoma cell lines
(a) Screening of hybridoma cell lines for antibody
secretion with antigen-coated plates
Hybridoma cell lines were screened for secretion of 
apoE-specific antibodies by a qualitative enzyme-linked 
immunosorbent assay (ELISA) using apoE-coated cell culture 
plates (292).
(i) Preparation of protein-coated plates: TMU-
soluble apo-VLDL was prepared as described previously. 
Non-apoB protein derived from 2 ml VLDL was dissolved in 
0.3 ml of 0.05 M sodium carbonate buffer, pH 9.6 and 
protein concentration was measured by the Lowry 
method (293). Protein concentration was adjusted to 
2 yug/ml and aliquots of 150 pi per well were dispensed on
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96 well cell culture plates. Plates were-incubated for 4 h 
at room temperature, emptied and filled with 3% BSA, 0.05 M 
sodium carbonate buffer, pH 9.6. After another 3 h 
incubation plates were emptied again, covered with 
transparent foil and stored at -20°C until required.
(ii) Screening for anti-apoE antibodies: Plates
coated with TMU-soluble apo-VLDL were rinsed with PBS, 
0.05% Tween 20, pH 7.4 and 100 jal of cell culture 
supernatant were added. After 3 h of incubation wells were 
rinsed as above, then 100 pi of a 1:100 dilution of anti- 
mouse-IgG, linked to horseradish peroxidase were added. 
Following another 1 h incubation wells were washed three 
times and 100 p1 of colour reactant was added. The colour 
reactant which released a soluble dye was made up as 
follows: 0.04% o-phenylenediamine-dihydrochloride, 0.012%
hydrogen peroxide (30% v/v) in 0.05 M citric acid, 0.01 M 
disodium-phosphate buffer, pH S.o . Wells containing anti- 
apoE antibodies showed a colour development from yellow to 
dark orange within 5 min of addition of colour reactant.
(iii) Cloning anti-apoE producing hybridoma cell 
lines: Cell lines secreting anti-apoE antibodies had 
to be cloned to ensure that the antibody originated from 
a single hybridoma cell. Cell lines which were found 
to secrete anti-apoE antibodies were placed into 2 ml 
wells together^' with 2 ml RPMI-1640 containing peritoneal 
macrophages and grown up until approximately 50% 
confluence. 100 yul of this cell suspension were
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transferred into each of the eight wells of the far left 
row of a 96-well plate which previously had been primed 
with 100 pi of RPMI-1640 per well. By subsequent transfer 
of 100 pi aliquots per well from one vertical row to the 
next, working from left to right, a serial dilution of 
cells ranging from 1:2 to 1:212 was carried out. After 
addition of another 100 ^ul of RPMI-1640, containing 
peritoneal macrophages, the plate was sealed and incubated 
for 7-14 days at 37°C. Then six vertical rows with the 
lowest cell concentrations were screened for anti-apoE 
antibodies. Cells in the highest dilution still positive 
for anti-apoE antibodies were assumed to be monoclonal.
(b) Screening of hybridoma clones for anti-apoE antibody
secretion
(i) Preparation of apoE-nitrocellulose test strips: 
Nitrocellulose strips with bound apoE were used for anti- 
apoE antibody screening. They were prepared in the same 
way as apoE Western blots (see 2.3.2.), except for the 
following modifications: 0.5 ml of plasma were delipidated 
in ethanol:ether twice. Delipidated proteins were 
resolubilised in 2-3 ml of sample buffer and 1 ml plus 
20 pi BPB-marker was applied on top of an IEF gel which was 
prepared with an even surface without sample wells. Strips 
from the vertical margins and from the centre of Western 
blots were tested for apoE in order to locate the position 
of apoE on the blot. The apoE carrying area was excised 
and sliced into strips (approximately 2.0 cm x 0.1 cm)
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which were used as test strips in the assay described 
below.
(ii) Anti-apoE antibody assay with apoE test strips: 
50 of cell culture medium were transferred from each
well into 3 ml test tubes containing 450 jil saline, 0.05% 
Tween 20, 10 mM Tris, pH 7.4. An apoE-nitrocellulose test
strip was added to each test tube and was incubated for 2 h 
on an orbital shaker. The nitrocellulose strip was washed 
with buffer (same as above) and then incubated with 0.5 ml 
of a 1:100 dilution of anti-mouse-IgG-HRP conjugate. 
Finally, after another 2 h incubation, test strips were 
washed once more and apoE-binding antibodies were 
visualised by addition of 1 ml of colour reactant.
2.2.5 Production of murine ascites containing monoclonal
anti-apoE antibodies
A hybridoma clone producing an anti-apoE antibody 
was transferred from a cloning plate into a 25 cm^ flask 
and grown up in 5 ml RPMI-1640 in the presence of 
peritoneal macrophages. After 7-14 days cells were 
centrifuged (800 rpm, 10 min) and resuspended in six 0.5 ml 
aliquots RPMI-1640.
Six mice (female, approximately 20 g) which had been 
primed by an intraperitoneal injection of 0.5 ml pristane 
1-3 weeks earlier were injected with 0.5 ml of the above 
cell suspension (5 x 105 to 8 x 1 0 6 hybridoma cells) into
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the peritoneal cavity. Thereafter their weight was checked 
every second day and when weight had increased by 5-10 g 
ascites fluid was collected via a peritoneal cannula. This 
procedure was repeated a maximum of two times. The ascitic 
fluid was centrifuged (3000 rpm, 10 min), aliquoted 
(250 pi) and stored at -20°C. Serial dilutions of the fluid 
ranging from 1:10^ to 1:10^ were tested with apoE strips as 
outlined above.
2.2.6. Storage of Cells
Hybridoma cell lines not used for intraperitoneal 
reinjection directly after cloning were resuspended in FCS, 
10% DMSO at a concentration of 10^ cells per 0.5 ml and 
stored in liquid nitrogen.
Cells were reactivated by thawing in a 37°C water 
bath. 10 ml of ice-cold RPMI-1640 were added immediately 
and cells were then centrifuged and resuspended in RPMI- 
1640 for counting and viability testing (Trypan Blue). 
After another centrifugation cells were resuspended 
in RPMI-1640, containing macrophages, and grown up as 
described above.
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2.2.7. Immunoglobulin Classification of Monoclonal Anti­
bodies
Monoclonal antibodies from cell supernatants were 
characterised by a commercially available isotyping kit 
(Serotec) based on agglutination of antibody-labelled red 
cells.
2.3. Phenotyping of ApoE Isoforms
ApoE isoforms were differentiated by a combination 
of isoelectric focussing and Western blotting. The method 
applied was a combination of the procedures published by 
Menzel et al. (294) and Havekes et al . (295).
2.3.1. Separation of apolipoproteins by isoelectric
focussing
(a) Delipidation of plasma samples
10 1 of plasma were injected into 2.5 ml of
ethanol:ether (3:1) and kept at -20°C overnight. After 
centrifugation (3000 rpm, 10 min) the precipitated protein 
was washed with ether and finally dissolved in sample
buffer (6 M urea, 0.1 M Tris, 5% beta-mercaptoethanol, 1%
DSS, pH 10) . After 30 min at 4°C the samples were ready 
for application on an IEF gel.
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(b) Delipidation of VLDL
VLDL was prepared from 5 ml of plasma and 
delipidated (see 2.1.1.). The moist protein pellet was 
dissolved in 0 .5-1.0 ml sample buffer as described above.
(c) Isoelectric focussing procedure
Vertical acrylamide slab gels, 8 M urea, pH 4-6, 
were used for IEF of delipidated plasma specimens. Slab 
size was 14 cm x 14 cm x 0.15 cm. Acrylamide concentration 
was 5.0% (w/v) and bisacrylamide accounted for 2.5% (w/w)
of the acrylamide content. The ampholyte mixture added 
was composed of equal volumes of ampholyte pH 4-6 from 
LKB (Bromma, Sweden) and Serva (Heidelberg, FRG) and 
20% ampholyte pH 3-10 (Serva). The final ampholyte 
concentration of IEF gels was 1.0%. TEMED at a 
concentration of 0.6% (v/v) and ammonium persulfate 0.17% 
(w/v) were added to initiate polymerisation. Acrylamide 
concentration of IEF gels was increased to 8.5% when 
delipidated VLDL was examined. Eighteen sample wells were 
formed per slab gel and 30 jil of sample were placed in each 
well and overlayered with layering solution (80% sucrose, 
5% ampholyte). For isoelectric focussing a vertical 
electrophoresis slab gel unit from Hoefer Scientific 
Instruments was used. The top buffer tray was filled with 
0.02 M NaOH, the bottom electrolyte solution was 0.1 M 
H 3PO4 . Electrical power applied for IEF was limited to 3 W 
per slab gel, ie voltage was set at maximal 250 V and 
current at maximal 24 mA for two slabs run in parallel.
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After 15 h the voltage was increased to 500 V for another 
1 h. The procedure was carried out at room temperature 
with water cooling.
(d) Protein staining of IEF gels
Proteins were stained on acrylamide gels after IEF 
by a modification of the method of Malik et al . (296).
Staining solution was prepared as follows: 3 g of
Coomassie Blue G-250 were dissolved in 150 ml water at 
80°C. Then 75 ml of 3 N H2SO4 were added slowly under 
constant stirring and heated at 80°C for another 10 min. 
Subsequently the solution was passed through filter paper 
and adjusted to pH 5.5 with 10 M KOH. Finally 0.25 g DSS 
and 25% (w/v) TCA were added.
Gels were transferred after IEF into 10% TCA for 
30 min and then incubated under gentle shaking in staining 
solution at 60-70°C for 1-2 h. For destaining gels were 
incubated under the same conditions in 20% ethanol for 4 h. 
Gels could be kept in 7.5% acetic acid for several weeks.
2.3.2. Western blotting of apolipoprotein E
(a) Electro-blotting of proteins
Following IEF, proteins were electrophoretically 
transferred from acrylamide slab gels to nitrocellulose 
membranes as originally described by Towbin et al. (297). 
IEF gels were recovered from the vertical slab gel 
apparatus and equilibrated for 30 min in transfer buffer
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(198 mM glycine-25 mM Tris, 20% methanol, pH 7.9). For 
electro-blotting the Trans-Blot Cell from Biorad was used. 
Nitrocellulose sheets were cut to size and laid on IEF gels 
with intimate contact. Both gel and membrane were placed 
in the electrophoresis cell in a way that the gel was 
facing the cathode while the membrane was facing the anode. 
Electrotransfer was performed in transfer buffer (see 
above) at 100 V, 400 mA for 3 h at 4°C with water cooling,
(b) Immunostaining of apolipoprotein E
ApoE which was bound to the nitrocellulose membrane 
was detected by sequential incubation with an apoE-specific 
antibody, followed by an IgG-binding antibody linked 
to HRP, which in turn catalysed a colour reaction. 
Incubations were carried out on an orbital shaker at room 
temperature. The buffer for all incubations and washes was 
saline, 10 mM Tris, 0.05% (v/v) Tween 20.
Following electro-blotting nitrocellulose blots were 
transferred into a 3% (w/v) aqueous solution of skimmed
milk powder for 30 min. Blots were washed (15 min) and 
then incubated for 2 h in 20 ml of a 1 :10^ to 1 :10^ 
dilution of an anti-apoE antibody preparation. This was 
either murine ascites fluid containing a MAB or polyclonal 
goat antiserum. A second wash was followed by another 2 h 
incubation with 20 ml of a 1:100 dilution of either an 
anti-mouse-IgG or an anti-goat-IgG antibody, both 
conjugated to HRP. After a final wash blots were incubated 
with colour reactant.
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The colour reactant which produced an unsoluble dye 
was made up as follows: 60 mg 4-chloro-naphthol was
dissolved in 10 ml of methanol and mixed with 60 ml saline
containing 30 F1 hydrogen peroxide (30% v/v) directly prior 
to use.
ApoE was clearly detectable on blots as dark blue 
bands after incubation for about 15 min. Blots were then 
washed, dried and stored in the dark.
2.4. RFLP Analysis of the Apolipoprotein B Gene
The methods in this section were applied as
described by Maniatis et al. (304) unless stated
t
otherwise.
2.4.1. Preparation of DNA
DNA was prepared from blood leucocytes by the Triton 
X-100 lysis method essentially as described by Kunkel et 
al. (298) .
10 ml of blood were collected into EDTA tubes and 
stored at -20°C until DNA was prepared. After thawing the 
samples were kept on ice. Blood cells were mixed with 
80 ml of ice-cold lysis buffer (0.32 M sucrose, 10 mM Tris, 
5 mM MgCl2 , 1% Triton X-100, pH 7.5). After centrifugation 
(10,000 rpm, 10 min, 4°C) the pellet of white cells was 
resuspended in 4.5 ml 75 mM EDTA and mixed gently using a
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disposable plastic Pasteur pipette. 250 pi of 10% SDS and
250 pi of proteinase K (2 mg/ml) were added and the mixture
incubated overnight at 37°C.
The sample was extracted with liquid phenol (water-
saturated) , centrifuged (10,000 rpm, 5 min, 20°C) and the
DNA-containing aqueous upper phase collected using a bent 
Pasteur pipette. This was followed by two extractions with 
5 ml chloroform:isoamylalcohol (24:1). Addition of 0.5 ml 
of 3.0 M sodium acetate and 11 ml ethanol (100%) caused the 
DNA to precipitate. The precipitate was transferred into a
1.5 ml Eppendorf tube. After a short centrifugation the 
remaining ethanol was removed and DNA was dissolved in 
0.5 ml of TE-buffer (10 mM Tris, 1 mM EDTA, pH 7.6) at 4°C 
over 2-3 days. The DNA solution was then stored at -20°C 
for up to several months.
2.4.2. Endonuclease digest of DNA
DNA dissolved in TE-buffer was diluted 1:50 with 
water and the optical density (OD) determined at 260 nm. 
The OD2 5o~reac^in9' multiplied by 2500 gives the DNA 
concentration in ug/ml. Simultaneous reading of OD2 8O 
provides a measure for protein and phenol contamination 
of the DNA preparation. The OD26o/^D280 ratio for 
sufficiently pure DNA is greater than 1.6.
A 5 pg aliquot of DNA plus an aliquot of distilled 
water to a total volume of 40 p1 was added to the following
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reagent mixture: 2 pi 0.1 M spermidine, 5 pi enzyme buffer 
(10 x concentrate, as supplied by the enzyme manufacturer) 
and 20 units (usually 2 pi) of the appropriate endonuclease 
(Xbal, EcoRI or MspI). This was incubated at 37°C
overnight. After addition of another ten units (1 pi) of 
enzyme, samples were incubated for a further 5 h at 37°C.
2.4.3. Separation of DNA fragments by agarose electro­
phoresis
DNA fragments resulting from an endonuclease digest 
were separated by agarose electrophoresis.
(a) Preparation of an agarose gel
0.8 g agarose (gelling temperature 36°C) were
dissolved in 100 ml TAE-buffer (40 mM Tris-acetate, 1 mM 
EDTA) by cooking for about 2 min in a microwave oven. 
After cooling to about 50°C the warm agarose solution was 
poured into a mould formed by a perspex plate
(113 cm x 11 cm) sealed with autoclave tape along the 
edges. Twelve wells for sample application were formed by 
an appropriate comb before the gel was set. For flat bed 
electrophoresis the gel was covered by TAE-buffer to a 
depth of about 1 mm.
(b) Agarose electrophoresis
50 pi of DNA sample were mixed with 10 pi of loading 
buffer (BPB and xylene cyanol in 5 x TAE-buffer, 50%
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glycerol) and applied in one of the sample slots of an 
agarose gel. For calibration of DNA fragments X  -phage 
markers (2-23 kb, 0.5 yug) were applied in a separate well. 
Electrophoresis was carried out at 40 mA overnight. After 
electrophoresis the gel was stained by transfer into a 
plastic dish with 200 ml distilled water and 50 jal ethidium 
bromide (10 mg/ml). DNA was visualised under UV light as 
an orange band across the gel, representing numerous DNA 
fragments sorted according to their size. The A  -markers 
showed as distinct bands of known molecular weight.
2.4.4 Southern blotting
DNA fragments were transferred from agarose to nylon 
membranes by capillary blotting, a procedure first 
described by Southern et al. (299). After electrophoresis 
the agarose slabs were successively incubated with the 
following solutions: (a) denaturing solution (0.5 M NaOH,
1.5 M NaCl) for 30 min, twice and (b) neutralising solution 
(1.5 M Tris, pH 5.5) for 30 min, twice.
Capillary blotting was performed as shown in Fig. 6 . 
Transfer buffer was 10 x SSC (1.5 M NaCl, 0.15 M sodium 
citrate, pH 7.5). Capillary flow was limited to the 
agarose gel and the nylon membrane by plastic strips 
separating the edges of the gel from the membrane and paper 
towels on top of it. After overnight blotting the nylon 
filter was washed with 2 x SSC and air dried. The dry
Fig. 6 :
Weight
Glass plate
Paper towel wads
■Paper towels
Whatman 3MM 
- Nitrocellulose filter 
Gel
Glass plate
Buffer
Experimental arrangement for preparation of a 
Southern blot.
(Modified from: Davis LG, Dibner MD, Battey JF: 
"Basic methods in Molecular Biology". 
Elsevier, New York, 1989)
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filter was irradiated for 3 min on an UV transluminator to
*
covalently bind the DNA.
2.4.5. Preparation of a 3^ P -labelled genetic probe
Genetic probes for the apoB gene were re-isolated 
from bacterial plasmids. Plasmid DNA was prepared by the 
alkaline lysis method using a 250 ml broth culture 
incubated overnight. 10 ^ug of plasmid DNA was digested 
using the appropriate enzyme to release the cloned human 
DNA from the plasmid backbone. The fragments were 
separated on a low melting point agarose gel and the probe 
region excised from the stained gel with a sterile scalpel. 
Single stranded DNA was obtained when agarose containing 
the probe was boiled for 3 min in a water bath.
For labelling the gene probe by random priming the 
following reagent mixture was incubated at 37°C for 5 h: 
25 pi DNA (denatured genetic probe) , 1 0 pi oligo-labelling 
buffer (see Reference 300) , 1 u^l BSA (20 mg/ml) , 5 pi 32P_ 
dCTP, 0.3 i^l Klenow (large fragment of DNA polymerase I),
8 .5 pi water. 32P_laben ed DNA and free 32P_dCTP were 
separated on a Sephadex G-50 column (NICK-column, 
Pharmacia) equilibrated with TE-buffer, 0.1% SDS. 100 i^l 
fractions were collected and the peak fractions pooled. 
The equivalent of 3 x 106 cpm was used to prepare 5 ml of 
hybridisation mix.
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2.4.6. Hybridisation of Southern filters
Prehybridisation solution was made up as follows: 
1.50 ml 20 x SSC, 0.50 ml 50 x Denhardt's solution, 0.25 ml 
10% SDS, 2.74 ml water, 10 p 1 salmon sperm DNA (10 mg/ml,
denatured by 5 min boiling in water bath). Hybridisation 
solution had the same composition, except that 50 pi of
denatured salmon sperm DNA and denatured 32p_iabelled 
gene probe (3 x 10^ cpm) were added. Denaturing of the 
32p-probe was carried out just before use by boiling for 
3 min and cooling rapidly on ice. Apolipoprotein B 
polymorphisms as defined by the restriction enzymes Xbal, 
EcoRI and MspI were detected: (a) by hybridising the two
Xbal fragments designated X]_ (8.6 kb) and X2 (3.5 kb) with 
the 3.5 kb probe pABC3.5; (b) in an EcoRI digest by
hybridising the two fragments Ri (10.5 kb) and R2 (12.5 kb)
with the cDNA probe pAB3 and (c) after digestion with MspI 
by probing with PH2, a 2 kb Hind III fragment subcloned 
from an apoB genomic recombinant. With the latter multiple 
hybridising fragments could be demonstrated (305). Those
of about 2.6 kb were designated M]_ and those of about
2.2 kb were designated M2 (section 3.7., Fig. 45) .
A Southern blot (approximately 100 cm2) was placed in 
a heat-sealable bag together with 5 ml of prehybridisation 
solution, the bag was sealed after careful elimination of
air bubbles and incubated at 65°C for 4 h in a
hybridisation oven. The prehybridisation solution was
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replaced by hybridisation solution and incubation was 
continued for another 12 h. After hybridisation blots were 
successively washed in 200 ml of the following solutions:
2 x SSC, 0.5% SDS for 10 min, at room temperature
- 2 x SSC, 0.1% SDS for 15 min, at room temperature
2 x SSC, 0.5% SDS for 60 min, at 65°C
2 x SSC, 0.5% SDS for 30 min, at 65°C.
Blots were finally air-dried, wrapped in cling film and 
applied to an x-ray film (Kodak X-mat S) . After 3-10 days 
storage at -70°C the film was developed. DNA fragments 
binding the labelled gene probe were detectable as black 
bands.
2.5. VLDL-Turnover Studies
The metabolism of large and small VLDL was 
investigated following protocols previously published by 
Shepherd, Packard et al. (154, 172). The multicompart- 
mental kinetic model used to calculate kinetic rate 
constants and protein fluxes was basically the same as 
published previously (301).
2.5.1. Cumulative gradient ultracentrifugation
ApoB containing lipoproteins in plasma were 
subtractionated into large VLDL or VLDL^ (Sf 60-400), small 
VLDL or VLDL2 (Sf 20-60), IDL (Sf 12-20) and LDL (Sf 0-12)
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by a modification of the cumulative gradient centrifugation 
technique described by Lindgren et al. (302) . The density 
of 2 ml of plasma was increased to d = 1.118 kg/1 by 
addition of 0.341 g NaCl. This was layered over a 0.5 ml 
cushion of d = 1.182 kg/1 NaBr solution in a Beckman SW40 
rotor tube and above it a discontinuous NaBr gradient 
ranging from d = 1.0988 kg/1 to d = 1.0582 kg/1 was placed 
as detailed in Fig. 7. Prior to gradient building 
centrifuge tubes were coated with polyvinylalcohol in order 
to obtain a wetable inner surface (282). Densities of salt 
solutions were checked with a digital densitometer.
For subfractionation of .apoB-containing lipoproteins 
the rotor was centrifuged at 39, 000 r p m ' for 1 h 38 ,min at 
23°C and decelerated without braking. VLDL^ was removed in 
the top 1.0 ml which was replaced with 1.0 ml of d = 1.0588 
kg/1 solution before continuing with the separation. 
VLDL2 was then recovered with the top 0.5 ml of the 
gradient following centrifugation at 18,000 rpm for 15 h 
41 min at 23°C. IDL was prepared from the top 0.5 ml after 
centrifuation at 39,000 rpm for 2 h 35 min and finally LDL 
was isolated from the top 1.0 ml after further 
centrifugation at 30,000 rpm for 21 h 10 min.
ml 
12 r
10
kg/1 (23 °C ]
1.0588 
1.0641
1.0722
1.0790
1.0860
1.0988
1.1180 4—  
1.1820
Plasma
Fig. 7: Discontinuous NaBr-gradient as used for the
subfractionation of apoB containing lipoprotein 
by ultracentrifugation.
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2.5.2. Preparation of radiolabelled VLDL subfractions
(a) Subtraction of total VLDL
Total VLDL was prepared from 250 ml of plasma as 
detailed in paragraph 2.1.1. VLDL from subjects with 
plasma triglyceride concentration higher than 2 mmol/1 
was diluted with saline to a concentration corresponding 
to a triglyceride concentration of 1.5 mmol/1. This was 
necessary to avoid VLDL]_ carry-over into the VLDL2 
subfraction and to confine variation of VLDL concentrations 
so that a standardised protocol for VLDL radioiodination 
could be applied. 12 ml of this VLDL were then adjusted to 
d = 1.118 kg/1 by addition of solid NaCl -and VLDL]_ (Sf 60- 
400) and VLDL2 (Sf 20-60) prepared as described above.
(b) Trace-labelling of VLDL subfractions
Radiolabelling was carried out by the IC1 method as
modified by Bilheimer et al. (287). 2 ml VLDL were mixed
with 0.5 ml 1 M glycine, pH 10 and 2 mCi of radioactive 
carrier-free sodium iodide. Then 6 pi IC1 (25 nM/yal) were 
added with gentle shaking. Usually VLDL]_ was labelled with 
131j and VLDL2 with 125j^ Unbound radioiodine was removed 
by dialysis against three times 2 1 saline.
Labelled VLDL were sterilised by filtration through 
plasma primed 0.45 yam disposable filters. Radioactivity 
concentration (yjCi/ml) was calculated by counting 
radioactivity in 10 pi of labelled VLDL and comparing to 
125I and 131i-simulated standards.
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2.5.3. Analysis of apolipoprotein B in VLDL subfractions
ApoB lipoproteins in Sf 60-400 subtractions were 
analysed by SDS-acrylamide electrophoresis. The method was 
similar to the procedure described previously for 
preparative electrophoresis (2.1.2.).
Delipidated VLDL from 5 ml of plasma was resolved 
in 1-2 ml of 0.5 M Tris, 3% SDS, 1% DTT, pH 9.1 in a
boiling water bath (3 min) . 20 pi BPB and glycerol were
added (final concentration 10%). Slab gels were 3% (w/v)
acrylamide with 2.5% (w/w) bisacrylamide in 0.5 M Tris,
0.1% SDS, pH 9.1. Running buffer was 0.1% SDS, 49 mM 
Tris - 380 mM Gly, pH 8.3. Approximately 20 pg of resol­
ubilised protein were applied per well and electrophoresis 
was carried out at 20 mA until the dye marker was at the
bottom of the slab (approximately 3 h) . Slabs were fixed
in ethanol:water:acetic acid (9:9:2) for 2 h, stained in 
0.0025% Coomassie Blue in 10% acetic acid (48 h) and 
destained in 10% acetic acid (28) .
2.5.4. Protocol for VLDL-turnovers
250 ml of plasma were collected from a fasting 
subject by plasmapheresis. VLDL subfractions were prepared 
and labelled with radioactive iodine by the above procedure 
which took altogether two-and-a-half days. On the third 
day after sampling, autologous ^ 1 1-VLDL^ and -*-25j-VLDL2
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were reinjected at 8.00 h into the fasting donor subject. 
10 ml blood samples were collected 10 min, 30 min, 1 h,
1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h and 14 h after 
injection. The first meal was taken after the 10 h sample 
was drawn. During the following twelve days 10 ml fasting 
bloods were taken each morning.
ApoB-containing lipoproteins (VLDL]_, VLDL2 , IDL and 
LDL) were prepared from 2 ml plasma aliquots as described 
(see 2.5.1.).
All subjects participating in the study were 
prescribed KI (60 mg thrice daily) for three days prior to 
and one month after isotope administration in order to 
minimise thyroidal sequestration of radioiodide.
2.5.5. Determination of apoB-specific radioactivity
ApoB was isolated from lipoprotein preparations by 
precipitation with TMU as published by Kane et al . (286).
TMU was redistilled before apoB precipitation 
(boiling point 176°C). Lipoprotein solutions, obtained by 
cumulative gradient centrifugation, were adjusted to 37°C 
before an equal volume of prewarmed TMU was added. After 
vigorous mixing the samples were kept at 37°C for 30 min 
and centrifuged (3000 rpm, 20 min). The TMU/water phase 
was removed carefully and the remaining apoB pellicle was 
delipidated with ethanol:ether (3:1) at -20°C overnight 
followed by ether for 2 h at -20°C. ApoB was dried at 40°C
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and finally hydrolysed in 1.0 ml 0.5 M NaOH at 40°C 
overnight. Radioactivity was counted in a y* -counter and 
the protein concentration of the specimen was determined by 
a modified Lowry procedure (Biuret reagent made up in water 
instead of 0.1 M NaOH). From these results specific 
activities for apoB were calculated as cpm/mg.
2.5.6. Determination of lipoprotein composition and of pool
sizes for apoB-containing lipoproteins
VLDL]_, VLDL2 , IDL and LDL were prepared from 12 ml 
plasma pooled during the course of a VLDL-turnover. Total 
cholesterol, free cholesterol, triglycerides, phospho­
lipids, total protein and TMU-soluble protein were measured 
for each lipoprotein fraction.
Total cholesterol and triglycerides were determined 
by enzymatic colorimetric assays on a Hitachi 704 
autoautoanalyser. Free cholesterol was measured by the 
same cholesterol assay, omitting the cholesterol esterase 
step, and phospholipids by another enzymatic colorimetric 
test. Protein was measured by modified Lowry procedures: 
to clarify the reaction mixture 1 mg/ml DSS was added to 
the Biuret reagent for total protein; for TMU-soluble 
proteins 40 /al TMU were added to calibration standards and 
a fixed volume of 80 /al was used for protein 
determination. Standard curves were obtained with aqueous
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solutions of human serum albumin.
All results were expressed as into mg/dl units and 
the composition of a lipoprotein species was calculated as
g/100 g. ApoB concentrations were calculated as the 
difference between total protein and TMU-soluble protein 
and expressed in mg/dl or as percentage of total protein. 
Plasma volume was either calculated by isotope dilution or 
assumed to account for 4% of the body weight. Pool sizes 
for apoB in the four lipoprotein fractions were derived
from plasma volume and apoB plasma concentrations.
2.5.7. Modification of the VLDL-turnover procedure for
studies in patients with hyperchylomicronaemia
Prior to cumulative gradient centrifugation for 
preparation of apoB containing lipoprotein subfractions, 
chylomicrons had to be removed from plasma of lipoprotein 
lipase deficient patients. 5 ml aliquots of plasma were 
overlayered with 1.5 ml of saline and centrifuged in a 
Beckman Ti40.3 rotor for 30 min at 10,000 rpm, 10°C. After 
removal of the top 1.5 ml, containing chylomicrons, the 
remaining sample was mixed and the procedure described 
above was repeated once again.
When VLDL and VLDL2 were prepared for radio­
labelling as metabolic tracers, the following protocol was 
adopted: chylomicrons were removed from plasma as
explained and total VLDL was prepared as detailed in 
paragraph 2.1.1. The VLDL preparation (15-20 ml) was then
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diluted 1:10 with plasma infranatant from the VLDL
centrifugation. VLDL^ and VLDL2 were prepared and labelled 
as outlined in paragraph 2.5.2.
2.5.8 Kinetic analysis of VLDL-turnover data by the SAAM
29 program
On the basis of measurements of pool sizes for apoB- 
containing lipoproteins and apoB-specific radioactivities 
10 min after tracer injection radioactivity of apoB
recovered from each of the four lipoprotein fractions at 
various time points was calculated as percentage of the 
dose initially injected. These data defined apoB decay 
curves which together with the mass of apoB protein 
associated with each lipoprotein fraction were used to 
simulate apoB metabolism in a multicompartmental model
computed by the SAAM 29 program (311) . This model is 
depicted in Fig. 8. The main features are:
(a) Large VLDL-apoB (Sf 60-400) is represented as a 
single species which decays monoexponentially. It is 
either catabolised directly or transferred to the range of 
small VLDL (Sf 20-60).
(b) Within the Sf 20-60 lipoproteins there is an 
arrangement akin to that described by Berman et al (94) . 
Some apoB enters a catabolic cascade and is converted to 
IDL (Sf 12-20) while other material is diverted into a pool 
of slowly metabolised remnant particles (compartment 6).
VLDL t
(Sf 60-400)
VLDL 2
(Sf 20-60)
IDL
(Sf 12-20)
LDL
(Sf 0-12)
Fig. 8: Mult icompartmental model describing the
metabolism of apoB containing lipoproteins 
in plasma.
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The lipolytic cascade comprised two or three sub­
compartments. The apoB metabolism of patients with hepatic 
lipase deficiency (see 3.5.) and with familial 
hypercholesterolaemia (see 3.6.) was analysed with a model 
containing three serial subcompartments. As it was found 
that a third subcompartment had little impact on the curve 
fitting process, this was abolished and all other analyses 
were performed with a simplified model with only two serial 
VLDL2 subcompartments.
(c) There is input of newly synthesised apoB into the 
Sf 20-60 density range (compartment 5) . This is required 
because firstly not all of the Sf 20-60 apoB mass can be 
accounted for by transport from large VLDL and secondly 
when large and small VLDL are labelled separately the
kinetics of appearance of these tracers in IDL and LDL apoB 
are different. Usually the radioactivity derived from 
labelled small VLDL appears more quickly in these denser 
fractions and accounts for a higher proportion of their 
mass. Provision is made for this phenomenon by 
incorporating in the model parallel pathways for VLDL^ and 
VLDL2 and their metabolic products appearing in IDL and
LDL.
(d) In the IDL range it was necessary to postulate the
existence of a slowly metabolised species (compartment 9).
(e) LDL was distributed between two plasma pools,
accounting for different metabolic properties of LDL 
derived either from VLDL]_ (compartment 11) or from VLDL2
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(compartment 10). This model provided an acceptable fit to 
the observed data. The calculated kinetic rate constants 
were with few exceptions defined with a fractional standard 
deviation (FSD) of less than 0.1 (see Tables 1-16, 1-17, 
1-18) . For VLDL2 an<^  f°r ^ L  the calculated masses derived 
from the kinetic analyses were within 10% of the measured 
values. With VLDL]_ and LDL deviations of calculated masses 
from measured pools were often greater. Reasons for these 
discrepancies will be discussed in paragraphs 3.4.3. and
4.4.
2.5.9. Nutritional Records
In order to estimate the impact dietary factors may 
have on lipoproteins during metabolic studies, participants 
were asked to record and weigh all food and fluid intake 
over seven days. These protocols were analysed by 
"Microdiet" (309), a computer program designed to calculate 
the percentage distribution of caloric intake from protein, 
carbohydrates and fat. In addition, total daily calories 
ingested are given and the ratio of polyunsaturated over 
saturated fatty acids (P:S ratio) is derived from analysis 
of the fat consumed.
Body weight was evaluated by an obesity index, ie 
the ratio of weight over height squared (310). An index 
smaller than 25 is considered to be normal, and an index of 
25-30 represents slight obesity.
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2.6. LDL-Turnover Studies
Trace-labelled native LDL and cyclohexanedione- 
modified LDL were used to study the LDL-receptor mediated 
and the LDL-receptor independent LDL catabolism in humans 
by turnover techniques published first by Shepherd et 
al. (27).
2.6.1. LDL preparation by rate-zonal centrifugation
LDL was isolated by rate-zonal centrifugation as 
described by Patsch et al. (303). 60 ml of plasma were
adjusted to d = 1.300 kg/1 by addition of 18 g NaBr. 
Separation of apoB-containing lipoproteins was carried out 
on a linear density gradient ranging from d = 1.000- 
1.200 kg/1 in a Beckman Til4 zonal rotor centrifuged at
45,000 rpm for 110 min at 10°C. The rotor was unloaded 
with heavy salt solution (d = 1.200 kg/1) and fractions 
from the LDL peak were pooled and concentrated by pressure 
filtration to a protein concentration of about 4-6 mg/ml.
2.6.2. Preparation of labelled native and cyclohexanedione-
modified LDL
1 ml of concentrated LDL solution was mixed with 
250 jdl 1 M glycine, pH 10, and 1 mCi of either 131I or 
125I. IC1 (25 mM/yul) was added under gentle shaking at a
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molar ratio of 25:1, the molecular weight of LDL being 
assumed as 640,000, ie equivalent to 1.56 nM. Non-reactant 
radioactive iodine was eliminated by passing samples over a 
PD-10 column (Pharmacia). 131I-LDL was modified by binding 
to cyclohexanedione according to the method of Mahley et 
al. (25). 2 ml of LDL (protein concentration 2-5 mg/ml)
were mixed with 4 ml of 0.15 M cyclohexanedione in 0.2 M 
sodium borate buffer, pH 8.1, and incubated for 2 h at room 
temperature under constant stirring. Non-reactant 
cyclohexanedione was eliminated by a second passage over a 
PD-10 column. Sterile filtration was carried out as 
described previously.
2.6.3. Protocol for LDL-turnover studies in humans
LDL used for tracer preparation (125j _l d l  and 131j- 
CHD-LDL)was isolated from 120 ml of blood and reinjected 
into the donor subject. Ten minutes after injection and 
then daily over a two-week period 10 ml blood samples were 
collected. The plasma clearance of each tracer was 
followed by counting radioactivity at the end of the study 
in 2 ml aliquots of plasma and decay curves for native and 
CHD-modified LDL were constructed by plotting the 
percentage of initially injected dosage left in plasma 
against time. KI tablets were prescribed as explained 
before.
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2.6.4. Kinetic analysis of LDL-turnover data
LDL metabolism was analysed on the basis of a two 
subcompartment model (319). One subcompartment representing 
the intravascular pool was in equilibrium with a second 
extravascular compartment. Mass input and fractional 
catabolic rate were linked to the intravascular 
compartment. This model assumes LDL-apoB is kinetically 
homogeneous and that degradation only occurs from the 
plasma compartment. It provided a .good fit to the observed 
LDL decay curves.
2.7. Ethical Considerations
All subjects gave informed consent to the study 
which met the requirements of the Ethical Committee of each 
host institution.
2.8. Statistical Methods
Differences between metabolic parameters as 
presented in Tables 11 and 12 were analysed by a non- 
parametric correlation test (Whitney-Mann).
Compositional data (Table 9) and cholesterol means 
(Table 24) were compared by the unpaired t-test.
Differences in gene frequencies (Table 24) were 
evaluated by the X^-test.
90
2.9. Materials and Equipment
Chemicals and reagents came from the following 
sources: 4-Chloro-l-naphthol, Dithiothreitol (DTT),
Dansylchloride, o-Phenylenediamine-dihydrochloride, Sperm­
idine, Salmon Sperm DNA, Agarose (gelling temp. 36°C), 
Pristane, Iodine-monochloride (IC1) Trishydroxymethylamino- 
methane (Tris) and Tetramethylurea (TMU) were obtained from 
Sigma (St Louis, MO, USA); N,N,N',N'-Tetramethylethylene- 
diamine (TEMED) and Decyl-sodiumsulphate from Eastman Kodak 
(Rochester, NY, USA); Agarose (low standard -mr) and
Coomassie Blue G-250 from Biorad (Richmond, CA, USA);
Phenol (water saturated) from Rathburn Chemicals Ltd
(Walkerburn, Scotland); 32-Phosphorus-labelled Cytidine- 
triphosphate (32p-dcTP) from DuPont (Boston, MA, USA) ;
12510^,30 and fr0m Amersham (Amersham, England) ;
Ampholyte pH 4-6 (Ampholine) from LKB (Bromma, Sweden); 
Ampholyte pH 4-6 and pH 3.10 (Servolyte) from Serva 
(Heidelberg, West Germany); RPMI 1640 medium and HAT 
solution from Flow Laboratories (Irvine, Scotland)
Cyclohexanedione from Fluka (Buchs, Switzerland). All other 
chemicals were of analytical grade and obtained from
British Drug House (Poole, England).
A molecular weight calibration kit for proteins 
("Rainbow Marker") was purchased from Amersham (Amersham, 
England); Sepharose-CL-4B, Nick-Columns and PD-10 Columns 
from Pharmacia (Uppsala, Sweden); Freund's Adjuvant from
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Difco Laboratories (Detroit, MI, USA); an agarose gel
electro-phoresis system from Corning Medical (Paolo Alto, 
CA, USA).
Biological and biochemical products were supplied by 
the following companies: Endonucleases (Xbal, EcoRI, MspI)
by Anglia Biotech (Colchester, England); Proteinase K and 
enzymatic kits for measurements of cholesterol (CHOD-PAP) 
triglycerides (GPO-PAP) and phospholipids by Boehringer 
(Mannheim, West Germany); Klenow (large fragment of DNA 
polymerase I) by Gibco (Paisley, Scotland); sheep serum
and HRP-anti-mouse IgG by SAPU (Carluke, Scotland); 
myeloma cells (X63-Ag8-653) b y . Flow Laboratories Ltd 
(Rickmansworth, England); an isotyping kit for , mouse 
monoclonal antibodies from Serotec (Oxford, England); an
immunochemical assay for apolipoprotein B from Orion
Diagnostica (Espoo, Finland).
Cell culture plates and the multiwell transfer 
device (Transplate) came from Costar (Northumbria 
Biologicals Ltd, Cramlington, England); sterile filters 
(0.45 i^M) from Millipore (Molsheim, France); filter paper 
(3 MM) from Whatman (Maidstone, England); nitrocellulose 
membrane (BA 85) from Schleicher and Schuell (Dassel, West 
Germany); nylon membrane from Amersham (Amersham, England).
Vertical slab gel electrophoresis was carried out 
with the electrophoresis unit SE 600 from Hoefer Scientific 
Instruments (San Fransisco, CA, USA). For Western blots 
the Trans-Blot-Cell and the power supply Model 200/2.0 from
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Biorad (Richmond, CA, USA) were used. Density gradients 
were made with a six-channel roller pump from Technicon Ltd 
(Dublin, Ireland). Densities of aqueous solutions were 
measured with a digital densitometer (DMA 35) from Paar 
Scientific Ltd (London, UK). DNA hybridisations were 
performed in a hybridisation oven from Bachofer 
(Reutlingen, West Germany). Pressure filtration was 
performed with a concentration cell from the Amicon 
Corporation (Danvers, MA, USA) using XM 300 filters 
from the same manufacturer.
For centrifugations up to 3000 rpm standard table 
centrifuges (rotor r = 15 cm) were used. Centrifugations 
of 5000-15,000 rpm were performed in a J2-21 Beckman 
centrifuge (rotor r = 11 cm). Ultracentrifugations (>10,000 
rpm) were carried out in Beckman ultracentrifuges using the 
specified rotors.
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3. RESULTS
3.1. Production of a Monoclonal Antibody against Apolipo- 
protein E
3.1.1. Preparation of apolipoprotein E
Apolipoprotein E was isolated from delipidated VLDL 
by preparative electrophoresis. Approximately 20 mg of 
VLDL-apoprotein was applied per slab gel. The yield was 
estimated by the preparation of apoE from radiolabelled 
non-apoB VLDL-apoproteins (ie TMU-soluble proteins). 4% to
5% of the initial radioactivity was recovered with apoE. 
As apoB accounts for about 4 0% of VLDL-apoprotein and apoE 
for about 10%, the preparative yield can be estimated as 
approximately 30%. Most of the loss occurred at the TCA- 
precipitation step which followed electrophoresis, as 
indicated by radioactivity counts measured before and 
after this step. The purity of the apoE was demonstrated 
by isoelectric focussing and subsequent protein 
staining (Fig. 9).
3.1.2. Raising of a monoclonal antibody against apolipo­
protein E
Ten mice were injected with apoE as outlined in 
paragraph 2.2.1. The antigenic response of each animal was
Apo E
Fig. 9:
Apo C
1
Isoelectric focussing of apoE (1), prepared 
from VLDL, and VLDL apolipoprotein (2) . Minor 
bands in the apoE range represent mono- and 
disialated apoE.
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determined by a blood spot antibody-binding test (see 
2.2.2). Specific antibody-binding ranged from 6-27% of the 
initial radioactivity. The spleen from the animal with the 
best antibody production was used for cell-fusion with 
myeloma cells. Two independent fusion procedures were 
carried out. When hybridoma cells were screened for anti- 
apoE antibody secretion, 94 wells out of a total of 960 
were positive. These antibody producing cells were further 
characterised by an assay for specific antibody-binding and 
for antibody-binding displacement by excess of unlabelled 
apoE. The displacement assay measures antibody affinity, 
large displacement indicating high binding affinity. It 
thereby differentiates the cause of specific antigen- 
binding, which can be either high-affinity antibodies in 
relatively low concentrations or low-affinity antibodies in 
higher concentrations.
The culture medium of fifteen wells showed in at 
least one out of three dilutions specific binding of more 
than 10% (mean 24% ± 12%) and binding displacement of 
more than 50% (mean 61% ± 6.5%). Supernatants from 
eleven wells showed specific apoE bands, when used as first 
antibody source with an apoE-Western blot. The four wells 
failing to produce bands in this assay were those with the 
lowest specific apoE-binding. To ensure that the anti-apoE 
antibodies tested were monoclonal, ie originated from a 
single hybridoma cell, cells from five wells with the best 
binding characteristics were cloned twice. Finally, two
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hybridoma cell lines were obtained producing two monoclonal 
antibodies against apoE. These were designated ME 21 and 
ME 59. Both were classified from cell supernatant as IgG]_ 
antibodies.
3.1.3. Production of antibody containing ascites
Pristane-primed mice were injected intraperitoneally 
with monoclonal hybridoma cells. Six to ten mice were used 
at one time for each cell line. Ascites yield varied 
considerably from 1 ml up to 23 ml per animal. Ascites 
dilutions ranging from 1:102 to 1:10^ were tested with apoE 
Western blots. Antibody titers - as defined by the highest 
dilution still producing apoE bands on blots - varied from 
1:102 to 1:10^. Animals producing only modest amounts of 
ascites fluid (< 3 ml) tended to have higher antibody 
titers. Ascites volume and antibody titer were dependent 
on both the specific cell line and on the number of 
injected cells. With one cell line (ME 59) a small ascites 
volume (1.4 ± 0.3 ml/animal, n = 6) with a high antibody 
titer (> 1:104) was recovered after injection of 5 x 10^ 
cells/animal, in contrast to much larger ascites volumes 
(8.6 ± 6.0 ml/animal, n = 8) with a lower titer (1:102 to 
1:102) after injection of only 5 x 10^ cells/animal.
With the other cell line (ME 21) 2.8 + 1.0 ml
ascites were produced per animal (n = 5) with a titer of 
1:10^ after injection of 7 x 10^ cells/animal.
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3.2. Apolipoprotein E Polymorphism and its Correlation with
Plasma levels of Cholesterol and Apolipoprotein B
Blood samples were collected as part of a cholesterol 
screening programme. Screening for elevated plasma 
cholesterol levels was opportunistic and Health Centre 
based. The apolipoprotein E polymorphism of 717 randomly 
selected subjects and of 858 subjects with cholesterol
levels between 5.0 and 6.2 mmol/1 was determined from 
plasma by isoelectric focussing and Western blotting 
(Fig. 10). Results for percentage distributions of apoE 
phenotypes and apoE allele frequencies are presented in 
Table 5 together with results obtained from population
studies published by other investigators. The gene 
frequencies observed in the randomly selected group 
resemble closely the frequencies reported from other
Caucasian populations, notably from Aberdeen (266) and from 
Munster, West Germany (268) . In the group with plasma 
cholesterol levels ranging from 5.0-6.2 mmol/1 the gene 
frequency for was lower (-25%) and the frequency for e4 
was higher (+34%) than in the random group, which can be 
explained by the association between apoE phenotypes and 
plasma cholesterol concentrations.
Mean values for plasma cholesterol were calculated 
for each apoE phenotype in the randomly selected study 
group. ApoE phenotypes could be ranked by their cholesterol
Fig. 10: Apo E phenotypes as visualised by Western blots.-
From left to right: Apo E 3/2, E 4/4, E 3/3, E 3/3, 
E 2/2, E 3/2, E 4/3, E 3/3, E 3/3, E 4/3, E 4/3,
E 4/3, E3/2.
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levels as follows: E3/2 < E2/2 < E3/3 < E4/3 < E4/4.
Thus, the apoE2 allele was associated with lower plasma 
levels (-4%) and the apoE4 allele with higher plasma levels. 
(+8%) as compared to apoE3 homozygosity (Table 6). In 
accordance with the reported gene frequencies the median 
cholesterol concentration for the whole of the population 
screened was determined as 5.6 mmol/1, which is between 
the means for apoE3/3 and apoE4/3 subjects. The low e2
frequency observed in the group with cholesterol levels of
5.0-6.2 mmol/1 is due to the fact that the cholesterol mean 
for apoE3/2 subjects is close to the lower limit of
5.0 mmol/1 whereas the mean for apo'E4/3 individuals is well
within the range of sampling.
ApoE phenotypes were correlated with plasma apoB 
concentrations in the same sense as with plasma 
cholesterol. In apoE3/2 subjects they were 16% lower and 
in apoE4/3 subjects they were 10% higher than in apoE3/3 
homozygotes. Numbers for apoE2/2 and apoE4/4 homozygotes 
were insufficient for proper evaluation.
Generally, these findings are well in line with the 
correlations found in a population study in the 
Netherlands (231). Total cholesterol concentrations there 
differed by -3.7% for apoE2/2, but only +3.7% for apoE4/4 
subjects. ApoE3/3 individuals presented with a mean 
cholesterol level of 5.6 ± 1.02 mmol/1. Differences for 
total apoB in plasma were given as -32% for apoE2/2 and +9% 
for apoE4/4 as compared to apoE3/3 subjects.
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3.3. Apolipoprotein B Metabolism in Normolipidaemic
Subjects Homozygous for ApoE2, ApoE3 or ApoE4
The metabolism of large (Sf 60-400) and small 
(Sf 20-60) VLDL was studied in normolipidaemic subjects 
homozygous for apoE2, apoE3 or apoE4. For each of the 
three groups five individuals were selected from 
participants in a cholesterol screening programme.
3.3.1. Characterisation of the study group
The median cholesterol level of the population from 
which participants for the study were selected was 
5.6 mmol/1. For recruitment of volunteers a plasma 
cholesterol range of 5.0-6.2 mmol/1 (median ± 10%) was 
observed. The mean lipid and lipoprotein concentrations of 
the five subjects in each group of apoE homozygotes are 
given in Table 7. Total cholesterol is only marginally 
lower in apoE2/2 and 10.5% higher in apoE4/4 individuals as 
compared to apoE3/3 individuals. This is similar to the 
correlation between total plasma cholesterol and apoE 
phenotypes observed in the population at large (Table 6).
LDL-cholesterol levels differed by -20% for apoE2/2 
and +11.8% for apoE4/4 subjects in comparison to apoE3/3 
subjects. Differences for apoB plasma concentrations were 
even more pronounced: total apoB levels were decreased by
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-49% in apoE2/2 and increased by +11.5% in apoE4/4
subjects, as compared to apoE3/3 homozygotes (Table 8). The
disproportionate changes observed in apoE2/2 homozygotes 
in total cholesterol and in LDL-cholesterol and apoB are
evidence for major alterations within the spectrum of apoB
containing lipoproteins in these subjects. This is further 
specified by the differences in percentage distribution of 
apoB among plasma lipoproteins as shown in Table 8. While 
percentage values for apoE3/3 and apoE4/4 are very similar 
and the LDL subfraction in both cases accounts for more 
than three-quarters of plasma apoB, concentrations of 
VLDL]_, VLDL2 and IDL are relatively increased in apoE2/2 so 
that LDL represents less than half of the apoB in the 
plasma.
Compositional data for apolipoprotein B containing 
lipoproteins are given in Table 9. The figures for apoB 
quantify the relative contribution of apoB to the total
protein component of the four lipoprotein subfractions. 
There is little difference between apoE2/2, apoE3/3 and 
apoE4/4. Data for lipid composition show that VLDL2 
in apoE2/2 is relatively cholesteryl ester-rich and 
triglyceride depleted, indicating the accumulation of 
ft-VLDL particles within the VLDL2 density range. 
These findings, complemented by a VLDL—cholesterol/total 
triglyceride ratio of < 0.6 are the hallmarks of 
dyslipoproteinaemia, typical of the apoE2/2 phenotype. The
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triglyceride content of LDL is significantly higher in 
apoE2/2 and significantly lower in apoE4/4 subjects as 
compared to apoE3/3 controls.
Some physical characteristics of the three groups 
investigated are presented in Table 10. The female/male 
relation was different in the apoE2/2 group as compared to 
the two other groups. Body weight in the apoE3/3 group was 
about 20% higher than in the two other groups, which - in 
addition to the slightly higher body mass index - was due 
to a larger average body size (+6%).
Before starting metabolic studies, volunteers were 
advised to carry on with their usual diet in order to 
maintain steady-state conditions. Diets were recorded by 
seven days weighed intake protocols. Daily energy intake 
(kcal/day) varied considerably between the study groups, 
probably because of different occupations in addition to 
the differences in body weight. Food composition, in 
contrast, was quite similar, in particular with regard to 
the percentage of dietary fat. The polyunsaturated: 
saturated fatty acid ratio (P/S ratio) showed substantial 
variation within each group ranging from 0.1-0.8. It is 
assumed that variation of the P/S ratio within this range 
has no major effect on lipoprotein metabolism.
The above characterisation of subjects participating 
in this study is based on mean values for the three apoE 
phenotype groups. Individual data for each subject are 
presented in Table 1-1 to 1-9.
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3.3.2. VLDL-turnover studies in apoE2/2, apoE3/3 and
apoE4/4 subjects
VLDL turnover studies were carried out as described 
in paragraph 2.5. Results are shown in Figs. 11-13 as 
percentages of initially injected radioactivity recovered 
as either VLDL]_ (Sf 60-400) , VLDL2 (Sf 20-60) , IDL (Sf 12- 
20) or LDL (Sf 0-12) plotted against time. The curve
patterns displayed in these figures were obtained after 
simultaneous injection of radiolabelled VLDL]_ (top panel) 
and differentially labelled VLDL2 (bottom panel).
Mean percentage values as measured in the five
subjects homozygous for apoE3 are plotted versus time in 
Fig. 11 and means for five apoE4/4 subjects are illustrated 
in Fig. 12. Means (AVG), standard deviations (STD) and
fractional standard deviations (FSD) are given in Tables 
1-10 and 1-11. FSD were usually well below 0.5. Four of 
the five apoE2/2 subjects showed a similar curve pattern 
which was distinctly different from the curves observed 
in apoE3/3 and apoE4/4 subjects. These curves are 
illustrated in Fig. 13 and the corresponding data are
listed in Table 1-12. The fifth subject (P.M.) homozygous 
for apoE2 displayed decay curves which were different from 
all other normolipidaemic subjects studied (Fig. I- 5). 
Therefore, her data were not included when apoE2/2 averages 
were calculated. Individual VLDL-turnover curves for each 
subject are shown in Figs. 1-1 to 1-15. In order to compare
Apolipoprotein B Metabolism in Apo E3/3
Metabolism of VLDL (Sf 60-400)
□ VLDL1 
♦ VLDL 2
♦ LDL
Time (hours)o 100 200
Metabolism of VLDL (Sf 20-60)
□ VLDL2
2 ’!
Time (hours) 200100o
Lipoprotein decay curves from VLDL]_ and VLDL2 
turnover studies in apoE3/3 subjects (n = 5) . - 
Averages from Table 1-10 A/B of individual data 
as shown in Fig. 1-1 to 1-5.
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Apolipoprotein B Metabolism in Apo E4/4
Metabolism of VLDL (Sf 60-400)
VLDL 1 
VLDL 2 
IDL 
LDL
Time (hours) 200100o
Metabolism of VLDL (Sf 20-60)
VLDL 2
IDL
LDL
Time (hours) 200100o
Fig. 12: Lipoprotein decay curves from VLDL]_and VLDL2
turnover studies in apoE4/4 subjects (n = 5). - 
Averages from Table I-11A/B of individual data 
as shown in Fig 1-6 to 1-10
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Apolipoprotein B Metabolism in Apo E2/2
Metabolism of VLDL (Sf 60-400)
VLDL 1 
VLDL 2 
IDL 
LDL
1000 Time (hours) 200
Metabolism of VLDL (Sf 20-60)
VLDL 2
IDL
LDL
O'1
200Time (hours)100o
Fig. 13: Lipoprotein decay curves from VLDL^ and VLDL2
turnover studies in apoE2/2 subjects (n = 4). - 
Averages from Table 1-12 A/B of individual data 
as shown in Fig. I—11 to 1-14.
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the decay curves obtained for different apoE phenotypes, 
curves for the same lipoproteins were displayed together 
in one diagram (Figs. 14-20).
VLDL]_, injected as tracer, disappeared from the 
plasma compartment rapidly in apoE3/3 and apoE4/4 subjects 
with about 1% of the initially injected dose left after
14 h. In apoE2/2 individuals clearance of this lipoprotein
subfraction was much slower with about 10% remaining in 
plasma after 14 h (Fig. 14) . Basically, VLDL]_ catabolism
could be described by a straight line on semilogarithmic 
paper, indicating a monoexponential decay process. In some 
subjects a second exponential occurred but this accounted 
only for less than 3% of the injected dose.
VLDL2 / derived from VLDL^, was cleared with the
highest rate in apoE3/3 subjects. Clearance in apoE4/4
individuals was slower. After 72 h 0.7% and 1.6%
respectively of the initially injected dose were left in 
the plasma compartment. In apoE2/2 subjects proportionally 
more VLDL^ was transferred into VLDL2 , which in turn was 
cleared at a much lower rate than seen in the other apoE
phenotypes (about 10% left in plasma 72 h after injection)
(Fig. 15).
Transfer of VLDL2 (derived from VLDL]_) to IDL and 
IDL decay were fastest in apoE3/3 individuals. IDL 
clearance in apoE2/2 individuals was slower, although the 
difference towards apoE3/3 subjects was less than with the 
previous two lipoprotein subfractions (3.6% versus 1.3%
VLDL (Sf 60-400)
(injected as tracer) 0 apo E3/3
♦ apo E4/4
n apo E2/2
0‘1
Time (hours)o 5 10 15
VLDL (Sf 20-60)
(derived from VLDL 1)
0 apo E3/3
♦  apo E4/4
■ apo E2/2
Time (hours) 200100o
Fig. 14 and Fig. 15:
Metabolism of VLDLi. - Decay curves for VLDL^ 
and VLDL2 derived from VLDL]_ in apoE3/3, 
apoE4/4 and apoE2/2 normolipidaemic subjects.
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IDL (Sf 12-20)
(derived from VLDL 1)
Q apo E3/3
♦ apo E4/4
B apo E2/2
0 100 Time (hours) 200
LDL (Sf 0-12)
10°
(derived from VLDL 1)
h apo E3/3
•  apo E4/4
n apo E2/2
Time (hours) 200100o
Fig. 16 and Fig. 17:
Metabolism of VLDL]_. - Decay curves for IDL 
and LDL derived from VLDL]_ in apoE3/3, apoE4/4 
and apoE2/2 normolipidaemic subjects.
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VLDL (Sf 20-60)
(injected as tracer)
apo E3/3 
apo E4/4 
apo E2/2
0 100 200
Time (hours)
IDL (Sf 12-20)
10°
(derived from VLDL 2)
□ apo E3/3
♦ apo E4/4
b apo E2/2
Time (hours) 200100o
Fig. 18 and Fig. 19:
Metabolism of VLDL2 • - Decay curves for VLDL2 
and IDL derived from VLDL2 in apoE3/3, apoE4/4 
and apoE2/2 normolipidaemic subjects.
LDL (Sf 0-12)
(derived from VLDL 2)
El apo E3/3
♦ apo E4/4
B apo E2/2
Time (hours)100 200o
Metabolism of VLDL2 • - Decay curve for LDL
derived from VLDL2 in apoE3/3, apoE4/4 and 
apoE2/2 normolipidaemic subjects.
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after 168 h ) . IDL clearance in apoE4/4 individuals was 
intermediate between the rates seen for the two other 
groups (Fig. 16).
In apoE3/3 subjects VLDL]_-derived LDL reached a peak 
of nearly 20% within 48 h. The slope of the following 
decay ,curve was slightly steeper than observed in apoE2/2 
and apoE4/4 subjects. The latter reached the peak of the 
LDL curve at nearly 15% after 72 h. In apoE2/2 subjects 
transfer from IDL to LDL was substantially lower. Less 
than 5% of the injected dosage reached the LDL density 
range (Fig. 17).
With VLDL2 injected as tracer, the following 
observations were made: VLDL2 clearance in apoE2/2
individuals was much slower than observed in apoE3/3 and 
apoE4/4 (1.5% versus 0.1% and 0.3%) respecively (Fig. 18). 
Throughput towards IDL occurred at the same rate, but IDL 
clearance in apoE2/2 and in apoE4/4 subjects was somewhat 
slower than in apoE3/3 subjects (Fig. 19).
The peak of the LDL curve (35% of the injected dose) 
was reached within 48 h by both apoE3/3 and apoE4/4 
subjects. The slope of the LDL curve in apoE4/4 was again 
slightly less than observed with apoE3/3 homozygotes. In 
apoE2/2 individuals only 12% of the labelled precursor 
was transferred into LDL. The slope of the decay curve 
was less well defined. However, it clearly was not steeper 
than the slope of LDL decay curves observed in E3/3 and 
E4/4 subjects (Fig. 20).
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In summary, apoE2/2 subjects differed from apoE3/3 
and apoE4/4 by a markedly slower catabolism of large and 
small VLDL and a significantly reduced transfer of IDL into 
LDL. Differences between apoE3/3 and apoE4/4 subjects were 
much smaller with a tendency for decreased clearance of all 
apoB containing lipoprotein subfractions.
It has been mentioned already that one of the 
apoE2/2 subjects (P.M.) showed lipoprotein decay curves 
with little similarity to the curve pattern observed in 
four other apoE2/2 homozygotes (Fig. I- 5). Her metabolism 
of VLDL^ and VLDL2 was as rapid as observed in apoE3/3 
subjects, but catabolism of IDL and notably of LDL was 
faster than seen in this group. As in the four other 
apoE2/2 subjects IDL to LDL interconversion was impaired 
although to a lesser extent with LDL curves peaking at 16% 
and 23% respectively.
Finally, a comparison of curves for LDL derived either 
from VLDL]_ or from VLDL2 is given in Figs. 21-23. In the 
three study groups two features were consistently observed: 
Firstly, VLDL]_ to LDL transfer occurred at a lower rate 
than transfer from VLDL2 to LDL and secondly, LDL derived 
from VLDL]_ was catabolised more slowly as compared to LDL 
derived from VLDL2 .
LDL Metabolism in E3/3
.01 -4
s LDL,derived from VLDL (Sf 20-60)
•  LDL, derived from VLDL (Sf 60-400)
.001
0 100 200 300
LDL Metabolism in E4/4
.01 □ LDL,derived from VLDL (Sf 20-60)
LDL, derived from VLDL (Sf 60-400)
.001
0 200 300100
TIME (hours)
Fig. 21 and Fig. 22:
Metabolism of LDL derived from VLDL]_ or VLDL2 -^n a-poE3/3 
and apoE4/4 homozygous normolipidaemic subjects.
LDL Metabolism in E2/2
□ LDL, derived from VLDL (Sf 20-60)
LDL, derived from VLDL (Sf 60-400)
.01 -J
.001
3002001000
Time (hours)
Fig. 23: Metabolism of LDL derived from VLDL^ or VLDL2 
in apoE2/2 homozygous normolipidaemic subjects
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3.3.3. Analysis of apolipoprotein B metabolism in apoE2/2,
apoE3/3 and apoE4/4 subjects by computer modelling
The decay curves for the four apoB containing 
lipoprotein subfractions which were discussed in the 
previous section were analysed using the SAAM 29 computer 
program. The model of apolipoprotein B metabolism 
which provides the basis for computer modelling and curve 
fitting is depicted in Fig. 8 and has been described in
paragraph 2.5.8. For comparison of the metabolic behaviour 
of apoB containing lipoproteins each set of individual 
turnover data was analysed using the same kinetic model. 
The computer calculations were aimed at an optimal fitting 
of observed data, ie decay curves as previously described, 
and calculated curves, thus minimising the sum of squared 
differences between the two. Calculated curves were 
derived from observed data on the basis of the kinetic
model. This required the calculation of kinetic rate
constants k(I,J) and masses M(I) for each subcompartment. 
Kinetic rate constants in the above notation describe the 
fractional transfer rate in terms of pools/day for material 
being transferred from compartment J to compartment I. 
Individual values for kinetic rate constants and masses for 
subcompartments are listed in Tables 1-13 for apoE3/3, 
Table 1-14 for apoE4/4 and Table 1-15 for apoE2/2 subjects. 
The quality of the data as defined by fractional standard
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deviations (FSD) can be evaluated from Tables 1-16, 1-17 
and 1-18. The FSD values were usually well below 0.1.
For comparison of the three apoE phenotypic groups, 
averages of the calculated metabolic parameters are 
presented in Table 11. In these comparisons, values 
obtained from apoE3/3 subjects serve as a normal reference,
as the apoE3 allele is by far the most frequent. When
kinetic rate constants from apoE3/3 and apoE2/2 subjects
were compared, the following statistically significant 
differences were revealed: k(0,l), k(0,4), k(8,4), k(0,6), 
k(10,7) and k(ll,8) were all smaller in the apoE2/2
homozygotes than in apoE3/3 homozygotes, whereas k(0,7) and 
k(0,8) were larger in the former as compared to the latter 
(Fig. 24). A comparison of rate constants between apoE4/4 
and apoE3/3 individuals showed only one significant 
deviation. This was observed for k(0,10), which was 
smaller in apoE4/4 as compared to apoE3/3 subjects
(p < 0.01). The only statistically significant difference 
between subcompartment masses was observed for M(ll) with 
apoE2/2 values smaller than values obtained from apoE3/3 
subjects.
From these calculated values the following 
parameters of apolipoprotein B metabolism were derived for 
each of the four apoB containing lipoproteins:
(a) Rate of direct synthesis, which is - steady-state 
conditions prevailing - equal to the sum of the fractional 
catabolic rates multiplied by the plasma pool.
TABLE 11:
Comparison of calculated metabolic parameters in 
apoE2/2, apoE3/3 and apoE4/4 homozygotes
M (1) k (0 ,1) k (2 ,1) M (2) k(4,2) k{6,2)
E2/2, n=4
mean 51 0.3* 3.75 9.5 21.1 0.25
± s ±12 ±0.32 ±1.35 ±4.03 ±3.0 ±0.24
E3/3, n=5
mean 61 5.26* 6.3 18 21.9 0.16
± s ±20 ±4.47 ±1.18 ±5 ±2.7 ±0.11
E4/4, n=5
mean 53 5.87 4.58 18.8 15.1 0.12
± s ±35 ±6.32 ±2.08 ±17.2 ±7.8 ±0.10
E2/2, n=4 
mean
M (4) k (0,4) k (8,4) k(9,4) k(ll,4) M(5)
159 0.03* 0.83** 0.24 0.05 45.8
± s ±44 ±0.04 ±0.10 ±0.14 ±0.04 ±39.2
E3/3, n=5
mean 91 1.61* 2.48** 0.52 0.06 64
± s ±43 ±0.76 ±1.26 ±0.17 ±0.12 ±41
E4/4, n=5
mean 74 1.02 1.23 0.28 0.11 40.8
± s ±33 ±0.86 ±0.63 ±0.12 ±0.18 ±37.0
k(0,5) k (7,5) k (10,5) M (6) k(0,6) M(7)
E2/2, n=4
mean 0 10.2 0.04 5.5 0.28** 165
± s ±4.9 ±0.07 ±1.2 ±0.03 ±64
E3/3, n=5 
mean 2.01 3.33 0.24 3.8 0.62** 94
± s ±1.13 ±1.03 ±0.48 ±1.7 ±0.19 ±54
E4/4, n=5
mean 0 9.68 0 2.6 0.41 141
± s ±4.42 ±1.6 ±0.09 ±54
: p<0 . 05, ** : p<0.025,
k (0 , 7 ) k (10,7) M (8) k(0,8) k(ll,8)
E2/2, n=4
mean 0.84** 0.72* 64 3.11** 0.16**
± s ±0.38 ±0.28 ±47 ±1.58 ±0.28
E3/3/ n=5 
mean 0** 2.41* 120 0.68** 1.26**
± s ±1.36 ±75 ±0.42 ±0.51
E4/4, n=5
mean 0 2.02 83 0.39 0.72
± s ±0.56 ±62 ±0.21 ±0.38
k (0,9) M (10) k (0,10) M (11) k (0,11)
E2/2, n=4 
lean
± s ±0.08 ±109 ±0.06 ±40 ±0.07
mea  0.31 383 0.29 77** 0.18
E3/3, n=5 
mean 0.34 723 0.28*** 702** 0.2
± s ±0.08 ±287 ±0.01 ±402 ±0.03
E4/4, n=5 
lean
± s ±0.08 ±254 ±0.01 ±224 ±0.04
mea  0.24 1165 0.22*** 402 0.17
M (9)
114
±50
105
±24
74
±28
* : p<0.05, ** : p<0.025, *** : p<0.01
©Fig. 24: Kinetic model of apoB metabolism in apoE2/2 
subjects. - Significant differences in comparison 
to apoE3/3 homozygotes are indicated (©, 0, if ) .
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(b) Plasma pool, ie the sum of masses from
subcompartments accounting for each lipoprotein.
(c) Fractional rates for either direct catabolism or for 
transfer to denser lipoproteins.
Averages for the three study groups are presented in 
Table 12, calculated from individual data compiled in 
Tables 1-19, 1-20 and 1-21.
In apoE2/2 subjects fractional rates for direct 
catabolism of VLDL^ and VLDL2 were smaller than observed in 
apoE3/3 subjects. IDL to LDL transfer was significantly 
reduced and direct catabolism of IDL was increased. The 
fractional catabolic rate for LDL was increased but this 
difference between apoE2/2 and apoE3/3 subjects was not 
statistically significant.
In apoE4/4 subjects, direct VLDL2 catabolism was 
also significantly reduced but in contrast to apoE2/2 
subjects this was partly compensated for by an increase of 
the transfer rate from VLDL2 to IDL. This increase however 
did not reach statistical significance. The fractional 
catabolic rate (FCR) for LDL was significantly lower in 
apoE4/4 as compared to apoE3/3 subjects.
The plasma pool of LDL was smaller in apoE2/2 as 
compared to apoE3/3 reflecting the different apoB plasma 
concentrations in these subjects (see Table 8). Direct 
synthesis of VLDL^ and total apoB synthesis were lower 
in apoE2/2 subjects. The same applied for total apoB 
synthesis in apoE4/4. In apoE2/2 subjects these
TABLE 12:
Comparison of apolipoprotein B metabolism in 
apoE2/2, apoE3/3 and apoE4/4 homozygotes
VLDL (Sf 60-400)
direct 
synth. 
[mg/d]
fract. rate of 
plasma direct transfer
pool catab. to VLDL2
[mg] [pools/d]
E2/2, n=4 
mean 
± s
208**
±75
51
±12
0.3*
±0.32
3.75
±1.35
E3/3, n=5 
mean 
± s
693
±240
** 61
±20
5.26*
±4.47
6.3
±1.18
E4/4, n=5 
mean 
± s
423
±168
53
±35
5.86
±6.3
4.58
±2.08
VLDL (Sf 20-60)
direct flux from 
synth. VLDL1
[mg/d]
E2/2, n=4
mean 274 189
± s ±142 ±65
E3/3, n=5
mean 335 386
± s ±179 ±125
E4/4, n=5
mean 260 188
± s ±64 ±7 5
fract. rate of 
plasma direct transfer
pool catab. to IDL&LDL
[mg] [pools/d]
220 0.03** 2.08
±12 ±0.03 ±0.58
176 1.65**'* 2.58
±55 ±0.47 ±0.49
136 0.58* 3.38
±69 ±0.46 ±1.29
* : p<0.05, ** : p<0.025
IDL (Sf 12-20)
E2/2, n= 
mean 
± s
E3/3, n= 
mean 
± s
E4/4, n= 
mean 
± s
LDL (Sf
E2/2, n= 
mean 
± s
E3/3, n= 
mean 
± s
E4/4, n= 
mean 
± s
direct flux from 
synth. VLDL2
[mg/d]
fract. rate of 
plasma direct transfer
pool catab. to LDL
[mg] [pools/d]
447
±125
344
±95
0.97
±0.18
**
0.41** 
±0.15
418
±106
319
±81
0.34 
:0 .14
** 1 .02**
±0.32
379
±97
297
:103
0.18 
:0.09
1.16
±0.32
0- 12)
direct flux from plasma LDL-FCR
synth. IDL&VLDL2 pool
[mg/d]
L
[mg] [pools/d]
142'
±39
458
±86
** 0.28
±0.06
total 
apo 5 
synth. 
[mg/d]
482
±150
**
38
±47
337'
±102
1576
±442
** 0.24
± 0.02
1102
±166
**
19
±37
327
±71
1695
±375
0 .2*
± 0.02
721
±168
* : p<0.05, p<0.025
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differences still persisted when body weight was taken into 
account. The body weight standardised total apoB synthetic 
rate in apoE4/4 subjects, however, was not significantly 
different from the rate of apoE3/3 subjects.
ApoB was synthesised in apoE2/2 subjects in about 
equal proportions either as VLDL^ or as VLDL2 . In apoE3/3 
and in apoE4/4 subjects about two-thirds of the apoB was 
synthesised as VLDL]_ and one-third as VLDL2 . Direct apoB 
synthesis in the LDL range occurred in some individuals of 
the apoE3/3 and the apoE4/4 phenotype but it hardly 
exceeded 10% of the total apoB synthesis.
In summary, in apoE2/2 individuals, the rates for 
direct catabolism of VLDL]_ and VLDL2 are decreased and the 
transfer rate of IDL to LDL is reduced, while the rate of 
direct IDL metabolism is increased. In apoE4/4 subjects 
the rate of direct catabolism of VLDL2 and the fractional 
catabolic rate of LDL are smaller than in apoE3/3 
individuals.
3.4. Apolipoprotein B Metabolism in Familial Hyperchylo-
micronaemia
The VLDL metabolism of two patients with familial 
hyperchylomicronaemia was studied. One subject suffers 
from classical lipoprotein lipase deficiency while the 
other has an inherited plasma inhibitor of lipoprotein 
lipase activity.
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3.4.1. Characterisation of patients
Study participants are characterised by the data 
compiled in Table 13. D.A., a 35 year old male, reported
from his childhood and adolescence repeated bouts of 
abdominal pain and several attacks of acute pancreatitis. 
His plasma triglyceride levels were found to be well above 
20 mmol/1 with cholesterol ranging between 5-10 mmol/1.
His apoE phenotype is apoE4/2. An assay for lipoprotein 
lipase revealed no enzyme activity in this patient.
The triglyceride and cholesterol concentrations 
given in Table 13 were measured during the administration 
of a low fat diet, which was maintained throughout the
metabolic study. Lipoprotein levels were determined after
removal of chylomicrons (see 2.5.7.).
D.S., a 58 year old woman, is a member of a family 
affected by familial hyperchylomicronaemia, which was 
described by Brunzell et a l . (117) (see 1.4.2.). She gave
a history of recurrent abdominal pain since the age of
16 years. Massive hypertriglyceridaemia of about 30 mmol/1
was diagnosed when she presented with eruptive xanthomas 
on the outer aspects of both feet. On physical examination 
the spleen was palpable but the liver appeared to be of 
normal size. Her apoE phenotype is apoE4/3. Adipose tissue 
lipoprotein lipase activity in this subject and in her son 
who also has massive hypertriglyceridaemia was found to be 
increased and in-vitro incubation experiments demonstrated
Ta
bl
e 
1
3
: 
Li
po
pr
ot
ei
n 
Li
pa
se
 
De
fi
ci
en
cy
 
an
d 
He
pa
ti
c 
Li
pa
se
 
De
fi
ci
en
cy
. 
-
Ph
ys
ic
al
 
Pa
ra
me
te
rs
/ 
Pl
as
ma
 
Li
pi
d 
an
d 
Li
po
pr
ot
ei
n 
Co
nc
en
tr
at
io
ns
.
rH rH 00 00• • • •
1—1 O  O o o
A 9 +i +i +1 +1
§  6
«*r 'sr o 00
t-M
o  o CM t—1
rH «H oo t—1
-K rH . . • •
■K r—I N. o  o o rH
J  Q i—1 +1 +1 +1 +i
Q  H  9 cn r- CM oP u s . . • •
o  o CM 00
O  CM 00
lb 1—1 rH O O o
Q  O +  1 +1 +  1 +1in o CO r-
>  O • • • •o o
o  o t—1 T-1
i—i » • • •
fd <—i l—1 T-1 t—1 t-1
4-> O +1 *H +1 + 1
o co rH o
Eh U . • • •
r- e'­ in UO
i—1
■—1 /"\C^
en r~ uo CO
i—1 ' cm in o o
rd tn +  1 +1 +  i +1
-P -h m  o oo i
o u • • • •
Eh Eh o CM rH
rH CM
4J 
>i£l X CM CO CT> cm in• « « • •
0 -H T3 ^  m 00 cm
0Q XU C, CM CM CM CM
S  M +  1
4-1
>ib —
t  DiDi CO CM O 00 CM
(8 *H w
CO CO r- r- rH
+  1
S  w
CO 
(1) p m  oo 00 (Tl rH
&  cd oo in CO 00 rH
C  <L> +  1
>H
<D
CO
sX Ua a
tn s
•rf
rH $
2  h
i M F 8 S 00 CMc •• Q, • •
•H >1 •H >i
<D a H  JT4_> q c CO
o <D o 5) 1-1 ^
M -H ■H -H o m
Qi 0 -k * 4J 0 p
*rH * * 4-1
ft 4h co c ^
Q  Q $  '8 d
o c u  — * * *
VL
DL
,L
DL
 
an
d 
HD
L 
we
re
 
me
as
ur
ed
 
af
te
r 
re
mo
va
l 
of
 
ch
yl
om
ic
ro
ns
.
"L
DL
-C
ho
l"
 
as 
de
te
rm
in
ed
 
by 
th
e 
LR
C-
pr
ot
oc
ol
 
(3
20
) 
in
cl
ud
es
 
LD
L 
(S
f 
0-
12
) 
an
d 
mo
st
 
of
 
ID
L 
(S
f 
12
-2
0)
 
.
110
an inhibitory effect of plasma from these patients on 
normal post-heparin plasma lipolytic activity (117). This 
was taken as evidence that in this family hyperchylo- 
micronaemia is caused by a dominantly inherited plasma 
inhibitor of lipoprotein lipase activity.
Plasma lipid levels, as shown in Table 13, were 
determined under a low fat diet as described for patient 
D .A. Native plasma from D.S. after overnight incubation at 
+4°C, plasma after removal of chylomicrons and plasma 
infranatant after removal of VLDL is shown together with 
normal plasma in Fig. 25.
The relative distribution of apolipoprotein B in 
plasma was found to be very different from normolipidaemic 
controls, whereas apoB plasma concentrations were perfectly 
normal (Table 14). More than 50% of plasma apoB accumulated 
as VLDL]_-apoB. VLDL2 pools were normal in D.A. but 
increasedin D.S. IDL pools were considerably lower than 
normal and LDL-apoB represented only one quarter to one- 
sixth of total plasma apoB.
Compositional studies of the four apoB containing 
lipoproteins revealed an increased triglyceride content 
for all four lipoprotein subclasses at the expense of 
cholesterol and cholesteryl ester. Phospholipid and 
protein compositions were little different from controls 
(Table 15) .
Fig. 25: Plasma from a patient with familial
hyperchylomicronaemia. - I: Native plasma
after 24 h az -i-40C; II: plasma after removal 
of chylomicrons (see paragraph 2.5.7.); Ill: 
plasma infranatant after VLDL preparation; 
n = normal plasma.
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3.4.2. VLDL-turnover studies in familial hyperchylomicron-
aemia
The metabolism of large and small.VLDL was studied 
using a protocol which included a step for chylomicron 
removal (see 2.5.7.) as this massively increased lipo­
protein subfraction would have disturbed the 
subfractionation of the apoB-100 containing lipoproteins. 
VLDLf used for preparation of metabolic tracers was 
analysed by electro-phoresis on 3% SDS-acrylamide gels 
(see 2.5.3.) . Only tracers of apoB-48, which was clearly 
present in total plasma and in chylomicron preparations, 
could be detected in preparations of VLDLf (Fig. 26). This 
is in line with results reported by Meng et al . (352),
where even without centrifugation for chylomicron removal 
little apoB-4 8 was recovered from the VLDL fraction 
(d < 1.006 g/ml) of Type I patients after overnight 
fasting.
Lipoprotein decay curves, as obtained from VLDL- 
turnover studies, are depicted in Fig. 27 for D.A. and in 
Fig. 28 for D.S. ‘The curve patterns from both subjects are 
very similar. Curves for each lipoprotein from patient 
D.A. are shown together with normal controls and with 
curves from a hepatic lipase deficient subject in Figs. 
29-32.
The clearance of large VLDL (Sf 60-400) is markedly 
delayed but that of small VLDL2 is only slightly slower 
than in normolipidaemic controls. In the IDL range less
Apo B 100
Apo B 48
1 2  3 1 2  3
50 u^l 1 00 pi
Pig. 26: SDS-gel electrophoresis of plasma (1),
chylomicrons (2) and VLDL^ (3) from a 
patient with familial hyperchylomicron- 
aemia.- 50 ul and 100 ul were applied 
per lane.
Lipoprotein Lipase Deficiency
Metabolism of VLDL (Sf 60-400) D.A.
VLDL1
VLDL2
IDL
LDL
.001
0 200100
Time (hours) 
Metabolism of VLDL (Sf 20-60)
D.A.
a VLDL2.1
LDL
.01
.001
0 200100
Lipoprotein decay curves from VLDL]_ and VLDL2 
turnover studies in a patient (D.A.) with 
lipoprotein lipase deficiency.
Lipoprotein Lipase Deficiency
D.S.
Metabolism of VLDL (Sf 60-400)
VLDL1
LDL
.001
0 100 200 3 0 0
Time (hours)
D.S.Metabolism of VLDL (Sf 20-60)
VLDL2
IDL
.01:
.001
3 0 00 200100
Fig. 28: Lipoprotein decay curves from VLDL]_ and
VLDL2 turnover studies in a patient (D.S.) 
with familial hyperchylomicronaemia.
VLDL (sf 60-400)
(injected as tracer)
Lpl (-)
HL (-)
.1 Cont.
.01
301
0 20 40 60 80 100
VLDL (sf 20-60)
Lpl (-) 
H L(-) 
Cont.
(injected as tracer)
.01
.001
0 100 200
Time (hours)
Fig. 29 and 30:
Metabolism of VLDL^ and VLDL2 in a patient with 
lipoprotein lipase deficiency (D.A.), a patient 
with hepatic lipase deficiency (G.P.) and in 
normolipidaemic controls (n = 5) .
IDL (sf 12-20)
* Lpl (-) 
B HL (-) 
0 Cont.
derived from VLDL (Sf 20-60)1
.1
.01
001
0 200100
LDL (sf 0-12) ♦ Lpl(-)
HL(-)
Cont.
derived from VLDL (Sf 20-60)
.1
.01
.001
0 200100
Time (hours)
^9* 31 and Fig. 32:
Metabolism of IDL and LDL derived from VLDL2 in 
a patient with lipoprotein lipase deficiency 
(D.A.), a patient with hepatic lipase 
deficiency (G.?.) and in normolipidaemic 
controls (n = 5).
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lipoprotein accumulates than in normal controls, and the 
slope of the decay curve is steeper, indicating an
increased IDL catabolism. The curve for LDL (derived from 
VLDL2 ) peaks at about 20% and falls off rapidly also 
showing an accelerated catabolism of this lipoprotein 
species.
3.4.3. Computer modelling of apolipoprotein B metabolism in
familial hyperchylomicronaemia
When the data from the two metabolic studies of 
apolipoprotein B metabolism in familial hyperchylo­
micronaemia were analysed using the SAAM 29 program, it 
became apparent that the underlying model, as shown in 
Fig. 8, was not adequate for a situation with a massively 
increased VLDL]_ pool size. Less than half of the measured 
VLDLi pool could be accounted for by computer calculation. 
A tendency for underestimating the VLDLi pool size had been 
observed even with computer modelling of turnover data from 
normolipidaemics but this was now greatly exaggerated and 
therefore required a modification of the metabolic model. 
This, however, could not be accomplished easily within
the capacity restraints of SAAM 29, as all available 
subcompartments were employed in the current metabolic
model already. The solution was to create a model for
metabolism of VLDL]_ and VLDL2 and to link this at a second 
stage with the calculations based on the previous model,
113
which showed an acceptable fit for IDL and LDL decay curves 
and pool sizes. The model used for calculations of VLDL]_ 
and VLDL2 metabolism is illustrated in Fig. 33. The new 
feature in this model are three subcompartments accounting 
for VLDL]_, two in serial alignment and one for "remnant" 
particles, which do not rejoin the delipidation cascade. 
With this model calculated masses derived from the kinetic 
analyses were within 20% of the measured values.
It has to be emphasised, that kinetic rate constants 
and pool sizes as determined by these calculations were not 
optimised on the basis of an integral metabolic model. In 
this sense calculated metabolic parameters for these 
turnover studies remain preliminary. Fractional standard 
deviations (FSD) for calculated rate constants were 
considerably higher than those in previously reported 
analyses. A final interpretation requires a more powerful 
computer program, capable of coping with more 
subcompartments at a time than SAAM 29. An advanced 
version of the current program, SAAM 30, will be available 
in the near future. The metabolic data as displayed in 
Figs. 27 and 28 will be re-analysed on the basis of an 
improved metabolic model with three VLDL]_ subcompartments.
The parameters of apolipoprotein B metabolism as 
defined by the currently available kinetic rate constants, 
are summarised in Table 16. The VLDL]_ pool size is more 
than ten-fold increased in both patients (D.A. and D.S.). 
The transfer rate of VLDL]_ to VLDL2 is reduced to about 5%
o o
Q
i  \ooo
VLDL !
(Sf 60-400)
VLDL 2
(Sf 20-60)
Kinetic model for VLDL metabolism in familial 
hyperchylomicronaemia.
TABLE 16:
Apolipoprotein B metabolism in lipoprotein lipase 
deficiency Lpl(-) and in hepatic lipase deficiency HL(-)
VLDL (Sf 60-400) fract. rate
direct plasma direct transfer
synth. pool catab. to VLDL2
[mg/d] [mg] [pools/d]
DA * L p l (-) 1005 787 1.05 0.23
DS * Lpl(-) 960 784 0.74 0.48
Contr. , mean 560 66 5.5 7.6
n=5 ± s ±280 ±44 ±6.4 ±4.7
GP HL(-) 91 9 1.8 8.3
VLDL (Sf 20-60) fract. rate
direct flux from plasma direct transfer
synth. VLDL1 pool catab. to IDL&LD
[mg/d] [mg] [pools/d]
DA * Lpl(-) 150 178 206 0.61 1.76
DS * Lpl(-) 767 377 468 1.5 0.95
Contr. , mean 278 331 191 0.49 2.8
n=5 ± s ±91 ±145 ±91 ±0.13 ±1.2
GP HL(-) 480 74 265 1.08 0.97
IDL (Sf 12-20) fract. rate
direct flux from plasma direct transfer
synth. VLDL2 pool catab. to LDL
[mg/d] [mg] [pools/d]
DA Lpl(-) 0 207 78 0.78 1.87
DS Lpl(-) 0 439 138 0.66 2.51
Contr. , mean 0 441 277 0.52 1.3
n=5 ± s ±204 ±134 ±0.34 ±0.9
GP HL(-) 0 262 886 0.25 0.05
Preliminary data, see paragraph 3.4.3.
LDL (Sf 0-12) total
direct flux from plasma LDL-FCR apo B
synth. IDL&VLDL2 pool synth.
[mg/d] [mg] [pools/d] [mg/d]
DA Lpl(-) 0 301 312 0.96 1155
DS L p l (-) 0 346 289 1.21 1727
Contr.f mean 18 380 1571 0.31 857
n=5 ± s ±36 ±102 ±788 ±0.11 ±349
GP HL(-) 0 43 215 0.21 571
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of the average value observed in normals. Rates for total 
VLDL2 catabolism are not very different from normal 
controls, although the rates for direct catabolism tend to 
be higher and the fractional transfer rates for VLDL2 to 
IDL transfer tend to be lower.
The fractional catabolic rates for IDL are higher 
than in the control group and equal or greater than the 
transfer rate from VLDL2 to IDL. Thus, IDL does not 
accumulate in plasma which is reflected by the low peak of 
the IDL decay curve and the small IDL plasma pool observed 
in patients. The fractional catabolic rate for LDL is 
three to four-fold higher than typical for normolipid- 
aemics. Accordingly, the LDL pool is much lower than in 
controls, in line with results reported before (see 
Table 14.) .
3.5. Apolipoprotein B Metabolism in Hepatic Lipase
Deficiency
Apolipoprotein B metabolism was assessed in a 
Swedish patient with hepatic lipase deficiency by means of 
a VLDL-turnover study (340).
3.5.1. Clinical data characterising the patient
G.P., a 63 year old male, is one of two brothers, 
first described in 1974 as having a new dyslipoproteinaemia
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called hyper-alpha-triglyceridaemia because of a pronounced 
increase of triglycerides in the HDL fraction (118) . Later 
it was discovered that this lipoprotein abnormality was 
due to the absence of hepatic lipase activity in the 
plasma (118) . Besides their disorder of lipid metabolism 
both patients are healthy and show in particular no signs 
of cardiovascular disease. Their parents died at an 
advanced age of unknown causes. The apoE phenotype of G.P. 
was determined as apoE4/3.
Lipid and lipoprotein concentrations from G.P.
are given in Table 13. Mild hypertriglyceridaemia and a
relatively high HDL level were the only deviations from
normal. However, agarose electrophoresis revealed the
presence of ft-VLDL in the lipoprotein subfraction of
d < 1.006 g/ml (Fig. 34).The plasma apoB concentration was
also normal whereas apoB distribution among lipoproteins
was distinctly different not only from normal controls
but also from the two patients with no plasma lipoprotein
lipase activity (Table 14). More than 60% of plasma apoB
accumulated in the IDL density range. VLDL2~apoB
/
concentration was doubled and LDL-apoB concentration 
was only one-fifth of the usual value. Rate zonal 
ultracentrifugation of plasma from G.P. showed a continuous 
profile of the lipoproteins in the density range of 1.006- 
1.063 g/ml. The peak of the main apoB-lipoprotein was 
clearly shifted to the left towards lighter densities as
HDL
F ig.
VLDL
LDL
IB - VLDL
n
34: Lipoprotein agarose gel electrophoresis with
plasma (1) and VLDL (2) from a patient with 
hepatic lipase deficiency; n = normal plasma.
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evidenced by comparison with a radioactively labelled 
LDL-marker prepared from normal plasma (Fig. 35).
Compositional data for apoB containing lipoproteins 
from three measurements are presented in Table 15. Large 
and small VLDL had normal triglyceride contents but were 
reduced in cholesteryl esters and enriched in free 
cholesterol. Triglycerides were markedly increased in IDL 
and LDL, at the expense of cholesteryl esters. Phospholipid 
and protein composition were normal.
3.5.2. VLDL-turnover study in a patient with hepatic lipase
deficiency
The results of a VLDL-turnover study are illustrated 
in Fig. 36 and in Figs. 2 9-32, where decay curves for 
individual lipoproteins are compared with those from normal 
controls and from a subject with lipoprotein lipase 
deficiency.
In hepatic lipase deficiency VLDL]_ catabolism is 
slightly slower than in normal controls but far less 
affected than in lipoprotein lipase deficiency. Fourteen 
hours after injection of the VLDL]_ tracer, 0.8% of the 
initial dosage remained in the plasma as VLDL]_-apoB in 
normals compared to 4.0% in hepatic lipase deficiency and 
40% in lipoprotein lipase deficiency.
VLDL2 catabolism was delayed in hepatic lipase 
deficiency and in lipoprotein lipase deficiency to roughly
AB
SO
RB
AN
CE
 
AT 
28
0 
nm LDL marker
0.2
0.1
0 200 400 
ZONAL ROTOR EFFLUENT (ml)
Fig. 35: Rate zonal ultracentrifugation profile of apoB
containing lipoproteins in a patient with 
hepatic lipase deficiency. - The radioactive 
marker indicates the flotation characteristics 
of LDL prepared from a normal subject.
Hepatic Lipase Deficiency
Metabolism of VLDL (sf 60-400) G.P.
VLDL1
VLDL2
LDL
.001
100 200
Metabolism of VLDL (sf 20-60) G.P.
VLDL2
IDL
LDL
.0 1 -
.001 d------------- .------------- 1------------- .------
0 100
Time (hours)
^9* 36: Lipoprotein decay curves from VLDL]_ and VLDL2
turnover stud'ies in a patient (G.P.) with
hepatic lipase deficiency.
200
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the same extent. After 48 h about 2% of the initial dosage 
was recovered as VLDL2 in both lipase deficient conditions 
in contrast to an average of 0.6% in the control group.
IDL clearance was markedly reduced in hepatic lipase 
deficiency. In fact, the IDL curve had the shape of the 
curve for LDL usually seen in normolipidaemics. The LDL 
curve in hepatic lipase deficiency, in contrast, was 
peculiar in that it plateaued for about 3 days (60-130 h 
after injection) at a level of about 6% of the initially 
injected dosage. This indicated a very low throughput of 
IDL to LDL. The final slope of the LDL curve was about the 
same as observed with normal subjects.
3.5.3. Computer analysis of apolipoprotein B metabolism in
hepatic lipase deficiency
The observed turnover data shown in Fig. 2 9 were 
analysed on the basis of the metabolic model as explained 
in paragraph 2.5.8. Calculated kinetic rate constants and 
masses for subcompartments are listed in Table 17. These 
are compared with average values from a group of 
normolipidaemics which are characterised by the data 
presented in Table 1-22 and Table 1-23. Kinetic rate 
constants observed in the hepatic lipase deficient subject, 
which were outside the range of normal values, are 
highlighted in Fig. 37. The figures from Table 17 are the
TABLE 17: Calculated masses and rate constants 
in hepatic lipase deficiency
Name M(l) k(0,l) k(2,l) M(2) k(3,2) k(6,2)
GP 9 1.8 8.3 8.5 3.4 5.3
Contr., n=5
mean 66 5.5 7.6 33 10.1 0.7
± s ±44 ±6.4 ±4.7 ±17 ±4.0 ±0.4
Name
GP
Contr 
mean 
± s
M (4)
12
n=5
52
±32
k (0,4) 
0.16
3.9 
±6.0
k (8,4) k (9,4) k (11,4)
0.2 0.58 0
5.9
±4.6
3.4
±5.3
0.7
± 0.8
M {5) 
180
55
±24
Name k(0,5)
GP 1.25
Contr., n=5 
mean 0.3
± s ±.7
k (7,5) k (10,5) 
1.41 0
4.8
±2.2
0.5
± 1.0
M (6) k (0 , 6) k (9 , 6)
56 0.81 0
24
±23
1.2
±0.4
Name
GP
M(7)
857
Contr., n=5 
mean 104
± s ±63
k (0,7) k (10,7) 
0.24 0.05
0.5
±0.7
2.2
±1.3
M (8) k (0,8) k (11,8)
42 0.27 0.32
113
±90
0.9
±0.53
1.41
±1.09
Name M(9) k(0,9)
GP 25 0.28
M (10) k (0 ,10) 
209 0.2
M(ll) k(0,11) 
6.4 0.21
Contr., n=5
mean 61
± s ±58
0.8 
±0.4
865 0.34
±463 ±0.14
693 0.25
±407 ±0.11
©| _ U  \
/  i  \ e > \I Ji t-
m) b eJL U \\ 1
y°v  v * v
T V
Kinetic model of apoB metabolism in hepatic 
lipase deficiency. - Significant differences in 
comparison to normal controls are indicated
(Qr 0  r ^  ^  )
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basis for a quantitative description of the apolipoprotein 
B metabolism in this patient, as given in Table 16.
Fractional catabolic rates for VLDL]_ were within the normal 
range but the VLDL]_ pool was low due to a low rate of
synthesis. The synthetic rate for VLDL2 , in contrast was
increased as was, to a lesser extent, the VLDL2 plasma
pool. The transfer rate towards IDL was reduced by two- 
thirds but at the same time direct catabolism of VLDL2 was 
doubled.
In spite of the reduced input from VLDL2 , the IDL 
plasma pool was markedly increased due to a substantial 
reduction in the fractional transfer rate of IDL to LDL, 
which was less than 5% of the normal value. Direct 
catabolism of IDL was not increased. As input from IDL was 
very low, the LDL pool was less than one-sixth of the 
average LDL pool observed in normolipidaemics. LDL was 
degraded at a low normal fractional catabolic rate.
3.6. Apolipoprotein B Metabolism in Homozygous Familial
Hypercholesterolaemia
The metabolism of apolipoprotein B was investigated 
in two patients with homozygous familial hypercholest­
erolaemia. This was part of a larger study where the apoB 
metabolism of seven homozygous FH patients was analysed and 
compared to normolipidaemic controls (301).
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3.6.1. Characterisation of patients
Data describing the two patients analysed here are 
presented in Table 18. J.C. is a 44 year old Englishman 
with widespread tendon xanthomas and severe left carotid 
artery stenosis. He is refractory to all lipid-lowering 
drug therapy including sequestrant resins. His three 
children are hypercholesterolaemic. Fibroblasts and 
lymphocyte assays failed to show any receptor activity 
(301). M.M., a 21 year old Ugandan of Indian extraction,
was found to be severely hypercholesterolaemic in 
childhood. He exhibited widespread tendon xanthomas and 
had coronary artery bypass surgery for occlusive disease 
at the age of 15 years. His lymphocytes expressed less 
than 10% of normal receptor activity (301). The apoE 
phenotype is apoE4/3. Lipid and lipoprotein levels in these 
patients were typical for their disease with massive 
increases of total cholesterol and LDL-cholesterol. ApoB 
plasma concentrations were increased to the same extent 
(Table 19). The distribution of apoB among plasma 
lipoproteins, however, was similar to the distribution seen 
in normolipidaemics. In both cases LDL was by far the 
dominating apoB-lipoprotein species, accounting for about 
three-quarters of plasma apoB.
Compositional analyses of apoB containing lipo­
proteins are summarised in Table 20. The main differences 
occurred with VLDL2 and IDL, which were both cholesteryl
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ester-enriched and triglyceride-depleted. The free 
cholesterol content of LDL was reduced, which was 
interpreted as an effect of the prolonged exposure to 
lecithin:cholesterol acyl transfer (LCAT) due to the long 
plasma residence time of these particles.
3.6.2. VLDL-turnover studies in homozygous familial hyper­
cholesterolaemia
Lipoprotein decay curves produced by VLDL-turnover 
studies are shown in Figs. 38-39 and together with curves 
from normal controls in Figs. 40-43.
VLDL]_ catabolism was only slightly slower in FH 
patients compared to controls. In contrast, VLDL2 
clearance differed markedly from normals. In patients 1% 
and 4% respectively, of the initial dosage was isolated 
from VLDL2 after 72 h as compared to 0.2% in controls.
The IDL curve reached a peak later in patients than 
in controls and the slope of the curve was less steep, 
indicating a delayed VLDL2 to IDL transfer and a decreased 
IDL catabolism. Both patients showed a very shallow LDL 
decay curve in agreement with the slow clearance rate for 
this lipoprotein in FH. The rising section of the LDL 
curve and thereby the time required to reach the maximum of 
the LDL curve differed considerably between the two 
patients.
Homozygous Familial Hypercholesterolemia
Metabolism of VLDL (Sf 60-400)
JC, 44 yrs.
-a,
♦
.01 -
.001
3002001000
□ VLDL1 ♦ VLDL2 a IDL o LDL
Metabolism of VLDL (Sf 20-60)
.001
100 TIME (hours) 200 3000
38: Lipoprotein decay curves from VLDL]_ and VLDL2
turnover studies in a patient (J.C.) with 
homozygous familial hypercholesterolaemia.
Homozygous Familial Hypercholesterolemia
Metabolism of VLDL (Sf 60-400)
MM, 21 yrs.
.0 1 -
.001
3002001000
a VLDL1 VLDL2 b IDL LDL
Metabolism of VLDL (Sf 20-60)
.001 + 
0 300100 TIME (hours) 200
39: Lipoprotein decay curves from VLDL]_ and VLDL2
turnover studies in a patient (M.M.) with
homozygous familial hypercholesterolaemia.
VLDL (Sf 60-400)
(injected as tracer)
.001
10 Time (hours) 200
♦ hm FH, J.C. 
b hm FH, M.M. 
□ Contr.
VLDL (Sf 20-60)
hm FH, J.C.(injected as tracer)
hm FH, M.M.
Contr.
.1
.01
.001
0 200100
Fig. 40 and Fig. 41: Time (hours)
Metabolism of VLDL]_ and VLDL2 in two patients 
(J.C.) and M.M.) with homozygous familial 
hypercholesterolaemia and in normolipidaemic
controls (n = 5) .
IDL (Sf 12-20)
hm FH, J.C.
derived from VLDL (Sf 20-60)
hm FH, M.M.
Contr.
.001
0 100 200
Time (hours)
LDL (Sf 0-12) derived from VLDL (Sf 20-60)
.1
hm FH, J.C.
.01
hm FH, M.M.
Contr.
.001
0 300200100
Fi9- 42 and Fig. 4 3 : Time (hours)
Metabolism of IDL and LDL in two patients 
(J.C. and M.M.) with homozygous familial
hypercholesterolaemia and in normolipidaemic 
controls (n = 5).
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3.6.3. Computer analysis of apolipoprotein B metabolism in
homozygous familial hypercholesterolaemia
Kinetic rate constants and subcompartment masses 
were calculated as in paragraph 2.5.8. (Table 21). Values 
from the two patients are compared with normal averages 
calculated from individual data in Table 1-23. Rate 
constants and masses outside the normal range are set in 
bold in Fig. 44. A quantitative description of apolipo­
protein B metabolism in the two FH homozygotes is given in 
Table 22.
Pool size, direct synthesis and fractional catabolic 
rates for VLDL^ were similar to values observed in the
control group. The pool size for VLDL2 was higher than 
normal because of a significant increase of the mass in 
subcompartment M(6) accounting for VLDL-remnant particles. 
The fractional transfer rate of VLDL2 to IDL was reduced by 
75%, whereas direct synthesis of VLDL2 , influx from VLDL^ 
and direct VLDL2 catabolism were normal.
The IDL pool was increased at least three-fold due 
to a significant reduction in both fractional rate of
direct catabolism and transfer rate to LDL. ApoB flux from
IDL to LDL, calculated as the product of increased IDL pool 
and decreased transfer rate, remained normal. The LDL pool 
size was three to six times above normal as the fractional 
catabolic rate for LDL was reduced to less than one-third 
of the normal value.
TABLE 21: Calculated masses and rate constants in
homozygous familial hypercholesterolaemia
Name M(l) k(0,l) k(2,l) M(2) k(3,2) k(6,2)
JC 59 3.6 7.7 21 14.4 7.7
MM 72 4.4 4.1 45 2.4 4.2
Contr., n=5
mean 66 5.5 7.6 33 10.1 0.7
± s ±44 ±6.4 ±4.7 ±17 ±4.0 ±0.4
Name M(4) k(0,4) k(8,4) k(9f4) k(ll,4) M(5)
JC 35 0 4.3 0 4.3 71
MM 81 0.1 1.2 0 0 59
Contr., n=5
mean 52 3.9 5.9 3.4 0.7 55
± s ±32 ±6.0 ±4.6 ±5.3 ±0.8 ±24
Name k(0,5) k(7,5) k(10,5) M(6) k(0,6) k(9,6)
JC 0.1 1.3 1.7 166 0.96 0
MM 0 3.6 0 302 0.5 0.12
Contr., n=5
mean 0.3 4.8 0.5 24 1.2 0
± s ±0.7 ±2.2 ±1.0 ±23 ±0.4
Name M(7) k(0,7) k(10,7) M(8) k(0,8) k(ll,8)
JC - 770 0 0.24 618 0.24 0
MM 513 0.05 0.37 184 0.17 0.36
Contr., n=5
mean 104 0.5 2.2 113 0.9 1.41
± s ±63 ±0.7 ±1.3 ±90 ±0.53 ±1.09
Name M(9) k(0,9) M(10) k(0,10) M(ll) k(0,ll)
JC 0 0 8586 0.11 1600 0.072
MM 144 0.25 3081 0.084 1563 0.084
Contr., n=5
mean 61 0.8 865 0.34 693 0.25
± s ±58 ±0.4 ±463 ±0.14 ±407 ±0.11
©© ©
Fig. 44: Kinetic model of apoB metabolism in homozygous
familial hypercholesterolaemia. Significant 
differences in comparison to normal controls 
are indicated {©, ©, f , \ ) .
TABLE 22: Apolipoprotein B metabolism in
homozygous familial hypercholesterolaemia
VLDL (Sf 60-400) fract. rate of
direct plasma direct transfer
synth. pool catab. to VLDL2
[mg/d] [mg] [pools/d]
JC 674 59 3.6 7.7
MM 614 72 4.4 4.1
Contr., mean 560 66 5.5 7.6
n=5 ± s ±280 ±44 ±6.4 ±4.7
VLDL (Sf 20-60) fract. rate of
direct flux from plasma direct transfer
synth. VLDL1 pool catab. to IDL&LD
[mg/d] [mg] [pools/d]
JC 217 462 310 0.53 0.78
MM 214 297 536 0.3 0.65
Contr., mean 278 331 191 0.49 2.8
n=5 ± s ±91 ±145 ±91 ±0.13 ±1.2
IDL (Sf 12-20) fract. rate of
direct flux from plasma direct transfer
synth. VLDL2 pool catab. to LDL
[mg/d] [mg] [pools/d]
JC 94 241 1388 0.11 0.24
MM 0 349 842 0.11 0.3
Contr.f mean 0 441 277 0.52 1.3
n=5 ± s 0 ±204 ±134 ±0.34 ±0.9
LDL (Sf 0-12) total
direct flux from plasma LDL-FCR apo B
synth. IDL&VLDL2 pool synth.
[mg/d] [mg] [pools/d] [mg/d]
JC 396 453 10186 0.083 962
MM 134 256 4644 0.084 1361
Contr., mean 18 380 1571 0.31 857
n=5 ± s ±36 ±102 ±788 ±0.11 ±349
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In both patients total apoB synthesis was slightly 
higher than on average in controls. Total LDL-apoB
synthesis and influx from IDL and VLDL was within the 
normal range in M.M., but markedly increased in J.C.
Direct apoB synthesis in the range of LDL accounted in M.M. 
for 10% of the total apoB synthesis which was higher than 
the normal average. In J.C. direct apoB synthesis occurred 
not only in the range of LDL but also in IDL and in this
subject 50% of the total apoB synthesis came from these two
sources.
3.7. Genetic Apolipoprotein B Polymorphisms and Lipo­
protein Metabolism
3.7.1. Apolipoprotein B gene polymorphisms and plasma 
cholesterol levels
ApoB genetic polymorphisms as defined by restriction 
enzymes Xbal, EcoRI and MspI were analysed in 19 moderately 
hypercholesterolaemic subjects (Fig. 45). Patients were 40- 
60 years of age. Hypercholesterolaemia was only diagnosed 
two months after dietary advice, designed to correct 
hyperlipidaemia had been given. Familial hypercholesterol­
aemia was ruled out by checking for tendon xanthomas, 
first-degree relatives with raised LDL-cholesterol or a 
strong family history of premature cardiovascular disease. 
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plasma did not differ significantly for the three 
genotypes, X^X^, X]_X2 and X2X2 as defined by Xbal (Table 23 
and Table I-2H). The same applied for the apoB 
polymorphisms detected by EcoRI and MspI. It should be 
noted that the MspI apoB polymorphism described here is due 
to a hypervariable satellite in the 3' flanking region of 
the gene (30 6). It was detected as described in paragraph 
2.4.6 and is different from the MspI-RFLP in exon 26, 
mentioned earlier (236).
In a second study, the Xbal apoB polymorphism was 
determined for three groups of apoE3/3 homozygotes with 
low, intermediate and high total plasma cholesterol (Group 
I, II and III). ApoE3/3 homozygotes were selected in an 
attempt to eliminate the impact of another known genetic 
factor influencing plasma cholesterol levels. The allele 
frequency for X]_ (ie the allele without the Xbal cutting 
site) was higher for the group with a low cholesterol mean 
(Group I) as compared to the intermediate cholesterol 
group (Group II). Similarly, the allele frequency for X2 
(ie the allele with the cutting site) was higher for 
the high cholesterol group (Group III) (Table 24). If 
cholesterol values for each genotype from each of the three 
study groups were averaged, the mean for X]_X^ was smaller 
than the mean for X2X2 with X^X2 falling in between. 
These findings fall short of statistical significance 
mainly because in group (I) there is no increase in X]_X^ 
subjects corresponding to the higher number of X2X2
Table 23: Plasma Cholesterol and LDL Concentrations from
Moderately Hypercholesterolaemic Patients with 
Different Xbal ApoB Genotypes
X 1X 1 XiX2 x2x2
n (5) (8) (6) ‘
Total Cholesterol 7.76 + 0.59 7.69 + 0.72 7.73 + 0.78
LDL Cholesterol 5.73 + 0.47 5.41 + 0.94 5.30 + 0.78
ApoB 1.87 + 0.19 1.68 + 0.20 1.84 + 0.34
Table 24: Xbal ApoB Polymorphism and Plasma Cholesterol Levels in 
ApoE3/3 Homozygotes
I II III Choi, mmol/1 
(mean ± SD)
n
Choi, mmol/1 
(mean + s)
4.2 + 0-3 5.5 + 0.2 6.9 ± 0.5
n 27 25 26
Gentoypes:
XiXi 9 5 6 5.23 + 1.10* 20
XiX2 10 12 7 5.44 + 1.11 29
x2x2 8 8 13 5.83 + 1.23* 29
Gene Frequencies:
h 0.52§ 0.44 0.363
*2 0.48 0.56 0.63
Groups I, ii and III were age and sex matched (male/female ratio: 15/12, 14/11 and 
and 15/11; mean age: 35 ± 5, 38 ± 6 and 38 ± 6 years respectively) . The three 
groups differed by their cholesterol mean as indicated.
Differences between cholesterol means (*) and gene frequencies (§) were not 
significant as tested by unpaired t-test and X2-test respectively.
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subjects in group (III). However, the results indicate a 
trend which is in line with other studies (see paragraph 
1.6.2 .) .
3.7.2. Apolipoprotein B gene polymorphisms and LDL
catabolism
In the 19 moderately hypercholesterolaemic subjects, 
described in the previous paragraph, LDL catabolism was 
assessed by turnover studies. Native and chemically 
modified LDL tracers were injected and LDL-receptor 
dependent and LDL-receptor independent LDL catabolic rates 
were calculated. The total fractional catabolic rate for 
LDL differed between the genotype groups defined by the 
Xbal apoB RFLP as shown in Table 25. Individuals with the 
XiXi genotype had on average 22% higher fractional 
catabolic rates for LDL compared with those with X 2X2 . 
Subjects with the genotype X^X2 had an intermediate mean 
FCR. When receptor dependent and receptor independent LDL- 
FCRs were calculated it became clear that the difference in 
overall catabolism was due to an increase in the fraction 
and amount of LDL degraded by the receptor route. Subjects 
of X]_X]_ genotype exhibited a 58% higher receptor mediated 
FCR than those with the genotype X2X2 and cleared 65% more 
LDL-apoB through this pathway. No such difference was 
observed in the fraction of LDL degraded by receptor
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independent mechanisms, nor was there a significant 
difference in the rate of LDL synthesis.
Kinetic parameters for the same individuals, grouped 
according to their apoB genotype as defined by the EcoRI 
and MspI endonucleases are given in Table 26. There is a 
tendency for higher receptor mediated LDL catabolism in 
R]_R2 and M]_M2 individuals but none of these correlations 
are statistically significant.
Details about individual values for plasma 
lipoprotein levels, kinetic parameters and apoB haplotypes 
are given in the original publication of this work (333) 
and in Table 1-25.
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4. DISCUSSION
As outlined before the metabolism of apolipop- 
protein B containing lipoproteins is influenced by
environmental and genetic factors. Genetic determinants of 
apolipoprotein B metabolism are the focal point of this 
study.
Genetic factors can be mutations with relatively 
small effects on individuals or rare defects, causing major 
disturbances of lipoprotein metabolism. While the former, 
because of their frequency, contribute significantly to 
the interindividual variation in lipoprotein metabolism 
in the population at large, the latter are particularly 
informative in that they provide clues to the physiological 
role of the affected gene product. The Xbal polymorphism 
of the apoB gene and the apoE polymorphism are examples for 
common mutations with comparatively small effects on an 
individual basis. In contrast, lipoprotein lipase or 
hepatic lipase deficiency as well as homozygous familial 
hypercholesterolaemia, are conditions, where key elements 
of apolipoprotein B metabolism are defective resulting in 
massive accumulations of distinct lipoprotein species. By 
comparison with normal subjects, the importance of the 
different lipolytic enzymes or the LDL-receptor can be 
inferred.
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4.1. The Xbal Restriction Site Polymorphism of the
Apolipoprotein B Gene and LDL Metabolism
Two papers from Law et a l . (24?) and from Berg (246)
reported in 1986 an association between an Xbal restriction 
site polymorphism of the apolipoprotein B gene and plasma 
concentrations for total cholesterol and apolipoprotein B 
in normolipidaemic healthy subjects (246, 247). In both 
studies, homozygotes for the apoB allele devoid of the Xbal 
cutting site (X]_X]_) exhibited cholesterol concentrations 
which were, respectively, 7% and 10% lower than those 
observed in heterozygotes (X]_X2 ) or homozygotes for the 
allele possessing an additional cutting site (X2X2 ) . 
Differences for apoB levels were 10% and 15%. Triglyceride 
levels were not significantly different in one study (246) 
but differed by 27% in the other study (247) . Altogether 
35 X]_X]_ subjects and 104 X]_X2 and X2X 2 subjects were
examined. Gene frequencies in both study groups were 0.48 
for Xi and 0.52 for X2 • From these findings an autosomal 
dominant form of inheritance was deduced with the X2 allele 
linked to an increase of plasma cholesterol concentrations. 
However, another study by Talmud et a l . (151) showed
intermediate cholesterol levels for X]_X2 heterozygotes 
suggesting a codominant mode of inheritance, which is 
easier to reconcile with the fact that each LDL particle 
carries only one apoB molecule, encoded for either by an X]_ 
or an X 2 allele.
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These findings formed the background for a study 
aimed at differentiation of possible reasons for the
observed variation in cholesterol and apoB levels.
Possible causes were either increased apoB synthesis or 
impaired apoB catabolism linked to the X2 allele as
compared to the allele. In order to distinguish between
these options LDL-kinetic parameters defined by turnover
studies were correlated with the genotype for the Xbal-RFLP 
of the apoB gene.
The subjects whose LDL metabolism was studied were
all middle-aged (40-60 years) and had moderate, diet- 
refractory hypercholesterolaemia with an average of
7.7 ± 0.7 mmol/1. Subjects suffering from heterozygous FH
were excluded from the study. Hypercholesterolaemia was
caused in this group by a combination of oversynthesis and
defective catabolism. The mean synthetic rate of
17.1 ± 3.3 mg/kg per day was in excess of normal values 
(11-13 mg/kg per day) and the mean total LDL-FCR was lower 
than observed in normal controls (0.24 ± 0.03 versus 
0.35 ± 0.06 pools/day) (323). Receptor mediated LDL
catabolism was on average only 28% of the total LDL-FCR,
distinctly lower than the 50% observed in 
normolipidaemics (27).
When values for LDL-FCR were related to the Xbal apoB
genotype, the group of five X^X]_ homozygous subjects had a
22% higher total FCR than the six X2X2 homozygotes.
Differences for receptor mediated LDL catabolism were even
wore marked while receptor independent catabolism was the
129
same in both groups. These findings suggest that 
apolipoprotein B as the product of the polymorphic gene has 
a structural defect in X2X2 individuals, which reduces 
its affinity for the LDL-receptor. In X^X2 heterozygotes, 
LDL particles carry either the defective apoB translated 
from the X2 allele or the structurally intact apoB 
derived from the X]_ allele. This implies that LDL in 
these subjects is metabolically heterogeneous and as a 
consequence the FCR for LDL should be intermediate as 
observed in this study.
As mentioned before, the DNA sequence change which 
creates the Xbal restriction site does not result in a 
change of the amino acid sequence of the translated 
protein, which makes it unlikely that the Xbal polymorphism 
itself is functionally significant. Rather, this mutation 
is probably in linkage disequilibrium with a functionally 
important change elsewhere in the coding region of the apoB 
gene. The receptor-binding domain is an obvious candidate 
area (324) but so far efforts have failed to identify a 
common DNA mutation in this region specifying X2X2 in 
contrast to X^X]_ subjects.
The association between the X2 allele and lower 
LDL-FCRs provides an explanation for the higher plasma 
cholesterol levels observed in X2X2 homozygous normo- 
lipidaemics. In subjects with normal LDL levels LDL-FCR 
and LDL concentration in plasma are inversely 
correlated (323). Lower clearance rates for LDL, possibly
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caused by impaired LDL-receptor binding in -^2^2 
individuals, may result in an accumulation of LDL in the 
plasma compartment. In hypercholesterolaemic patients, 
such as in the present study, oversynthesis of apoB partly 
overrides the correlation between LDL-FCR and LDL plasma 
concentration, thus explaining the lack of a correlation 
between the Xbal apoB genotype and LDL-cholesterol in this 
group of subjects (Table 23) .
The correlation between LDL-FCR and the Xbal apoB 
genotype has been confirmed by two other papers: Houlston
et al. (324) found in their study of 22 normolipidaemic 
males, aged 35-49 years, that X2 homozygosity was 
associated with 13% higher cholesterol concentrations and 
a significantly lower LDL-FCR (-11%). x ix2 heterozygotes 
in this study had the lowest cholesterol levels and the 
highest LDL-FCR, a finding which could not be explained 
satisfactorily.
The second study by Series et al. (325) investigated 
in-vitro degradation of LDL isolated from X^X^ and X2X2 
homozygotes. LDLs were labelled with different iodine 
isotopes and in-vitro degradation by fibroblasts was 
monitored. LDL derived from an X]_X]_ subject and LDL from 
an X2X2 subject were incubated in the same culture dish and 
paired rates of degradation were measured. In a group of 
nine normolipidaemics with a mean age of 48 years and in a 
group of fourteen hypercholesterolaemics (mean cholesterol 
8.3 mmol/1; mean age 57 years) in-vitro degradation of LDL
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from X2X2 subjects was significantly lower than observed 
with LDL derived from XiX^ subjects (-15% and -18% 
respectively, for the two study groups). No such 
difference was observed in a group of ten younger 
normolidaemics (mean age 31 years). These findings confirm 
the results of the in-vivo studies discussed before. In 
addition the possibility emerges of an age dependent 
manifestation of the effects a structural LDL-defect may 
have on LDL metabolism.
Another observation in support of the concept that 
the Xbal apoB gene polymorphism is responsible for 
structurally different apoB isoforms is the fact that this 
restriction site polymorphism is strongly associated with 
the Ag (c/g) antigenic polymorphism (237, 246, 278-279).
The antigenic group (Ag) variation is due to a series of 
LDL specific antigens detected by antisera from multiple 
transfused patients (249). The close linkage between the
Ag system and several apoB restriction site polymorphisms 
including the Xbal-RFLP (Table 4) suggests that DNA
mutations are causing changes in the apoB structure which 
give rise to the development of homospecific antibodies. 
From a study in Finland it was reported that the combined 
genotype with both, X2 and apoB(c), alleles present 
correlated even better with elevated plasma cholesterol
levels than either allele alone (248) .
The fact that the Xbal apoB polymorphism is not
identical with the functionally important apoB mutation but
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only linked to it may explain, in part, why some population 
studies failed to detect a significant association between 
plasma cholesterol and Xbal apoB genotype. An example is 
the study reported in paragraph 3.7.1., which showed trends 
for a higher X2 allele frequency in hypercholesterolaemics 
but no corresponding increase of the X^ allele frequency in 
subjects with low plasma cholesterol (Table 24). Other 
negative results are from Sweden (251) , where 200 randomly 
selected subjects were analysed and from the United States 
(238), where 168 subjects with and without coronary heart 
disease were studied. In Japan no . association between 
the Xbal RFLP and cholesterol levels was observed and 
an X2 allele frequency of 0.04 was reported, a value 
significantly lower than 0.5, the frequency usually 
observed in Caucasian populations. This demonstrates that 
ethnic heterogeneity is another factor complicating 
population studies of this polymorphism.
So far only one study reported a significant 
correlation between the Xbal apoB gene polymorphism and 
coronary heart disease (238). Here the X^ allele 
frequency was significantly higher in patients with 
myocardial infarction as compared to controls. As 
mentioned before, cholesterol levels did not correlate with 
the Xbal genotype. Similar results were reported by Myant 
et al. (241) with an increased allele frequency for X^, 
though this difference was significant only in a subset of 
normolipidaemic patients. Again cholesterol levels did not
133
correlate with the Xbal polymorphism. In the study 
presented in paragraph 3.7.2 a trend towards higher LDL 
synthetic rates in subjects is noticeable. Vega et
al. have found overproduction of LDL to be associated with 
coronary heart disease in patients with hyper- 
triglyceridaemia and in a subgroup of normolipidaemic 
patients (327). The same applies for familial combined 
hyperlipidaemia (93) and hyperapobetalipoproteinaemia (180) 
both conditions strongly associated with coronary heart 
disease. Further investigations will clarify the link 
between coronary heart disease, the X]_ allele of the apoB 
gene and possible oversynthesis of apolipoprotein B. While 
the X 2 allele is associated with increased plasma 
cholesterol levels, these future studies will show whether 
or not the X^ allele is an independent risk factor for 
coronary heart disease.
4.2. Apolipoprotein B Metabolism in Normolipidaemics:
The Influence of Apolipoprotein E Polymorphism
4.2.1. The current model
Many studies from a number of different countries 
including the one presented in paragraph 3.2. have 
demonstrated that plasma cholesterol levels are correlated
with the apolipoprotein E phenotype (255) . Homozygotes for 
apoE3, the common "wild type” variant, who account for 60-
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70% in Caucasian populations, have plasma cholesterol 
levels higher than apoE3/2 and apoE2/2 subjects but lower 
than apoE4/3 and apoE4/4 individuals. It was this 
observation that initiated the present study of
apolipoprotein B metabolism in individuals homozygous 
either for apoE3, apoE4 or apoE2. VLDL-turnovers in these 
subjects provide insights into the mechanisms by which 
different apoE isoforms might modulate the metabolism of 
apolipoprotein B. These can be compared with the current 
hypothesis of how apoE isoforms interact with apoB
metabolism (258, 330).
The current concept of apoB metabolism is depicted 
in Fig. 46. The diagram for apoE3 homozygosity resembles 
Fig. 2, where the areas A and B illustrate the metabolism 
of chylomicrons and of apoB containing lipoproteins. As 
mentioned before (paragraph 1.6.2), the metabolism of apoE2 
is delayed in-vivo as well as in-vitro when compared 
to apoE3 metabolism (51, 153). In contrast, apoE4 is 
catabolised at an increased rate when injected into
normolipidaemic subjects (260) in spite of identical
behaviour in-vitro (51). Further insights into the role of 
apolipoprotein E in apoB metabolism came from metabolic 
studies in patients with familial dyslipoproteinaemia or 
with an inherited deficiency of apoE. In both conditions 
the patients have decreased catabolic rates for VLDL and 
chylomicron remnants (137, 147). In patients with apoE 
deficiency transfer of VLDL into IDL and LDL is reduced
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and the catabolism of normal LDL, produced by apoE3/3 
homozygotes, is enhanced (147, 331) . These observations 
led to the following model of apoB metabolism in apoE2/2 
homozygotes: in the absence of functional apoE chylomicron
uptake by the liver is impaired resulting in up-regulation 
of the LDL-receptor. This in turn increases the fractional 
catabolic rate of LDL and reduces LDL plasma levels. In. 
addition the LDL synthetic rate is reduced as the 
conversion of LDL precursors into LDL seems to depend on 
functional apoE (Fig. 4 6). The inverse of these mechanisms 
may apply for apoE4/4 homozygotes whose more rapid 
clearance of chylomicrons may lead to down-regulation 
of the LDL-receptor and a consequent increase of LDL 
concentration (Fig. 4 6). LDL-receptor activity, according 
to this model, has a pivotal role in the apoE dependent 
modulation of apoB metabolism.
4.2.2. Apolipoprotein E2 and apoB metabolism
Results of VLDL-turnover studies in apoE2/2 
homozygous normolipidaemics are reported in section 3.3.2. 
The main differences as compared to apoE3/3 homozygotes 
are repeated again: direct catabolism of large and small 
VLDL were reduced (0.3 versus 5.3 pools/day and 0.03 versus
1.7 pools/day, respectively) as was the transfer rate of 
IDL to LDL (0.4 versus 1.0 pools/day). In contrast, direct 
catabolism of IDL was faster (1.0 versus 0.3 pools/day) but
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the fractional catabolic rate of LDL was not significantly 
increased. As pointed out previously, apoE2 does not bind 
efficiently to the LDL-receptor. However, this is not 
sufficient to explain reduced direct catabolism of VLDL]_ 
and VLDL2 in apoE2/2 homozygotes, since in-vitro studies 
have shown that normolipidaemic VLDL is not degraded by the 
LDL-receptor pathway. This may be due to a conformational 
peculiarity of apoE in VLDL of normolipidaemics, which 
makes it inaccessible to receptor binding (334) . An 
alternative explanation is that some apoE is lost from VLDL 
during preparation by ultracentrifugation before it is used 
for in-vitro studies. This view is supported by the 
observation that receptor mediated uptake and degradation 
of VLDL can be induced in-vitro by addition of purified 
apoE (335) . Therefore, some VLDL clearance via the LDL- 
receptor seems possible in spite of the negative findings 
mentioned before.
The "apoEM-receptor provides another potential 
pathway for direct VLDL clearance. Evidence for the 
existence of a lipoprotein-receptor, distinct from the LDL- 
receptor has been discussed in paragraph 1.3.1. The 
putative receptor protein was discovered by its close 
structural and biochemical similarities with the LDL- 
receptor (53). Thus, one would expect that apoE2 is also a 
poor ligand for this receptor. Reduced catabolic rates in- 
vivo for VLDL]_ and VLDL2 in apoE2/2 homozygotes can then be
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explained as the result of impaired receptor mediated 
degradation.
The second important finding in apoE2/2 homozygotes, 
a reduced transfer rate of IDL to LDL, parallels results of 
in-vitro studies with lipoproteins from patients with 
familial dysbetalipoproteinaemia (337, 338). In contrast 
to normal VLDL (167), apoB-100 containing L-VLDL from these 
patients could be converted only into IDL but not into LDL 
by addition of lipoprotein lipase. The formation of "LDL" 
could be achieved by the further addition of apoE3 and 
lipoprotein deficient plasma (338). Another paper reports 
that VLDL from apoE2/2 normolipidaemics, containing varying 
amounts of I3-VLDL was a relatively poor substrate for 
lipoprotein lipase and hepatic lipase (362). This may be a 
consequence of a prolonged exposure to the action of CETP 
with the result of relative triglyceride depletion in 
exchange of cholesteryl esters derived from HDL. However, 
even if this is a contributing factor to the impairment of 
IDL to LDL conversion, the mechanism by which apoE3 can 
enhance this process remains obscure. ApoE3 does not seem 
to be a cofactor of lipolytic enzymes, since normal pre-ft- 
VLDL from patients with familial dysbetalipoproteinaemia 
can be converted to LDL by addition of lipoprotein lipase 
and apoCII (338).
VLDL-turnover studies in patients with familial 
dyslipoproteinaemia and with apolipoprotein E deficiency 
also confirm a reduced IDL to LDL conversion in the absence
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of receptor-binding apoE (155, 274, 331). In summary, both 
in-vitro and in-vivo studies suggest an important role of 
apoE in the conversion of IDL into LDL but the underlying 
mechanism is not understood at present.
The significantly lower LDL plasma pool results 
mainly from the low influx of material from the IDL density 
range. The overall fractional catabolic rate for LDL is 
somewhat higher in apoE2/2 as compared to apoE3/3 subjects 
but this falls short of statistical significance, possibly 
because of greater interindividual variation among the four 
apoE2/2 subjects. LDL decay curves (Figs. 17 and 20) and 
the kinetic rate constants k(0,10) and k(0,ll) show that 
FCRs for both LDL subspecies, whether derived from VLDL]_ 
or from VLDL2 , are very similar in apoE2/2 and in apoE3/3 
subjects. However, the relative proportion of the LDL 
masses in subcompartment M(10) and M(ll) is clearly 
different (ratios M(10) over M(ll) are 4.97 and 1.02 in 
apoE2/2 and apoE3/3, respectively). LDL accounted for by 
M(10) is derived from VLDL2 and is the dominant LDL 
subspecies in apoE2/2 subjects. In all apoE phenotypes 
this LDL subspecies is catabolised faster than VLDL]_- 
derived LDL, represented by M(ll). The total LDL-FCR 
accounts for LDL catabolism as a whole, no matter what the 
relative contributions of metabolically distinct 
lipoprotein subspecies are. It is higher in apoE2/2 than 
in apoE3/3 subjects, in spite of almost identical LDL 
kinetic rate constants k(0,10) and k(0,ll), because the
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balance between LDL in M(10) and LDL in M(ll) is shifted 
towards the former.
A crossover experiment by Gregg et a l . has 
demonstrated that LDL from apoE2/2 homozygotes is 
catabolised at a slower rate than LDL from apoE3/3 
subjects (339). Therefore, the LDL decay curve in apoE2/2 
subjects does not necessarily reflect the level of LDL- 
receptor activity as compared to control subjects, as a 
decay curve with a normal descending slope may represent 
degradation of LDL with reduced binding affinity by an 
increased number of receptors. Direct catabolism of IDL, 
which is also mediated by LDL receptors (334), was 
significantly increased in apoE2/2 subjects. This probably 
reflects up-regulation of LDL-receptors in apoE2/2 subjects 
which because of the poor binding qualities of their LDL 
is masked when only LDL metabolism is taken into account.
Finally, the significantly lower rate of apolipo- 
protein synthesis in apoE2/2 homozygotes has to be 
addressed. At present the regulation of apoB synthesis is 
poorly understood at the molecular level. Evidence is 
emerging now from recent studies with macrophages that 
cholesterol derived from different lipoproteins, such 
as LDL or ii-VLDL, may enter different intracellular 
cholesterol pools (332). Whether or not this is of 
importance for the regulation of apoB synthesis is yet 
unknown.
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One apoE2/2 subject (P.M.) provided VLDL-turnover 
data, which were markedly different from the other four 
subjects studied in this group (Fig. I- 5) . Therefore 
these were excluded when average values were calculated. 
Repeated Western blot analyses showed that there is 
no doubt about the apoE phenotype of P.M. and this was 
confirmed by a method (347) using an oligonucleotide
specific for the apoE2 (Arg 158 ----► Cys) allele (Dr. R.
Houlston, unpublished observation). Dyslipoproteinaemia, 
reflected by the apoB distribution in plasma was 
further proof of apoE2 homozygosity. The VLDL-cholesterol/ 
triglyceride ratio in P.M., however, was lower than with 
the other apoE2/2 subjects, possibly because her mean total 
triglyceride value was increased by 65% (Table 1-3). Also, 
the composition of VLDL]_ from P.M. was abnormal in that it 
was triglyceride-rich mainly at the expense of cholesteryl 
esters and phospholipids. Synthesis of VLDL^-apoB was 
three-fold increased in comparison with the average rate 
for apoE2/2 homozygotes (Table I—2 1) . These findings 
suggest that this patient presents a combination of 
apoE2/2 homozygosity and hypertriglyceridaemia due to 
an oversynthesis of large VLDL. The diet consumed by P.M. 
was not carbohydrate-rich, no alcohol intake was recorded 
(Table 1-9) and there were no signs of conditions causing 
secondary hypertriglyceridaemia. Unfortunately, family 
members required for establishing the diagnosis of familial 
hypertriglyceridaemia were not available. It should be
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noted that VLDL^ oversynthesis only occurred in comparison 
to values from other apoE2/2 subjects but not if compared 
to apoE3/3 individuals. However, a comparison between P.M. 
and apoE3/3 subjects is invalid in this context, as apoE2 
homozygosity per se seems to be associated with a reduced 
rate of apoB synthesis.
It is known that large VLDL from hyper- 
triglyceridaemic subjects (HTG-VLDL) in contrast to 
normolipidaemic VLDL is degraded via LDL-receptor 
uptake (348) . The receptor-binding domain of apoE 
associated with HTG-VLDL^ can be blocked with a monoclonal 
antibody which still leaves appreciable binding affinity 
for the LDL-receptor (349). This is only abolished by 
complete proteolytic degradation of apoE (348). Thus, in 
HTG-VLDL apoB epitopes can replace apoE as a receptor 
ligand to some extent. This does not contradict the 
observation that apoE is necessary and sufficient for 
receptor mediated uptake of triglyceride-rich lipid 
particles as demonstrated by experiments with artificial 
liposomes with incorporated apoE (350).
The VLDL-turnover in P.M. can be interpreted as an 
in-vivo study, complementing the in-vitro observations 
mentioned above. VLDL^ and VLDL2 were cleared at normal 
rates, possibly because of the interaction of two 
independent abnormalities: firstly, oversynthesis of VLDL^ 
produces particles which bind to the LDL-receptor, even in 
the absence of receptor-binding apoE; secondly, there is
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some evidence for up-regulation of LDL-receptor activity in 
apoE2/2 homozygotes as mentioned in the previous paragraph. 
Both together result in an increased turnover where 
oversynthesis is balanced by increased catabolic rates. As 
hypertriglyceridaemia was only moderate, lipoprotein lipase 
activity was likely to be far from saturated, explaining 
the significant increase of VLDL^ to VLDL2 transfer (171) . 
The transfer rate of IDL to LDL, however, was also 
distinctly higher than the typical rates for apoE2/2 
subjects. This and the significantly increased FCR for 
LDL are difficult to explain, since the particle 
compositions were the same as measured for apoE2/2 and 
apoE3/3 normolipidaemics. Hypermetabolism as observed in 
severe hypertriglyceridaemia may be involved since it is 
conceivable that mild hypertriglyceridaemia combined with 
impaired lipoprotein-receptor binding activates alternative 
non-receptor dependent routes of metabolism which operate 
in severe hypertriglyceridaemia (see paragraph 4.3.1.). 
However, the precise mechanisms involved remain uncertain.
It is well possible that the combination of 
hypertriglyceridaemia and apoE2 homozygosity will develop 
into familial dysbetalipoproteinaemia in this subject. A 
follow-up measurement of her plasma lipoproteins after 
18 months, however, has shown only insignificant changes.
4.2.3. Apolipoprotein E4 and apoB metabolism
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The main finding with VLDL-turnovers in apoE4/4
homozygotes as compared to apoE3/3 subjects was a delayed
direct catabolism for VLDL2 / IDL and LDL. These 
differences were significant for VLDL2 and for LDL, but not 
for IDL. As discussed earlier, LDL decay curves for LDL 
derived from VLDL]_, and for LDL, derived from VLDL2 / were 
both less steep than the equivalent curves for apoE3/3
subjects. The kinetic rate constant k(0,10), ie the FCR
for VLDL2_derived LDL was significantly smaller in apoE4/4 
than in apoE3/3 subjects (p < 0.01). The mass ratio of 
M(10) over M(ll) was again in favour of M(10) although to 
a lesser extent than observed in apoE2/2 homozygotes 
(2.89 and 1.02 in apoE4/4 and apoE3/3, respectively). 
Nevertheless, the total FCR for LDL was significantly 
smaller in apoE4/4 subjects due to the marked reduction in 
k(0,10). Together these findings suggest that receptor 
mediated LDL degradation is reduced in apoE4/4 subjects.
The switch from apoE to apoB as the primary 
determinant of lipoprotein-receptor binding occurs within 
the range of VLDL2 (Sf 20-60) (334). It is possible
therefore that down-regulation of LDL-receptors results in 
a reduced up-take and degradation of VLDL2 , as some of 
these particles may be cleared physiologically by the LDL- 
receptor pathway. However, the decrease in direct 
catabolism is less marked than in apoE2/2 individuals,
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because clearance by the "apoE"-receptor is unimpaired in 
apoE4/4 individuals.
From this study of apoB-100 metabolism it is not 
clear why LDL-receptor activity should be down-regulated 
in apoE4/4 homozygotes. Some hints may come from two 
recent papers which addressed the relationship between 
apolipoprotein E polymorphism and the metabolism of dietary 
fat. One study found the efficiency of intestinal 
cholesterol adsorption to be 35% higher in a group of 
apoE4/3 and apoE4/4 subjects than in apoE3/2 subjects with 
values for apoE3/3 subjects in between (341). In an 
earlier study with male Finns it had been demonstrated that 
the efficiency of cholesterol adsorption correlates well 
with plasma cholesterol levels (342) .
In the second trial (343) the rate of dietary fat 
clearance was measured using the vitamin A fat loading 
test. Chylomicron remnants were cleared more rapidly in 
seven apoE4/3 subjects and more slowly in nine E3/2 
subjects as compared to the clearance in ten apoE3/3 
individuals. In another similar study a prolonged 
chylomicron remnant clearance time was observed only in 
apoE2/2 but not in apoE3/3 subjects, while apoE4/3 and 
apoE3/3 were not analysed separately (344) .
As apoE3 and apoE4 show the same receptor-binding 
characteristics in-vitro in contrast to apoE2, it is not 
obvious why apoE3/3 and apoE4/4 subjects in-vivo should 
differ in the way described. A possible mechanism
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explaining these observations has to do with the 
distribution of apoE among plasma lipoproteins (260, 345). 
Most apoE in apoE3/3 homozygotes is associated with HDL 
where at least some apoE forms a covalent complex with 
apoAII via a disulphide bond (12). In contrast, a markedly 
higher proportion of apoE4 is attached to VLDL, probably 
because apoE4, which lacks a cysteine residue in position 
112, cannot form apoE-AII complexes in HDL (345) . In 
addition the added positive charge in apoE4 seems
to increase the affinity for lipoproteins of lower 
density (346) . As a result apoE4 is catabolised faster 
than apoE3, which is to a greater extent associated with 
relatively slowly degraded HDL (2 60). Moreover, apoE4 is 
readily available for association with chylomicrons and 
chylomicron remnants which become targeted for rapid
receptor mediated uptake by the liver. If in apoE4/4 
homozygotes intestinal cholesterol adsorption is more
efficient and exogenous fat clearance faster and probably 
more efficient, too, down-regulation of the LDL-receptor is 
a natural consequence of relatively high intracellular 
cholesterol supplies.
4.2.4. Conclusions: a modified model
In principle the model of apoE dependent 
modification of apolipoprotein B metabolism, which was
introduced at the beginning of this chapter, is compatible
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with the results of the metabolic studies discussed in 
the last two sections. By these studies the relative 
importance of specific mechanisms underlying the 
correlations between plasma apoB concentrations and apoE 
phenotypes has been clarified to some extent and it is now 
possible to draw a picture in some more detail.
In apoE2/2 homozygotes the most significant 
mechanism resulting in low LDL levels is reduced formation 
of LDL from IDL precursors. LDL decay curves on the 
other hand do not provide evidence for increased LDL 
catabolism as a result of up-regulated LDL-receptor 
activity. Nevertheless this cannot be ruled out and 
indirect evidence as increased catabolism of IDL suggests 
that LDL-receptor activity is indeed up-regulated to some 
extent. Receptor up-regulation might be a consequence of 
delayed metabolism of dietary fat.
In contrast, high LDL concentrations in apoE4/4 
homozygotes can be explained by diminished LDL-receptor 
activity since the LDL-FCR is lower in apoE4/4 as compared 
to apoE3/3 subjects as reflected by a lesser gradient of 
the LDL decay curves. Higher efficiency of intestinal 
cholesterol adsorption and faster clearance of chylomicrons 
are appropriate causes for down-regulation of LDL-receptor 
activity in apoE4/4 homozygosity.
In summary, apoE2 lowers LDL levels mainly by 
reduced LDL-synthesis from precursor particles and apoE4
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increases LDL concentrations indirectly as a consequence of 
a more efficient metabolism of dietary fat supplies.
These conclusions have interesting repercussions for 
the quantitative aspects of the correlation between plasma 
cholesterol and apoE phenotypes. In most population 
studies published so far, plasma cholesterol levels were 
markedly lower in apoE2/2 than in apoE3/3. In six studies, 
presented in a recent review by Davignon et a l . (255), the
mean difference was -16% or 0.8 ± 0.2 mmol/1. In contrast 
the increase of cholesterol levels observed in apoE4/4 
was only +5% or 0.3 ± 0.2 mmol/1 and appeared to be more 
variable, ranging from +12% in Helsinki to +2% in 
Framingham. The more prominent difference between apoE2/2 
and apoE3/3 subjects may be caused by an inherited 
metabolic defect and some additional variation as a result 
of dietary habits. The increased cholesterol levels in 
apoE4/4 subjects, in contrast, probably depend largely on 
the diet ingested and are therefore quite pronounced in 
populations with high intake of saturated fatty acids and 
cholesterol and almost absent in communities on a low-fat 
diet. Thus, the correlation between plasma cholesterol and 
apoE phenotype is an example for a combined peristatic and 
genetic interaction (258) .
In the study reported in paragraph 3.2. apoE2/2 
subjects presented with a rather small reduction of 
cholesterol in plasma while the increase observed in 
apoE4/4 was above average. This may be an indication for
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an "atherogenic" diet prevailing in the population studied, 
as suggested by the high incidence rate for coronary heart 
disease in the Scottish community.
4.3. Apolipoprotein B Metabolism in Genetically Defined
Disorders of Lipid Metabolism
4.3.1 Familial hyperchylomicronaemia
Two etiologically distinct patients, one with 
classical lipoprotein lipase deficiency and one with 
lipoprotein lipase activity blocked by a plasma 
inhibitor (117) were studied. VLDL-turnovers produced 
results, which were remarkably similar: firstly, VLDL^
conversion into VLDL2 was markedly reduced, causing a 
massive increase of VLDLi plasma concentrations. Secondly, 
IDL and even more so LDL were metabolised at rates 1.5 to 
3.5-fold higher than in normal controls.
The first apoB metabolic study of Type I 
hyperlipidaemia was published by Nicol et a l . (73), who
investigated two patients, one with lipoprotein lipase 
deficiency and one with apoCII deficiency. Total VLDL 
(d < 1.00 6 g/ml) was used as a tracer and conversion into 
IDL and LDL was monitored. Fractional catabolic rates for 
VLDL and the mean conversion time of VLDL to LDL were found 
to be within the normal range. As a result apoB-100 
metabolism was described as unimpaired by lipoprotein
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lipase deficiency (73). In another study Stalenhoef et 
al. (109) analysed the metabolism of VLDL^ and chylomicrons 
in two lipoprotein lipase deficient subjects. They found 
clearance of both lipoproteins, which were distinguished by 
their content of apoB-100 and apoB-48 respectively, 
markedly delayed. No transfer of protein was observed from 
VLDL]_ or chylomicrons into the density range of LDL. A 
third metabolic experiment by Goldberg et al. was carried 
out in monkeys, whose lipoprotein lipase was blocked by an 
infusion of lipase-antibodies (351). Shortly afterwards 
trace-labelled human VLDL]_ and VLDL2 were injected. The 
most significant findings were a marked decrease of VLDL]_ 
catabolism and a complete block in the transfer of VLDL]_ 
and VLDL2 into LDL.
Results of the first publication are in obvious 
contradiction to the findings reported in the two other 
papers. Some of this inconsistency could be resolved by 
the double turnover approach used in the present study, 
where metabolism of autologous large and small VLDL was 
investigated simultaneously. The results, as presented in 
paragraph 3.4.2 and 3.4.3, were different from both, the 
previous study in humans (73) and from the animal 
experiment (351). In the following it is tried to explain 
how these discrepancies could occur.
Radioiodination of total VLDL (Sf 20-400) results in 
preferentially labelling VLDL2 and only little VLDL^ since 
the iodine reacts proportionally to the protein mass.
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Therefore, the tracer used in the VLDL-turnover reported 
by Nicol (73) was in fact VLDL2 which was cleared at low 
normal rates as in the present study (Table 17). The 
blocked transfer of VLDL^ into VLDL2 was obviously 
undetectable by a VLDI^-tracer injection.
Marked reduction of in-vivo conversion of VLDL]_ into 
VLDL2 as observed in the present study and by Stalenhoef et 
al. (109) is in line with in-vitro studies, where the 
enzyme activity was tested by incubation with various 
lipoprotein preparations. Native chylomicrons and large 
VLDL were the preferred substrates for lipoprotein 
lipase (353) .
The complete block of LDL formation observed in the 
animal experiment could not be confirmed by the study in 
humans, in which apoB was found to be transferred from 
VLDL2 and VLDL2 into LDL at a percentage of 5% and 15% 
respectively. The difference may be explained by different 
pathways for preferential LDL formation. In cynomolgus 
monkeys a substantial proportion of LDL is not derived from 
circulating VLDL2 but from a small pool of VLDL which is 
rapidly, within minutes, converted into LDL (72, 381). 
This process may be largely dependent on lipoprotein lipase 
activity, which was blocked in this experiment.
The second abnormality observed in the VLDL-turnover 
study of Type I patients was hypermetabolism of denser apoB 
containing lipoproteins. A similar observation was first 
made by Sigurdsson et a l . as a result of LDL-turnovers in
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patients with severe hypertriglyceridaemia (354) . Six
patients with a mean triglyceride concentration of
17.8 ± 9.2 mmol/1 catabolised LDL at a rate almost double 
what had been determined for normal controls (0.7 ± 0.14 
versus 0.41 ± 0.09 pools/day). The two patients in the 
present study had slightly higher triglyceride levels and 
LDL-FCRs were 3.5 times higher than normal. Further
investigations by Shepherd et a l ., employing the double- 
turnover technique described in paragraph 2 .6 ., provided 
insights into the underlying mechanisms (355). The five 
subjects with the highest triglyceride concentrations 
(mean 20.6 ± 9.4 mmol/1) in this study had a total LDL- 
FCR of 0.75 ± 0.34 pools/day. While 0.20 ± 0.10 pools/ 
day were cleared via the LDL-receptor pathway, 0.55 ±
0.27 pools/day were degraded by non-receptor dependent
mechanisms. Comparison with reference values shows that 
only the latter was significantly increased. This increase 
could be reversed by lowering triglycerides through drug 
treatment. The precise nature of LDL-receptor independent 
LDL degradation is still not known, but some evidence 
suggests an important role of the reticuloendothelial 
system in this process. Saturation of the RES by 
ethyloleate injections into rabbits produced a marked 
fall in receptor independent catabolism of human LDL (356) 
and in patients with myeloproliferative disorders LDL 
clearance by the non-receptor pathway was shown to be 
accelerated (357) . Spleenomegaly, as present at least in
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one of the patients (D.S.) reported in this study, is 
common in severe hypertriglyceridaemia and provides further 
evidence for involvement of the RES in this metabolic 
disorder (106).
4.3.2. Hepatic lipase deficiency
Hepatic lipase is the second lipolytic enzyme 
involved in apolipoprotein B metabolism. Its physiological 
role was analysed on the basis of observations, including a 
metabolic study, obtained from a patient with hepatic 
lipase deficiency (340).
A first hint on the role of hepatic lipase in apoB 
metabolism comes from the abnormal pattern of apoB 
distribution among plasma lipoproteins seen in 
this subject (G.P.) and reported from two other patients 
(118-120). The main apoB containing lipoprotein was 
recovered in the IDL fraction by cumulative gradient 
ultracentrifugation (Table 14), in accordance with the 
shift of the peak of apoB containing lipoproteins towards 
a smaller density observed in the rate zonal ultra­
centrifugation profile (Fig. 36). For another hepatic 
lipase deficient subject, the density of the major 
apoB-lipoprotein was determined as 1.023 g/ml, in contrast 
to 1.044 g/ml for normal LDL (120). A similar lipoprotein 
profile was found in a patient with acquired hepatic lipase 
deficiency as a consequence of vitamin A intoxication,
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where a marked increase was noted for LDL of lighter
density (359). None of these subjects had significant 
amounts of typical LDL. The lipoprotein subfraction 
recovered as LDL by cumulative gradient centrifugation, as 
listed in Table 14, represents the "tail" of the peak for 
the main apoB containing lipoprotein (Fig. 36) rather than 
a distinct lipoprotein species. As mentioned for
lipoprotein lipase, hepatic lipase has been tested 
in vitro to determine its lipolytic activity for different 
lipoprotein substrates. The highest activities were 
found with IDL (Sf 12-20), VLDL (d < 1.006 g/ml) and LDL 
(1.006 < d < 1.063 g/ml) but lipolytic activity against 
chylomicrons was very low (73, 353). Prior to this study 
the only in-vivo experiments investigating the role of 
hepatic lipase for apoB metabolism had been animal 
experiments, where the enzyme was inactivated by infusion 
of appropriate polyclonal antibodies (360, 361). In an 
experiment with cynomolgus monkeys, within hours after 
antibody infusion the mass of VLDL, IDL and light LDL
(Sf > 9) increased while the total mass of LDL decreased.
Injection of radiolabelled VLDL revealed, that these 
changes were due to a decreased catabolic rate of VLDL, 
resulting in a delayed VLDL to LDL transformation.
In the present study of apoB metabolism in a hepatic 
lipase deficient subject the most significant finding was 
the almost complete block of IDL to LDL conversion, 
resulting in a markedly increased IDL pool. This was in
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spite of a reduced transfer from VLDL2 to IDL of less than 
half of the normal rate. In contrast, the rate of transfer 
from VLDL2 to VLDL2 was unaffected. The in-vitro findings 
mentioned above and the results of the in-vivo studies 
discussed here and in the previous paragraph suggest that 
both enzymes, lipoprotein lipase and hepatic lipase mediate 
the delipidation of VLDL2 to form IDL. In contrast, for 
the transformation of IDL to LDL only hepatic lipase is 
essential. In the absence of hepatic lipase IDL or 
particles slightly denser than IDL become the end product 
of the apoB-lipoprotein delipidation cascade in plasma. 
Thus hepatic lipase is crucial for the formation of typical 
LDL, but also contributes to the delipidation of less dense 
apoB containing lipoproteins.
Total apoB synthesis in G.P. is below the normal 
average mainly because of very low VLDL^-apoB synthesis, 
while VLDL2~apoB synthesis is higher than normal. This 
constellation resembles the situation in apoE2/2 homo­
zygosity, another condition associated with accumulation of 
ft-VLDL resulting from impaired IDL to LDL transformation 
(see paragraph 4.2.4.).
Another abnormality of lipoprotein metabolism in 
hepatic lipase deficiency is the marked increase of HDL2 
at the expense of HDL3 , as the HDL2 to HDL3 conversion 
dependents on hepatic lipase activity. This means that 
CETP can no longer effectively exchange triglycerides from 
apoB-lipoproteins with cholesteryl esters from HDL which
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may explain a relative increase of the triglyceride content 
in these lipoprotein subfractions (Table 15).
4.3.3. Homozygous familial hypercholesterolaemia
In the previous discussion of apoB metabolism the 
role of LDL-receptors was repeatedly addressed. Patients 
with homozygous FH provide the unique opportunity to study 
human apoB metabolism in the absence of this metabolic 
route (301, 369). Langer et a l . concluded in 1972 from 
their LDL-turnover studies in patients with heterozygous 
FH that hypercholesterolaemia in these subjects was due 
to a decreased FCR for LDL (130). In 1974 the discovery of 
the LDL-receptor and its defect in FH by Goldstein and 
Brown unveiled the molecular basis for this disorder of 
lipoprotein metabolism (77, 121). Only gradually it became 
apparent that the function of the LDL-receptor in 
apolipoprotein B metabolism is far more versatile than just 
to mediate the degradation of LDL via receptor-binding. 
Turnover studies in heterozygous and homozygous FH patients 
by Soutar et al. (363) suggested that the catabolism of IDL 
is also delayed, while VLDL metabolism was not 
significantly different from normal controls. However, a 
more detailed analysis of VLDL-turnover requires a 
comprehensive kinetic model of apoB metabolism as applied 
in the metabolic studies discussed in previous sections.
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Results from two studies of apoB metabolism in homozygous 
FH patients were presented in paragraph 3.6.
While VLDL]_ metabolism was unaltered in both 
patients as compared to controls, VLDL2 metabolism differed 
in several respects. The pool size of VLDL2 was higher 
because of a significant increase of remnant particles, 
represented in the metabolic model by M ( 6) (Fig. 44, 
Table 21). This was reflected by a corresponding change in 
VLDL2 composition with a cholesteryl ester/triglyceride 
ratio of 1.6 versus 0.6 in normal controls (Table 20). 
The accumulation of remnants is probably due to a prolonged 
VLDL2 residence time in plasma allowing for more extensive 
cholesteryl ester transfer from HDL. A tendency for 
subnormal clearance rates k(0 ,6 ) also contributed to 
increased remnant concentrations. The main reason, however, 
for the increased plasma residence time of VLDL2 (Fig. 41) 
and IDL (Fig. 42) was a delay in the delipidation process, 
mirrored by 75% reductions of the transfer rates of VLDL2 
to IDL and of IDL to LDL. These delipidation steps have 
been linked in the previous paragraph with the action of 
hepatic lipase. As there are no clues to a reduced hepatic 
lipase activity in homozygous FH, it can be inferred 
that the LDL-receptor is an additional important functional 
component for the conversion of VLDL to LDL by delipidation 
in the plasma compartment. A model of this process based 
on the results of the metabolic studies presented so far 
will be discussed in section 4.4.
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Besides a reduced IDL to LDL transfer rate, the 
fractional rate for direct catabolism of IDL was 
significantly reduced. This confirms that IDL degradation 
is mediated in part by the LDL-receptor as previously 
shown by VLDL-turnover studies (363) and by direct 
investigation of IDL metabolism (358). As a result, the 
IDL pool size increased four-fold. Expectedly, LDL-FCRs in 
both patients were markedly reduced to less than one-third 
of the normal value. Studies with native and chemically 
modified LDL have shown that this residual LDL-FCR is 
almost entirely due to receptor independent LDL 
catabolism (364). Because of decreased catabolism LDL pool 
size was increased proportionally to the same extent as 
observed for IDL.
Two observations with the present study are related 
to apoB synthesis rather than to apoB catabolism. Firstly, 
both patients had relatively high rates of total apoB- 
synthesis and in the case of J.C. there was a marked 
increase of total LDL-apoB production. Five homozygous FH 
patients (including J.C. and M.M.) had on average a total 
apoB synthetic rate which was 65% higher than normal (301). 
This confirms findings from several other studies in 
heterozygous and homozygous FH patients, where on the basis 
of LDL-turnover data increased rates of LDL synthesis were 
calculated (70, 131). Secondly, direct synthesis of LDL 
and, in the case of J.C., also of IDL was far higher than
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observed in the control group, again confirming previous 
reports (70, 132) .
In this context, animal experiments, using the WHHL 
rabbit as a model for the human disease, are of particular 
interest (365). In one metabolic study a markedly 
increased conversion of VLDL to LDL was noted due to a 
reduction in direct catabolism of IDL which increased the 
fraction of IDL particles transformed through further 
delipidation into LDL (366). This mechanism was proposed 
as an explanation for LDL oversynthesis in humans (365). 
However, mass transfer from IDL to LDL in the two FH 
patients of the present study was not increased and was 
not significantly different from normal controls when three 
additional homozygous FH patients were considered (301). 
The effects of reduced IDL clearance were balanced in 
humans by an equally significant reduction in the transfer 
rate of IDL to LDL. While a diversion of LDL precursors 
from direct catabolism to conversion into LDL can, in 
principal, explain some of the observed increase of 
LDL-apoB synthesis, this mechanism does not contribute to 
an understanding, why total apoB synthesis is often 
increased in familial hypercholesterolaemia.
Another discrepancy between results obtained from 
experiments with WHHL rabbits and findings in patients with 
homozygous FH became apparent when the problem of direct 
LDL synthesis was addressed. In the animal experiments all 
apoB was found to be synthesised as VLDL accounting as a
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precursor for the whole of LDL production (367). 
Accordingly, in the density range of LDL no apoB-100 was 
found in liver perfusates from WHHL rabbits (368) .
The metabolic study of five homozygous FH patients, 
including the two subjects discussed in this paragraph, 
showed some variation of the degree of direct LDL-apo B 
synthesis ranging from no LDL-apoB synthesis in one subject 
to 29% of the total apoB synthesis as the other extreme. 
This correlates negatively with the total triglyceride 
level observed in these patients (r = -0.84) and with the 
percentage of apoB in plasma being associated with VLDL]_ 
(r = -0.90). The number of patients investigated is too 
small to draw further conclusions. Nevertheless, it is 
worth noticing that WHHL rabbits are usually mildly 
hypertriglyceridaemic. It can be speculated that the apoB 
metabolism in these animals represents the situation in 
human patients with homozygous FH combined with some 
hypertriglyceridaemia but little or no direct synthesis of 
LDL-apoB. Other patients with normal triglyceride levels 
showed significant input of LDL not derived from VLDL 
precursors into the LDL pool. Variability of triglyceride 
levels in homozygous FH has been noticed by several 
authors (122, 369) but observations regarding the clinical 
significance of this variation are scarce. In a group of 
92 patients with heterozygous FH elevated triglyceride 
levels were of predictive value for the development of 
coronary heart disease (Dr M Seed, personal communication).
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Recently quantitative and qualitative differences in the 
VLDL subfraction were reported from WHHL rabbits with 
high and low incidence rates for CHD (372, 373). It remains 
to be seen whether or not these observations are of 
significance for the understanding of the disease in 
humans.
4.4. The Current Concept of VLDL to LDL Interconversion
Throughout the previous sections the significance of 
various genetically determined factors for the metabolism 
of apolipoprotein B has been examined. In this final 
chapter the results will be presented as part of an 
integral concept based on the metabolic model which was 
used for the analyses of the metabolic studies. Moreover, 
some general features of apoB metabolism will be 
addressed.
The metabolic model illustrated in Fig. 8 provides 
for two parallel pathways of delipidation for particles 
which enter the plasma compartment either as VLDLf (Sf 60- 
-400) or as VLDL2 (Sf 20-60) . Two independent delipidation 
routes are required because the two VLDL subfractions show 
quantitative and qualitative differences in their metabolic 
behaviour (154) . In all turnover studies where the metab­
olism of both VLDL species was monitored simultaneously the 
following observations were made: VLDL2 was transferred
into LDL at a higher rate and more rapidly than VLDL]_ and
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LDL derived from VLDL2 was catabolised faster than LDL 
derived from VLDL^. Consequently, the decay curves for LDL 
derived either from small or from large VLDL show different 
maxima and terminal decay rates (Fig. 21-23). This has led 
to the concept of metabolic channels in the VLDL to LDL 
conversion process. That is, the metabolic characteristics 
of an apoB containing lipoprotein are in part determined by 
its origin (374). It has been argued that, since it takes 
longer for large VLDL to get delipidated and reduced to the 
particle size of LDL, randomly occurring degradation and 
elimination from the plasma is more probable, thus reducing 
the chance of large VLDL becoming LDL. However, different 
metabolic properties of LDL subfractions derived from 
different precursor particles are strong evidence for 
genuine metabolic heterogeneity between VLDL subfractions 
and support the concept of metabolic channelling. 
Quantitatively, the percentage of VLDL2 converted into LDL 
was about double that which had been observed for VLDL^ to 
LDL conversion. This ratio was remarkably constant for 
normolipidaemic as well as hyperlipidaemic subjects, 
indicating that metabolic channelling is a universal 
feature of apolipoprotein B metabolism. The differences 
between FCRs for LDL, derived from VLDL2 , and LDL, derived 
from VLDL]_, was greatest in apoE2/2, intermediate in 
apoE3/3 and smallest in apoE4/4 subjects (see k(0,10) and 
k(0,ll) in Table 11). It may be speculated that this has
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to do with different levels of receptor-mediated LDL- 
clearance (see paragraph 4.2.4.) provided LDL derived from 
VLDL2 binds better to the LDL-receptor than LDL derived 
from VLDL„.
Examination of LDL metabolism in normolipidaemics 
with different apoE phenotypes (paragraph 4.2.2.) provides 
an example for the importance of metabolic heterogeneity 
within the VLDL density range. Due to different synthetic 
rates for VLDL]_-apoB and VLDL2~apoB, the relative 
proportions of LDL subspecies were changed in apoE2/2 as 
compared to apoE3/3 subjects, resulting in a different 
overall catabolic rate for LDL despite very similar 
catabolic rates for LDL subspecies.
The mechanisms which predispose different VLDL 
subspecies for different metabolic fates are unknown yet. 
One possibility is that the particles differ in their 
apolipoprotein composition. Havel et a l . studied, in 
rabbits, the metabolism of apoB containing lipoproteins 
with and without concomitant apoE (375, 37 6 ). They found 
that VLDL which contains both apoB and apoE, is removed 
from the plasma more rapidly than VLDL containing apoB only 
and that a smaller fraction of apoB/E particles was 
converted into LDL. There are obvious similarities between 
the results of these animal studies and VLDL-turnovers in 
humans. However, unless it is demonstrated that in humans 
particles derived from VLDL]_ differ in their apoE content 
from VLDL2 derived lipoproteins, the significance of these
163
findings remains uncertain. Heterogeneity, other than 
defined by metabolic properties, has been demonstrated 
for all apoB containing lipoprotein subclasses (377). 
Equilibrium density-gradient ultracentrifugation and non­
denaturing gradient-gel electrophoresis have revealed for 
instance the existence of three or even four LDL subclasses 
which are present in different proportions in males or 
females, normo- or hypertriglyceridaemia or subjects with 
or without CHD (378). For the production of IDL and LDL 
subspecies a hypothetical metabolic model with two pathways 
for large and small IDL has been proposed and it remains to 
be seen whether this coincides with the dual pathways of 
VLDL to LDL transfer outlined above.
A second more general aspect of VLDL to LDL 
conversion deals with the quantitative relationships 
between metabolic precursors, VLDL^ and VLDL2 , and the 
end product, LDL. In normolipidaemic apoE3/3 subject about 
one-third of VLDL-apoB, synthesised as VLDL^ or VLDL2 was 
transferred into LDL while the remainder was directly 
catabolised from the VLDL and IDL subcompartments. In 
three out of five subjects this accounted for 80-100% of 
the measured LDL pool. In two subjects, however, VLDL 
precursors accounted for only 65% and 50% of the measured 
LDL pool, which made it necessary to accept direct LDL 
synthesis and input into the LDL pool. The rate of 
direct LDL-apoB synthesis was on average less than 10% of 
the total apoB synthesis. In apoE4/4 homozygotes 
approximately half of the VLDL-apoB was transferred into
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LDL accounting, in four out of five subjects, for the
measured LDL pool. The higher rates of apoB transfer from
VLDL to LDL in apoE4/4 was the result of impaired clearance 
of potential LDL-precursors because of LDL-receptor down- 
regulation as previously discussed (see section 4 .2 .). 
Wherever direct LDL-apoB synthesis occurred, the assumption 
was that de novo input distributed evenly between the two 
LDL subcompartments. This, however, is not necessarily so, 
causing a degree of uncertainty for the calculation of the 
total LDL-FCR in this situation. In apoE2/2 subjects only 
one quarter of the apoB synthesised as VLDL]_ or VLDL2 was 
converted into LDL due to the marked decrease of IDL to LDL 
transfer coupled with increased direct catabolism of IDL 
and despite the significantly reduced direct catabolism of 
VLDL lipoproteins. Direct LDL-apoB synthesis was not
observed in these subject.
In summary, in normolipidaemic subjects 25-50% of
VLDL-apoB are converted into LDL. In some individuals, 
notably of the apoE3 and apoE4 phenotype, direct LDL-apoB 
synthesis occurs, but this is less than 15% of total apoB 
synthesis. Higher percentages of direct LDL-apoB synthesis 
were observed in homozygous FH where it contributed up to 
30% of the total apoB synthesis. These results are similar 
to findings reported in several studies reported by Grundy 
and his colleagues (95, 177, 380). The rate of VLDL
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conversion into LDL was about 40% and LDL de novo synthesis 
occurred in a range between 0 and 50% of apoB synthesis.
Experiments with monkeys where the metabolism of 
deferentially labelled VLDL and LDL was studied 
simultaneously confirm that significant amounts of LDL are 
derived from sources other than circulating VLDL (72, 381). 
Several mechanisms for direct input of LDL are possible. 
Firstly, particles of the size of LDL may be secreted by 
the liver, but data are only available from cholesterol fed 
animals where the directly secreted lipoproteins were 
markedly different from circulating LDL (382). Secondly, 
direct input may occur in the density range of IDL with 
subsequent rapid transformation into LDL (178). Finally, a 
small VLDL pool may be converted rapidly, within minutes, 
into LDL. Such a pool would escape exogenous labelling and 
evidence for this mechanism, using ^H-Leu labelled hepatic 
VLDL, has been established recently in African green 
monkeys (72).
A synopsis of the mechanisms involved in VLDL-LDL 
transformation in humans is given in Fig. 47. In normo- 
lipidaemics, apoB enters the plasma compartment as VLDL]_ or 
VLDL2 at a ratio of about 2:1. Some VLDL]_ particles are 
rapidly removed from the plasma but most are delipidated by 
lipoprotein lipase to form particles of the same density as 
de novo synthesised VLDL2 . Further delipidation of the two 
lipoprotein subspecies within the density range of VLDL2 
and transfer into IDL is mediated by both lipolytic
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enzymes, lipoprotein lipase and hepatic lipase. Remnants 
from this density interval are cleared by receptor mediated 
uptake either through the "apoE"-receptor or through the 
LDL-receptor (334) . The conversion of IDL into LDL depends 
on the interaction of three components: hepatic lipase, the 
LDL-receptor and functional apoE are all important. The 
anatomical site of IDL to LDL transformation is most likely 
the liver, as demonstrated by liver perfusion studies in 
humans, showing hepatic extraction of VLDL2 and IDL (69). 
Hepatic lipase has been localised by immunofluorescence and 
immuno-electron microscopy in rat livers exclusively on the 
liver endothelial cells (383) . Endothelial cells also 
express the LDL-receptor, however, when contact-inhibited 
they bind lipoproteins but do not internalise them (384). 
These observations, taken together suggest a mechanism 
whereby IDL in the hepatic sinusoids is first immobilised 
by binding to the LDL-receptor, then exposed to the 
lipolytic activity of hepatic lipase and subsequently 
released as mature LDL. In-vitro and in-vivo studies show 
that functional apolipoprotein E is also important for this 
step but the mechanism of action is not yet known.
The results presented in this thesis were derived 
from turnover studies, where the metabolic rate of one or 
two exogenously labelled lipoprotein species had been 
followed. Observed data from such studies described 
primarily the catabolism of lipoproteins and only by 
inference synthetic rates can be obtained. Some of the
I
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most interesting results, such as reduced synthesis of apoB 
in apoE2 homozygosity or oversynthesis of apoB in 
homozygous FH, address the problem of how the synthesis 
of apolipoprotein B is regulated. Reliable measurements 
of synthetic rates for apolipoprotein B containing lipo­
proteins would probably enhance the understanding of the 
regulatory mechanisms involved in a way comparable to the 
contribution made by metabolic studies based on tracer 
kinetics. In a recent paper (385) a first approach in this 
direction was reported. Apolipoprotein B was labelled 
endogenously by infusions of a stable isotope incorporated 
in an amino acid (15 N-Gly). Fractional synthetic rates 
for VLDL-apoB were in good agreement with values obtained 
by tracer experiments. It is hoped that future 
investigations employing new techniques such as stable 
isotope kinetics for in-vivo studies in humans will produce 
useful information, enhancing our knowledge of 
apolipoprotein B metabolism and contributing to the 
prevention of atherosclerotic disease.
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TABLE 1-10 A:
Metabolism of large VLDL (Sf 60-400) in apoE3/3 homozygotes
n = 5
averages are % of initially injected radioactivity 
E3/3: VLDL1 (injected as tracer)
TIME AVG STD FSD
0 0.742 0.042 0.057
0.5 0.618 0 .068 0.11
1 0.475 0.105 0.221
1.5 0.374 0.101 0.271
2 0.264 0.097 0.368
3 0.178 0.076 0.429
4 0.103 0.046 0.454
6 0.047 0 .026 0.568
8 0.026 0 .013 0.53
10 0.013 0.009 0.69
14 0.006 0.002 0.353
24 0.009 0 .008 0.692
E3/3: VLDL2 (derived from VLDL1)
TIME AVG STD FSD
0 0.2 0.028 0.141
0.5 0.289 0.101 0.349
1 0.35 0.035 0.1
1.5 0.443 0.075 0.169
2 0.452 0.085 0.187
3 0.463 0.106 0.229
4 0.45 0.129 0.259
6 0.384 0.123 0.321
8 0.331 0.134 0.399
10 0.236 0.079 0.337
14 0.132 0.063 0.479
24 0.038 0.012 0.317
48 0.014 0.006 0.449
72 0.007 0.003 0.412
96 0.003 0 0.255
120 0.004 0.001 0.267
1-12
E3/3: IDL (derived from VLDL1)
TIME AVG STD FSD
0 0.023 0.007 0.31
1 0.057 0.02 0.36
2 0.063 0 0
3 0.1 0.034 0.331
4 0.106 0.023 0.22
6 0.147 0.057 0.392
8 0.21 0.071 0.376
10 0.194 0.05 0.259
14 0.224 0.043 0.194
24 0.174 0.042 0.245
48 0.1 0.022 0.224
72 0.053 0.012 0.238
96 0.028 0.011 0.249
120 0.018 0.005 0.305
144 0.015 0.007 0.483
168 0.013 0.009 0.672
192 0.008 0.005 0.608
216 0.005 0.002 0.396
240 0.003
E3/3: LDL (derived from VLDL1)
TIME AVG STD FSD
0 0.014 0.005 0.35
1 0.02 0.005 0.285
2 0.029 ERR ERR
3 0.028 0.004 0.159
4 0.041 0.01 0.286
6 0.041 0.013 0.322
8 0.059 0.028 0.469
10 0.077 0.03 0.397
14 0.132 0.057 0.434
24 0.163 0.083 0.508
48 0.166 0.063 0.382
72 0.154 0.039 0.259
96 0.132 0.037 0.284
120 0.109 0.04 0.37
144 0.078 0.023 0.3
168 0.068 0.023 0.345
192 0.057 0.021 0.381
216 0.051 0.019 0.376
240 0.038 0.015 0.408
264 0.025 0.012 0.481
288 0.024 0.012 0.501
TABLE 1-10 B:
1-13
Metabolism of small VLDL (Sf 20-60) in apoE3/3 homozygotes
n = 5
averages are % of initially injected radioactivity 
E3/3: VLDL2 (injected as tracer)
TIME AVG STD FSD
0 0.82 0.026 0.031
1 0.737 0.035 0.048
2 0.587 0.028 0.048
3 0.54 0.05 0.093
4 0.444 0.089 0.177
6 0.329 0.053 0.176
8 0.206 0.047 0.231
10 0.148 0.026 0.241
14 0.061 0.016 0.263
24 0.019 0.008 0.437
48 0.005 0.002 0.413
72 0.002 <0.001 0.267
96 0.001 <0.001 0.222
E3/3: IDL (derived from VLDL2)
TIME AVG STD FSD
0 0.098 0.014 0.152
1 0.164 0.036 0.223
2 0.211 0.075 0.419
3 0.269 0.061 0.206
4 0.316 0.082 0.26
6 0.368 0.08 0.219
8 0.382 0.072 0.181
10 0.365 0 .052 0.143
14 0.302 0.038 0.128
24 0.192 0.052 0.251
48 0.083 0.023 0.277
72 0.043 0.012 0.279
96 0.024 0 .007 0.303
120 0.014 0.006 0.484
144 0.01 0.003 0.379
168 0.008 0.004 0.562
192 0.007 0.004 0.536
216 0.005 0.002 0.588
240 0.005 0.002 0.599
264 0.004 0.003 0.75
1-14
E3/3: LDL (derived from VLDL2)
TIME AVG STD FSD
0 0.007 0.004 0.571
1 0.017 0.008 0.514
2 0.016 0.005 0.374
3 0.036 0.017 0.475
4 0.088 0.047 0.531
6 0.114 0.05 0.438
8 0.191 0.091 0.482
10 0.225 0.093 0.414
14 0.327 0.089 0.289
24 0.37 0.091 0.249
48 0.306 0.063 0.208
72 0.235 0.043 0.171
96 0.196 0.048 0.247
120 0.156 0.053 0.34
144 0.105 0.027 0.262
168 0.089 0.031 0.346
192 0.073 0.024 0.329
216 0.06 0.02 0.337
240 0.05 0.021 0.418
264 0.039 0.004 0.122
288 0.041 0.013 0.393
1-15
TABLE 1-11 A:
Metabolism of large VLDL (Sf 60-400) in apoE4/4 homozygotes
n = 5
averages are% of initially injected radioactivity
: VLDL1 (injected as tracer)
TIME AVG STD FSD
0 0.742 0.104 0.141
0.5 0.673 0.116 0.172
1 0.497 0.139 0.279
1.5 0.463 0.209 0.452
2 0.462 0.176 0.381
3 0.269 0.183 0.679
4 0.193 0.151 0.776
6 0.142 0.109 0.771
8 0.085 0.067 0.794
10 0.041 0.041 1.012
14 0.016 0.014 0.866
E4/4: VLDL2 (derived from VLDL1)
TIME AVG STD FSD
0 0.222 0.096 0.435
0.5 0.334 0.155 0.462
1 0.394 0.179 0.456
1.5 0.422 0.175 0.415
2 0.502 0.135 0.269
3 0.496 0.128 0.258
4 0.518 0.076 0 .148
6 0.476 0.101 0.213
8 0.426 0.133 0.314
10 0.346 0.073 0.212
14 0.226 0.069 0.311
24 0.129 0.037 0.289
48 0.032 0.012 0.387
72 0.016 0.007 0.449
96 0.011 0.003 0.374
120 0.007 0.003 0.484
1-16
E4/4: IDL (derived from VLDL1)
TIME AVG STD FSD
0 0.066 0.002 0.037
0.5 0.037 0.026 0.702
1 0.031 0.032 1.024
2 0.039 0.028 0.725
3 0.053 0.029 0.559
4 0.074 0.035 0.481
6 0.084 0.041 0.472
8 0.135 0 .057 0.424
10 0.145 0.061 0.426
14 0.188 0.056 0.301
24 0.224 0.079 0.353
48 0.152 0.032 0.213
72 0.093 0.027 0.294
96 0.069 0.043 0.616
120 0.046 0.021 0.447
144 0.028 0.011 0.363
168 0.017 0.006 0.399
192 0.014 0.006 0.406
216 0.017 0.006 0.362
240 0.011 0 .006 0.545
264 0.009 0.004 0.481
288 0.009 0.004 0.444
E4/4: LDL (derived from VLDL1)
TIME AVG STD FSD
0 0.008 0 .005 0.614
0.5 0.009 0.004 0.453
1 0.012 0.008 0.657
1.5 0.013 0.007 0.555
2 0.012 0.004 0.322
3 0 .018 0 .005 0.302
4 0.011 0.008 0.809
6 0.032 0.021 0.646
8 0.031 0.022 0.727
10 0.038 0.024 0.634
14 0.062 0.031 0.503
24 0.102 0.043 0.427
48 0.129 0.054 0.417
72 0.148 0.058 0.394
96 0.144 0.043 0.302
120 0.127 0.027 0.212
144 0.106 0.021 0.195
168 0.081 0.025 0.314
192 0.069 0.021 0.305
216 0.055 0.017 0.322
240 0.051 0.015 0.308
264 0.041 0.014 0.341
288 0.039 0.005 0.133
TABLE 1-11 B:
1-17
Metabolism of small VLDL2 (Sf 20-60) in apoE4/4 homozygotes
n = 5
averages are% of initially injected radioactivity 
E4/4: VLDL2 (injected as tracer)
TIME AVG STD FSD
0 0.811 0.059 0.073
0.5 0.809 0.079 0.098
1 0.781 0.095 0.122
1.5 0.712 0.102 0 .144
2 0.616 0.094 0.152
3 0.629 0.154 0.244
4 0.555 0.149 0.269
6 0.406 0.122 0.301
8 0.309 0.097 0.316
10 0.225 0.058 0.258
14 0.108 0.034 0.315
24 0.066 0.026 0.391
48 0.011 0.003 0.328
72 0.006 0.002 0.413
96 0.003 0.001 0.415
E4/4: IDL (derived from VLDL2)
TIME AVG STD FSD
0 0.145 0.051 0.345
0.5 0.122 0.038 0.311
1 0.107 0.011 0.099
1.5 0.183 0.061 0.337
2 0.175 0.032 0.182
3 0.234 0.057 0.245
4 0.337 0.033 0.099
6 0.332 0.072 0.219
8 0.388 0.096 0.249
10 0.375 0.107 0.286
14 0.356 0.109 0.307
24 0.292 0.071 0.242
48 0.131 0.034 0.261
72 0.092 0.027 0.303
96 0.044 0.028 0.646
120 6.037 0.023 0.627
144 0.024 0.012 0.508
168 0.021 0.008 0.402
192 0.015 0.008 0.597
216 0.018 0.005 0.303
240 0.012 0.008 0.712
264 0.013 0.004 0.353
288 0.009 0.004 0.456
1-18
E4/4: LDL (derived from VLDL2)
TIME AVG STD FSD
0 0.004 0.002 0.431
0.5 0.006 0.001 0.272
1 0.012 0.007 0.642
1.5 0.021 0.011 0.583
2 0.012 0.004 0.339
3 0.042 0.021 0.492
4 0.057 0.014 0.247
6 0.113 0.063 0.553
8 0.139 0.075 0 .541
10 0.159 0.044 0.275
14 0.258 0.071 0.275
24 0.348 0.088 0.254
48 0.351 0.088 0.251
72 0.309 0.071 0.231
96 0.264 0.051 0.195
120 0.217 0.039 0.182
144 0.174 0.026 0.152
168 0.135 0.019 0.144
192 0.113 0.021 0.191
216 0.095 0.018 0.197
240 0.079 0.014 0.185
264 0.065 0.017 0.271
288 0.047 0.029 0.633
1-19
TABLE 1-12 A:
Metabolism of large VLDL (Sf 60-400) in apoE2/2 homozygotes
n = 4
averages are % of initially injected radioactivity 
E2/2: VLDL1 (injected as tracer)
TIME AVG STD FSD
0 0.741 0.051 0.068
0.5 0.756 0.071 0.094
1 0.585 0.015 0 .025
1.5 0.532 0.025 0.047
2 0.512 0.116 0.227
3 0.466 0.145 0.311
4 0.394 0.115 0.293
6 0.197 0.045 0.231
8 0.217 0.106 0.491
10 0.214 0.101 0.473
14 0.081 0.042 0.529
24 0.067 0.042 0.629
48 0.021 0 .006 0.331
72 0 . 008 0.005 0.677
E2/2: VLDL2 (derived from VLDL1)
TIME AVG STD FSD
0 0.198 0.022 0.111
0.5 0.356 0.081 0.225
1 0.465 0.118 0.254
1.5 0.581 0.118 0.204
2 0.638 0.102 0.159
3 0.691 0.116 0.169
4 0.744 0.132 0.177
6 0.83 3 0.033 0.041
8 0.732 0.067 0.092
10 . 0.695 0.062 0.089
24 0.508 0.042 0 . 083
48 0.175 0 .009 0.059
72 0.104 0.041 0.401
96 0.043 0.003 0.087
120 0.034 0.021 0.627
144 0.028 0.015 0.556
168 0.016 0.006 0.389
192 0.012 0.005 0.461
216 0.007 0.003 0.505
240 0.005 0.003 0.596
264 0.005 0.001 0.399
1-20
E2/2: IDL (derived from VLDL1)
TIME AVG STD FSD
0 0.012 0.003 0.317
0.5 0.028 0.015 0.552
1 0.031 0.015 0.486
1.5 0.045 0.035 0.763
2 0.034 0.017 0.519
3 0.049 0.022 0.449
4 0.057 0.026 0.456
6 0 .076 0.025 0.329
8 0.107 0.042 0.395
10 0.129 0.042 0.324
14 0.223 0.036 0.162
24 0.217 0.083 0.382
48 0.196 0.064 0.326
72 0.125 0.043 0.348
96 0.091 0.023 0.253
120 0.056 0.006 0.111
144 0.041 0.005 0.137
168 0.036 0.004 0.135
192 0.028 0 .005 0.176
216 0.021 0.006 0.276
240 0.018 0.003 0.185
264 0.007 <0.001 0.066
288 0.006 <0.001 0.076
E2/2: LDL (derived from VLDL1)
TIME AVG STD FSD
0 0.007 0.001 0.143
0.5 0.008 0.003 0.408
1 0.011 0 .003 0.361
1.5 0.012 0.003 0.232
2 0.012 0.002 0 .226
4 0.012 0.004 0.333
6 0.015 0.005 0.354
8 0.018 0.008 0.467
10 0.022 0.008 0.394
14 0.043 0.012 0.292
24 0.042 0.014 0.331
48 0.039 0.012 0.322
72 0.043 0.016 0.379
96 0.044 0.022 0.522
120 0.043 0.019 0.442
144 0.026 0 .008 0.313
168 0.023 0.008 0.347
192 0.021 0.011 0.512
216 0.022 0.009 0.445
240 0.019 0.008 0.435
TABLE 1-12 B:
1-21
Metabolism of small VLDL (Sf 20-60) in apoE2/2 homozygotes
n = 4
averages are % of initially injected radioactivity 
E2/2: VLDL2 (injected as tracer)
TIME AVG STD FSD
0 0.885 0.049 0.056
0.5 0.891 0.041 0.046
1 0.807 0.101 0.125
1.5 0.853 0.093 0.109
2 0.783 0.073 0.093
3 0.717 0 .098 0.136
4 0.633 0 .038 0.061
6 0.633 0.106 0.167
8 0.532 0 .091 0.169
10 0.427 0.056 0.131
14 0.319 0.089 0.281
24 0.223 0.012 0.055
48 0.071 0.011 0.162
72 0.033 0.011 0.331
96 0.015 0.002 0.134
120 0.011 0.003 0.324
144 0.005 0.002 0.408
168 0.004 0 .001 0.353
192 0.003 <0.001 0.128
E2/2: IDL (derived from VLDL2 )
TIME AVG STD FSD
0 0.073 0.038 0.519
0.5 0.112 0 .041 0.363
1 0.149 0 .066 0.442
1.5 0.178 0.069 0.386
2 0.173 0.084 0.491
3 0.224 0.089 0.397
4 0.266 0.082 0.309
6 0.296 0 .048 0.161
8 0.316 0.068 0.217
10 0.351 0.062 0.177
14 0.373 0.068 0.183
24 0.279 0.043 0.154
48 0.192 0.036 0.189
72 0.101 0.029 0.287
96 0.066 0 .011 0.155
120 0.037 0.001 0.049
144 0.027 0.002 0.104
168 0.022 <0.001 0.037
192 0 .016 0.002 0.159
216 0.013 0 .003 0.252
240 0.011 0 .003 0.264
264 0 .005 0 .001 0.201
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E2/2: LDL (derived from VLDL2)
TIME AVG STD FSD
0 0.003 0.002 0.622
0.5 0.003 0 .002 0.509
1 0.007 0.004 0.536
1.5 0.011 0.002 0.143
2 0.009 0.001 0.129
3 0.011 0.001 0.129
4 0.017 0.007 0.411
6 0.028 0.007 0.253
8 0.046 0.019 0.427
10 0.064 0 .018 0.286
14 0.102 0.032 0.321
24 0.089 0 .021 0.229
48 0.071 0.012 0.172
72 0.063 0 .017 0.269
96 0.059 0.007 0.131
120 0.052 0.005 0.109
144 0.036 0.011 0.322
168 0.031 0.008 0.284
192 0.023 0.008 0.378
216 0.023 0.005 0.248
240 0.021 0.005 0.279
TABLE 1-13: 1-23
Calculated compartment masses and rate constants 
in apoE3/3 homozygotes
Name M (1) k(0,l) k (2,1) M (2) k (4 , 2) k {6 , 2)
NC 50 0.48 7.87 20 19.9 0.07
CD 47 2.13 6.94 19 17.4 0.04
MF 78 6.43 6.67 22 24 0.23
EK 41 13.28 4.43 8 24 0.34
MM 91 3.98 5.61 21 24 0.11
mean 61 5.26 6.3 18 21.9 0.16
± s ±20 ±4.47 ±1.18 ±5 ±2.7 ±0.11
Name M (4) k(Q,4) k ( 8,4) k (9 , 4) k (11 r 4) M (5)
NC 83 1.26 2.77 0.71 0 59
CD 66 2.91 1.44 0.62 0 143
MF 129 1.29 2.2 0.2 0.3 48
EK 29 0.69 4.76 0.68 0 36
MM 147 1.92 1.24 0.26 0.02 34
mean 91 1.61 2.48 0.49 0.06 64
± s ±43 ±0.76 ±1.26 ±0.21 ±0.12 ±41
Name k (0,5) k (7 , 5) k (10,5} M (6) k (0 , 6) M (7)
NC 2.61 4.05 0 3 0.51 49
CD 2.28 2.33 0 2 0.41 199
MF 0 3.66 0 7 0.72 66
EK 3.38 1.94 0 3 0.93 71
MM 1.74 4.67 1.21 4 0.52 85
mean 2.01 3.33 0.24 3.8 0.62 94
± s ±1.13 ±1.03 ±0.48 ±1.7 ±0.19 ±54
Name k (0 , 7) k (10 f 7) M (8) k(0,8) k (11,8) M (9)
NC 0 4.92 71 1.1 2.15 125
CD 0 1.67 63 0.38 1.12 141
MF 0 2.63 241 0.31 0.87 83
EK 0 0.98 51 1.28 1.44 83
MM 0 1.86 176 0.34 0.7 93
mean 0 2.41 120 0.68 1.26 105
± s 0 ±1.36 ±75 ±0.42 ±0.51 ±24
TABLE 1-13 (contd.)
1-24
Name k ( 0 , 9 }
NC 0.47
CD 0.29
MF 0.31
EK 0.24
MM 0.41
mean 0.34
± s ±0.08
M (10) k (0,10)
797 0.3
1148 0.29
644 0.27
257 0.27
769 0.26
723 0.28
±287 ±0.01
M (11) k (0,11)
725 0.21
470 0.15
1459 0.17
308 0.24
548 0.23
702 0.2
±402 ±0.03
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TABLE 1-14:
Calculated 
in apoE4/4
compartment masses 
homozygotes
and rate constants
Name M (1) k (0,1) k (2,1) M (2) k (4, 2) k (6,2)
TS 85 4.15 3.58 13 24 0.23
CB 39 4.57 5.29 9 24 0.24
WB 105 2.53 1.98 53 3.89 0.01
MW 21 18.1 3.91 7 12.43 0.08
MD 17 0 8.16 12 11.21 0.03
mean 53.4 5.87 4.58 18.8 15.1 0.12
± s ±35.3 ±6.32 ±2.08 ±17 .2 ±7.8 ±0.10
Name M (4) k (0 , 4) k (8 , 4) k (9 , 4) k (11,4) M (5)
TS 118 0.6 1.88 0.07 0 114
CB 87 1.56 0.46 0.28 0.04 25
WB 91 0 1.84 0.44 0 24
MW 34 0.5 1.5 0.36 0.06 13
MD 38 2.42 0.49 0.27 0.47 28
mean 73.6 1.02 1.23 0.28 0.11 40.8
± s ±32.5 ±0.86 ±0.63 ±0.12 ±0.18 ±37.0
Name k (0 , 5) k (7 , 5) k (10,5) M (6) k (0 , 6) M (7)
TS 0 2.84 0 5 0.53 212
CB 0 9.78 0 4 0.48 193
WB 0 7.51 0 2 0.28 89
MW 0 15.96 0 1 0.38 76
MD 0 12.29 0 1 0.4 135
mean 0 9.68 0 2.6 0.41 141
± s 0 ±4.42 0 ±1.62 ±0.09 ±54
Name k (0 ,7) k (10,7) M (8) k ( 0 f8) k (11,8) M (9)
TS 0 1.53 202 0.52 0.58 52
CB 0 1.27 52 0 0.77 110
WB 0 2.03 84 0.58 1.41 103
MW 0 2.71 49 0.48 0.57 63
MD 0 2.54 28 0.39 0.28 41
mean 0 2.02 83 0.39 0.72 73.8
± s 0 ±0.56 ±62 ±0.21 ±0.38 ±27 .7
TABLE 1-14 (contd.) 1-26
Name k(0,9) M (10) k (0,10) M (11) k (0,11)
TS 0.16 1473 0.22 688 0.17
CB 0.22 1114 0.22 435 0.1
WB 0.39 819 0.22 592 0.2
MW 0.19 986 0.21 176 0.17
MD 0.25 1434 0.24 118 0.22
mean 0.24 1165 0.22 402 0.17
± s ±0.08 ±254 ±0.01 ±224 ±0.04
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'TABLE 1-15:
Calculated compartment masses and rate constants
in apoE2/2 homozygotes
Name M (1) k(0,l) k (2,1) M (2) k(4,2) k (6 , 2)
AY 38 0 2.08 3 24 0.66
MB 41 0 5.66 10 24 0.11
GS 68 0.77 2.99 11 19.01 0.11
EW 57 0.41 4.25 14 17.33 0.13
mean 51 0.3 3.75 9.5 21.1 0.25
± s ±12.2 ±0.32 ±1.35 ±4.03 ±3.0 ±0.24
PM 50 2.84 11.32 23 24 0.09
Name M (4) k (0 , 4) k (8 , 4) k (9 , 4) k (11,4) M (5)
AY 92 0 0.67 0.14 0.03 104
MB 194 0 0.9 0.29 0 6
GS 146 0.03 0.83 0.44 0.08 59
EW 202 0.09 0.92 0.08 0.1 14
mean 159 0.03 0.83 0.24 0.05 45.8
± s ±44 ±0.04 ±0.10 ±0 .14 ±0.04 ±39.2
PM 176 0.43 2.3 0 0.46 52
Name k (0 , 5) k (7,5) k (10,5) M (6) k (0 , 6) M (7)
AY 0 3.2 0 7 0.3 192
MB 0 15.3 0 4.6 0.23 93
GS 0 7.99 0 4 0.29 255
EW 0 14.2 0.17 6.4 0.28 118
mean 0 10.2 0.04 5.5 0.28 165
± s 0 ±4.9 ±0.07 ±1.24 ±0.03 ±64
PM 0 5.13 0 4 0.47 53
Name k (0,7) k (10,7) M (8) k (0 , 8) k (11,8) M (9)
AY 1.21 0.52 13 4.8 0 41
MB 0.43 0.56 34 4.56 0.64 151
GS 1.24 0.61 70 1.73 0 169
EW 0.49 1.2 137 1.36 0 95
mean 0 . 84 0.72 63.5 3.11 0.16 114
± s ±0 . 38 ±0.28 ±47.1 ±1.58 ±0.28 ±50
PM 0 5.04 270 1.5 0 0
1-28
TABLE 1-15 (contd.)
Name k (0,9) M (10) k (0,10) M (11) k (0,11)
AY 0.31 417 0.24 23 0.13
MB 0.37 217 0.24 135 0.16
GS 0.38 520 0.3 84 0.14
EW 0.17 378 0.38 67 0.3
mean 0.31 383 0.29 77.3 0.18
± s ±0 .08 ±109 ±0.06 ±40.1 ±0.07
PM 0 282 0.94 261 0.31
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TABLE I
k (0,1) 
k (2 ,1) 
k(4,2) 
k (6 , 2) 
k (0 , 6) 
k (0 , 4) 
k (0 , 5) 
k ( 8 , 4) 
k(0,8) 
k (7 , 5) 
k (0 , 7 ) 
k (9 , 4) 
k (0,9) 
k (11, 8) 
k(0,11) 
k (10,7) 
k (0,10) 
k (10,5) 
k(ll,4)
mean 
± s
16: FSD of rate constants (apoE3/3)
NC CD MF EK MM
0.423 0.164 0.035 0.016 0.034
0.026 0.051 0.031 0 .046 0.023
0 .166 0.239 0.157 0.098 0.087
0.137 0.212 0 .138 0 .089 0 .087
0.012 0.022 0 .008 0.01 0.013
0 .133 0.058 0 . 099 0.362 0 .028
0.266 0.082 0 0 .063 0.669
0.057 0.093 0 .043 0.051 0.031
0.144 0.282 0.149 0.073 0.081
0.136 0.055 0 .215 0 .054 0.173
0 0 0 0 0
0.044 0.084 0.172 0.04 0.073
0.015 0.029 0.038 0.015 0.015
0.059 0.107 0 .059 0.034 0.036
0.017 0.041 0.144 0.011 0.014
0.11 0.044 0.178 0.056 0.092
0.037 0.022 0.059 0.028 0.038
0 0 0 0 0.194
0 0 0.125 0 0.368
0.094 0.083 0.087 0.055 0.108
±0.105 ±0.081 ±0.068 ±0.078 ±0.157
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TABLE 1-17: FSD of rate constants (apoE4/4)
TS CB WB MW MD
k (0 ,1) 0.019 0.027 0.022 0.009 0
k (2 ,1) 0 .022 0.023 0 .027 0 .029 0.034
k(4,2) 0.086 0.115 0.08 0.073 0.111
k (6 , 2) 0.092 0.115 0.082 0.078 0.094
k (0 , 6) 0.017 0.012 0.019 0.011 0.008
k (0 , 4) 0.123 0.027 0 0 .108 0.026
k (0,5) 0 0 0 0 0
k(8,4) 0.031 0.051 0 .069 0.034 0.083
k (0 , 8) 0 .066 0 0.179 0.075 0.125
k (7 , 5) 0 .047 0.096 0 .109 0.073 0 .062
k (0 , 7) 0 0 0 0
k (9 , 4) 0.135 0.069 0.041 0.054 0.098
k (0,9) 0. 067 0.027 0.011 0.021 0.023
k(ll,8) 0.033 0.08 0.046 0.047 0.143
k(0,ll) 0.018 0.045 0.014 0.021 0.024
k (10,7) 0.037 0.034 0.091 0.047 0.032
k (0,10) 0.023 0.038 0.047 0.026 0.018
k (10,5) 0 0 0 0 0
k (11,4) 0 0.126 0 0.187 0.063
mean 0.043 0.047 0.044 0.05 0 .05
± s ±0.04 ±0.041 ±0.047 ±0.045 ±0.045
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TABLE 1-18:
AY
FSD o
k (0,1) 0
k (2,1) 0.028 0.
k(4,2} 0.172 0.
k (6 , 2) 0.162 0.
k (0 , 6) 0.005 0.
k(0,4) 0
k (0 , 5) 0
k (8 , 4) 0.119 0.
k (0 , 8 ) 0.134 0.
k (7 , 5) 0.039 0.
k (0 , 7 ) 0.05 0.
k (9 , 4) 0.029 0.
k (0 , 9) 0.009 0.
k (11,8) 0 0.
k (0 ,11) 0.036 0.
k (10,7) 0.027 0 .
k (0,10) 0.016 0 .
k(10,5) 0
k (11,4) 0.181
mean 0.056 0.
± s ±0.063 ±0.
constants (apoE2/2)
GS EW PM
0.094 0.214 0.085
0.024 0.021 0.021
0.108 0.076 0.088
0.101 0.076 0 .08
0.006 0.005 0.006
2.369 0.389 0.187
0 0 0
0.069 0.032 0.026
0 .098 0.038 0.019
0.081 0 .452 0 .121
0 .077 0.371 0
0.037 0.074 0
0.012 0.05 0.017
0 0 0
0.031 0.027 0.016
0.038 0.077 0.155
0.029 0.06 0.054
0 1.234 0
0.056 0.04 0.038
0.174 0.168 0.046
±0.533 ±0.293 ±0.059
f rate
MB
0
014
134
132
009
0
088
103
294
442
026
012
083
023
108
119
0
0
093
114
TABLE 1-19:
Apolipoprotein B metabolism in apoE3/3 homozygotes
VLDL (Sf 60-400) fract. rate
direct plasma direct transfer
synth. pool catab. to VLDL2
[mg/d] [mg] [pools/d]
NC 418 50 0.48 7.87
CD 426 47 2.13 6.94
MF 1022 78 6.43 6.67
EK 726 41 13.28 4.43
MM 872 91 3.98 5.6
mean 693 61 5.26 6.3
± s ±240 ±20 ±4.47 ±1.18
VLDL (Sf 20-60) fract. rate
direct flux from plasma direct transfer
synth. VLDL1 pool catab. to IDL&LDL
[mg/d3 [mg] [pools/d]
NC 393 394 154 1.58 3.22
CD 659 326 230 2.26 2.04
MF 174 520 205 0.84 2.55
EK 190 182 75 1.91 3.04
MM 259 510 208 1.65 2.04
mean 335 386 176 1.65 2.58
± s ±179 ±125 ±55 ±0.47 ±0.49
IDL (Sf 12-20) fract. rate
direct flux from plasma direct transfer
synth. VLDL2 pool catab. to LDL
[mg/d] [mg] [pools/d]
NC 0 528 242 0.57 1.62
CD 0 469 405 0.16 1.01
MF 0 484 389 0.26 0.98
EK 0 228 204 0.42 0.7
MM 0 380 353 0.28 0.8
mean 0 418 319 0.34 1.02
± s ±106 ±81 ±0.14 ±0.32
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TABLE I- 19 (contd.)
LDL (Sf 0-12) total
direct flux from plasma LDL-FCR apo B
synth. IDL&VLDL2 pool synth.
[mg/d] [mg] [pools/d] [mg/d]
NC 0 391 1495 0.26 811
CD 97 404 2000 0.25 1307
MF 0 422 2141 0.2 1196
EK 95 143 950 0.25 1063
MM 0 326 1294 0.25 1131
mean 38 337 1576 0.24 1102
± s ±47 ±102 ±442 ±0.02 ±166
TABLE 1-20:
Apolipoprotein B metabolism in apoE4/4 homozygotes
1-34
VLDL (Sf 60-400)
fract. rate
direct plasma direct transfer
synth. pool catab. to VLDL2
[mg/d] [mg] [pools/d]
TS 657 85 4.15 3.58
CB 384 39 4.57 5.29
WB 474 105 2.53 1.98
MW 461 21 18.05 3.91
MD 139 17 0 8.16
mean 423 53 5.86 4.58
± s ±168 ±35 ±6.3 ±2.08
VLDL (Sf 20-60)
fract. rate
direct flux from plasma direct transfer
synth. VLDL1 pool catab. to IDL&LDL
[mg/d] [mg] [pools/d]
TS 324 304 250 0.3 2.22
CB 245 206 125 1.1 2.5
WB 180 208 170 0.01 2.28
MW 207 82 55 0.32 4.95
MD 344 139 79 1.15 4.95
mean 260 188 136 0.58 3.38
± s ±64 ±75 ±69 ±0 .46 ±1.29
IDL (Sf 12-20)
fract. rate
direct flux from plasma direct transfer
synth. VLDL2 pool catab. to LDL
[mg/d] [mg] [pools/d]
TS 0 554 466 0.24 0.95
CB 0 309 355 0.07 0.8
WB 0 387 272 0.33 1.1
MW 0 272 191 0.18 1.23
MD 0 373 203 0.1 1.73
mean 0 379 297 0.18 1.16
± s ±97 ±103 ±0.09 ±0.32
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TABLE 1-20 (contd.)
LDL (Sf 0-12)
direct flux from 
synth. IDL&VLDL2 
[mg/d]
TS 0 441
CB 93 289
WB 0 298
MW 0 237
MD 0 370
mean 19 327
± s ±37 ±71
total
plasma LDL-FCR apo B
pool synth.
[mg] [pools/d] [mg/d]
2161 0.2 981
2100 0.18 817
1417 0.21 654
1215 0.2 668
1581 0.23 483
1695 0.2 721
±375 ±0.02 ±168
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TABLE 1-21:
Apolipoprotein B metabolism in apoE2/2 homozygotes
VLDL (Sf 60-400) fract. rate
direct plasma direct transfer
synth. pool catab. to VLDL2
[mg/d] [mg] [pools/d]
AY 79 38 0 2.08
MB 232 41 0 5.66
GS 255 63 0.77 2.99
EW 265 57 0.41 4.25
mean 208 51 0.3 3.75
± s ±75 ±12 ±0.32 ±1.35
PM 708 50 2.84 11.32
VLDL (Sf 20-60) fract. rate
direct flux from plasma direct transfer
synth. VLDL1 pool catab. to IDL&LDL
[mg/d] [mg] [pools/d]
AY 333 79 206 0.01 1.99
MB 92 232 215 0 1.5
GS 471 203 220 0.02 3.04
EW 201 242 238 0.08 1.78
mean 274 189 220 0.03 2.08
± s ±142 ±65 ±12 ±0.03 ±0.58
PM 266 566 258 0.3 2.91
IDL (Sf 12-20) fract. rate
direct flux from plasma direct transfer
synth. VLDL2 pool catab. to LDL
[mg/d] [mg] [pools/d]
AY 0 407 250 1.23 0.64
MB 0 323 283 0.88 0.26
GS 0 656 498 1.01 0.31
EW 0 401 345 0.75 0.41
mean 0 447 344 0.97 0.41
±s ±125 ±95 ±0.18 ±0.15
PM 0 671 325 1.25 0. 82
TABLE 1-21 (contd.)
1-37
LDL (Sf 0-12)
direct flux from 
synth. IDL 
[mg/d]
plasma LDL-FCR 
pool
[mg] [pools/d]
total 
apo B 
synth. 
[mg/d]
AY 0 164
MB 0 74
GS 0 168
EW 0 161
mean 0 142
± s ±39
PM 0 347
438 0.24 412
358 0.21 324
596 0.28 726
439 0.37 466
458 0.28 482
±86 ±0.06 ±150
549 0.63 974
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FIG. 1-1: 1-42
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FIG. 1-2: 1-43
G.S. (apoE2/2) - Metabolism of VLDL 1
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FIG. 1-3: 1-44
E.W. (apoE2/2) - Metabolism of VLDL 1
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FIG. 1-4: 1-45
A.Y. (apoE2/2) - Metabolism of VLDL 1
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FIG. 1-5: 1-46
P.M. (apoE2/2) - Metabolism of VLDL 1
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FIG. 1-6: 1-47
M.D. (apoE4/4) - Metabolism of VLDL 1
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FIG. 1-8: 1-49
T.S. (apoE4/4) - Metabolism of VLDL 1
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FIG. 1-9: 1-50
C.B. (apoE4/4) - Metabolism of VLDL 1
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FIG. 1-10: 1-51
W.B. (apoE4/4) - Metabolism of VLDL1
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FIG. 1-11: 1-52
M.F. (apoE3/3) - Metabolism of VLDL 1
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M.F. (apoE3/3) - Metabolism of VLDL 2
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FIG. 1-12: 1-53
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FIG. 1-13: 1-54
N.C. (apoE3/3) - Metabolism of VLDL 1
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FIG. 1-14: 1-55
M.M. (apoE3/3) - Metabolism of VLDL 1
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FIG. 1-15: 1-56
E.K. (apoE3/3) - Metabolism of VLDL 1
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Introduction
Plasma very low density lipoproteins (VLDL) are an heterogeneous 
population of particles isolated in the density interval 0 . 95- 1 .006 
g/ml (Sf 20-400). The largest, least dense VLDL are rich in 
triglyceride while smaller species have increased contents of 
cholesterol and protein. Apolipoprotein B is the major protein 
constituent of VLDL. When labeled with iodine it acts as a useful 
tracer of the particle's metabolism.
Normal individuals given a bolus injection of autologous 
125 i_v l d l  transfer more than half of the labeled apo B into low 
density lipoprotein (d 1.019-1.063 g/ml; Sf 0-12) via an intermediate 
species (IDL, d 1.006-1.019 g/ml; Sf 12-20) (1,2). That i s , a
precursor-product relationship exists between VLDL and denser apo B 
containing lipoproteins. In dyslipoproteinemic states, however this 
link is broken and other novel routes of apo B synthesis and 
catabolism appear (3,4) . These conclusions drawn from early metabolic 
studies are based on the thesis that VLDL and its catabolic products 
can be viewed as homogeneous entities whose behavior within a given 
density interval is uniform. However, recent structural investi­
gations of VLDL, IDL and LDL reveal the presence of multiple species 
which may exhibit individual rates of formation and breakdown. VLDL, 
for example, contains, particles of varying lipid and apoprotein 
compositions. Some, the smaller species, are readily assimilated by 
cells via receptor mediated processes while larger VLDL are resistant 
to these effects (5). On the other hand, lipid exchange interactions 
seem to occur more readily with large triglyceride-rich VLDL (6). It 
is clear then that numerous mechanisms other than simple triglyceride 
hydrolysis are responsible for the remodelling and degradation of VLDL 
and that to begin to understand these we must dissect the apo B 
containing lipoproteins into relatively homogeneous sub-populations 
whose metabolic properties can be defined with some certainty. Since 
it is not yet clear what the basis of such a separation technique 
should be, we have as a first approximation used cumulative flotation 
ultracentrifugation (7) to separate lipoproteins on the basis of 
density and size. This procedure has been used to follow the metabolic 
properties of large (Sf 60-400) and small (Sf 20-60) VLDL in normal 
and hyperlipidemic states.
\/Lbl_ Uv\ Ui*-r-vvv*j2^
Cell culture studies have shown that hepatocytes can synthesise 
and secrete particles covering a broad size range (8), and in vivo it 
has been observed that apo B is inserted into VLDL throughout the Sf 
20-400 distribution (9). The key question raised by Fisher (10) is 
whether such heterogeneous nascent particles ever attain metabolic 
equilibrium in the circulation, or alternatively .are they catabolised 
via different metabolic channels depending on their origin? In a pre­
liminary series of investigations (Study 1, Table 1) the transit of B 
protein was followed from large VLDL through its smaller delipidation 
products to LDL. Little of the radioactivity which was originally 
associated with large VLDL reached LDL. In light of that, the Sf 
20-400 VLDL spectrum was fractionated in an attempt to define more 
clearly the origins and fates of its constituent particles.
Table 1 APOLIPOPROTEIN B METABOLISM
EXPERIMENTAL PROTOCOL
Sf 400 8 0 20 12Study Subjects
125
Normal
125,
HTG 125,
125,
DYS B
131
FH hetero 125, +  131
I CHD
125,FH homo
^  + bezafibrate 
£  + cholestyramine
Within a few hours of injection of ^ f > I - l a b e l e d  sf 60-400 VLDL into 
normoliperaic subjects, the tracer transferred virtually quantitatively 
to the Sf 12-60 flotation interval. Thereafter, however, it failed to 
progress into Sf 0-12 LDL 0 T ) . We concluded on the basis of this 
observation that Sf 12-60 remnants of VLDL lipolysis must be subject 
to direct clearance from the circulation, possibly by a process which 
involves the agency of cell membrane receptors. This hypothesis was 
tested by modifying the arginine residues on the B protein of the VLDL 
tracer in order to interfere with any potential receptor interaction.
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The modification did not change the rate at which large triglyceride 
rich particles were converted to smaller remnants (Figure 1)/ a 
metabolic step which is thought to depend on lipoprotein lipase 
activity, but it did retai^c^the clearance of the Sf 12-60 particle 
from the circulation . So, receptors do seem to have an
involvement in remnant catabolism. Some of the B protein in the tracer 
(about 10%) appeared in LDL, but at a rate which was also delayed by 
arginine modification. This raises the question of another, possibly 
separate role for receptors in mediating the conversion of Sf 12-60 
remnants of VLDL metabolism to LDL.
Figure 1 Transit of native and 1,2 cyclohexanedione-raodified apo B 
from VLDL (Sf 100-400) through IDL (Sf 12-100) to LDL (Sf 0-12)
S f 12 -60
OOT
100 12040 140
HO URS O 10
Sf 0 -1 2
»- ai
•  observed 
• calculated
0XH▲ observed 
- -  calculatedCHD treated >
280200 2401608040 1200
H O U R S
Clearly, most LDL cannot originate from large VLDL but pre­
sumably is derived from smaller particles of Sf 20-60. When these were 
labeled directly, the majority transferred into LDL (11). So, the Sf 
12-60 density range contains a mixture of lipoproteins only some of 
which are destined to make LDL and within this interval there are 
particles whose fate depends on their pedigree; that is, there appears 
to be metabolic channelling within the VLDL flotation interval.
4VLDL metabolism in hypertriglyceridemia
The protocol devised to examine B protein metabolism in Study 1 
was extended to hypertr iglycer idemic individuals (Study 2, Table 1). 
In this group, large VLDL was catabolised more slowly than normal, 
with a consequent increase in its plasma concentration. Bezafibrate 
corrected the defect and reduced the VLDL pool size by 70% (13). 
Interestingly, the drug did not alter the rate of catabolism of the 
remnants generated from these large triglyceride-rich particles, 
although it did diminish the catabolic rate of LDL and expand its 
circulating mass (Table 2).
Table 2 EFFECTS OF BEZAFIBRATE ON APOLIPOPROTEIN B METABOLISM IN 
HYPERTRIGLYCERIDEMIA*
Fractional 
Sf 100-400
Catabolic Rate 
Sf 12-100
(pool3/d) 
Sf 0-12
Control 7.0+7.5 1.23+0.55 0.47+0.25
Bezafibrate 22.9+24.0 0.98+0.38 0.35+0.12
paired t test <0.05 NS <0.05
* n=6
It is apparent therefore that fibrates can exert various effects at 
different points on the Sf 0-400 metabolic cascade. Their known 
stimulatory influence on lipoprotein lipase accords with the 
suggestion (see above) that this enzyme governs the clearance rate of 
large triglyceride rich VLDL. But the lack of effect on the rate of 
Sf 12-60 remnant catabolism, a process which in fact was not abnormal 
in the hypertriglyceridemic individuals indicates that lipase is not 
critical in their catabolism. Presumably their removal was mediated 
by "receptors" as suggeste'd for the normolipemic group examined in 
Study 1.
The response of LDL to fibrate therapy was investigated in 
greater detail in another group of hypertriglyceridemic volunteers. It 
transpired that the drug suppressed the hyperactivity of catabolic 
processes operating independently of the LDL receptor which apparently 
were responsible for the low circulating LDL levels in this group 
(Ta) . As a result, during treatment, more LDL became channelled into 
t!te receptor route.
5VLDL metabolism in dysbetalipoproteinemia
Apolipoprotein E (Apo E) exist3 in three major isoforras, 
designated E2 , E3 and E4 . Apo £3, the wild type protein, is common in 
the population, while the rarer E 2 and E 4 appear to have arisen by 
point mutations (15). Recent studies have shown, that the isoforms 
exert an influence on B protein metabolism in that subjects homozygous 
for E4 have higher plasma LDL levels while in E2 homozygotes this 
parameter is reduced (16). When en as yet unknown second stimulus is 
applied to the latter group, frank Type III hyperlipoproteinemia 
ensues (15) , with characteristic compositional anomalies in VLDL and 
accumulation of IDL in the plasma. Previous investigations have shown 
that the conversion of VLDL through IDL to LDL is slower in these 
individuals (17). We set out to reinvestigate the problem further as 
outlined in Table 1, Study 3. Large and small VLDL of Sf 60-400 and 
20-60 were radiolabeled and their metabolic fate followed in six 
subjects before and during bezafibrate therapy (18). The rate of 
catabolism of large VLDL was slow in these subjects and, as noted for 
other hypertriglyceridemic subjects (Table 2) accelerated during 
fibrate therapy. This effect, coupled with the reduction in B protein 
synthesis which accompanied administration of the drug, led to an 80% 
decrement in the circulating level of Sf 60-400 apolipoprotein B 
(Table 3).
Treatment also reduced the input of apo B into small VLDL but 
did not increase the characteristically slow rate of catabolism of 
these particles in the Type III subjects. So again> bezafibrate had 
diverse effects at different points in the metabolic cascade. 
Interestingly, although treatment^ reduced LDL catabolism by up to 
50%, as it had done in the hypertr iglycer idemic subjects (Table 2) , we 
did not record a rise in the plasma concentration of the fraction. 
This was because therapy had simultaneously suppressed LDL synthesis 
by promoting direct clearance of IDL from the circulation. Such an 
effect might be due to increased hepatic B/E receptor activity.
Apolipoprotein B metabolism in Familial hypercholesterolemia
Familial hypercholesterolemia (FH) derives from defective 
expression of the LDL receptor on cell membranes and, in consequence, 
there is failure to clear the lipoprotein normally from the 
circulation. Not only does this lead to an increase in the level of 
LDL in the plasma but there are also increments in VLDL and IDL (19). 
Studies 1-3 (Table 1) provide evidence that the B/E receptor appears 
to be involved in VLDL and IDL metabolism as well as that of LDL. Two 
additional investigations (Studies 4 and 5) were designed to follow 
the metabolic consequences of partial or complete receptor deficiency. 
FH heterozygotes, who express only half of the normal LDL receptor 
complement have high circulating levels of intermediate (Sf 12-60) 
lipoproteins, partly because they can convert them only slowly to LDL. 
Treatment with cholestyramine reduced their plasma concentration by 
promoting their catabolism.
In a more detailed assessment the metabolism of large and small 
VLDL apo B was examined in a group of 7 subjects homozygous for the FH 
defect. Here, large VLDL underwent normal conversion to smaller 
remnants which accumulated in the circulation because their subsequent 
turnover was defective. Two distinct patterns of metabolic behavior 
characterised the smaller VLDL fraction. Some subjects converted VLDL
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apo B through IDL to LDL at a very slow rate but in sufficient 
quantity to account for all apo LDL synthesis. In others there was 
rapid transmission of some VLDL apo B radioactivity directly into LDL 
but this pathway contributed little to the LDL B protein mass. It 
was therefore necessary to postulate a direct influx of apolipo- 
protein B into the IDL or LDL density interval in such individuals. 
So, receptor deficiency seems to be associated with (a) reduced 
direct catabolism of remnants derived from large VLDL; (b) slow B 
protein transit from VnDL though IDL to LDL; (c) prolonged residence 
of LDL in the circulation. The severe impairment of IDL to LDL 
conversion in these subjects provides strong supportive evidence that 
the receptor might be involved in this process.
Conclusions
The kinetic studies described above indicate that VLDL (Sf 
20-400) can be viewed as containing at least three separate entities. 
Large triglyceride rich VLDL are found at the upper (least dense) end 
of the spectrum. The formation of these is probably favored in 
carbohydrate feeding and familial hypertriglyceridemia. The 
delipidation of these large VLDL mainly by the action of lipoprotein 
lipase results in the formation of remnants in the Sf 12-60 density 
interval. It is possible that the size of the remnant formed depends 
on the activity of lipase. If this enzyme is functioning normally 
then the residence time of VLDL is short and there is only a limited 
opportunity for cholesteryl ester to be incorporated by exchange from 
HDL into the VLDL core (20). Reduced lipase activity, in contrast 
prolongs the circulation time of large VLDL and favors the enrichment 
of the particle in cholesteryl esters. This then results in larger 
remnants in the VLDL density range. Little of this apo B transits 
the delipidation cascade to LDL and in fact it appears to have a 
metabolism analogous to that of gut-derived chylomicrons ie the 
formation of nascent triglyceride-rich particles which are lipclysed 
to remnants and cleared directly from the plasma via receptor-mediated 
pathways. Most LDL comes from small VLDL secreted into the Sf 20-60 
density interval. The initial catabolic rate of these particles is 
slower than that of the larger species and from the results of type 
III and FH studies appears to involve both the 'B/B1 (LDL) receptor 
and apolipoprotein E. In one extreme case of homozygous FH we 
observed that the conversion of small VLDL, through IDL to LDL took 9 
days to complete. There is evidence to suggest that the formation of 
small VLDL is favored in familial combined hyperlipideraia and in 
dietary cholesterol supplementation and this may to a degree explain 
the increased levels of LDL associated with these conditions.
The further analysis of VLDL metabolism requires that methods 
are devised to permit the separation of metabolically distinct species 
that are at present co-isolated by size or density fractionation. One 
likely approach will be to prepare subfractions of differing 
apoprotein content by immunoaffinity chromatography and test their 
metabolic properties both in vitro and in vivo.
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Ubersicht
Very Low Density Lipoprotein Apolipoprotein B Metabolism 
in Humans
Th. D em ant. J. Shepherd, and C.J. Packard
University Department o f  Pathological Biochemistry. Royal Infirmary, G lasgow
Summary. The hum an plasm a lipoproteins encom ­
pass a broad spectrum  o f particles o f widely vary­
ing physical and chemical properties whose m etab­
olism is directed by their protein  com ponents. 
A polipoprotein B100 (apo B100) is the m ajor struc­
tural protein resident in particles w ithin the Sved- 
berg flotation range 0-400. The largest o f these, 
the very low density lipoprotein  (VLDL), rich in 
triglyceride, are m etabolised by sequential delipi­
dation through a transien t interm ediate density li­
poprotein  (IDL) to cholesterol-rich low density li­
poproteins (LDL). Several com ponents contribute 
to the regulation of this process, including (a) the 
lipolytic enzymes lipoprotein  lipase and hepatic li­
pase (b), apolipoproteins B, CII, C III and E. and 
(c) the apolipoprotein B E or LD L receptor. Lipo­
protein  lipase acts prim arily  on large V LD L of 
Sf 60-400. Hepatic lipase on the o ther hand seems 
to be critical for the conversion o f smaller particles 
(Sf 12-60) to LDL (Sf 0-12). A lthough m ost apo 
B 100 flux is directed to the production o f the delipi­
dation end product L D L , along the length of the 
cascade there is potential for direct removal of p ar­
ticles from the system, probably via the actions 
o f cell m em brane receptors. This alternative path ­
way is particularly evident in hypertriglyceridaem ic 
subjects, in whom the delipidation process is re­
tarded.
V LD L m etabolism  shows inter subject variabil­
ity even in norm al individuals. In this regard, apo­
lipoprotein E plays an  im portan t role. Norm olipi-
A bbreviations: apo B. C, E =  A polipoprotein B, C, E; CETP =  
Cholesteryl ester transfer protein; FCH =  Familial com ­
bined hyperlipidaemia; FH =  Familial hypercholesterolaemia; 
FHTG  =  Familial hvpertriglyceridaemia; H D L  =  High density 
lipoprotein; HL =  Hepatic lipase; IDL =  Intermediate density 
lipoprotein; LDL = Low density lipoprotein; LpL =  Lipoprotein 
lipase; RFLP =  Restriction fragment length polymorphism; 
Sf= S ved b erg  flotation coefficient; VLD L =  Very low density 
lipoprotein; WHHL =  Watana'oe heritable hyperlipidemic
daem ic individuals hom ozygous for the apo E 2 
varian t exhibit gross d isturbances in the transit o f 
B p ro tein  through the V L D L -ID L -L D L  chain.
Key words: V L D L -L D L  conversion in norm al and 
hyperlipoproteinaem ic subjects -  M ulticom part- 
m ental m odelling -  M etabolic channelling
A polipoprotein  B is unique in several respects. It 
is larger than m ost proteins, and, to date, is the 
longest sequenced polypeptide. M oreover, it oc­
curs in two forms in the plasm a [24]. The larger, 
called apo B 100 is found  in very low and low den­
sity lipoproteins (V L D L  and L D L) and derives 
from  synthesis in the liver. It comprises a single 
chain o f 4536 am ino acids [7] and is responsible 
for m aintaining the structu ral integrity of its par­
ent lipoproteins. The o ther variant, approxim ately 
one h a lf the size o f apo  B 100, has been designated 
apo B.4.8 [24], It constitu tes the structural polypep­
tide in chylom icrons and  is synthesised exclusively 
in the intestine. It is in fact a truncated  form of 
hepatic apo B in w hich translation has been ter­
m inated at am ino acid 2152 [7]. These two apo 
B variants differ in one im portan t respect in that 
B 100 encapsulates a binding site for the “ L D L ” 
or “ apo B /E ” receptor in its C term inal half. This 
has been deleted in B4 .8 and  therefore the chylomic­
ron does no t bind to the LD L receptor [22].
W hen the apo lipopro tein  B-100 containing li­
poproteins are isolated from  plasm a they consti­
tute a spectrum  ranging in density from 0.95 to 
1.063 kg/'L ie w ith Svedberg flo tation coefficients 
o f Sf 0-400. The least dense particles are triglycer­
ide rich (Table 1) w ith a low content o f cholesterol 
and protein -  the la tte r com prising apo B-100, apo 
C and  apo E. W ith increasing density (decreasing
704 Th. Dem ant et al.: Very Low Density Lipoprotein A polipoprotein  B M etabolism in Humans
Table 1. C om position o f apoliprotein B containing subfractions in normal subjects
Lipoprotein
Subfraction
Triglyceride Free cholesterol Esterified cholesterol 
gram,/100 grams, m ean ±  1SD
Phospholipid Protein
S f 60-400  
VLD L,
5 6 .2 ± 4 .8 1.7 ±  2.3 1 6 .0^ 4 .3 17.0 ± 1 .4 9.1 ± 2 .4
S f 20-60 3 5 .1 + 4 .0 8.1 +  1.4 21.1 + 5 .9 21.4 +  2.4 14.4 +  1.6
V L D L ,
S f 12-20  
IDL
12.4 ± 2 .0 11.2 ± 2 .3 3 3 .4 ± 4 .8 23.9 ± 1 .3 19.1 ± 2 .3
S f 0-12  
LDL
5.1 ± 0 .2 13.5 ±  1.5 34.8 ± 2 .2 23.0 ±  1.6 23.6 ± 1 .6
flotation rate) the lipoproteins become triglyceride 
depleted and enriched in cholesterol, cholesteryl 
ester and protein. The com position o f the protein 
com ponent alters so th a t apo  C and apo  E are 
lost while apo B becomes dom inant. This spectrum  
can be viewed as a “ delip idation cascade” in which 
the less dense Sf 100-400 V L D L  are hydrolysed 
to form  denser in term ediate lipoproteins (IDL) 
and then finally LD L. A num ber of enzymes parti­
cipate in this rem odelling process including lipo­
protein lipase, hepatic lipase and  lecithin: choles­
terol acyl transferase [14]. O ther proteins too such 
as cholesteryl ester transfer protein  and the B/E 
receptor are im portant. The details o f how  these 
lipoprotein transform ations occur have been re­
cently reviewed in this Jo u rn a l [14]. In the follow­
ing discussion we focus on the quantitative aspects 
o f this delipidation sequence and how it differs 
in norm al and hyperlipidaem ic subjects.
VLDL -  LDL Conversion in Normals
The first investigations o f the m etabolic fate of 
trace-labelled V LD L in m an dem onstrated  [18] 
that radioactivity initially present in Sf 10-200 
“ V L D L ” was rapidly transferred  to the S f 3—9 
LDL density interval. L ater w ith appreciation  of 
the protein heterogeneity in V LD L, apo B was spe­
cifically exam ined and found  to be the m oiety that 
was conserved in this process [13] in tha t all LDL 
apo B in the plasm a could be a ttribu ted  to the 
delipidation of VLDL. S igurdsson et al. [42] initial­
ly quantified this conversion and  found th a t in nor­
mals not only did all “ L D L ” (d 1.006-1.063 g/ml) 
come from  V LD L but in add ition  all o f the VLDL 
was catabolised to LD L. This ra ther strict precur- 
sor-product relationship was later shown to be not 
altogether correct in th a t while the m ajority  of 
VLDL apo B did appear in the 1.006-1.019 kg/L 
density range (ie ID L), in norm als a sm aller p ro ­
portion  of this ultim ately becam e LD L [23]. The
transient interm ediate, ID L , is short lived and of 
low concentration  in m ost subjects bu t can be sub­
stantially elevated in certa in  dyslipidaemias. F u r­
ther investigations o f the V L D L -ID L -L D L  m eta­
bolic cascade have revealed th a t there are multiple 
sites o f entry and exit w hich can only be quantified 
using com puter-based m ulticom partm ental m odel­
ling techniques. These no t only perm it the calcula­
tion of apoprotein  flux rates bu t also allow for 
the testing o f quantita tive hypotheses regarding the 
physiology of the V L D L -L D L  conversion.
Berm an et al. [2] were the first to form ulate 
a m athem atical m odel describing the V LD L-LD L 
conversion. This includes features required to ex­
plain both apo B, and apo C kinetics (Fig. 1 a). 
In  norm al individuals, inpu t o f newly synthesised 
m aterial occurred into the largest triglyceride-rich 
V LD L, which was converted  through a chain of 
com partm ents (the delip idation cascade) to IDL. 
The V LD L spectrum  also contained a slowly m e­
tabolised species (term ed (3-VLD L) which did not 
contribute to ID L or L D L . The latter were m od­
elled as single com partm ents in which ID L was 
restricted to the plasm a space. Any m odel o f this 
kind should allow for no t only the behaviour of 
the apoproteins bu t also for that o f the m ajor 
V LD L lipid, triglyceride. Such a scheme (Fig. 1 b) 
has been proposed by Beltz and colleagues [1]. It 
differs from  the original m odel in that it (1) permits 
a variable delipidation chain length (2) proposes 
an extravascular ID L  sub-com partm ent derived 
from  very large, rapidly catabolised V LD L and 
(3)-allows slowly m etabolised “ rem n an t” VLDL 
to contribute to LD L production .
In order to test some o f the hypotheses implied 
in these models, we have used two approaches. 
First, V LD L (Sf 20-400) was split into two frac­
tions, V L D L j (S f6 (M 0 0 ) and V L D L 2 (Sf 20-60) 
on the basis o f the results o f a num ber o f metabolic 
studies in which the behaviour of m any discrete 
subfractions of V LD L were examined (Fig. 2).
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Fig. 1. D evelopm ent o f  mathematical models 
describing V L D L -L D L  conversion. A Original model 
proposed by Berman et al. [9] in which VLD L is a 
single chain delipidation cascade feeding IDL and 
L D L . A compartment is included in V LD L to 
represent a slowly metabolised species. B This 
modified model by Beltz et al. [10] permits variable 
delipidation and the possibility o f  L D L  production 
from rapidly catabolised large V L D L  via an 
extravascular ID L  pool
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Fig. 2. Plasma decay curves o f  trace labeled large and small V L D L  in A a normolipidaemic subject and B an hom ozygous 
FH individual. N ote that the clearance o f  large VLDL is the sam e in both individuals. The im pact o f  the LDL receptor defect 
is on the smaller VLD L species
From  these it was clear th a t the denser more cho­
lesterol rich V L D L 2 were in certain circumstances, 
like hom ozygous fam ilial hypercholesterolaem ia, 
m etabolised at rates th a t were distinct from  that 
o f  the triglyceride rich V L D L ^  This has also 
proved to be the case in type III hyperlipidaem ic 
patients [37] and hepatic  lipase deficiency (Th D e­
m ant, J Shepherd, CJ Packard , unpublished obser­
vations). In the second approach, V LD L! was 
m odified chemically w ith  1,2 cyclohexanedione in 
order to block po ten tia l interaction o f the tracer 
or its m etabolic products with lipoprotein recep­
tors [36]. This study indicated th a t receptors had 
no role in the initial lipolysis o f triglyceride rich 
V L D L i but were im p o rtan t in later stages where 
ID L  was converted to L D L  or catabolised directly 
from  the plasma. A m algam ation o f these results
p roduced  the working model, show n in Figure 3, 
w hich forms a useful basis for the consideration 
o f apolipoprotein  B kinetics in bo th  norm al and 
hyperlipidaem ic subjects. The flux o f B protein 
th rough  this system in norm al individuals is enu­
m erated  in Figure 4. I t was necessary to postulate 
th a t there was direct synthesis o f apo B into both 
large and  small V LD L. Two thirds o f this m aterial 
was transm itted th rough  to ID L and  LD L while 
the rem ainder generated a “ rem n an t” pool which 
was cleared slowly from  the circulation, probably 
via receptors. One im portan t finding o f these inves­
tigations which is dem onstrated  in Figure 4 is the 
subcom partm entalisation of ID L and LDL. This 
was needed to allow for the observation tha t apo 
B associated with the small VLDL tracer appeared 
m ore rapidly and in greater am ount in ID L and
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Fig. 3. M etabolic scheme outlining V LD L m etabolism. D e novo  
input o f  large and small V LD L feeds delipidation chains that 
lead to ID L and LDL. Parallel processing pathways within 
these fractions account for their m etabolic heterogeneity. Initial 
delipidation is thought to depend on the activity o f  lipoprotein  
lipase and the small molecular weight regulatory C apolipopro- 
teins. Further down the chain, hepatic lipase plays an increas­
ingly important role. Direct receptor mediated catabolism  is 
permitted at multiple points along the cascade. This may be 
governed by the presence o f B or E proteins on the particles
L D L  than  apo B from large V LD L. T ha t is, m eta­
bolic channels are present in the V L D L -L D L  con­
version process so that the fate of an apo B con­
taining lipoprotein depends to a certain extent on
its pedigree. Indeed, since V LD L is such an hetero­
geneous m ixture of particles we ought to expect 
m etabolic heterogeneity in its products, ID L and 
LD L. The recognition o f  this phenom enon is an 
exciting developm ent in ou r understanding o f the 
structure and function o f  these lipoproteins [32, 
16].
Q uantitative investigations o f the rates of 
tran sp o rt o f apo B th rough  the V L D L -ID L -L D L  
cascade reveal how m uch o f each species is m ade 
and indicate its probable precursor. However, fur­
ther w ork is needed to elicit the mechanism s in ­
volved in these transform ations. The study of p a th ­
ological conditions w here a specific com ponent is 
im paired allows us to build  a picture o f the key 
proteins, enzymes and receptors th a t are involved 
in such a scheme (Fig. 3).
VLDL-LDL Conversion in Hypertriglvceridaemia
Early studies o f hypertriglvceridaem ic subjects [38] 
have shown that these individuals m ake more 
V LD L apo B than is required  for LD L synthesis. 
We have seen above th a t abou t 30-50%  of ID L 
apo B in norm al individuals does not reach LDL. 
So, the cascade from  V L D L  to L D L  m ust allow 
for direct catabolism  at m ultiple sites along its 
length. The nature o f these catabolic mechanisms 
is not com pletely clear n o r is it know n w hat causes 
a particle to take the rou te  o f direct catabolism  
rather than  be subject to fu rth e r delipidation. One 
possibility, suggested by in vitro studies, is that 
if a V L D L  particle has a prolonged residence in. 
the plasm a it may acquire too m uch cholesteryl 
ester in its core to perm it it to shrink to the size 
of L D L. In support o f this view, it has been shown 
that V L D L  subfractions from  norm al subjects may 
be hydrolysed in the test-tube to LD L-like particles 
[8]. Large V LD L from  hypertriglyceridaem ics on 
the o ther hand seems to be unable to be lipolysed
/ ID L
20 60VLDLi VLDL 2 LD L
30© 50 50 50560 * 693113300300330 300 220
280 * 55 ,104 (865)
260 230
\
U n it s
@  Pool s izes  = mg 
( § )  F luxes = m g / d
Fig. 4. M ulticompartmental model 
describing the flux o f  apolipoprotein B 
through the cascade system in a normal 
subject
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sufficiently to form  LD L in vitro and in vivo would 
constitu te a fraction o f  VLDL that fails to transit 
the delipidation cascade [34]. M etabolic studies 
from  our laboratory  have shown that hypertrigly- 
ceridaem ic patients, in com m on with norm als, ca- 
tabolise V L D L i to sm aller rem nants within the 
d <  1.006 kg/L density interval but these fail to 
progress to ID L and  LDL. In con trast smaller 
V LD L (Sf 20-60) is a much better precursor of 
LD L  [35]. This aspect o f V LD L-LD L conversion 
(Fig. 3) offers an explanation of a num ber of find­
ings. Kissebah et al. [25] divided hypertriglyceri- 
daem ic subjects into those with familial hypertri- 
glyceridaem ia (FH T G ) and those who had familial 
com bined hyperlipidaem ia (FCH ). V LD L in the 
form er tends to be larger and m ore triglyceride- 
rich than  norm al while the lipoprotein fraction in 
the la tter disorder has a com position and size simi­
lar to th a t of control subjects. V LD L apo B and 
triglyceride is overproduced in the F H T G  subjects 
bu t L D L  synthesis is norm al, suggesting that it 
is V L D L i that is being generated by the liver. On 
the o ther hand, F C H  is associated w ith an excess 
o f bo th  V LD L and L D L  synthesis and  so it may 
be postulated  that in this situation it is V L D L 2 
ra th er than  V L D L X th a t is being elaborated. A 
sim ilar explanation m ay be offered for other situa­
tions in which V LD L and LD L behave discre- 
pantly. C arbohydrate feeding to norm al individ­
uals leads to increased triglyceride (VLDL) levels 
and decreased LD L [41], whereas fish oils cause 
a decrease in V LD L and  a rise in L D L [48]. It 
can be postulated th a t on the form er diet, larger 
V LD L are synthesised which are p o o r LDL pre­
cursors while the opposite is true in the latter.
The mechanisms responsible for the conversion 
o f large and small V L D L  to ID L and LDL are 
partly  understood. L ipoprotein lipase (LpL) situ­
ated  on the capillary endothelium , is responsible 
for the removal o f triglyceride from triglvceriderich 
particles. In vitro studies o f the suitability o f differ­
ent lipoprotein fractions as substrates for this en­
zyme have dem onstrated  that chylom icrons and 
larger V LD L are better than the sm aller denser 
lipoproteins. Conversely the o ther m em brane 
bound lipase released in to  post-heparin plasm a -  
hepatic lipase (HL) -  shows particular affinity for 
sm aller V LD L and ID L  [33] suggesting that these 
two enzymes may have com plem entary roles in the 
delipidation cascade. M etabolic studies in hyper- 
triglyceridaem ia provide further evidence for this. 
Classically, LpL deficiency is associated with the 
accum ulation of chylom icrons. However recent in­
vestigations [47] have dem onstrated  tha t large apo 
B-100 containing V L D L  also accum ulate. These
particles are triglyceride-rich, and when trace-la- 
belled and re-injected into LpL deficient subjects 
fail to be degraded to ID L and LD L. LpL m ust 
therefore be the key rate controlling step in the 
conversion of large to small VLDL (Fig. 3). O f 
course, triglyceride hydrolysis is not the only pro ­
cess involved in this conversion. The whole particle 
m ust be remodelled w ith loss o f surface com po­
nents (phospholipid, apo C and free cholesterol) 
to H D L  and acquisition of cholesteryl ester by the 
action of cholesteryl ester transfer protein CETP 
[15, 49]. The activity o f the enzyme is m odulated 
by horm ones, particularly  insulin [39] and it can 
be activated by hyperlipidaem ic drugs such as be­
zafibrate. If the la tte r is given to hypertnglyceri- 
daem ic subjects an increased rate of clearance o f 
large V LD L is observed [44] but catabolism  of 
sm aller VLDL and ID L  is not affected. The small 
m olecular weight apoproteins C II and C III appear 
to have opposing effects on the activity of this en­
zyme and on V LD L triglyceride hydrolysis. Apo 
C II is an essential cofactor for LpL action and 
if it is absent or defective [4] a clinical picture simi­
lar to prim ary LpL deficiency (Type I) results with 
the accum ulation o f VLDL and chylomicrons. 
Equally rare individuals who have a genetic lesion 
which causes an absence of CIII from  the plasma 
have low triglyceride levels and V LD L catabolism  
is accelerated above norm al [17]. These findings 
from  studies of inherited disorders together with 
the observed inverse correlation between the CII/ 
C III ratio  and V LD L triglyceride levels [6] in other 
subject groups suggests a strong influence of these 
apopro teins on LpL activity.
It is strange tha t despite an absence of func­
tional LpL. Type I individuals can convert 
“ V L D L  apo B “ to ID L  and LDL at approxim ate­
ly norm al rates [33]. A possible explanation for 
this paradox is that when whole VLDL is trace 
labelled most of the B protein is present in smaller 
V LD L. Its conversion to denser lipoproteins is not 
critically dependent on LpL. R ather, this com po­
nent o f the delipidation process seems to depend 
on the activity of hepatic lipase. Prelim inary stu­
dies in our laboratory  o f VLDL m etabolism  in a 
p a tien t with hepatic lipase deficiency indicate that 
while the catabolism  o f VLDL t to V L D L 2 is unim­
paired. the transfer o f apo B through V LD L2 to 
ID L  and LDL is dim inished. In fact, in this indi­
v idual norm al LDL was virtually absent from the 
plasm a. These results are in accord with animal 
experim ents in which antibody-induced inhibition 
o f H L leads to accum ulation o f small VLDL and 
ID L and  a fall in L D L [19], If  it is postulated 
th a t ID L-LD L conversion involves hepatic lipase
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then this activity m ust be located in the liver, a 
contention supported  by exam ination o f  lipopro­
tein flux across the splanchnic bed. T urner et al. 
[52] found tha t while there was evidence for secre­
tion o f large (Sf 100-400) V L D L t from  the liver 
there was no detectable up take  of this lipoprotein 
fraction. On the other hand , radio-iodinated lipo­
proteins o f Sf 12-60 (V L D L 2 and ID L ) were ex­
tracted from  the circulation by the splanchnic bed 
and abou t half o f the radioactivity  reappeared  in 
the hepatic vein as LD L (Sf 0-12). Therefore, this 
enzyme occupies a pivotal role in the transfo rm a­
tion of apo B containing lipoproteins in the lower 
part o f the delipidation cascade.
VLDL-LDL Conversion in 
Dvsbetalipoproteinaemia
So far we have introduced two enzymes (LpL and 
H L) and two apoproteins (CII and C III) as key 
com ponents in the V L D L -L D L  conversion. Partial 
or complete deficiency o f these moieties has a p ro ­
found im pact on the regulation  of the delipidation 
process. One further condition  that is associated 
with prim ary hypertriglyceridaem ia is Type III hy- 
perlipidaem ia (dvsbetalipoproteinaem ia). Individ­
uals with this disorder appear to have inherited 
a double defect. They possess m utan t apo lipop ro ­
tein E [54] whose lipoprotein  receptor binding 
properties are com prom ised by the substitu tion  of 
cysteine for arginine at position  158 in the polypep­
tide chain [31, 58]. In add ition  another gene pre­
disposing to hyperlipidaem ia seems to be necessary 
to produce the elevated lipid levels. A bou t 1% of 
the population possess the apo  E m utation (E 2/'E2) 
present in the Type III condition. A fu rther 2% 
are homozygous for a m u ta tion  at a separate site 
in which cysteine is substitu ted  by arginine (E4/4) 
at position 112. These ab erran t E proteins influ­
ence the levels o f the apo B-containing lipoproteins 
in plasm a [12. 55. 56. 57]. N orm olipidaem ic indi­
viduals with the E 2;2 phenotype have low er plasma 
apo B and LDL cholesterol than the 60%  o f sub­
jects who express the norm al E 3/E 3 wild type p a t­
tern. An E 4 ..4 . individual, conversely, tends to ex­
press higher plasma apo B and LDL cholesterol 
levels. The explanation for this relationship is not 
known although it has been postulated [56] that 
the E 2;2 m utation leads to decreased up take o f chy­
lomicron rem nants and their associated cholesterol 
by the liver. As a result, the liver expresses more 
LDL receptors in order to fulfil its sterol require­
ments. LD L catabolism  is increased and plasm a 
levels fall. An alternative hypothesis is tha t individ­
uals with E 2/2 produce less LD L from V LD L pre-
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Fig. 5. Plasma decay curves describing the transit o f  apo B 
from small VLDL through ID L and LDL in subjects homozy­
gous for the E2 and E3 proteins. A utologous trace labeled small 
VLDL was injected and its flow  into IDL and LDL followed 
over the course o f 150 hours. The pool sizes o f  small VLDL, 
IDL and LDL for the E3/E 3 subject were 148. 205 and 1280 mg 
respectively: and for the E2/E 2 individual. 294, 426 and 710 mg
cursors because the p ro te in  is essential for this pro­
cess [11]. M ore V LD L apo  B would then be chan­
nelled into rem nants w hich would accum ulate in 
the plasm a. There is su pport from  m etabolic stud­
ies for bo th  hypotheses. F o r  example. Type III pa­
tients have a characteristically low rate o f conver­
sion o f VLDL to L D L [37, 53] which fails to re­
spond to  fibrate-induced activation o f LpL. In 
fact, although fibrates do lower the lipid levels in 
these individuals, they fail to rectify the basic dis­
tortion  o f their lipopro tein  spectrum. Relatively 
high levels o f V LD L rem nants and ID L  persist. 
A similar pattern  underlies the lipoprotein profile 
in norm olipidaem ic E 2/E 2 individuals. Recent 
studies in our laboratory  exam ined the flux o f apo 
B through the plasm a o f norm al individuals o f de­
fined apo E phenotype. C om pared to E 3/'E3 sub­
jects an E 2/E 2 individual expresses slower VLDL 
and ID L  decay rates an d  higher levels o f these
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fractions, and a reduced conversion to LDL 
(Fig. 5). The catabolic rate of the product LDL 
is no different from norm al.
As noted above, type III individuals treated 
with fibrates retain cholesteryl ester rich VLDL 
in their plasma suggesting, as was found in our 
m etabolic study, tha t the lipoprotein class still con­
tained a high p roportion  o f VLDL 're m n a n ts ’ de­
spite the successful hypolipidaem ic therapy. These 
drugs act mainly to reduce overall V LD L synthesis 
w ithout accelerating the characteristically slow ca­
tabolic rate of small V LD L seen in these individ­
uals [37], In contrast two other agents, oestrogen 
[28] and mevinolin [10], correct the lipid com posi­
tion o f VLDL in type III, presum ably by facilitat­
ing clearance of the 'r e m n a n t’ population . These 
drugs are known to upregulate hepatic lipoprotein 
receptors and may well act to overcom e the ineffi­
cient interaction between E2/2 containing lipopro­
teins and receptors. The exception to this rule 
seems to be the apo E deficient pa tien t reported 
by Schaefer et al. [40] who failed to respond appro­
priately to oestrogen therapy. This observation in­
dicates the need for some apo E, however defective, 
to m ediate VLDL rem nant removal.
VLDL-LDL Conversion in Hypercholesterolaemia
Fam ilial hypercholesterolaem ia results from  a par­
tial or complete deficiency of the L D L or B/E re­
ceptor. This protein, present on the m em branes 
o f m ost cells in the body, is able to bind LDL 
and internalise it. The lipoprotein is delivered to 
secondary lysosomes where its cholesterol is re­
leased into the cell to m eet structural and m etabol­
ic requirem ents [5, 20]. This receptor-m ediated 
pathw ay is autoregulated. K nowledge o f its opera­
tion is the key to our understanding o f how LDL 
levels are controlled in man. Early studies of the 
FH  condition focused on the gross increase in LDL 
cholesterol and the im pact tha t this had an athero­
sclerosis. M ore recently it has become appreciated 
th a t the B/E receptor has a much wider role in 
apolipoprotein  B m etabolism . Its absence affects 
no t only LDL but also V LD L and  ID L. The dis­
covery of a m utant strain  o f rabbits (the W atanabe 
H eritable Hyperlipidaem ic -  W H H L  -  rabbit) that 
lack functioning LD L receptors, provided a model 
for the detailed study o f hepatic secretion and in­
terconversion of lipoproteins in the receptor defi­
cient state. The m arked hypertriglyceridaem ia in 
W H H L  animals was the first indication that lack 
o f the receptor might have an im pact on the clear­
ance o f VLDL as well as LD L [3, 27]. These ani­
mals, like FH  patients, m etabolised chylom icrons
norm ally  [26]. So their increased plasm a triglycer­
ide could not be a ttrib u ted  to an inability to clear 
dietary fat from the circulation. Trace labeled 
V L D L  was retarded in its clearance from  the rab ­
b its’ plasm a [27] and the lipoprotein therefore ac­
cum ulated  there. This phenom enon did not seem 
to m irro r the situation in hum ans. In an early m et­
abolic study, Soutar and  her colleagues [45, 46] 
reported  norm al V L D L  apo B turnover rates and 
norm al plasma triglyceride levels in a group of ho­
m ozygous FH  subjects. The picture is further con­
fused if V LD L-LD L conversion is examined. The 
hum an  studies indicated that LDL production ex­
ceeded by up to 2 fold the VLDL catabolic rate 
and  consequently d irect input o f apo B into LDL 
had  to be postulated [45]. Evidence gained from 
perfusion studies on the W H H L rabbit, however 
indicated  that the liver m ade only V LD L [21]. No 
lipoproteins of LD L density were found in the per­
fusate medium. The m easured increase in LDL 
synthesis in the rabb it was attribu ted  to a reduc­
tion  in direct VLDL catabolism  and an increase 
in its conversion to L D L ; whereas norm al rabbits 
transferred  about 8%  o f VLDL-B to LDL this 
value was increased to 40%  in receptor-deficient 
anim als [59], The discrepancy between the animal 
m odel and hum ans is no t fully resolved. However, 
we have recently re-exam ined the situation in a 
group  o f seven FH  hom ozygotes in w hom  we in­
vestigated the m etabolism  of large V LD L, and 
sm all V L D L 2 (Th D em ant, J Shepherd, CJ Pack­
ard, unpublished observations). A num ber of inter­
esting findings emerged. First, the conversion of 
V L D L ! to V LD L2 was unim paired by the lack 
of receptors, consistent with the role o f LpL as 
the m echanism  responsible for this step (Fig. 3). 
Small (Sf 20-60) V L D L  m etabolism , on the other 
hand, was grossly abnorm al (Fig. 2). Both the 
clearance of rem nants from  this density interval 
and  the rate of delipidation to ID L and LD L were 
inhibited. We observed tha t the FH  subjects with 
the highest triglyceride levels oversynthesised apo 
B and derived m ost o f  their LDL from  VLDL pre­
cursors. O ther FH  patients did not derive all LDL 
from  V LD L and in these subjects (as in those stud­
ied by Soutar et al. [50] de novo L D L  synthesis 
had  to be invoked in order to account for the ob­
served plasm a LDL mass.
New Horizons in Apolipoprotein B iMetaboIism
R ecom binant D N A  technology provides a power­
ful new tool for the investigation o f  the role o f 
genetics in the regulation  o f lipoprotein m eta­
bolism. The um brella term  "n o rm a lity ” which
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encom passes plasm a cholesterol levels ranging 
from 2.5-6.5 mmol/1 and triglyceride from  
0.5-2.5 mmol/1 needs to be redefined since it 
clearly incorporates a spectrum  of individuals with 
widely varying lipid m etabolism . Some studies on 
the effects o f apoprotein  polym orphism  such as 
that described for apo E above have been com ­
pleted. M uta tion  in this protein alone has been 
estim ated to account for 16% of the phenotypic 
variance in LD L  cholesterol [43]. A no ther varia­
tion at the gene level has been described for apo 
B. By digestion with the endonuclease X b a l a re­
striction fragm ent length polym orphism  (R FL P) 
in the apo B gene can be detected th a t appears 
to correlate with the L D L cholesterol level [29, 
50], The m echanism  o f this effect is no t clear but 
initial investigations [9] indicate that alterations in 
the B protein  may result in its perturbed receptor 
binding and catabolism . Given the im portance of 
lipoprotein-receptor interactions, such polym or­
phisms m ay have a num ber o f consequences which 
impinge on V L D L -L D L  conversion. O ther m eth­
ods for detecting variation in apo B structure using 
m onoclonal and polyclonal antibodies [30, 51] 
have been published. The application o f these tech­
niques should allow us to  subdivide “ n o rm a l” in ­
dividuals in to  groups whose m etabolism  can be 
subjected to vigorous scrutiny to determ ine those 
factors responsible for the regulation o f the system.
Acknowledgem ents: Dr Dem ant, a visiting scientist from the 
Medical Polyclinic o f the University o f M unich. Munchen, 
FR G . was the recipient o f  a scholarship from the Stiftung 
Volkswagenwerk, Hannover (FR G ). Joyce Pollock provided 
excellent secretarial help. This work was supported by grants 
from the British Heart Foundation (87/6: 87/101).
References
1. Beltz W. Kesaniemi Y A . Howard BV. Grundy SM (1985) 
Developm ent o f an integrated model for analysis o f  apolipo­
protein B in plasma very low density lipoprotein, intermedi­
ate density lipoproteins and low density lipoproteins. J Clin 
Invest 76:575—585
2. Berman M, Hall M, Levy RI, Eisenberg S. Bilheimer DW , 
Phair R D , Goebel RH (1978) M etabolism o f  apo B and 
apo C lipoproteins in m an: kinetic studies in normal and 
hyperlipoproteinemic subjects. J Lipid Res 19:38-56
3. Bilheimer DW , W atanabe Y, Kita T (1982) Impaired recep­
tor-mediated catabolism o f  low density lipoprotein in the 
W HHL rabbit, an animal model o f  familial hypercholester­
olemia. Proc Natl Acad Sci U SA  79:3305-3309
4. Breckenridge WC, Little JA, Steiner G, Chow A, Poapst 
M (1978) Hypertriglyceridemia associated with deficiency 
of apolipoprotein C II. N Engl J Med 298:1265-1273
5. Brown MS, Goldstein JL (1976) Familial hypercholesterole­
mia : A genetic defect in the low density lipoprotein receptor. 
N E n g fj M ed 294:1386-1390
6. Carlson L, Ballantyne D (1976) Changing relative propor­
tions o f apolipoprotein CII and CIII o f  very low density 
lipoproteins in hypertrislvceridaemia. Atherosclerosis 
23:563-568
7. Chen SH. Habib G, Y oung CY, Gu ZW, Lee BR. W'eng
S. Silberman SR, Cai SJ, Deslypere JP, Chan L (1987) A po­
lipoprotein B48 is the product o f a messenger RN A  with 
an organ-specific in-frame stop codon. Science 238:363-366
8. Deckelbaum RJ, Eisenberg S, Fainaru M, Barenholz Y, 
Olivecrona T (1979) In vitro production o f  human plasma 
low density lipoprotein-like particles. A m odel for very low  
density lipoprotein catabolism . J Biol Chem 254:6079^6087
9. Dem ant T, Houlston R, Caslake M, Series J J, Humphries 
SE, Packard CJ, Shepherd J (1987) Apolipoprotein B D N A  
polymorphism associated with differences in LDL metabo­
lism. Atherosclerosis 68:273 (Abstr)
10. East CA, Grundy SM, Bilheimer DW  (1986) Preliminary 
report: treatment o f type 3 hyperlipoproteinemia with Me- 
vinolin. M etabolism 35:97 -98
11. Ehnholm C. Mahley RW, Chappell D A , Weisgraber KH, 
Ludwig E. Witztum JL (1984) Role o f apolipoprotein E 
in the lipolytic conversion o f  -very low density lipoproteins 
to low' density lipoproteins in type III hyperlipoproteinemia. 
Proc Natl Acad Sci U SA  81:5566-5570
12. Ehnholm C, Lukka M, K uusi T, Nikkila E, Utermann G 
(1986) Apolipoprotein E polymorphism  in the Finnish pop­
ulation: gene frequencies and relation to lipoprotein con­
centrations. J Lipid Res 27:227-235
13. Eisenberg S. Bilheimer D W , Levy R l, Lindgren FT (1973) 
On the metabolic conversion o f  human plasm a very low 
density lipoprotein to low density lipoprotein. Biochem Bio- 
phys Acta 326:361-377
14. Eisenberg S (1985) Lipoproteins and lipoprotein m etabo­
lism. A dynamic evaluation o f the plasma fat transport sys­
tem. Klin Wochenschr 61:119-132
15. Eisenberg S (1985) Preferential enrichment o f  large-sized 
very low density lipoprotein populations with transferred 
cholesteryl esters. J Lipid Res 26:487-494
16. Fisher W (1983) Heterogeneity o f  plasma low density lipo­
protein: manifestations o f  the physiologic phenomenon in 
man. M etabolism 32:283-291
17. Ginsberg H N , Le N A . G oldberg IJ, Gibson JC, Rubinstein 
A. Wang-Iverson P. Norum  R. Brown WV (1986) Apolipo­
protein B metabolism in subjects with deficiency o f  apolipo- 
proteins CIII and AL Evidence that apolipoprotein CIII 
inhibits catabolism o f  triglvceride-rich lipoproteins by lipo­
protein lipase in vivo. J Clin Invest 78:1287-1295
18. Gitlin D. Cormvell D G . N akasato D. Oncley JL. Hughes 
WL. Janeway CA (1958) Studies on the m etabolism o f plas­
ma proteins in the nephrotic syndrome II The lipoproteins.
J Clin Invest 37:172-184
19. Goldberg I. Le N A, Paterniti J. Ginsberg H (1982) Lipopro­
tein metabolism during acute inhibition o f hepatic triglycer­
ide lipase in the cvnom olgus monkey. J Clin Invest 
70:1184-1192
20. Goldstein JL, Brown MS (1977) The low density lipoprotein  
pathway and its relation to atherosclerosis. Ann Rev Bio­
chem 46:897-930
21. Hornick CA, Kita T, H am ilton RL, Kane JP, Havel RJ
(1983) Secretion o f normal and Watanabe heritable hvperli- 
pidemic rabbits. Proc Natl Acad Sci U SA  80:6096-6100
22. Hui D Y , Innerarity TRL, M ilne RW, M ahley RW (1984) 
Binding o f chylomicron remnants and -very low density li­
poproteins to hepatic and extrahepatic lipoprotein recep­
tors. J Biol Chem 269:15060-15068
23. Janus ED, Nicoll A, W ootton R, Turner PR, Magill PJ.
h. Demant et a!.: Very Low Density Lipoprotein Apolipoprote in  B Metabolism in H um ans 711
Lewis B (1980) Q uantitative studies o f  vary low density 
lipoprotein conversion to low density lipoprotein in normal 
controls and primary hyperlipidaemic states and the role 
of direct secretion o f low  density lipoprotein in heterozy­
gous familial hypercholesterolaemia. Eur J Clin Invest 
10:149-159
24. Kane JP, Hardman D A , Paulus HE (1980) Heterogeneity 
o f  apolipoprotein B: Isolation o f a new species from human 
chylomicrons. Proc Natl Acad Sci U SA 77:2465-2469
25. Kissebah AH, Alfarsi S. Adam s PW (1981) Integrated regu­
lation o f very low density lipoprotein triglyceride and apoli­
poprotein B kinetics in man: normolipemic subjects, fami­
lial hypertriglyceridemia and familial hyperlipidemia. M e­
tabolism 30:865-868
26. Kita T, Goldstein JL, Brown MS, W atanabe Y, Hornick 
CA, Havel RJ (1982) H epatic uptake o f  chylomicron rem­
nants in W HHL rabbits: A mechanism genetically distinct 
from the low density lipoprotein receptor. Proc Natl Acad 
Sci U SA  79:3623-3627
27. Kita T, Brown MS, Bilheimer DW , Goldstein JL (1982) 
Delayed clearance o f very low density and intermediate den­
sity lipoproteins with enhanced conversion to low density 
lipoprotein in W HHL rabbits. Proc Natl Acad Sci U SA  
79:5693-5697
28. Kushwaha RS, Hazzard W R, Gagne C, Chait A. Albers 
JJ (1977) Type III hyperlipoproteinemia: Paradoxical hypo­
lipidemic response to estrogen. Ann Int Med 87:517-525
29. Law A, Powell LM, Brunt H, Knot TJ, Altman D G , Rajput 
J, Wallis SC, Pease RJ. Priestley LM, Scott J, Miller GJ, 
Miller NE (1986) C om m on D N A  polymorphism within 
coding sequence o f apolipoprotein B gene associated with 
altered lipid levels. Lancet 1:1301-1303
30. Ma Y, Schumaker V N . Butler R. Sparkes RS (1987) Two 
D N A  restriction fragment length polymorphisms associated 
with Ag (t/z) and Ag (g/c) antigenic sites o f human apolipo­
protein B. Arteriosclerosis 7:301-305
31. M ahley RW (1983) Apolipoprotein E and cholesterol m e­
tabolism. Klin W ochenschr 61:225-232
32. Musliner TA, McVicker KM , Iosefa JF, Krauss RM (1987) 
M etabolism o f human intermediate and very low density 
lipoprotein subfractions from normal and dvsbetaiipopro- 
teinemic plasma. Arteriosclerosis 7:408-420
33. Nicoll A, Lewis B (1980) Evaluation o f  the roles o f lipopro­
tein lipase and hepatic lipase in lipoprotein metabolism: 
in vivo and in vitro studies in man. Eur J Clin Invest 
10:487-495
34. Oschry Y, Olivecrona T, Deckelbaum  RJ, Eisenberg S
(1985) Is hypertriglvceridemic very low density lipoprotein 
a precursor o f normal low density lipoprotein? J Lipid Res 
26:158-167
35. Packard CJ, Munro A, Lorimer A R. G otto  A M , Shepherd 
J (1984) M etabolism o f apolipoprotein B in large tnglvcer- 
ide-rich very low density lipoproteins o f  normal and hvper- 
triglyceridemic subjects. J Clin Invest 74:2178-2192
36. Packard CJ, Boag DE, Clegg RJ, Bedford D K , Shepherd 
J (1985) Effects o f 1,2 cyclohexanedione m odification on 
the metabolism o f  very low density lipoprotein apolipopro­
tein B: potential role o f  receptors in intermediate density 
lipoprotein catabolism. J Lipid Res 26:1058-1067
37. Packard CJ, Clegg RJ, Dom iniczak M H, Lorimer AR, 
Shepherd J (1986) Effects o f  bezafibrate on apolipoprotein  
B m etabolism in type III hyperlipoproteinemic subjects. J 
Lipid Res 27:930-938
38. Reardon M F, Fidge N H . Nestel PJ (1978) Catabolism o f  
very low density lipoprotein B apoprotein in man. J Clin 
Invest 61:850-860
39. Sadur CN. Eckel RH (1982) Insulin stimulation o f adipose 
tissue lipoprotein lipase. U se o f  the euglycemic clamp tech­
nique. J Clin Invest 69:1119-1125
40. Schaefer EJ. Gregg RE, Ghiselli G, Forte TM . Ordovas 
JM. Zech LA, Brewer HB (1986) Familial apolipoprotein 
E deficiency. J Clin Invest 78:1206-1219
41. Schonfeld G. Weidman SW, Wicztum JL, Bowen RM  
(1976) Alterations in levels and inter-relationships of plas­
ma apolipoproteins induced by diet. M etabolism  25:261- 
275
42. Sigurdsson G. Nicoll A, Lewis B (1975) Conversion o f very 
low density lipoprotein to low  density lipoprotein. A meta­
bolic study of apolipoprotein B kinetics in human subjects. 
J Clin Invest 56:1481-1490
43. Sing C, Davignon J (1985) Role o f the apolipoprotein E 
polymorphism in determ ining normal plasma lipid and lipo­
protein variation. Am J Human Genet 37:268-285
44. Shepherd J. Packard CJ. Stewart JM, Atmeh RF. Clark 
DS, Boag DE. Carr K, Lorimer AR, Ballantyne D. Morgan 
H G , Lawrie TDV (1984) Apolipoprotein A and B (Sf 100— 
400) metabolism during Bezafibrate therapy in hypertrigly- 
ceridemic subjects. J Clin Invest 74:2164—2177
45. Soutar AK. Myant N B. Thom pson G R (1977) Simulta­
neous measurement o f  apolipoprotein B turnover in very- 
low  and low-density' lipoproteins in familial hypercholester­
olaemia. Atherosclerosis 28:247-256
46. Soutar AK. Myant N B . Thom pson G R (1982) The metabo­
lism o f  vgry low density and intermediate density lipopro­
teins in patients with familial hypercholesterolaemia. Ath­
erosclerosis 43:217-231
47. Stalenhoef AFH, M alloy MJ, Kane J, Havel RJ (1984) M e­
tabolism of apolipoprotein B-48 and B-100 o f  triglvceride- 
rich lipoproteins in normal and lipoprotein lipase-deficient 
humans. Proc Natl A cad Sci U SA  24:839-843
48. Sullivan DR. Sanders TAB, Trayner IM , Thom pson GR
(1986) Paradoxical elevation o f LDL apoprotein B levels 
in hypertriglyceridaemic patients and normal subjects in­
gesting fish oil. Atherosclerosis 61:129-134
49. Tall A R . Sammett D . Vita GM , Deckelbaum R, Olivecrona 
T (1984) Lipoprotein lipase enhances the cholesteryl ester 
transfer protein-mediated transfer o f cholesteryl esters from 
high density lipoproteins to very low densitv lipoproteins. 
J Biol Chem 259:9587-9594
50. Talmud PJ. Barni N , K essling AM , Carlsson P, Dam fors 
C, Bjursell G. Galton D, W ynn V, Kirk H, Hayden MR, 
Humphries SE (1987) Apolipoprotein B gene variants are 
involved in the detem ination o f serum cholesterol levels: 
a study in normo- and hyperlipidaemic individuals. Athero­
sclerosis 67:81-39
51. Tikkanen MJ. Ehnholm C, Kovanen PT, Butler R. Young 
SG. Curtiss LK, W itztum JL (1987) Detection o f two apoli­
poprotein B species (apo Be and apo Bg) by a monoclonal 
antibody. Atherosclerosis 65:247-256
52. Turner PR. Miller N E , Cortese C, Hazzard W, Coltart J, 
Lewis B (1981) Splanchnic metabolism o f plasma apolipo­
protein B. Studies o f  artery-hepatic vein differences o f mass 
and radiolabel in fasted human subjects. J Clin Invest 
67:1678-1686
53. Turner PR. Cortese C, W ootton R, Marenah C, Miller NE, 
Lewis B (1985) Plasma apolipoprotein B metabolism in fa­
milial type III dvsbetalipoproteinaemia. Eur J Clin Invest 
15:100-112
54. Uterm ann G. Hess M , Steinmetz A (1977) Polymorphism  
o f  apolipoprotein E and occurrence o f  dysbetalipoprotein- 
aemia in man. Nature 296:604—607
55. Utermann G. Kindermann I, Kaffarnik H, Steinmetz A
712 Th. Dem ant et al.: Very Low Density  Lipoprotein Apolipoprote in  B Metabolism in Humans
(1984) Apolipoprotein E phenotypes and hyperlipidemia. 
Hum G enet 65:232-236
56. Uterm ann G (1987) Apolipoprotein E polymorphism in 
health and disease. Am  Heart J 113:433—440
57. Wardell M R, Suckling PA, Janus ED (1982) Genetic varia­
tion in human apolipoprotein E. J Lipid Res 23:1174-1182
58. Weisgraber KH, Rail SC, Mahley RW (1981) Human E 
apoprotein heterogeneity. Cysteine-Arginine interchanges in 
the am ino acid sequence o f  the apo E isoforms. J Biol Chem  
256:9077-9083
59. Yam ada N , Shames D M , Havel RJ (1987) Effect of low  
density lipoprotein receptor deficiency on the metabolism  
o f  apolipoprotein B-100 in blood plasma. Kinetic studies
in normal and W atanabe heritable hyperlipidemic rabbits. 
J Clin Invest 80:507-515
Received: December 31, 1987 
Accepted: June 8, 1988
Th. D em ant, M .D.
Lipid Laboratory
D epartm ent o f  Pathological Biochemistry 
R oyal Infirmary 
G lasgow  G 4 OSF, U K
Catabolic Rats of Lew Density Lipoprotein Is influenced by Variation in the 
Apoiipcprotein B G ene
Thomas Dem ant,' Richard S. Houiston,*1 Muriel J. C aslake,' John J. S eries ,' James Shepherd ,' Christopher J. Packard,* 
and Stephen E. Humphries1
•Department o f Pathological Biochemistry, Royal Infirmary, Glasgow, G4 OSF Scotland;x Department o f Metabolic Disorders and 
Chemical Pathology, St. Thomas's Hospital Medical School, London, SE1 TEH. England; a n d 9Charing Cross Sunley Research Centre, 
Hammersmith. London. W6 8L W  England
Abstract
This study examines the potential influence of generic varia­
tion on the metabolism of LD L . Restriction fragment length 
polymorphisms (RFLP) of the gene coding for apo B were 
identified using the endonucleases Xba I, Eco RI, and Msp I in 
a group of 19 subjects with moderate hyperiipidemia. There 
was a significant association between the Xba I polymorphism 
and the totai fractional clearance rate (FCR) of LDL. The 
individuals with the X I X I  genotype had, on average, a 22% 
higher FCR {?  < 0.025) than those with the genotype X2X2  
[X2  allele = presence of Xba I cutting site). This difference 
was attributable to increased clearance by the receptor-me­
diated pathway of LDL cataboiism. In this group of subjects, 
there  was no association  of LD L kinetic param eters and 
R FLPs of the LDL receptor gene or the Al- CIII- AIV gene 
d uster. The data suggest tha t variation in apo 3  itself, presum­
ably acting through variable binding to the LDL receptor, 
makes a significant contribution to the rate of cataboiism of 
LDL.
introduction
Ape 3, the major protein com ponent of LDL, contains the 
binding site for the LDL receptor and consequently plays a 
pivotai role in the metabolism o f the lipoprotein, by facilitat­
ing its ceiiuiar uptake and degradation (I, 2). In recent years, 
attention has focused on the receptor as the mediator of cho­
lesterol homeostasis in the body, and we now knew that a 
variety of mutations in this protein may produce gross distur­
bances in plasma LDL levels (3. 4). Now, with the isolation of 
the gene coding for apo B (5), we are aoie to use the techniques 
of molecular bioiogy to analyze the contribution that the li­
gand might make to alterations in iipoprctein metabolism.
DNA probes for the hum an apo 3 gene have recently been 
isolated (6-9) and a num ber of com m on restriction fragment 
length polymorphisms (R FL P)1 have been described (9-11).
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One o f these, an RFLP detected using the restriction enzyme 
X ba I, has been shown in normal individuals to be associated 
with variations in plasma cholesterol and triglyceride (1 2 -1 4 ) .  
The same polym orphism has also been reported to represent 
an independent risk factor for ischemic heart disease (15), al­
though there is not universal agreement on this point (16). In 
this study, we use three polymorphisms of the apo 3 gene locus 
to examine the relationship between variation in the apo B 
gene and the metabolism of LDL in a group of individuals 
with moderate hyperlipemia.^
Methods
Subjects. Volunteers aged between 40 and 60 yr were identified as 
hyperiipidemic during an opportunistic screening program in b e  city 
of Glasgow. Those detected were given dietary advice designed to 
correct their lipid abnormality and reassessed after 2 mo. At this point, 
potential sufferers from familial hypercholesterolemia were diagnosed 
on the basis o f recognized criteria (17) and excluded if they had tendon 
xanthomata or a first-degree relative (particularly a chiid) with raised 
LDL cholesterol. Two subjects with total choiesteroi values o f  S. 5 and 
8.3 m m oi/’iter were rejected on this basis. None of the remaining 19 
unrelated Caucasian subjects (4 male. 15 female; Tabie I) who failed to 
respond adequately to the diet, had a strong family history o f prema­
ture cardiovascular disease (i.e., more than one affected first-degree 
relative aged < 5 5  yr). Two presented with xanthelasmata, two 'with 
corneal arcus, and two with angina of effort (Table !). Their plasma 
cholesterol leveis were, on average. 7.69=0.73 mmci/Iiter and their 
die: was maintained during the evaluation of LDL metabolic parame­
ters. 60 mg potassium iodide was giver, thrice daily for 3 d before and 2 
wic after the study to prevent thyroidal sequestration of radioiodidc. 
Biochemical tests showed that none of the subjects suffered from he­
patic. renal, or endocrine disease and none had over, ischemic heart 
disease. AH subjects gave informed consent to the study, which was 
approved by the Eihicai Committee c f Glasgow Royal Infirmary.
M etabolic studies. LDL turnover was assessed in the patients using 
a protocol described elsewhere (IS. 19). 3rieffy, autologous LDL id  
= l.03-i.G 5 kg/liter) was prepared by rate zona! ultracer.trifugation 
(20) and divided into two aliquots, which were labeled separately with 
l2JI and ,3I1 (21). The latter was then subjected to modification with 
I, 2-cyc!ohexanedione, which blocks the arginyl residues on its protein 
moiety (22) and provides a tracer of receptor-independent LDL metab­
olism (18, 19). Such modification prevents interaction of the lipopro­
tein with the receptor and denies it access to the receptor-dependent 
degradation pathway. Plasma clearance of each tracer was followed 
over a 2-wk period and the radioactive decay curves were constructed 
and analyzed using the SAAM 29 computer program (23). This gave 
fractional clearance rates (FCRs) for the native and chemically modi­
fied LDL that were used to obtain values for total, receptor-indepen­
dent, and, by difference, receptor-mediated catabolism of the lipopro­
tein (18, 19). Plasma apo LDL concentrations were determined from 
calculations based on serial LDL cholesterol measurements and on 
compositional data derived from analyses of the isolated lipoprotein 
(24). The absolute clearance rate for LDL apoprotein was then calcu­
lated as the product of the total FCR and the plasma LDL pcol (i.e..
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apo LDL concentration times the plasma volume). This parameter is 
commonly expressed per kilogram o f body weight, and under the 
steady state conditions o f the study equals the synthetic rate o f  the 
protein. Separate absolute clearance rates can also be calculated for the 
receptor-dependent and independent routes as the product o f the apo 
LDL pool and the FCR can be determined for each pathway.
DMA analysis. Blood was collected into 2.0 mg/ml K2 EDTA and 
stored at -2 0 °C  until analysis. DNA was prepared from these speci­
mens by the Triton X100 lysis method (25), and a 5.0-y.g aliquot was 
digested using a panel o f enzymes (Eco RI, Xba I, Pvu II, Xmn I, and 
Nco I) at 2-10 U of enzyme per microgram of DNA according to the 
supplier’s instructions (Anglian Biotech, Colchester, England).
The fragments generated in each digest were separated by agarose 
electrophoresis and transferred to Hybond filters (Amcrshum Corp., 
Amersham, England) by Southern blotting.
Polymorphisms of the apo B gene were detected (Fig. 1): (a) by 
hybridizing the two Xba I digest fragments designated X I  (8.6 kb) and 
X2  (3.5 kb), with the 3.5-kb probe pABC3.5 (11); (b) in an Eco RI 
digest by hybridizing the two fragments, R I  (10.5 kb) and R 2 (  12.5 kb), 
with the cDNA probe pA33 (11); and (c) after digestion with Msp I and 
probing with PH2 (a 2-kb Hind III fragment subcloned from an apo B 
genomic recombinant). Multiple hybridizing fragments could be dem­
onstrated (11). Those 2.6 kb and larger were designated A ll  and those 
2.2 kb and smaller were designated M2. Polymorphisms of the LDL 
receptor gene were detected using a 1.9-kb Bam HI cDNA (26, 27) 
after digestion with either ?vu II or Nco I.
Apolipoprotein AI/CIII/AIV gene cluster polymorphisms were 
identified using (a) a 2.2-kb Pst I fragment (28) o f the apo AI gene after 
Xmn I digestion and lb) a I.G-kb Pvu II fragment (29) o f the C-III gene 
after Pvu II digestion.
Ail probes were labeled with 3JP dCTP at a specific activity o f 800 
Ci/mmol (Amersham Corp.) by a random oligonucleotide priming 
method (30). The hybridization, filter washing, and autoradiographic 
procedures are described eisewnere (28).
Statistical analysis. Statistical analysis was carried out by the Min­
itab program (State College, PA). A one-way analysis o f variance was 
performed to test the null hypothesis that kinetic variation was not 
associated with genetic variation detected by the different RFLPs. The 
F  statistic was employed to test the significance o f differences between 
the genotypes. We considered significance to be at the 0.05 level.
Resuits
The 19 subjects couid be divided into three groups on the basis 
of the polymorphisms detected using the Xba I endonuciease
(Table I). There was no difference in body weight or mean age, 
nor in the plasma concentrations o f cholesterol, triglyceride, 
LDL cholesterol, or apoprotein between those with the geno­
type X1X1  (absence of cutting site) and those with the geno­
type X2X2. There were also no significant differences in these 
parameters when the subjects were grouped according to the 
polymorphisms detected with the Msp I and the Eco RI en­
zymes. Similarly, the gross composition of LDL was not al­
tered in individuals of different X ba I genotype (Table II).
However, the metabolic properties of LDL did differ be­
tween the genotype groups. The catabolic rate of LDL apo­
protein measured as the fraction of the plasma pool catabo- 
lizcd each day (FCR), wus significantly higher in individuals 
with the X1X1 genotype com pared with those with X 2X2  (F  
= 9.18; P < 0.025). The subjects with the genotype X1X2  had 
an intermediate m ean FCR. Sim ultaneous with the,injection 
of native lipoprotein, subjects received a tracer of cyclohex- 
anedione-treated LDL that perm itted the estimation of recep­
tor-dependent versus receptor-independent removal (Table 
III). This reveaied that the difference in overall catabolism was 
due to an increase in the fraction and am ount of LDL de­
graded by the receptor route. Subjects o f X1X1  genotype ex­
hibited a 58% higher receptor-m ediated FCR than those with 
the genotype X 2X2 (F  = 9.08; P < 0.025) and cleared 65% 
more LDL protein through this pathway. No such difference 
was observed in the fraction of LDL degraded by receptor-in­
dependent mechanisms. Likewise, when the synthetic rate of 
LDL apoprotein was calculated, no significant association 
with genotype was observed, although this param eter was 
highly variable within the groups.
There was a weak association between LDL apoprotein 
clearance rate and the apo B polym orphism detected using 
Msp I (Table IV ), but the differences did not reach statistical 
significance. In the i9 subjects examined, LDL kinetic param ­
eters were not significantly different in individuals with differ­
ent RFLP genotypes o f the LDL-receptor gene or the AI-CIII- 
AIV gene cluster (data not shown).
Discussion
The individuals examined in this study had diet-refractory hy- 
periipidemia that arose from a com bination of oversynthesis
Xbal EcoR 1 Msp1
Kb
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Figure 1. Southern blot analysis o f the Xba I, Eco RI, and Msp I polymorphism of the apo B gene. 5 ug o f DNA from three individuals is 
shown. The Msp I polymorphism is a length variation due to different numbers o f copies of a 14-bp repeat sequence in the 3' flanking region of 
the gene (36).
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Table I. Plasma Lipids, Lipoproteins, and Clinical Data from Individuals with Different Apo B Xba I Genotype
Subject Genotype CholateroJ
PUima
Triglyceride LDL-cholencrot LDL-ipoprotaa Ginkai data
1 X1X1 8.10
mmoil liter
1.95 5.90
mgjdl
193 Angina
2 X1X1 7.74 1.24 . 5.99 192 Xanthelasmata
3 X1X1 6.89 1.66 4.93 149 Normal
4 X 1X I 8.49 3.24 6.23 211 Corneal arcus
5 X 1X I 7.08 1.43 ■ 5.23 . 179 Normal
« -  5 M ean±l SD 7.76±0.59 1.88±0.65 5.73=0.47 187=19
6 X 1X 2 8.09 1.20 5.76 151 Normal
7 X1X2 8.79 1.90 6.63 204 .. Normal
8 X IX 2 7.12 2.60 . * 4.80 ■ 173 Normal
9 X 1X 2 6.97 1.30 4.99 167 Angina
1° X1X2 8.09 2.31 6.01 174 Myocardial infarction in mother
11 X IX 2 6.85 0.83 3.76 156
(age 55) 
Normal
12 X IX 2 7.05 2.14 4.75 135 Normal
13 X 1X 2 8.53 2.15 6.58 186 ' Myocardial infarction in brother
n -  8 M ean*! SD 7.69=0.72 1.37=0.55 5.41=0.94 163=20
(age 54)
14 X 2X 2 8.33 2.23 5.46 253 Arcus.
15 V-V-I 8.56 2.76 6.23 175 Myocardial infarction in father
16 X2X2 6.36 0.82 3.79 . 146
(age 45) 
Normal
17 X2X2 8.00 3.11 5.62 176 Normal
18 Y* V* 7.03 1.68 4.83 160 Xanthelasmata
19 X2X2 8.09 2.57 5.34 . 192 • Normal
n -  6 Meanrt: SD 7.73±0.78 2.32=0.77 5.30=0.78 184=34
Ail values given in the table are means of at least three independent determinations. Analysis o f variance showed no significant differences in 
plasma lipid parameters between any o f the three groups (X IX I, X1X2, or X 2X 2).
and defective cataboiism. M ost Harj LD L apoprotein synthetic 
rates (Table III) in excess (31-33) o f norm al values (1 1-13 
mg/kg per d), whereas their total X D L  FCRs lay between the 
values observed (32, 33) in controls (0.35±0.06 pools/d) and 
those (18, 31) in familial hypercholesterolemia heterozygotes 
(0.19±0.046 pools/d) that have oniy a partial com plem ent of 
LDL receptors. They also exhibited reduced receptor-m e­
diated FCRs that varied from 9 to 39% of the total. This is 
lower than the 50% we have previously observed in norm ciip-
idcmic controls (33, 34) because o f the general inverse rela­
tionship between plasma LDL concentration and receptor ac­
tivity (31). Note also that there are differences seen in the 
estimated contribution of the receptor pathway when alterna­
tive m ethods o f modifying LDL are used. For example, Ke* 
sanicmi et ai. (35) reported m uch higher values for receptor- 
m ediated clearance using glucosylated LDL. The relative 
merits o f the different approaches have been discussed in de­
tail (34).
Table II. L D L  C om position in Ind ividuals with Different A po  S  X ba I  G enotype
LDL oompocition
Genotype Free cholesterol EsteriAed choletterol Triglyceride Phocpholipid Protein
X1X1 ( r t -  5) 
X 1X 2 (n -  8) 
X 2X 2 (n -  6)
9.29=0.81*
9.25=0.77
8.42=0.80
36.93=2.77
38.26=1.93
37.64=1.34
gJlOO g 
8.06=0.99  
7.02=1.28  
7.26=0.73
20.52=0.35  
21.43=1.29 = 
20.97=0.58
25.21 =  1.15,
23.91=0.72
25.69=1.73
No significant differences were present in composition between any of the three groups. 
• M c a n i lS D .
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Table III. LDLKinetic Parameters and Xba I Genotype
Subject Sex •
RFLP oenotypea Fractional catabolic rata
Synthesis*
Absolute* 
receptor-mediated 
catabolic meXba I Eco RJ Msp I Total Receptor mediated
pooh/d mg/kg per d
I F X1X1 R1R1 M l M2 0.248 0.088 19.10 6.80
2 F •X IX l R1R2 M l M2 0.236 0.101 • 19.70 7.80
3 F X I X l R1R1 M2M2 0.270 0.079 16.10 4.71
4 F X IX 1 R1R1 M l M2 0.282 0.069 23.80 5.82
3 M X IX l R1R2 M1M2 0.297 0.072 21.27 5.16 ’
5 M ean±l SD 0.271 ±0.020 0.082±0.013 19.99±2.84 6.06±1.25
6 F X 1X 2 R1R2 M1M2 0.219 0.078 13.23 4.7!
7 F X 1X 2 R1R1 M2M2 0.229 0.087 18.69 7.10
8 F X 1X 2 R1R2 0.252 0.022 17.40 1.50
9 F X 1X 2 R1R2 M l M2 0.251 0.044 16.80 2.90
10 F X IX 2 RIR1 M1M2 0.241 0.070 16.77 4.87
11 F X 1X 2 R1R2 M l M2 0.218 0.084 13.60 5.20 ‘
12 M X 1X 2 R1R2 M1M2 0.280 0.114 15.12 6.16
13 M X 1X 2 R1R1 M2M2 . . 0.2O5 0.056 15.25 4.16
n ■ 8 M ean±l SD 0.237±0.024 0.069±0.02S 15.86±1.89 4.58±1.77
14 F ’ X 2X 2 R!RS 0.218 0.020 22.10 2.00
13 M X 2X 2 R iR l M2M2 0.197 0.067 13.79 4.69
16 F X 2X 2 R1R1 M2M2 0.182 0.042 10.60 2.50
17 F X 2X 2 R1R1 M2.M2 0.265 0.054 18.66 / 3.80
18 F X 2X 2 R1R1 M2M2 0.217 0.070 13.90 4.50
19 F X 2X 2 R IR i M2M2 0.250 . 0.059 19.20 4.53
n -  6 Meaner! SD 0.222±0.031 0.052±0.019 16.38±4.29 3.67±1.15
Analysis o f X 1X 1:X 1X 2:X 2X 2 P  <  0.025 NS NS P <  0.050
variance X 1X L X 2X 2
'
P  <  0.025 P  <  0.025 NS P <  0.010
N o significant differences could be detected when genotypically different groups (R1R1 versus RIR2; M l M2 versus M2M2) were compared by 
analysis o f variance. • The synthetic rate is equal to the product o f  the total FCR and the plasma LDL pool (LDL concentration X plasma 
volume). * The absolute receptor-mediated catabolic rate is the product o f the receptor-mediated FCR and the plasma LDL pooL
It is difficult to make a definitive diagnosis of familial hy­
percholesterolem ia in individuals with m oderately elevated 
cholesterol levels using available techniques. Clinical criteria 
rem ain the best guide, bu t even here, lack of available family 
history may cioud the issue. In this study, comm only accepted 
exclusion criteria were set for individuals with famiiial hyper­
cholesterolemia (see M ethods). However, it is im portant to 
note in interpreting the data that these criteria are ne t abso­
lute.
Although individuals with famiiial hypercholesterolemia 
were excluded from the study and all o f the subjects had simi­
lar plasma lipid and lipoprotein levels, the FCR for LDL var-
T a b l e  I V .  L D L  Ki n e t i c  P a r a m e t e r s  a n d  E c o  R I  a n d  M s p  I  R F L P  G e n o t y p e s
Fractional catabolic rate
Absolute* receptor-mediated
Genotype Total Receptor mediated Synthesis* catabolic rate
pooh/d mg/kgperd
Eco Rl-RFLP
R1.R1 n -  12 0.234±0.031 0 .063± 0 .0 l9 17.33±3.70 4.62± 1.50
R1R2 n -  7 0.253±0.029 0.074±0.032 16.73±3.01 4.78±2.07
Msp I-RFLP 
M l M2 / t - 9 0.255±0.027 0.080±0.020 16.20±6.87 5.49± 1.39
M2M2 n -  8 0.227±0.032 0.064±0.014 15.77±3.00 4.50±1.28
•  1 For definitions see Table III. 
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ied by up to 50%. This variability was related to the apo B 
genotype of the individual. The group o f five subjects with 
genotype X I X l  had a 22% higher total FCR than the six who 
had genotype X2X2. More detailed exam ination o f the cause 
of this difference, using a receptor-blocked LDL tracer, re­
vealed that the difference was due to an increased flux through 
the receptor pathway. Both the proportion of the plasma LDL 
apoprotein pool and the am ount cleared via receptors was 
significantly elevated in X I X l  individuals. It is unlikely that 
these observations can be explained by changes of the consti­
tutive activity of the receptor. Rather, they indicate that varia­
tions in the structure of the ligand LDL are responsible. Our 
data suggest that apo B produced in X 2X 2  individuals has a 
perturbed structure that diminishes its ability to interact with 
the receptor on ceil membranes. Since it is known that only 
one B protein is present on each particie, this hypothesis also 
implies that individuals who are heterozygous for the polymor­
phism would produce two forms of LDL (one receptor active, 
the other relatively inactive) and wouid express an interm e­
diate FCR (Table III).
The DNA sequence change that creates the Xba I restric­
tion site occurs at the third base of the codon for threonine 
2,488 in apo B (36). No amino acid change results, and so it is 
unlikely that the Xba I polym orphism itself is functionally 
significant. Rather, this site is probably in linkage disequilib­
rium ’with an im portant change elsewhere in the coding region. 
One possibility is that the im portant m utation lies in the puta­
tive receptor binding site (5), i.e., between amino acids 3,147- 
3,157 or 3.35 i—3,367, a region dose to the X ba I cutting site.
The findings presented here also suggest a mechanism for 
the association of Xba I genotype and plasma cholesterol in 
the normal population (1 2 -1 4 ) . In subjects with norm al lipid 
levels, there is a strong relationship between the receptor-me­
diated FCR and LDL concentration (31). The observed higher 
plasma cholesterol in individuals of X 2X 2  versus X I X l  geno­
type thus might be explained by the production of a relatively 
receptor-inactive apo B in the former group that would lead to 
accumulation of LDL in the rircuiation. Where the influence 
of synthesis becomes predom inant, as in our present cohort of 
hyperchoiesteroiemic patients, this relationship with plasma 
LDL concentration wouid be dim inished. It is not yet dear 
whether the metabolic changes described in this study relate to 
the higher inddence ofischem ic hear, disease reported in one 
study to be associated with thc X I  allele (15). However, if the 
trend toward higher LDL apoprotein synthesis in the X I X l  
group (Table IV) is confirmed in subsequent studies, then it 
may point to the importance of LDL flux and plasma concen­
tration as risk markers for ischemic hear, disease.
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Abstract Hepatic lipase deficiency produces significant distortion 
in the plasm a lipoprotein profile. Particles with reduced electro­
phoretic mobility appear in very low density lipoprotein (V L D L ). 
Interm ediate density lipoprotein (ID L ) increases markedly in the 
circulation and plasma low density lipoprotein (L D L ) levels fall. At 
the sam e time there is a mass redistribution within the high den­
sity lipoprotein (H D L ) spectrum leading to dom inance in the less 
dense H D L 2 subfraction. T he present study exam ines apolipo­
protein B turnover in a patient with hepatic lipase deficiency. The 
m etabolism  o f large and small very low density lipoproteins was 
determ ined in four control subjects and com pared to the pattern 
seen in the patient. Absence o f the enzym e did not affect the rate 
at which large very low density lipoproteins were converted to 
sm aller particles within this density interval (i.e., o f V L D L ). 
However, subsequent transfer of sm all very low density lipopro­
teins to interm ediate density particles was retarded by 50%, ex­
plaining the abnormal accum ulation o f  V L D L  in the patient’s 
plasma. Despite this, intermediate density panicles accumulated to 
a level 2.4-tim es normal because their subsequent conversion to 
low density lipoprotein has been alm ost totally inhibited. C onse­
quently, the plasm a concentration o f low density lipoprotein was 
only 10% o f normal. SIS On the basis o f these observations, 
hepatic lipase appears to be essential for the conversion o f small 
very low density and intermediate density particles to low density 
lipoproteins. T he pathways o f direct plasm a catabolism  o f these 
species were not affected by the enzym e defect. In vitro studies 
were perform ed by adding purified hepatic lipase to the patient’s 
plasm a. T h is did not m odify the size o f H D L 2 significantly, but 
resulted primarily in triglyceride hydrolysis in the less dense apo­
lipoprotein B-containing particles. —D em a n t, T., L. A. C arlson, 
L . H o lm q u is t, F. K arpe, P. N ilsso n -E h le , C. J. Packard, and  
J. Shepherd. Lipoprotein metabolism in hepatic lipase deficiency: 
studies on the turnover of apolipoprotein B and on the effect o f  
hepatic lipase on high density lipoprotein. J . L ipid Res. 1988. 29: 
1603-1611.
S u p p le m e n ta ry  key  w ords  V L D L  • H D L  • apoB  • H D L 2 • H D L j
T h e  lipolytic degradation  of c ircu lating  triglyceride-rich 
lipopro teins involves sim ultaneous loss of core triglycerides
and coat phospholipid from  the panicles. Two key enzymes, 
located  on the endothelial surfaces of capillary beds, are 
believed to participate in this process (1). L ipoprotein lipase, 
the b e tte r  characterized  o f the two, is associated prim arily  
w ith adipose tissue and skeletal muscle. It shows particu lar 
affinity for larger lipoprotein particles (2) like chylom icrons 
an d  very low density  lipop ro te in  (V L D L ) w ith Svedberg 
flotation rates (Sf) g rea te r th an  100. H ered ita ry  absence 
of the enzym e therefore results in accum ulation of such par­
ticles in the circulation , lead ing  to the phenotyp ic  lipopro ­
tein d iso rder called Type I hyperlipopro te inem ia  (3).
T h e  function of the o ther enzym e, hepatic lipase, synthe­
sized and  secreted by hepatocytes, is less well docum ented
(1). It possesses both triglyceride hydrolase and  phospho- 
lipase activities in vitro (4) and  has a h igher affinity for 
sm aller, d enser lipopro tein  particles (2). A nim al studies 
(5, 6) have suggested th a t its actions m ay be directed 
p rim arily  at the m etabolism  of sm all V L D L , in term ed ia te  
density  lipopro tein  (ID L ), and  high density  lipoprotein  
(H D L ). A ntibody infusions (5), designed to inhibit the en­
zym e, lead, w ithin a few hours to the accum ulation  of S( 
20-100 V L D L  and Sf 12-20 ID L  in plasm a, w ith a con­
com itan t reduction  in c ircu la ting  low density  lipoprotein 
(L D L ). At the sam e tim e, the m ass o f phospholipid w ithin 
the H D L 2 density  interval (1.063-1.125 kg/1) increases (5, 
6). However, it has also been proposed that hepatic  lipase
A b b rev ia tio n s : S |, negative sed im e n ta tio n  coefficient at d 1.063 kg • l ' 1 
an d  2 6 °C ; V L D L , very low density  lipopro teins, d <  1.006 kg • l* 1; ID L , 
in te rm e d ia te  d en s ity  lip o p ro te in s , d  1.006-1.019 kg ■ I ' 1; L D L , low d e n ­
sity lip o p ro te in s , d 1.019-1.063 kg ■ l* 1; T M U , 1 ,1 ,3 ,3 -te tram e thy lu rea; 
H D L , h ig h  d e n s ity  lip o p ro te in s , d  1.063-1.210 kg • I " 1; H D L 2, h igh  d e n ­
sity  lip o p ro te in  su b frac tio n  2, d  1.063-1.125 kg • r ‘; H D L ) , h igh  d ensity  
l ip o p ro te in  sub frac tion  3, d 1.125-1.210 kg • l " 1; LCAT, lecith in .cholestero l 
ac y ltran s fe ra se ; FFA, free fa tty  ac id s .
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is involved in the e lim ination  o f H D L 2 constituen ts by the 
liver (7-10). Recently*two pairs o f  b ro thers, one C an ad ian
(11) and  one Swedish (12), were reported  to have a deficiency 
o f postheparin  hepatic  lipase activity. T h e  lipoprotein  
profile in all four pa tien ts was d is to rted , w ith the accum u­
lation  o f sm all V L D L  (/3-VLDL) and  H D L 2, bu t it was not 
c lear from  the observations w hether the enzym e acted 
p rim arily  on  V L D L  or H D L . Since both o f these particles 
are  linked m etabolically, d is tu rbances in the m etabolism  
o f one w ould have an im pact on the other, possibly via the 
agency o f plasm a lipid transfer activities. T h e  present report 
describes in vivo and  in v itro  stud ies on  the lipoproteins 
o f one o f the Swedish patien ts.
M A T E R IA L S  A N D  M E T H O D S
Subjects
T h e  four subjects who form ed the contro l g roup  in this 
study were healthy males aged 32-65 years. R outine clinical 
an d  labo ra to ry  screen ing  revealed no evidence o f cardio- 
logic, renal, hepatic, endocrine, o r metabolic disease. Plasma 
lip id  and  lipopro tein  levels were de te rm ined  accord ing  to 
the L ip id  R esearch C linics protocol (13).
T h e  hepa tic  lipase-deficient p a tien t (GP, age 63 years), 
one o f two affected Swedish brothers, has been described in 
detail elsew here (12). H e is an  ap o E 3/E 4 heterozygote. At 
th e  tim e of this study he had  a m odera te  hypertrig lycer­
idem ia w ithout any increase in V L D L  cholesterol (T able 1) 
and w ith v irtually  im m easurable postheparin  hepatic lipase 
bu t no rm al lipopro tein  lipase activity. H is general health  
rem ains good. Specifically, there  was no clinical evidence 
o f cen tra l o r periphera l vascular disease. All subjects gave 
th e ir in fo rm ed  consent to the study  w hich followed the 
guidelines o f the E thical C om m ittees of G lasgow  Royal 
In f irm ary  an d  the K aro linska H osp ita l, S tockholm .
In vivo studies
Isolation and characterization of plasm a lipoproteins was 
perfo rm ed  using two u ltracen trifugation  techniques. T he 
cum ulative flotation u ltracen trifugation  procedure, a 
m odification  (14) of the m ethod  of L indgren , Jen sen , and 
H a tch  (15) was em ployed to isolate apo lipopro tein  B- 
co n ta in in g  particles in four subfractions: St 60-400  (large 
V L D L ), 20-60  (small V L D L ), 12-20 (ID L ), and  0-12 
(L D L ). T h e  detailed m ethodology is described in earlier 
pub lica tions (14,16). Since the m ajority  of the apo lipopro ­
tein  B -contain ing  lipopro te ins lie w ith in  the density  in te r­
val 1.006-1.063 kg • l ' 1, this m ateria l was also subjected to 
continuous gradient analysis by the rate zonal u ltracentrifu­
gation m ethod of Patsch et al. (17). To facilitate ch aracteri­
za tion  o f G P ’s profile, a m arker o f rad io iod inated  norm al 
L D L  (18) was added to his p lasm a specim en p rio r to an a l­
ysis. T h e  H D L  profile in this pa tien t has already  been 
show n to be abnorm al by u ltracen trifugation  (19) as well 
as polyacrylam ide gel electrophoresis (12). It was re ­
exam ined  by the ra te  zonal separa tion  procedure  (17).
F ractions isolated by the cum ulative o r rate zonal u ltra ­
cen trifugation  procedure were analyzed to determ ine their 
contents of free and esterified cholesterol, triglyceride, phos­
pholip id , an d  pro tein  as ou tlined  elsewhere (20).
K in etic studies
Total V L D L  of density  less than  1.006 kg • l " 1 was p re ­
p a red  in a B eckm an T i 60 ro to r (B eckm an Instrum en ts, 
Palo Alto, C A) by u ltracen trifuga tion  of 250 ml of fasting 
p lasm a for 18 h r at 10°C and  40,000 rpm . T h e  lipoprotein  
was aspirated, pooled, and its density was increased to 1.182 
kg • l ' 1 by add ition  o f solid N aB r (0.384 g ■ m l-1). A d is­
con tinuous salt g rad ien t from  density  1.0988 kg • I -1 to 
1.0588 kg ■ l " lwas constructed  over 2.0-m l aliquots of the 
V L D L  in an  SVV40 rotor, and  the p repara tion  was cen­
trifuged  accord ing  to a m odification  (14) of the p rocedure 
of L indgren  et al. (15) to isolate large and small V L D L  frac-
T A B L E  1. P la s m a  lip id s  a n d  lip o p ro te in s  in  co n tro l su b jec t a n d  a h ep a tic  lip a se -d e fic ien t su b jec t
C h o le s te ro l  in
Total Total
Subjects Triglyceride Cholesterol V LD L LDL H D L
m m ol/l
N l 4 1.71 ± 0 .3 8 4 4 .9 6 ± 0 .5 4 0 .7 9 ± 0 . 2 1 3 .1 4 ± 0 .3 5 1 . 0 1 ± 0 .13
N 2 2 .5 5 ± 0.71 6 .2 3 + 0 .7 9 1 . 0 2 ± 0 .2 5 4 .0 9 ± 0 .5 0 1.36 ± 0 .1 9
N 3 0 .9 4 ± 0 .25 3 .7 6 ± 0 .4 0 0 .3 3 ± 0 .1 7 1 . 6 6 ± 0 .3 2 1.78 ± 0 .2 4
N 4 2 . 0 0 ± 0 .7 5 6 .5 5 ± 1 . 0 0 1.08 ± 0 .5 4 4 .37 ± 0 .8 3 1 . 1 0 ± 0 . 2 2
M e a n 1.80 ± 0 .5 8 5 .3 8 ± 1 . 1 0 0.81 t 0 .2 9 3 .32 ± 1.06 1.31 ± 0 .3 0
H L ( - ) ‘ 2 .82 ± 0 .4 9 5 .1 0 ± 1.05 0 .7 5 ± 0.41 2 .18 ± 0 .2 9 1.96 i 0 .25
‘ N o rm a l sub jec ts  1 to  4.
* M ean  ± S D , n -  5.
‘ H e p a tic  lip ase -d efic ien t p a t ie n t G P .
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tions of Sf 60-400 and 20-60 , respectively. T hese fractions 
were than  labeled  w ith t31I an d  125I by a m odification (21) 
o f the M acfarlane  IC1 p ro ced u re  (22). L abeling  efficiency 
varied  betw een 5 and  15% and  the conditions used gave 
less than  1 mol of iodine per 300,000 daltons of B protein  
as described previously (16). T h e  labeled tracers were steri­
lized by m em brane filtration (0.45 p.m A m icon filters (Ami- 
con C orp., B edford, M A )) p rio r to rein jection  into the 
donor. P rep ara tio n  tim e overall was less than  48 hr. T he 
tracers were adm in is te red  at 8:00 AM after an  overnight 
fast and, in o rder to m inim ize chylom icron production, the 
subjects received a hypocaloric fa t-restric ted  (less than  5 
g) d iet d u rin g  the first day o f the study. P lasm a sam ples 
were collected at frequen t in tervals over the first 72 h r  and 
then daily in the fasting state for 14 days. P lasm a from each 
tim e poin t was used to isolate large and  small V L D L , ID L, 
and L D L  by the m ethod outlined above (14, 16). These lipo­
pro te ins were treated  w ith 1 ,1 ,3 ,3-tetram ethylurea (T M U ) 
as described elsewhere (16) to p rep a re  apo lipopro te in  B, 
whose specific activity was calcu lated  following direct m ea­
su rem en t of p ro tein  (16) an d  rad ioactiv ity  content. T he 
apo lipopro te in  B pool c ircu la tin g  w ith  each of these lipo­
p ro te in  fractions was d e te rm in ed  by rep licate  analyses of 
plasm a samples collected interm ittently  throughout the tu rn­
over study. Losses d u rin g  cen trifuga tion  were corrected 
by com paring  the total cholesterol m ass recovered in all 
four fractions w ith tlfct d <  1.063 kg • l " 1 cholesterol con­
ten t of the subject’s p lasm a de te rm in ed  by the s tandard  
Lipid Research Clinics protocol (13). Further correction was 
m ade for possible B p ro te in  loss d u rin g  selective T M U  
precip itation  by com paring  the apolipoprotein  B recovered 
at the end o f the p rocedure  w ith tfie values calculated  as 
the difference betw een to tal an d  T M U -so lub le  (apolipo- 
p ro te ins E and  C) p ro te in  con ten ts (23)!
K inetic analysis
T h e  radioactiv ity  associated  w ith  the B p ro te in  present 
in each fraction was calcu lated  from  the apo lipopro te in  B 
specific activities and the ind iv idual pool sizes. T hese were 
expressed as a percen tage o f the total B p ro tein  rad ioac­
tivity  p resen t in the p lasm a 10 m in  after injection and the 
resulting  values were used to construct decay curves which 
were analyzed by the SA A M  29 m u lticom partm en ta l 
m odeling  program  (24). T h e  m odel tha t was em ployed is 
described elsew here (16). Its m a in  features allow for: a) 
apo lipopro te in  B inpu t at the level of bo th  large and  small 
V L D L  and  L D L ; b) stepwise de lip ida tion  o f V L D L  fol­
low ing the concept o f B erm an  et al. (25); and  c) parallel 
pathw ays o f a B p ro tein  p rocessing  from  sm all V L D L  
th rough  ID L  to LD L.
R ate  constan ts were d e te rm in ed  and , in com bination  
w ith B p ro tein  pool sizes, w ere used to calculate flux ratios 
an d  steady-state syn thetic  inpu t.
In vitro studies
T hese  studies were perfo rm ed  in Sweden. T h e  m ethods 
for lipid analysis, lipopro te in  separations and isolations, 
and  polyacry lam ide g rad ien t gel electrophoresis have all 
been described  (12). Blood taken from the fasting subject 
was pu t into chilled ED TA -tubes kept on ice arid plasm a 
was recovered w ithin 30 m in  by low speed centrifugation  
at 2°C . H epatic  lipase was isolated in L und  from posthepa­
rin  p lasm a o f healthy vo lun teers by repeated  heparin- 
Sepharose ch rom atography  (26) and  shipped on dry ice to 
S tockholm . T h e  enzym e p rep a ra tio n  had a hepatic lipase 
activity  of 9.2 U /m g protein (1 unit representing the release 
o f 1 pm ol fatty acid per m in  at 37°C ) and was devoid of 
lipopro tein  lipase activity, as de term ined  by specific assays 
using  radio labeled  trioleoylglycerol em ulsions as substrate  
(27). Incubations were perform ed in triplicate in the dark at 
37°C  (to prevent au to -ox idation ) for the indicated  periods 
o f tim e and  were term inated  by pu tting  the incubation  ves­
sels on ice. Two series of incubations were perform ed. In 
one series whole p lasm a was used while in the o ther we 
used p lasm a from w hich V L D L  and L D L  had been re ­
m oved by tube  slicing after p reparative u ltracentrifugation  
at d 1.063 kg • I -1. Before use, the preparation  was dialvzed 
aga in s t 0.15 M N aC l and  its orig inal volum e was restored 
w ith the sam e solution (28). To the incubation  m ixtures 
were added  e ither 0.15 ml o f enzym e solution or 0.15 ml 
o f 0.15 M N aC l per m l o f p lasm a.
Two identical studies perfo rm ed  1 year ap a rt gave the 
sam e results. In the first, the enzym e activity was 135 
m U /m l (27); in the second ,.no t reported  here, the activity 
was 225 m U /m l. E nzym e activ ity  was assayed the day b e ­
fore the experim ent.
R E S U L T S
T h e  lip id  and  lipopro tein  profiles of the control subjects 
an d  o f the hepatic  lipase-deficient pa tien t (G P) are shown 
in Table 1. T h e  hypertrig lyceridem ia in CP, whose plasm a 
V L D L  cholesterol co ncen tra tion  was norm al, is explained 
by the finding noted earlie r (11, 19) tha t the m ajority  o f the 
trig lyceride was present in L D L  and H D L  (1.42 and 0.64 
m m ol - I " 1, respectively). T hese lipoproteins were enriched 
in trig lyceride (cholesterol/trig lyceride ratio  in L D L  was
1.5, versus 6.0-16.0 in norm als; in H D L  the ratio  was 3.0, 
versus 5.0-16.0 in norm als). O n  the o ther hand , the 
cho lestero l/trig lyceride ra tio  in G P ’s V L D L  was high (1.1 
versus 0 .4 -0 .8  in norm als).
C om positional analysis o f the four apolipoprotein  B- 
con ta in ing  lipoprotein subfractions is presented in Table 2. 
T h e  large and  small V L D L  in G P  had norm al triglyceride 
contents bu t were reduced in cholesteryl esters and enriched
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T A B L E  2. C o m p o s it io n s  o f  a p o B -c o n ta in in g  lip o p ro te in s  in  h e p a tic  lipase  defic iency
C h o le s te ry l  F re e
T r ig ly c e r id e  E s te r  C h o le s te ro l  P h o s p h o lip id  P ro te in
g /1 00  g ( n  -  3 )
V L D L ,4 62.2 ± 3 .1 a,‘ 9.3 ± 0.5 3.9 ± 1.8 14.6 ± 3.4 10.0 ± 0.2
(56.2 ± 4.8) (16.0 ± 4.3) (1.7 ± 2.3) (17.0 ± 1.4) (9.1 ± 2.4)
v l d l 2 34.6 ± 0.9 12.7 ± 2.2 13.3 ± 2.6 23.4 ± 1.2 16.0 ± 0.6
(35.1 ± 4.0) (21.1 ± 5.9) (8.1 ± 1.4) (21.4 ± 2.4) (14.4 ± 1.6)
ID L 27.9 ± 1.7 13.5 ± 3.7 12.7 ± 2.0 24.7 ± 1.2 21.0 ± 0.8
(12.4 ± 2.0) (33.4 ± 4.8) (11.2 ± 2.3) (23.9 ± 1.3) (19.1 ± 2.3)
L D L 23.6 ± 1.4 24.5 ± 4.9 7.1 ± 0.2 26.4 ± 1.2 18.6 i 4.9
(5.1 ± 0.2) (34.8 ± 2.2) (13.5 ± 1.5) (23.0 ± 1.6) (23.6 t 1.6)
V a lu e s  in  p a re n th e s e s  a re  f ro m  n o rm o lip id e m ic  co n tro l su b jec ts .
" V L D L ,,  S r 6 0 -4 0 0  l ip o p ro te in s ;  V L D L 2, S f 2 0 -6 0  lip o p ro te in s; I D L , S f 1 2 -2 0  lip o p ro te in s ; a n d  L D L , Sf 0 -1 2  
lip o p ro te in s .
‘ M e a n  ± S D .
fE a ch  frac tio n  w as iso la ted  from  G P  o n  th re e  occasions a n d  a s say ed  as d esc rib ed  in  M e th o d s .
in free cholesterol. However, the ID L  and  L D L  fractions 
w ere qu ite  ab n o rm al in com position. B oth fractions were 
enriched  in trig lyceride at the expense o f cholesteryl ester. 
T he phospholipid, protey^ and free cholesterol contents were 
unchanged . In  the lipase-deficient subject, m ost V L D L  
apoB  (T able 3) resided at the denser end of the spectrum  
(i.e., Sf 20-60); and  the level o f ID L  apoB was raised 
severalfold.
Tracers of large and  sm all V L D L  were used to investi­
gate the origins o f the above ab n o rm al d is tribu tions. T he 
results are presented in Fig, 1 and Table 3. T h e  distribution 
o f apolipopro tein  B in the no rm al subjects reflected their 
lipopro tein  p a tte rn  (Table 1) in th a t m ost o f its m ass was 
found in the L D L  density interval. In  contrast, most B p ro ­
tein in G P  was associated w ith ID L . T h e  norm al subjects 
synthesized ab o u t 1000 m g o f total V L D L  apolipopro tein  
B each day, 70%  o f w hich ap p ea red  first in the large Sf 
60-400 com ponent. A pproxim ately  ha lf o f this p ro tein  was 
m etabolized  th ro u g h  ID L  to L D L , the rem a in d er leaking
ou t o f the delip idation  cascade at the levels o f large and 
sm all V L D L  and  ID L . G P  p roduced  570 m g  o f total 
V L D L  apo lipopro tein  B, m ost of which was secreted with 
sm all V L D L  particles. T h a t po rtion  of pro tein  tha t ap ­
peared  first in large V L D L  was transferred  to the sm aller 
V L D L  range  (Sf 20-60) at a no rm al rate. T h e  m ass of B 
pro te in  in G P ’s small V L D L  pool was norm al. However 
its fractional clearance rate (Table 3; Fig 1) was re tarded  
and  its ra te  o f transfer to the ID L  fraction was delayed. 
O n  the o th e r hand , its d irect catabolism  from the circu la­
tion was at least as high as norm al. D espite the reduced 
in p u t o f p ro tein  from V L D L , the plasm a pool o f ID L  was 
elevated 2.4-times, principally because the plasm a clearance 
of this fraction  was so slow (Table 3, Fig. 1). T h e  transfer 
o f B p ro te in  from  ID L  to L D L  occurred  only at abou t 5% 
o f no rm al, although  it should be noted that, as in the case 
of V L D L , the rate  of direct rem oval of ID L  apolipoprotein 
B from  the circu lation  (0.25 pools • d"1) was not reduced. 
A sm all am o u n t of ID L  apo lipopro tein  B did transfer into
T A B L E  3. A p o lip o p ro te in  B m e tab o lism  in n o rm a l sub jec ts
Subject
Large V LD L ApoB Small V LD L ApoB
Synthesis
Plasma
Pool'
Fractional Rate
Synthesis
Direct
Synthesis 
from VLDL,
Plasma
Pool'
Fractional Rate
Direct
CulutHilisin
Transfer 
to V LD L,
Direct
Catabolism
Transfer 
to IDL
mg/day mg pools/day mg/day mg/day mg pools/day
N lN C 802 79 3 .7 6 .5 393 512 246 0 .3 6 3.3
N 2 C D 710 80 2 .9 6 . 0 467 478 226 1.32 2 . 0
N 3 M Q 290 18 0 . 0 16.2 137 290 1 0 0 0 .7 0 2 . 8
N 4 T S 954 115 5 .0 3 .2 238 372 258 0 .35 1.9
M e a n  ± SD 689 ± 246 73 ± 35 2 .9  ± 1.8 8 .0  ± 4 .9 259 ± 91 413 ± 8 8 208  ± 63 0 .6 8  ± 0 .3 9 2 .5  ± 0 .6
H L ( - ) 91 9 1 . 8 8 .3 480 74 265 1.08 0 .97
'P la s m a  pool d e r iv e d  from  s tea d y -s ta te  ana ly sis  u s in g  S A A M  29 p ro g ram . T h is  ag ree s  w ith  th e  observed  ap o lip o p ro te in  B pool to  w ith in  ± 15% .
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the L D L  fraction (Fig. 1, Table 3) which was degraded at a 
low norm al fractional clearance rate. Table 2 indicates that 
this L D L  was not norm al in com position, and indeed from 
rate zonal u ltracentrifugation  o f the ID L /L D L  lipoproteins 
in G P ’s p lasm a (F ig. 2) it is c lear tha t there was no dis­
crete L D L  peak. T h e  sm all am o u n t of m aterial isolated as 
“LDIT by cum ulative flotation u ltracentrifugation  probably 
rep resen ts the denser com ponen t o f the ID L  spectrum .
In vitro studies
In cu b a tio n  o f whole p lasm a from  the hepatic lipase- 
deficient p a tien t for 24 h r  w ith  o r w ithout added purified 
hepatic  lipase resulted in the form ation  of about 1 m m ol of 
cholesteryl ester per lite r of p lasm a in both cases (Table 4), 
very close to earlie r repo rted  values (12). A  corresponding  
decrease of phospholip ids, the d o n o r of the fatty acid in 
the esterification reaction, occurred  in the two incubations. 
T h e  percentage of p lasm a cholesterol that was esterified in­
creased from  51% — a lower th an  norm al value as pointed 
out before (12) —to 67%. These incubation-induced changes 
are due to lecith im cholesterol acyltransfera.se (LCAT) ac­
tivity as both a- and /3-LCAT activity are norm al in hepatic 
lipase deficiency (1!^.
T h e  p lasm a triglyceride concen tra tion  rem ained  u n ­
changed  d u rin g  the contro l incubation , while the addition  
o f hepatic  lipase resulted  in a decrease o f the triglyceride 
con ten t of abou t 0.5 m m ol • l -1.
T h e  incubations of the V L D L - and  L D L -depleted  plas­
m as, w hich con tain  H D L  as the m ajo r lipopro tein  class, 
resulted in changes sim ilar to those observed for whole plas­
m a (Table 4). T h e  cholesteryl ester concen tra tion  rose by 
0.7 m m ol • I -1 w hether o r no t hepatic  lipase was present. 
T h e  decrease in phospholip ids was o f the sam e order.
T h e  hepatic  lipase caused a slight decrease in the 
trig lyceride con ten t o f  H D L  (0.1 m m ol • l " 1). At the sam e 
tim e the concen tra tion  of free fatty acids (FFA) increased 
by 0.14 m m ol ■ 1"‘ as com pared  to 0.08 m m ol • l -1 w ithout 
added  lipase. T h is la tte r  increase is due to release of FFA 
from  lecith in  d u rin g  the L C A T  reaction  (29).
100
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5 2001000LU
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F ig . 1. P la s m a  decay cu rves  o f  a p o lip o p ro te in  B in  sm all V L D L . ID L , 
a n d  L D L  fro m  con tro l su b jec t ( N l)  a n d  p a tie n t G P  fo llow ing in jec tio n  
o f  l2i I - la b e led  sm all V L D L . S y m b o ls  rep re se n t o b se rv ed  d a ta  a n d  lines 
re p re s e n t th e  c o m p u te r-d e r iv e d  fit.
T h e  H D L  pan icles o f G P ’s p lasm a m igrate  exclusively 
as large H D L 2 panicles on gradient gel electrophoresis (12). 
In  conform ity, w hen G P ’s H D L  was exam ined  using the 
s tan d a rd  rate  zonal m ethod  (F ig . 3), the m ajority  of p a n i­
cles were associated w ith the H D L 2 density interval. H D L 3 
was v irtua lly  absent. T h e  size of the H D L  particles of this
a n d  in  a  h e p a tic  lip a se -d e fic ien t su b jec t (H L (  - ) )
ID L ApoB
Fractional Rate LD L ApoB
Synthesis 
from V LD Lj
Plasma
Pool*
Direct
Catabolism
Transfer 
to LDL
Synthesis
Direct
Svnthesis from 
IDL + V L D L ,
Plasma
Pool*
Fractional 
Catabolic R ate
mg/day mg pools/day mg/day mg/day mg pooh/day
817 337 0 .7 7 1.65 0 . 0 556 1750 0 .3 2
445 420 0 .0 9 0 .90 279 379 2630 0 .25
275 2 1 0 0 .3 2 0 .98 0 . 0 290 635 0 .46
499 
509 ± 196
496 
366 ± 106
0 .1 5
0 .3 3  ± 0 .2 7  I
0 .85  
.10 ± 0 .33
90
92 ± 114
423 
412 ± 96
2650 
1916 ± 824
0 . 2 0  
0.31 ± 0 .1 0
262 8 8 6 0 .2 5 0 .05 0 . 0 43 215 0 . 2 1
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Ec
o
00
^  0.2
LDL marker
LU
4 0 02000
ZO NA L ROTOR EFFLUENT (m l)
F ig . 2 . R a te  zona l u ltra c e n ir ifu g a i io n  pro file  o f  cl 1 .006-1 .063 kg ■ I " 1 
lip o p ro te in s  in  p a tie n t G P. T h e  ra d io a c tiv e  m a rk e r  in d ica te s  th e  d o ta tio n  
c h a ra c te r is tic s  o f  L D L  p re p a re d  fro m  a  c o n tro l sub jec t.
hepa tic  lipase-deficient patien t was no t m odified by the in­
cu b a tio n  w ith hepatic lipase (F ig .  4 ) .
D IS C U S S IO N
In travenous heparin  ad m in is tra tio n  triggers the release 
in to  the p lasm a of two lipases w hich are  d is tinc t in their 
s tru c tu re  an d  function (1, 30). T h e  b e tte r  characterized  
lipop ro te in  lipase plays a p rim ary  role in the m etabolism  
o f large triglyceride-rich lipopro teins. Its deletion , there ­
fore, results in the accum ulation  in the c ircu la tion  o f gut- 
derived chylom icrons con ta in ing  apo lipopro tein  B-48- and 
B-100-containing large V L D L  of hepatic  o rig in  (31). E n ­
dogenously  labeled V L D L  trig lyceride is c leared  slowly
from  the p lasm a of such patien ts (32). However, Nicoll and 
Lewis (2) have shown that lipoprotein lipase cannot be sole­
ly responsible for the catabo lism  of these particles since, 
even in its absence, V L D L  (d <  1.006 kg • l ' 1) is converted 
to ID L , albeit at a reduced  rate. C learly  the o ther lipase 
in p lasm a m ust con tribu te , and indeed these au thors (2) 
and  o thers (33) have d em onstra ted  tha t it is able to use 
sm all V L D L  and ID L  as efficient substrates for triglycer­
ide hydrolysis. C erta in ly  its action is inversely correlated  
w ith the levels of ID L  in p lasm a (34); and, as indicated 
from  the an tibody  inh ib ition  experim ents of G o ldberg  et 
al. (5), abolition of its activity  causes an acute increase in 
the circulating  mass of sm all V L D L  and ID L  w ith a reduc­
tion  in L D L  in cynom olgus m onkeys. Such studies would 
im plicate hepatic lipase in the V L D L  dclip idation  cascade 
a lthough  the lite ra tu re  is no t a ltogether consistent in this 
regard  since R eardon , Sakai, and  S te iner (35), in a study 
o f the m etabolism  of large and  sm all V L D L , were led to 
the conclusion tha t hepatic  lipase has no role to play here. 
C ertainly, hepatic lipase seem s to have little activity against 
V L D L  in vitro (N ilsson-Ehle, R, unpublished  data). Most 
o f the available evidence (7-10) suggests tha t the high 
density  fraction, particu larly  H D L 2, is the p referred  sub ­
stra te  for the enzym e. T h e  recent discovery of hepatic 
lipase-deficient patien ts allows us to m ake a d irect assess­
m en t o f the m ode of action  o f the enzym e. O u r earlier 
studies (12) suggested tha t the disease was associated with 
delayed clearance of both V L D L  and H D L  w ith the resul­
tan t accum ulation  o f /3-VLDL and H D L 2.
T h e  p a tien t G P  synthesized V L D L  apolipoprotein  B 
at abou t ha lf of the rate seen in controls. M ost (80% ) of 
the m ateria l which he p roduced  com prised  sm aller p a rti­
cles o f Sf 20-60. T his abnorm al pattern  of secretion, favor­
T A B L E  4. E ffects o f  in c u b a tio n  a t 3 7 ° C  fo r v a rio u s  tim es on  lip id  c o n c e n tra t io n s  in  w ho le  p la sm a  an il V L D L - 
a n d  L D L -d e p le te d  p la sm a  from  case  G P , w ith  a n d  w ith o u t a d d e d  h e p a tic  lipase (H L )
Incubation
Tim e
Concentration of*
Phospholipids Cholesteryl Ester Triglycerides Free Fatty Acids
W ithout
H L
With
HL
Without
HL
With
H I.
W ithout
H I.
With
H L
Without
H L
With
H L
hr m m ol/l plasma
W h o le  p la sm a 0 4 .8 6 2.85 2 .79 4.22 3 .9 6
W h o le  p la sm a 0 .5 4.51 4 .92 2.87 2 .83 4 .16 4 .2 8
W h o le  p la sm a 1.5 4 .5 3 4 .73 2.93 2 .92 3 .98 4 .1 0
W h o le  p la sm a 6 4 .5 5 4 .16 3 .13 3 .18 4.13 3 .4 6
W h o le  p la sm a 24 4 .1 2 3 .9 0 3.81 3 .6 8 4 .24 3 .6 2
D ep le ted  p la s m a 0 1.77  • 1.83 0 .83 0.81 0 .82 0 .8 2 0 . 1 0 0 . 1 2
D ep le ted  p la sm a 0 .5 1.97 1.85 0 . 8 6 0 .8 2 0 .9 0 0 . 8 6 0 .1 5 0 .1 5
D ep le ted  p la sm a 1.5 1.85 1.81 0.91 0 . 8 8 0 .85 0 .8 2 0 .1 4 0 .1 9
D ep le ted  p la sm a 6 1.75 1.63 1.03 1.03 0 .87 0.71 0 .15 0 . 2 0
D ep le ted  p la sm a 24 1.44 1.40 1.47 1.47 0 .82 0.71 0 .1 8 0 .2 6
‘ M e a n  values; tr ip lic a te  in c u b a tio n s .
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ing sm aller particles, is responsible for the ap p aren t 
cholesterol en rich m en t which we no ted  in the total V L D L  
(Table 1, ref. 12). T h e  rate at w hich the large V L D L  in 
G P  was converted  to sm aller rem n an ts  was norm al, in ac­
cord w ith o u r previous suggestion th a t this process is en ­
tirely lipopro tein  lipase-dependent. S ubsequen t processing 
of the sm aller V L D L , however, occurred  at abou t one-half 
of the norm al rate. T h is seems, therefore, to be the first 
poin t at w hich hepatic lipase plays a significant p a rt in the 
delip idation  process. C ertainly the decrease in the observed 
fractional ra te  o f V L D L  to ID L  conversion canno t be a t­
tr ibu ted  to an  expansion o f the V L D L  pool since this was 
obviously not p resen t in G P  (Table 3). T h e  m ost rem ark a ­
ble defect in G P ’s apolipoprotein B m etabolism  was the v ir­
tual com plete block in particle tran sfe r betw een ID L  and 
L D L . T h is resulted  in a m ajo r increase in the circu la ting  
m ass of ID L  an d  a 90%  decrease in L D L . In fact, exam i­
na tion  of G P ’s L D L  zonal profile raises doub ts about the 
existence o f any tru e  (i.e., “n o rm al”) L D L  in this patien t. 
W h at was identified by the cum ulative flotation p rocedure 
m ay in fact have been con tam inating  ID L . T hus, we would 
conclude that G P  largely or entirely lacks the ability to form 
no rm al L D L . T h e  ID L  that accum ula ted  in his p lasm a is 
rem oved at a rate  rem in iscen t of L D L , and  earlie r studies 
from  this laborato ry  (36) suggest th a t a recep to r pathw ay 
m ay be im plicated  in the process. In d eed , exam ination  in 
Table 3 of the fractional rates of d irec t rem oval of any of 
the four B pro te in -con ta in ing  particles indicates tha t there 
was no defect in these pathways. T h u s , lipopro tein  and 
h epatic  lipases are  discrete in the ir activities. L ipopro tein  
lipase focuses on large V L D L  catabolism  and also con trib ­
utes approxim ately 50% to the conversion of sm aller V L D L  
to ID L . H epa tic  lipase, on the o th e r hand , w hile sharing
HL d e f ic ie n t0.2
co
CN
control
U 0.2
h p l2 H DL
0 200 4 0 0
Z O N A L  ROTOR EFFLUENT (m l)
F ig . 3 . R a te  zo n a l u lt ra c e n ir ifu g a t io n  pro file  o f  H D L  fro m  a con tro l 
su b jec t a n d  p a t ie n t G R
I ncuba t i on
t i m e . h r s  0  1.5 6 24 0  1.5 6 24
. ■*- S t a t
jflBSBBB® JQQQQQgQSi.
Kd
*** ~  -  6 6 9
No add i t i on  H e p a t i c  l i p a s e  
a d d e d
F ig . 4 . P o ly ac ry lam id e  g rad ie n t gel e lec tro p h o re sis  o f to tal p la srna  lipo ­
p ro te in  iso la ted  a f te r  in c u b a tio n  o f  p la sm a  fro m  p a tien r G P  at 37 °C  w ith  
o r  w ith o u t a d d e d  pu rified  h ep a tic  lipase . M a r k e r  p ro te in s  as in ref. 12. 
N o te  1) th e  p re sen ce  o f  la rge H D L  p a n ic le s  in  the reg ion  c o rre sp o n d in g  
to  m o le c u la r  m asses o f  3 0 0 -4 0 0  k D a  as th e  to ta lly  d o m in a tin g  H D L  s p e ­
cies, a n d  2) th e  lack o f  effect o f  in c u b a tio n  w ith  o r  w ith o u t th e  lip ase  on  
H D L  p a rtic le  size.
in the la tte r process, is alm ost entirely  responsible for catal­
ysis, o f the conversion of ID L  to L D L . E x trapo la tion  from 
this suggests th a t such a process m ust occur in the liver, 
in ag reem en t w ith published tran shepa tic  catheterization  
studies (37). T h e  m echanism  itself, though still specu la­
tive, m ay well also involve the agency of receptors since it 
is known tha t individuals w ith hom ozygous familial hyper­
cholesterolem ia also accum ulate ID L  in the plasm a (38). A 
separate , though  possibly linked, function for the enzym e 
relates to the interconversion o f H D L  subspecies. H epatic  
lipase has been proposed to be the principal enzym e in ­
volved in rem oving phospholip id  and triglyceride from 
H D L , and individuals with low hepatic lipase activities have 
been found to have h igher H D L 2/H D L 3 ratios (7). A gain, 
w hat is rem arkable in this patien t is the virtual absence of 
H D L j, as recorded by rate zonal u ltracen trifugation  (Fig. 
4) o r n o n d en a tu rin g  g rad ien t gel electrophoresis (12). T he 
H D L  th a t accum ulates is trig lyceride-rich . A ccording to 
cu rren t concepts, this lipid com es from triglyceride-rich 
particles in the circulation and  its transfer is m ediated  by 
cholesteryl ester transfer protein . It has been suggested that 
H D L 2 phospholip ids would norm ally  be hydrolyzed by 
hepatic  lipase w ith sim ultaneous shrinkage of the particle 
to the size o f H D L 3 (9). Indeed , R ao et al. (39) have ob­
served that heparin infusions in lipoprotein lipase-deficient 
p atien ts lead to an acute m ass tran sfe r from H D L 2 to 
H D L 3. However, our in v itro  studies failed to confirm  this 
suggestion. W hen plasm a from  G P  was incubated  with 
purified  hepatic  lipase, no decrease in H D L 2 particle size 
was observed and what triglyceride hydrolysis did take place
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seem ed to result from  an action  o f the enzym e on V L D L  
and  L D L . But, this m ust be viewed w ith cau tion  since it is 
possible tha t the com position  o f G P ’s H D L 2 is abnorm al 
and  the particle may have decreased affinity for the enzyme.
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Apolipoprotein B metabolism in homozygous 
familial hypercholesterolemia
R. W. Jam es, B. M artin, D. Pometta, J. C. Fruchart,* P. D uriez.’ P. Puchois,*
J. P. Farriaux,* A. Tacquet,* T. Demant, t  R. J. Clegg, T A. Munro,T 
M. F. Oliver,** C. J. Packard,T and J. Shepherd1
Division o f  Diabetology. C a n to n a l  Hospital,  G eneva .  Switzerland: Ins t i tu te  Pasteur.*  Lille. France; 
D e p a r tm e n t  o f  B iochemis try , t  Royal Infirmary, Glasgow. U n i ted  K in g d o m :  a n d  D e p a r tm e n t  of 
C a rd io logy ,”  Royal Infirmary, E d inburgh .  U n i ted  K in g d o m
A b s t r a c t  T h is  report  describes the m etabol ism  of apo l ipopro­
tein B-con ta in ing  l ipoproteins in seven familial  hypercholestero- 
lemic (FH )  hcmozvgotes and  c o m p a r e  rhe results to the values 
o b ta ined  f rom five healthy control  subjects.  T h e  concentrat ion ,  
composit ion, a n d  m etabolism  of large,  t r iglyceride-rich very low 
density  l ipoproteins (V L D L ! ,  Sf 60 -400)  were the same in the 
control a n d  F H  groups,  ind ica t ing  tha t  this com p o n en t  of the 
V L D L  delipidation cascade was unaffected hv the absence of 
receptors.  In  contrast, familial  hypercholesterolernic small 
V L D L o (Sf 20-60)  was enr iched  with choles terol and  depleted  
in triglyceride. Moreover , its p la sm a  concen tra t ion  was elevated 
as a result  of  an increase in its synthesis and  a defect  in the 
removal oi a rem n an t  popu la t ion  within this densirv  interval. 
T h e  latter  accounted  ter  up to 5Oft of  the total mass of  the frac­
tion. O n w a rd  transfer  of  apo l ipopro te in  B l apoB) from small 
V L D L  th rough  in termedia te  dens ity  lipopro te in  ( ID L )  to low 
density  l ipoprotein (L D L )  was re ta rded ,  suggesting that recep­
tors were involved in this supposedly  lipase-media ted  event. ID L  
and  L D L  concentra t ions increased up  to fourfold above normal 
in the p lasm a of the F H  patients  d u e  part ly  to the delav in m a tu ­
rat ion and  part ly  to defective direc t  catabolism. G2 We con­
clude that  the L D L  receptor  plays mult ip le  and  im portan t  roles 
in the m etabolism  and  t r ansfo rm a tion  of  ap o B -con ta in in?  p a r t i ­
cles in the Sf 0 -400  flotation i n te rv a l .—J a m e s .  R. W., B. M a r ­
t in ,  D. P o m e t ta .  J .  C. F r u c h a r t .  P. D u r ie z .  P. P u ch o is .  J .  P. 
F a r r i a u x ,  A. T a c q u e t .  T. D e m a n t .  R. J .  Clegg,  A. M u n ro .  
M . F. O liver ,  C. J .  P a c k a rd ,  a n d  J .  S h e p h e rd .  Apolipoprote in 
B m etabol ism  in homozygous familial  hvpercholesteroiemia. 
J . L ipid Res. 1989. 30: 159-169.
S u p p l e m e n t a r y  k e y  w o r d s  V L D L ,  (Si 6 0 - 4 0 0 )  • V L D L .  (Sf 2 0 -  
60 )  • L D L  r e c e p t o r  • I D L  • L D L
F a m i l ia l  h y p e r c h o l e s t e r o l e m i a  ( F H )  is a c o m m o n  m e t a ­
b o l ic  d i s o r d e r  c a u s e d  b y  d e f e c t i v e  e x p r e s s i o n  o f  t h e  g e n e  
t h a t  c o d e s  fo r  low d e n s i ty  l i p o p r o t e i n  ( L D L )  r e c e p to r s  o n  
cell  m e m b r a n e s .  A f fe c te d  i n d i v i d u a l s  a c c u m u l a t e  th e  l i p o ­
p r o t e i n  in  t h e i r  p l a s m a  w h e r e  it p r e d i s p o s e s  to  t issue  
s te ro l  d e p o s i t i o n  ( x a n t h o m a t o s i s )  a n d  p r e m a t u r e  v a s c u l a r  
d i s e a s e .  T h e  t r a i t  sh o w s  a u t o s o m a l  c o d o m i n a n t  i n h e r i ­
t a n c e  a n d  t h e r e fo r e  o c c u r s  in  h e t e r o z y g o u s  a n d  h o m o z y ­
g o u s  f o rm s .  W i t h i n  t h e s e  tw o  s u b d i v i s i o n s  t h e r e  is a  b r o a d  
s p e c t r u m  o f  c l in ica l  p r e s e n t a t i o n s  w h i c h  is t h o u g h t  to  
r e s u l t  f r o m  m u l t i p l e  p o t e n t i a l  m u t a t i o n s  a f f e c t in g  th e  
s t r u c t u r e  o f  th e  r e c e p t o r  p r o t e i n .  F H  is t h e r e f o r e  a  c l i n i ­
c a l ly  u s e fu l  u m b r e l l a  t e r m  fo r  a  g r o u p  o f  c o n d i t i o n s ,  all  
o f  w h i c h  re f lec t  a d e f e c t  in  L D L  r e c e p t o r  a c t iv i t y  (1).
E a r l v  c lu es  to th e  e t i o l o g y  o f  th e  d i s e a s e  c a m e  f ro m  a 
se r ie s  o f  m e t a b o l i c  s t u d i e s  t h a t  s h o w e d  t h a t  its c h a r a c t e r i s ­
tic f e a t u r e ,  h y p e r c h o l e s t e r o l e m i a ,  a r i se s  p r i m a r i l y  f ro m  
d e l a v e d  c l e a r a n c e  o f  L D L  f r o m  th e  c i r c u l a t i o n  (2.  3). 
H o w e v e r ,  in  s o m e  p a t i e n t s ,  o v e r s v n th e s i s  o f  L D L  a p o p r o ­
t e in  ( a p o L D L )  also  s e e m s  to  c o n t r i b u t e  to t h e  e x p a n d e d  
p l a s m a  L D L  po o l  (3). T h i s  i n t r i g u i n g  f i n d in g  led  to  m o r e  
d e t a i l e d  i n v e s t ig a t io n s  d e s i g n e d  to lo c a te  th e  s o u r c e  o f  
L D L  o v e r p r o d u c t i o n .  I n  n o r m a l  su b je c t s ,  m o s t  if  n o t  all  
a p o L D L  c o m e s  (4) f r o m  t h e  l ip o ly s is  o f  v e ry  low  d e n s i t y  
l i p o p r o t e i n  ( V L D L ) .  D u r i n g  th is  p ro c e s s  t h e  V L D L  a p o ­
l i p o p r o t e i n  B ( a p o B )  m o i e t y  is c o n s e r v e d  a n d  c o n s t i t u t e s  
a  m a r k e r  o f  th e  fa te  o f  t h e  l i p o p r o t e i n  p a r t i c le .  S o u ta r ,  
M y a n t .  a n d  T h o m p s o n  i5» u s e d  th is  i n f o r m a t i o n  to t r a c e  
t h e  f lux  o f  B p r o t e i n  f ro m  V L D L  to L D L  in  F H .  a n d  c o n ­
c l u d e d  t h a t  s u c h  i n d i v i d u a l s  s y n t h e s i z e d  in su f f ic ie n t  
V L D L  to  a c c o u n t  fo r  t h e  m a s s  o f  L D L  in  t h e i r  c i r c u l a ­
t io n .  I t  fo l low ed  t h a t  d i r e c t  s e c r e t i o n  o f  L D L .  p o ss ib ly  by  
th e  liver , m i g h t  be  a f e a t u r e  o f  F H  h o m o z y g o s i ty .  T h e  d is-  
c o v e r v  o f  a  s p o n t a n e o u s  m u t a t i o n  (6)  in  t h e  L D L  r e c e p t o r  
p r o t e i n  in  r a b b i t s  ( t h e  W a t a n a b e  H e r i t a b l e  H y p e r l i p e m i c  
r a b b i t )  p r o v i d e d  a  m e a n s  o f  a d d r e s s i n g  th is  q u e s t io n .  I n  
c o n t r a s t  to  th e  h u m a n  s t u d ie s ,  a n a ly s i s  o t  a p o l i p o p r o t e i n  
B t r a n s i t  f r o m  V L D L  to  L D L  in th e  a n i m a l  m o d e l  su g -
A b b r e v i a c i o n s :  Sr. n e g a t i v e  s e d i m e n t a t i o n  c o e f f ic i e n t  a t  d  1.063 
kg  • I' 1 a n d  2 6 : C ;  V L D L , .  v e r y  low  d e n s i t y  l i p o p r o t e i n s .  Sf 6 0 - 4 0 0 ;  
V L D L . . .  v e r y  low d e n s i t y  l i p o p r o t e i n s .  Sf 2 0 - 6 0 ;  I D L .  i n t e r m e d i a t e  
d e n s i t y  l i p o p r o t e i n s .  Sf 1 2 - 2 0 :  L D L .  low  d e n s i t y  l i p o p r o t e i n s .  Sf 0 -1 2 ;  
H D L ,  h i g h  d e n s i t y  l i p o p r o t e i n s :  a p o B .  a p o l i p o p r o t e i n  B; F H .  f am i l i a l  
h y p e r c h o l e s t e r o l e m i a .
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TABLE 1. Plasma lipids and lipoproteins in control and in horr.ozvgous FH subjects
Subject Sex Age
Body
W eig h t
Pl asm a
Trig lyceride
Plasma
Cholesterol V L D L
Cholesterol  ir. 
L D L H D L C u r r e n t  T h e r a p y
>'T ■'? mrr.'A’
X , M 36 71 1.71 4 . 9 6 0 . 7 9 3 . 1 4 1 . 0 1
F 56 51 0 . 9 4 3 . 7 6 0 . 3 3 1 . 6 6 1 .7 8
^ 3 F 28 7 7 0 . 5 5 3 .7 1 0 . 3 0 1 .95 1 .4 6
M M 45 7 9 2 . 0 1 6 . 1 9 0 . 9 9 3 . 9 6 1 .23
N s M 29 35 2 . 0 0 6 . 5 5 1 .0 8 4 . 3 1 1 . 1 0
F H , M 15 53 3 . 5 4 1 4 .1 5 3 . 4 3 8 . 7 0 0 . 6 9 P l a s m a p h e r e s i s
F H , M 2 1 5 0 2 . 3 7 1 4 . 1 0 1 .4 7 1 1 .9 8 0 . 6 5 P l a s m a p h e r e s i s
F H , M 14 59 2 . 2 5 1 2 .3 0 0 . 7 1 0 .3 0 0 . 9 0 C h o l e s t y r a m i n e
f h 4 M 1 0 40 1 .95 1 4 .6 3 0 . 8 3 1 2 .9 5 0 . 8 5 C h o l e s t y r a m i n e
f h 5 M 4 4 70 1 .93 1 6 .7 5 0 . 9 2 1 5 .4 3 0 . 8 3
F H , F 15 50 0 . 3 5 1 0 .9 0 ( 0 . 1 ) ' 1 0 . 0 0 0 . 7 3 P o r t a c a v a l  s h u n t / p l a s m a p h e r e s i s
f h 7 M 25 6 6 0 . 3 0 1 1 .5 0 (0 .  i v 1 0 . 2 0 1 . 2 0 P o r t a c a v a l  s h u n t / p l a s m a p h e r e s i s
’A s s e s s m e n t  o f  V L D L  c h o le s t e r o l  in  s u b j e c t s  F H ,  a n d  F H 7 is a t  t h e  l i m i t  o f  d e t e c t i o n .
g e s t e d  (7)  t h a t  t h e r e  w a s  n o  r e q u i r e m e n t  fo r  d i r e c t  L D L  
s e c r e t i o n ,  a  p r o p o s a l  s u p p o r t e d  (8 )  b y  p e r f u s i o n  e x p e r i ­
m e n t s  t h a t  s h o w e d  t h a t  W H H L  r a b b i t  l ive rs  e l a b o r a t e  
V L D L  b u t  n o t  L D L .  H o w e v e r ,  t h e  e x p e r i m e n t a l  a n i m a l  
d i d  d e m o n s t r a t e  t h a t  d e f e c t iv e  r e c e p t o r  a c t i v i t y  r e s u l t e d  
in  p e r t u r b a t i o n s  in  b o t h  V L D L  a n d  L D L  m e t a b o l i s m ;  
a n d  S o u t a r .  M v a n t .  a n d  T h o m p s o n  (9)  h a v e  a lso  r e p o r t e d  
t h a t  i n t e r m e d i a t e  d e n s i t y  l i p o p r o t e i n  ( I D L )  m e t a b o l i s m  is 
a l t e r e d  in  t h e  h u m a n  d e f i c i e n c y  s ta te .  T h u s ,  r e c e p t o r  
d e f i c i e n c y  h a s  w i d e r  c o n s e q u e n c e s  fo r  a p o B  m e t a b o l i s m  
t h a n  w as  firs t  a p p r e c i a t e d .  T h e  p r e s e n t  s t u d y  sh o w s  t h a t  
t h e  L D L  r e c e p t o r  h a s  m u l t i p l e  ro le s  in  V L D L .  I D L ,  a n d  
L D L  a p o B  m e t a b o l i s m .
M E T H O D S
S u b j e c t s
F iv e  n o r m o l i p e m i c  a n d  se v e n  h o m o z y g o u s  F H  i n ­
d i v i d u a l s  p a r t i c i p a t e d  in t h e  s tu d y .  T h e i r  p l a s m a  l ip id  
a n d  l i p o p r o t e i n  profi les  a r e  p r e s e n t e d  in T a b l e  1. T h e  
n o r m a l  s u b je c t s  w e re  r e c r u i t e d  f r o m  th e  g e n e r a l  p o p u l a ­
t i o n  o f  G l a s g o w  v ia  a c o r o n a r y  s c r e e n i n g  p r o g r a m .  All 
w e re  h e a l t h y  i n d i v i d u a l s  r e c e i v i n g  n o  d r u g  th e ra p y .  S p e ­
cif ically, n o n e  o f  th e  p a r t i c i p a n t s  s h o w e d  e v i d e n c e  o f  
h e p a t i c ,  r e n a l ,  o r  e n d o c r i n e  d y s f u n c t i o n  o n  th e  b a s i s  o f  
b i o c h e m i c a l  a n d  h e m a t o l o g i c a l  s c r e e n in g .
S u b j e c t  F H ,  w as  b o r n  o f  a n  I t a l i a n  f a t h e r  a n d  Sw iss  
m o t h e r .  B o t h  p a r e n t s  w e re  h e t e r o z y g o u s  fo r  F H .  O n e  
b r o t h e r  d i e d  a t  t h e  ag e  o f  14 o f  m y o c a r d i a l  i n f a r c t i o n  a n d  
a n o t h e r ,  a l t h o u g h  al ive, is s e v e re ly  h y p e r c h o le s t e r o l e m ic .  
F H ,  o r ig in a l l y  p r e s e n t e d  w i t h  x a n t h o m a t a  o f  t h e  A chi l les  
t e n d o n s  a n d  o f  th e  e x t e n s o r  t e n d o n s  o f  h a n d s  a n d  knees .  
A r c u s  se n i l i s  w as  e v i d e n t  a n d  t h e r e  w e re  c h o le s te ro l  
d e p o s i t s  in h is  n a t a l  cleft . T r ip l e  b y p a s s  g r a f t i n g  h a d  b e e n  
p e r f o r m e d  3 y e a r s  p r i o r  to t h e  s t u d y  b e c a u s e  o f  c o r o n a r y
insu f f ic iency .  H i s  f i b ro b la s t s  e x h i b i t e d  less t h a n  15 T  o f  
n o r m a l  L D L  r e c e p t o r  a c t i v i t y  a s  d e t e r m i n e d  b y  s t a n d a r d  
p r o c e d u r e s  (10).
V LD L
*
u
u
v l d l 2
ID L
LDL
1 I
Fig. 1. M u l t i c o m p a r t m e n t a l  m o d e l  d e s c r i b i n g  t h e  k i n e t i c s  o f  \  L D L , ,  
Y L D L . , ,  I D L .  a n d  L D L .  T h e  p a r a m e t e r s  U , ,  U 5, U 7, a n d  U 9 r e p r e s e n t  
d e  n o v o  i n p u t  o f  ap o B .  E x c h a n g e  b e t w e e n  c o m p a r t m e n t s  11 a n d  12 was  
fixed at  k , , . , ,  = 0 .0 5  poo ls  • d " 1 a n d  k , . , i 2 = 0.13 p o o l s  ■ d  ' .
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TABLE 2. Compositions of apolipoprotein B-containing subfractions in control and in homozygous FH subjects
Subfraction Subject' FC CE TO PL Protein
V L D L . A
g /1 0 0
5 .1  ±
a
2 . 5 1 4 .9 3 .5 5 3 . 6 3 .9 14 .9 1 . 6 1 2 . 2 4 . 4
V L D L , B 9 . 4 = 0 . 4 2 1 . 8 + 0 . 9 3 5 . 2 = 2 .7 19 .3 ± 1.4 14.3 ± 0 . 8
V L D L , C 1.7 ± 2 . 3 1 6 .0 + 4 .3 5 6 . 2 = 4 .8 17 .0 ± 1.4 9.1 ± 2 . 4
V L D L ; , A 9 . 6 _ 3 . 2 3 4 . 5 ± 2 . 6 1 9 .2 _ 2 . 3 1 9 .6 ± 1.3 17 .2 ± 3 . 2
V L D L , B 9 .5 = 0 . 1 3 4 . 0 ± 4 . 2 2 2 . 3 3 . 6 1 8 .6 ± 0 . 6 15.3 ~ 0 . 1
V L D L , C 8 . 1 = 1.4 21.1 ± 5 . 9 3 5 .1 _ 4 . 0 2 1 . 4 ± 2 .4 1 4 .4 z 1 . 6
I D L A 1 0 .5 j . 3.1 3 8 . 2 ± '2 . 0 6 . 5 _ 1.3 2 0 . 2 ■7 0 2 4 . 5 4. 4 .5
I D L B 1 0 . 0 = 0 . 6 4 2 . 6 + 2 . 1 4 . 8 = 1 .4 2 1 . 3 ± 2 .3 2 1 . 4 ± 0 . 6
I D L C 1 1 . 2 = 2 .3 3 3 . 4 ± 4 . 8 2 3 . 6 = 1 .4 2 3 . 9 ± 1.3 19.1 ± 2 .3
L D L • A 8 . 0 _ 2 . 8 3 7 . 5 - 4 . 2 5 .3 _ 1.5 1 9 .0 1.9 3 0 . 2 3 .2
L D L B 8 . 6 ± 0 . 1 4 3 . 9 ± 1 . 8 2 . 2 0 . 6 11 .9 ± 1.4 2 2 .5 + 0 . 1
L D L C 13 .5 - 1.5 3 4 . 3 ± 2 . 2 5.1 = 0 . 2 2 3 . 0 ± 1 .5 2 3 . 6 ± 1 . 6
A .  h o m o z y g o u s  F H  <n = 5):  B.  h o m o z y g o u s  F H  +• p o r t a c a v a l  s h u n t  ( n  = 2):  C ,  c o n t r o l s  i n  = 5).
S u b je c t s  F H 3 a n d  F H 4 a r e  b r o t h e r s  o f  S c o t t i s h  o r ig in .  
B o t h  p a r e n t s  h a d  p l a s m a  L D L  c h o le s t e ro l  c o n c e n t r a t i o n s  
in  excess  o f  t h e  r e f e r e n c e  v a lu e s  fo r  t h e i r  c o m m u n i t y ,  a n d  
th e  b o y s  h a d  w i d e s p r e a d  t e n d o n  x a n t h o m a t a  a n d  s u b ­
c u t a n e o u s  c h o le s te ro l  d e p o s i t s  in  t h e i r  g l u t e a l  fold. T h e i r  
f ib ro b la s t  L D L  r e c e p t o r  a c t i v i t y  w a s  less t h a n  3 0 %  o f  n o r ­
m a l .  S ig n s  a n d  s v m p t o m s  o f  c a r d i o v a s c u l a r  d y s f u n c t i o n  
w e re  a b s e n t .
T h e  c l in ica l  a n d  b i o c h e m i c a l  f e a t u r e s  o f  s u b je c t s  F H 6 
a n d  F H 7 a r e  p r e s e n t e d  in  e a r l i e r  r e p o r t s  (11, 12). F H 6 is 
M o r o c c a n  a n d  F H -  F r e n c h .  C e l l  c u l t u r e  s tu d ie s  p e r ­
f o r m e d  in  t h e  l a b o r a t o r y  o f  G o l d s t e i n  a n d  B r o w n  (10) 
sh o w e d  t h a t  t h e i r  f ib ro b la s t s  e x p r e s s e d  v i r t u a l l y  n o  n o r ­
m a l  L D L  r e c e p t o r  b i n d i n g  ac t iv i ty .  B o t h  p a t i e n t s  h a d  
u n d e r g o n e  p o r t a c a v a l  s h u n t  s u r g e r y  in  1975. T h e i r  r o u ­
t in e  l iv e r  f u n c t i o n  tes ts  r e m a i n  n o r m a l .
F H 5 is a 4 4 - y e a r -o ld  E n g l i s h m a n  w i th  w i d e s p r e a d  t e n ­
d o n  x a n t h o m a t a  a n d  s e v e re  lef t  c a r o t i d  a r t e r y  s te n o s is .  
H e  is r e f r a c t o r y  to all l i p i d - l o w e r i n g  d r u g  t h e r a p y  i n c l u d ­
in g  s e q u e s t r a n t  res in s .  H i s  t h r e e  c h i l d r e n  a r e  h y p e r c h o -  
le s te ro le m ic .  F i b r o b l a s t  a n d  l y m p h o c y t e  a s sa y s  (13) fa i led  
to revea l  a n y  d e t e c t a b l e  r e c e p t o r  ac t iv i ty .
FH n. a U g a n d a n  su b je c t  o f  I n d i a n  e x t r a c t i o n ,  was 
f o u n d  to b e  s e v e re ly  h y p e r c h o l e s t e r o l c m i c  in  c h i ld h o o d .  
H e  e x h i b i t e d  w i d e s p r e a d  t e n d o n  x a n t h o m a t a  a n d  h a d  
c o r o n a r y  a r t e r y  b y p a s s  s u r g e r y  fo r  o c c lu s iv e  d i s e a s e  a p ­
p r o x i m a t e l y  6 y e a r s  ago. H i s  l y m p h o c y t e s  e x p r e s s e d  less 
t h a n  10% o f  n o r m a l  r e c e p t o r  a c t i v i t y  (13).
Therapy
F H ^  F H o .  F H ^ ,  a n d  F H 7 h a d  b e e n  r e c e i v i n g  b iw e e k ly  
p l a s m a p h e r e s i s ,  a n d  FH,-  a n d  F H 4 w e r e  p r e s c r i b e d  c h o ­
l e s ty r a m i n e .  T h e s e  i n t e r v e n t i o n s  w e r e  d i s c o n t i n u e d  a t  
lea s t  6 w eek s  p r i o r  to i n i t i a t i o n  o f  t h e  k in e t i c  s tu d ie s  o u t ­
l in e d  below.
Protocol
T h e  p r o c e d u r e s  t h a t  w e re  u s e d  to e x a m i n e  th e  k in e t ic s
o f  a p o B  m e t a b o l i s m  a r e  d e t a i l e d  e l s e w h e r e  (14, 15). 
Briefly ,  o n e  u n i t  o f  p l a s m a  w a s  o b t a i n e d  f r o m  e a c h  f a s t in g  
s u b j e c t  b y  p l a s m a p h e r e s i s  a n d  u s e d  to p r e p a r e  to ta l  
V L D L  ( d  <  1.006 k g - 1 ’ 1) b y  u l t r a c e n t r i f u g a t i o n  in  a 
B e c k m a n  T ibO r o t o r  fo r  2 4  h r  a t  5 0 .0 0 0  r p m  ( 4 ° C ) .  T h e  
s u p e r n a t a n t  V L D L  w a s  c o l l e c t e d  a n d  its d e n s i t y  w as  i n ­
c r e a s e d  to  1.118 k g  - 1~1 b y  t h e  a d d i t i o n  o f  so l id  N a C l  (170 
m g / m l  o f  V L D L  s o lu t io n ) .  A  2 - m l  a l i q u o t  o f  th is  p r e p a r a ­
t io n  w a s  l a y e r e d  o v e r  a  0 . 5 - m l  c u s h i o n  o f  d 1.182 k g - P  
N a B r  s o l u t i o n  in a  B e c k m a n  SW  40 r o t o r  t u b e  a n d  a  d i s ­
c o n t i n u o u s  salt  g r a d i e n t  f r o m  d 1 .0 9 8 8 -1 .0 5 8 2  k g - I " 1 was 
c o n s t r u c t e d  ab o v e  it (16). T h e  r o t o r  w as  s u b je c t e d  to c e n ­
t r i f u g a t i o n  a t  3 9 .0 0 0  r p m  f o r  1 h r  a n d  38 m i n  a t  23 : C  a n d  
d e c e l e r a t e d  w i t h o u t  b r a k i n g .  V L D L ,  o f  Sf 6 0 - 4 0 0  w as 
r e m o v e d  in  th e  to p  1.0 m l  o f  s o lu t i o n  w h ic h  w as r e p l a c e d  
w i t h  1.0 m l  o f  d  1 .0588  k g - P  s o lu t io n  b e f o re  c o n t i n u i n g  
w i th  th e  s e p a r a t i o n .  V L D L ,  (Sf 2 0 - 6 0 )  w as  t h e n  i so la ted  
f ro m  th e  to p  0.5 m l  o f  t h e  g r a d i e n t  f o l lo w in g  c e n t r i f u g a ­
t io n  a t  18,500 r p m  fo r  15 h r  a n d  41 m i n  a t  2 3 ° C .  T h e  S. 
6 0 - 4 0 0  a n d  S. 2 0 - 6 0  V L D L  f ra c t io n s  w e re  l a b e le d  w i th  
I31I a n d  I2T .  r e sp ec t iv e ly ,  by  th e  p r o c e d u r e  o f  B i ih e im e r .  
E i s e n b e r g ,  a n d  L e v y  (17). a n d  s u b s e q u e n t l y  s te r i l i z e d  by 
m e m b r a n e  f i l t r a t io n  (0 .4 5  fj.m A r n i c o n  f ilters , A m i c o n  
C o r p . ,  B e d fo r d .  M A ) .  F i f ty  /xCi ( a p p r o x i m a t e l y  0.5  m g  
V L D L  p r o t e i n )  o f  e a c h  w a s  t h e n  in j e c t e d  in to  th e  b l o o d ­
s t r e a m  o f  t h e  r e s p e c t iv e  d o n o r .  T h e  t r a c e r s  w ere  r o u t in e ly  
a d m i n i s t e r e d  at 8 :00  A M ,  a n d  t h r o u g h o u t  t h e  first  d a y  of 
t h e  t u r n o v e r  th e  s u b j e c t s  w e r e  g iv e n  a d ie t  t h a t  c o n t a i n e d  
less t h a n  5 g o f  fat  b u t  t h e i r  n o r m a l  i n t a k e  o f  c a r b o h y d r a t e  
a n d  p r o t e i n .  T h i s  a p p r o a c h  w a s  d e s ig n e d  to m i n i m iz e  
c h y l o m i c r o n  p r o d u c t i o n  a n d  h a s  b e e n  u s e d  in  a  n u m b e r  
o f  p r e v i o u s  s tu d ie s  (14. 15). V e n o u s  b lo o d  s a m p le s  w ere  
c o l le c te d  a t  f r e q u e n t  i n t e r v a l s  o v e r  th e  first 72 h r  a n d  
t h e r e a f t e r  o n  a  d a i ly  b a s i s .  S, 6 0 - 4 0 0  a n d  S, 2 0 - 6 0  
V L D L  w e re  i so la te d  d i r e c t l y  f ro m  th e  p l a s m a  s p e c i m e n s  
a t  e a c h  t i m e  p o in t ,  f o l lo w in g  th e  c e n t r i f u g a t i o n  s c h e d u le  
o u t l i n e d  above .  A d d i t i o n a l l y ,  i n t e r m e d i a t e  d e n s i t y  l i p o ­
p r o t e i n  ( I D L .  Sf 1 2 - 2 0 )  a n d  L D L  (Sf 0 —12) w e re  p r e ­
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TABLE 3. Apolipoprotein B metabolism in normal and
L a r g e  V L D L  A p o B  (S.- 6 0 -4 0 0 )  S .- .L l V L D L  A p o B  (S.- 2 0 - 6 0 ,
Fractional Rate Fractional Rate
Subject Synthesis
Plasma
Pool
Direct Transfer 
Cataboiism to V LD L,
Synthesis Flux 
Direct from V LD L:
Plasma
Pool
Direct Transfer 
Cataboiism to IDL
m g/d mg pools/d m g/d mg pool r /d
N . 802 79 3 .7 6.5 393 512 246 0 .3 6  3.3
No 290 18 0 .0 16.2 137 290 100 0 .7 0  2.3
N j 237 9 17.7 8 .4 252 77 65 0 .52  4 .7
520 108 1.1 3 .7 3 6 i 403 289 0.51  1.1
N s 954 115 5 .0 3 .2 233 372 258 0 .3 5  1.9
M e a n  ± S I ) 560 ± 280 66 ± 44 5.5  ±  6 .4  7 .6  ± 4.7 273 -  91 331 z  14c 191 -  91 0 .49  = 0 .1 3  . 2 . 3  = 1.
F H , 1045 108 3.7 6 .0 390 643 660 0 .5 7  3.1 1
F H : 614 72 4 .4 4.1 214  297 536 0 .3 0  0 .65
f h 3 398 110 1.2 2 .4 1200 25! 896 0 .55  0 .5 4
F H + 181 28 3.7 2 .8 933 73 475 0 .33  1.23
f h 5 674 59 3 .6 7.7 ■> ~ 310 0 .53  0 .73
M e a n  r  S D 582 ± 289 75 + 31 3 .3  ± 1.1 4 .6  ± 2 .0 601 = 411 350 = 193 563 ±  192 0 .5 6  ± 0 .1 7  0 .83  = 0.
F H ^ 226 9 1.3 24 .0 13 210 120 0 .2 8  1.41
F H - 165 8 3.6 18.0 74 137 75 0 .2 8  1.41
M e a n 196 9 2 .7 21 44 174 98 0 .3 6  1.64
p a r e d  b y  s u b j e c t i n g  th e  S W  4 0  r o t o r  c o n t e n t s  to  tw o  f u r ­
t h e r  2 3 ° C  c e n t r i f u g a t i o n  s te p s  o f  3 9 ,0 0 0  r p m  fo r  2 h r  a n d  
3 4  m i n  a n d  3 0 ,0 0 0  r p m  for  21 h r  a n d  10 m i n ,  r e spec tive ly .  
I D L  w as  r e m o v e d  f ro m  th e  t o p  o f  t h e  g r a d i e n t  in a  
v o l u m e  o f  0 .5  m l  a n d  L D L  in  a  1 .0 -m l a l i q u o t .
E a c h  l i p o p r o t e i n  f ra c t io n  w as  t r e a t e d  w i th  1,1,3,3 te t r a -  
m e t h y l u r e a  (18) a n d  th e  r e s u l t i n g  in s o l u b l e  p e l le t  w as  e x ­
t r a c t e d  w i th  o r g a n i c  s o lv e n ts  ( c h l o r o f o r m - m e t h a n o l  1:1. 
vo l /v o l )  to i so la te  a p o l i p o p r o t e i n  B p r i o r  to d e t e r m i n a t i o n  
o f  its specif ic  a c t iv i ty  by  p r e v i o u s l y  p u b l i s h e d  p r o c e d u r e s  
(14). T h e  m e a n  a p o l i p o p r o t e i n  B p r e s e n t  in  e a c h  f ra c t i o n  
d e r i v e d  f r o m  f a s t i n g  b lo o d  s p e c i m e n s  w as  u s e d  to  c a l c u ­
l a te  t h e  p l a s m a  c o n c e n t r a t i o n  o f  B p r o t e i n  in  t h a t  d e n s i tv  
in t e r v a l .  To c o m p e n s a t e  for  p o t e n t i a l  losses in t h e  p r e c i p i ­
t a t i o n  p r o c e d u r e ,  a n  i n d e p e n d e n t  e s t i m a t e  o f  th is  p a r a m ­
e t e r  w a s  o b t a i n e d  as  the  d i f f e r e n c e  b e t w e e n  th e  to ta l  p r o ­
t e in  a n d  t e t r a m e t h y l u r e a - s o l u b i e  p r o t e i n  c o n t e n t  o f  ea c h  
f r a c t i o n  (18). C o m p o s i t i o n a l  a n a ly s i s  o f  t h e  f r a c t io n s  ( S : 
6 0 —100, 2 0 - 6 0 ,  1 2 -2 0 .  a n d  0 —12) w a s  p e r f o r m e d  bv 
m e t h o d s  r e p o r t e d  e l s e w h e r e  (14, 15). T h i s  i n f o r m a t i o n  
p e r m i t t e d  c o r r e c t io n  fo r  losses i n c u r r e d  d u r i n g  c e n t r i f u ­
g a t i o n ,  viz: t h e  c h o le s te ro l  c o n t e n t  o f  all  f o u r  f r a c t i o n s  was 
s u m m e d  a n d  th e  r e s u l t i n g  v a lu e  w a s  c o m p a r e d  w i th  the  
t o ta l  a p o B - a s s o c i a t e d  c h o le s te ro l  ( t o ta l  c h o le s t e ro l  m i n u s  
H D L  c h o le s t e ro l )  m e a s u r e d  b y  th e  s t a n d a r d  L ip i d  R e ­
s e a r c h  C l in i c s  m e t h o d o l o g y  (19). C a l c u l a t e d  losses o f  
a p o B  d u r i n g  c e n t r i f u g a t i o n  w e re  o f  t h e  o r d e r  o f  1 0 -1 5 ‘T .
A p o l i p o p r o t e i n  B  k i n e t i c  a n a l y s i s
K i n e t i c  a n a ly s i s  o f  t h e  d a t a  w a s  p e r f o r m e d  u s i n g  th e  
S A A M  29 p r o g r a m  (20). T o ta l  a p o B  r a d i o a c t i v i t y  d e c a y
c u r v e s  a n d  th e  m a s s  o f  B p r o t e i n  a s s o c i a t e d  w i th  e a c h  
l i p o p r o t e i n  f ra c t io n  w e re  u s e d  to  d e r iv e  r a t e  c o n s t a n t s  a n d  
p r o t e i n  f luxes. T h e  m o d e l  ( F i g .  1) is a  d e v e l o p m e n t  o f  a n  
e a r l i e r  p u b l i s h e d  v e r s io n  (14):
1) L a r g e  V L D L  a p o B  ( V L D L . .  S.- 6 0 - 4 0 0 )  b e h a v e s  
as  a  s in g le  species  w h i c h  d e c a y s  m o n o e x p o n e n i i a i l y  
in  b o t h  n o r m a l  a n d  F H  s u b je c t s .  T h i s  is e i t h e r  
c a t a b o l i z e d  d i r e c t ly  o r  t r a n s f e r r e d  to  t h e  V L D L ?  (Sf 
2 0 - 6 0 )  r a n g e .
2) \ \  i t h in  th e  3 :- 2 0 - 6 0  l i p o p r o t e i n s  t h e r e  is a n  a r ­
r a n g e m e n t  a k in  to t h a t  d e s c r i b e d  b y  B e r m a n  e t  al. 
(21). S o m e  a p o B  e n t e r s  a  c a t a b o l i c  c a s c a d e  a n d  is 
c o n v e r t e d  to I D L  (S. 1 2 - 2 0 )  w h i le  o t h e r  m a t e r i a l  is 
d i v e r t e d  in to  a s low ly  m e t a b o l i z e d  r e m n a n t  spec ies  
( c o m p a r t m e n t  6. Fig .  1).
J )  T h e r e  is i n p u t  o f  n e w l y  s y n t h e s i z e d  a p o B  in to  th e  
S : 2 0 - 6 0  d e n s i tv  r a n g e .  T h i s  is r e q u i r e d  b e c a u s e  n o t  
al l  o f  th e  S; 2 0 - 6 0  a p o B  m a s s  c a n  b e  a c c o u n t e d  for  
b y  t r a n s p o r t  f ro m  la r g e  V L D L .  a n d  w h e n  l a r ? e  (S.- 
6 0 - 4 0 0 )  a n d  s m a ll  (S.- 2 0 - 6 0 )  V L D L  a r e  l a b e l e d  
s e p a r a t e l y  th e  k in e t ic s  o f  a p p e a r a n c e  o f  th e s e  t r a c e r s  
in  I D L  a n d  L D L  a p o B  is d i f f e r e n t .  U s u a l l y  th e  
r a d i o a c t i v i t y  d e r iv e d  f r o m  l a b e l e d  s m a l l  V L D L  a p ­
p e a r s  m o r e  q u ic k ly  in  t h e s e  d e n s e r  f r a c t i o n s  a n d  a c ­
c o u n t s  fo r  a h i g h e r  p r o p o r t i o n  o f  t h e i r  m a s s .  P r o v i ­
s io n  is m a d e  fo r  th is  p h e n o m e n o n  b y  i n c o r p o r a t i n g  
in  th e  m o d e l  p a r a l l e l  p a t h w a y s  l e a v i n g  s m a l l  V L D L  
a n d  a p p e a r i n g  in I D L  a n d  L D L .
4) I n  t h e  I D L  r a n g e  it w a s  n e c e s s a r y  to  p o s t u l a t e  th e  
e x i s te n c e  o f  a  s low ly  m e t a b o l i z e d  sp e c ie s  ( c o m p a r t ­
m e n t  9, Fig. 1).
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IDL ApoB (S,- 12-20) LDL ApoB (Sr 0-121
Fractional Rate
Fractional
Synthesis Flux from Plasma Direct Transfer Synthesis Fluxfrom Plasma Catabolic Totai B
Direct V LD L, Pool Catabolism to LDL Direct ID L + V LD L. Pool Rate Synthesis
m g/d mg pools/d m g/d mg pools/d mg/d
0 .0 317 337 0 .77 1.65 ’ 0 .0 556 1750 0 .32 1195
0 .0 275 210 0 .32 0 .98 0 .0 290 635 0 .46 427
0 .0 305 95 0 .32 2 .37 0 .0 273 710 0 .39 499
0 .0 312 245 1.07 0 .23 0 .0 359 2110 0 .17 881
0 .0 499 496 0 .15 0 .85 9 .0 423 2650 0 .20 1282
0.0 441 ± 204 277 + 134 0 .5 2  ± 0 .3 4 1.3 ± 0.9 18 ± 36 380 ± 1 0 2 1571 ± 783 0.31 ± 0.11 857 ± 349
0 .0 668 1278 0 .0 6 0 .4 6 0 .0 628 5698 0.11 1435
0.0 349 842 0.11 0 .3 0 134 256 4644 0 .0 8 4 962
i j . o 577 1047 0.32- 0 .23 140 636 6743 0.11 1733
0 .0 586 2222 0 .0 6 0.21 315 543 5046 0 .17 1479
94 241 1388 0.11 0 .2 4 396 453 10186 0.083 1381
*L
t
II 03 CO 484  ± 161 1555 ± 473 0 .13  ± 0 .0 9 6  0 .2 9  ± 0 .09 197 ± 141 503 + 140 6464  ±  1992 0.11 ± 0 .03 1399 ± 250
5 i 174 848 0.21 0 .0 2 224 62 3537 0 .080 . 514
163 140 1613 0 .0 2 0 .18 304 323 4964 0 .1 2 8 706
107 157 1231 0 .12 0.1 264 193 4276 0 .10 610
J )  L D L  w a s  d i s t r i b u t e d  b e t w e e n  tw o  p l a s m a  c o m ­
p a r t m e n t s  ( c o m p a r t m e n t s  10 a n d  11), o n l y  o n e  o f  
w h i c h  w a s  p e r m i t t e d  to  e q u i l i b r a t e  w i t h  t h e  e x t r a  
v a s c u l a r  sp a ce .  T h i s  w a s  n e c e s s a r y  to  a c c o m m o d a t e  
t h e  o b s e r v a t i o n  t h a t  t h e r e  w e r e  d i f f e r e n t i a l  r a t e s  o f  
a p p e a r a n c e  a n d  r e m o v a l  o f  L D L  a p o B  d e p e n d i n g  o n  
w h e t h e r  t h e  p r o t e i n  w a s  d e r i v e d  f r o m  l a r g e  o r  s m a l l  
V L D L .
T h e  m o d e l  p r o v i d e d  a n  a c c e p t a b l e  fit to  t h e  o b s e rv e d  
d a t a  in  b o t h  t h e  c o n t r o l  a n d  F H  s u b je c t s ,  a n d  th e  c a l c u ­
l a t e d  m a s s e s  d e r i v e d  f ro m  th e  k i n e t i c  a n a ly s e s  w e r e  w i t h i n  
20 V  o f  th e  m e a s u r e d  v a lues .
Ethical considerations
All s u b je c t s  ( o r  t h e i r  p a r e n t s )  g av e  i n f o r m e d  c o n s e n t  to 
th e  s t u d y  w h i c h  m e :  th e  r e q u i r e m e n t s  o f  t h e  E th i c a l  C o m ­
m i t t e e  o f  e a c h  h o s t  i n s t i t u t i o n .  T h e y  w e r e  p r e s c r i b e d  K I  
(60  m g  th r ic e  d a i i y  i for  3 d a y s  p r i o r  to a n d  1 m o n t h  a f t e r  
i s o to p e  a d m i n i s t r a t i o n  in  o r d e r  to  m i n i m i z e  t h y r o id a l  se ­
q u e s t r a t i o n  o f  r a d io io d id e .
R E S U L T S
Plasma lipids and lipoproteins
In  f a m i l ia l  h y p e r c h o l e s t e r o l e m i a ,  p l a s m a  L D L  c h o le s ­
te ro l  is c h a r a c t e r i s t i c a l l y  e l e v a t e d  s e v e ra l - fo ld  (1) w h i le  
H D L  c o n c e n t r a t i o n s  a r e  g e n e r a l l y  low ( T a b le  1). P l a s m a  
t r ig ly c e r id e  va r ie s ,  a n d  m a y  b e  i n c r e a s e d  a b o v e  n o r m a l .
P o r t a c a v a l  s h u n t  s u r g e r y  is k n o w n  to  lo w e r  c i r c u l a t i n g  
V L D L  (1. 5)  a n d  p r e s u m a b l y  w a s  r e s p o n s ib l e  fo r  th e  low 
t r ig ly c e r id e  c o n c e n t r a t i o n s  r e c o r d e d  in FH ^ a n d  F H 7.
T a b l e  2 p r e s e n t s  t h e  m e a n  c o m p o s i t i o n a l  a n a ly s e s  o f  
V L D L , ID L . a n d  L D L  s u b t r a c t i o n s  in  th e  c o n t r o l  a n d  
F H  g r o u p s .  T h e  c o m p o s i t i o n  o f  Sf 6 0 -4 0 0  l i p o p r o t e i n s  
d i f f e r e d  in  t h e  F H  s u b je c t s  o n l y  in t h e i r  c o n t e n t  o f  free 
c h o le s t e ro l  (P <  0.02). T h e  s m a l l e r  V L D L  (S f 2 0 -6 0 ), 
o n  th e  o t h e r  h a n d ,  w a s  e n r i c h e d  in  c h o le s te ry l  e s te rs  a n d  
d e p l e t e d  in  t r ig ly c e r id e  (P <  0.005 in  e a c h  case )  as  w as  
ID L . T h e  d e p l e t i o n  o f  f ree  c h o le s t e ro l  in F H  L D L  
(P <  0 .005) p r o b a b l y  r e s u l t e d  f ro m  th e  p r o l o n g e d  r e s i ­
d e n c e  t i m e  o f  t h e  p a r t i c le s  in  t h e  p l a s m a ,  i n c r e a s i n g  th e i r  
e x p o s u r e  to  l e c i th im c h o le s t e r o l  a c y l t r a n s f e r a s e .
Apolipoprotein B kinetic analysis
T h e  m e t a b o l i s m  o f  a p o l i p o p r o t e i n  B in  t h e  F H  
h o m o z y g o t e s  n o t  o n ly  d i f f e r e d  s u b s t a n t i a l l y  f ro m  n o r m a l  
in se v e ra l  m a j o r  r e s p e c ts  ( T a b l e  3 )  b u t  a lso  s h o w e d  c o n ­
s i d e r a b l e  v a r i a t i o n  w i t h i n  t h e  g r o u p  itself. R a d io a c t iv e  
a p o B  in i t i a l ly  p r e s e n t  in l a r g e  (Sf 6 0 -4 0 0 ) V L D L ; was 
m e t a b o l i z e d  r a p id ly  in b o t h  F H  a n d  n o r m a l  su b je c t s  
(F ig .  2 a n d  F ig .  3 ,  r e s p e c t iv e ly ) ,  a t  r a te s  t h a t  w e re  n o t  
s i g n i f i c a n t ly  d i f fe r e n t  ( f r a c t i o n a l  c l e a r a n c e  in  c o n t r o l s  = 
13.1 ± 7.5 p o o l s -  d~‘ v e r s u s  7.9  ±  2.7 p o o l s - d ' 1 in th e  
F H  g r o u p ) .  T h e  m a j o r i t y  o f  th is  B p r o t e i n  t r a n s f e r r e d  
in to  t h e  Sf 2 0 -6 0  sm a l l  V L D L 2 d e n s i ty  in te rv a l ,  a t  w h ic h  
p o in t  t h e  tw o  g r o u p s  s h o w e d  d i v e r g e n t  m e t a b o l i c  p a t ­
te rn s .  T h e  c l e a r a n c e  o f  s m a l l  V L D L  a p o B  in t h e  F H
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g r o u p  w a s  s u b s t a n t i a l l y  d e l a y e d ,  r e s u l t i n g  in  a  slow a p ­
p e a r a n c e  o f  r a d i o a c t i v i t y  in  I D L  a n d  u l t i m a t e l y  in  L D L .  
T h i s  t r a n s f e r ,  u s u a l ly  c o m p l e t e  w i t h i n  24  h r  in  c o n t r o l  
s u b j e c t s ,  to o k  120-140  h r  in  t h e  F H  h o m o z y g o t e s ,  a n d  e x ­
a m i n a t i o n  o f  t h e  m e t a b o l i c  b e h a v i o r  o f  d i r e c t l y  l a b e l e d  
s m a l l  V L D L  a p o B  s h o w e d  a  s i m i l a r  p a t t e r n .  T h e  d a t a  o b ­
t a i n e d  f r o m  th e  tw o  t r a c e r s  ( 131I - l a b e l e d  V L D L  a p o B  (Sf 
6 0 - 4 0 0 )  a n d  125I - I a b e l e d  V L D L 2 a p o B  (Sf 2 0 - 6 0 ) )  w e re  
m e r g e d  in  th e  S A A M  p r o g r a m  to g ive  a  s in g le  se t  o f  
k in e t i c  p a r a m e t e r s  w h i c h  p e r m i t t e d  q u a n t i t a t i o n  o f  t h e  
r a t e s  o f  t r a n s p o r t  o f  t h e  B p r o t e i n  t h r o u g h  th e s e  d e n s i t y  
c las ses  (T a b le  3 a n d  T a b l e  4) .
T h e  p a r a m e t e r s  d e s c r i b i n g  th e  m e t a b o l i s m  o f  l a r g e  Sr 
6 0 - 4 0 0  V L D L  a p o B  in  t h e  g r o u p  o f  five m e d i c a l l y  t r e a t e d  
F H  s u b je c t s  ( F H ^ F H s ,  T a b le s  3 a n d  4) w e re  n o t  
s i g n i f i c a n t ly  d i f fe r e n t  f r o m  th o s e  o f  t h e  c o n t r o l s .  B o t h  th e  
r a t e s  o f  s y n th e s i s  a n d  c a t a b o l i s m  a n d  t h e  p l a s m a  p o o l  o f  
a p o B  in  t h e  p a r t i c l e s  p r e s e n t  in  th is  d e n s i t y  i n t e r v a l  w e re  
n o r m a l .  A b o u t  6 0 %  o f  th i s  l a r g e  V L D L  t r a n s f e r r e d  to  t h e  
s m a l le r ,  d e n s e r  Sf 2 0 -6 0  r a n g e .  T h e  r e m a i n d e r  w as  r e ­
m o v e d  d i r e c t l y  f r o m  t h e  p l a s m a  c o m p a r t m e n t .  I n  t h e  n o r ­
m a l  g r o u p ,  th is  t r a n s f e r  a c c o u n t e d  fo r  5 4 %  o f  t h e  B p r o ­
t e i n  m a s s  p r e s e n t  i n  t h e  Sf 2 0 -6 0  i n t e r v a l .  T h e  re s t  o f  t h e  
V L D L 2 a p o B  c a m e  f r o m  d i r e c t  sy n th e s i s ,  p r e s u m a b l y  by
th e  liver .  T h e  m a g n i t u d e  o f  th e  a e  n o v o  i n p u t  o f  V L D L 2 
a p o B  in th e  F H  g r o u p  w a s  o n  a v e r a g e  tw ice  n o r m a l ,  b u t  
T a b le  3 show s t h a t  t h i s  w a s  n o t  a  u n i v e r s a l  p h e n o m e n o n  
b u t  r a t h e r  w as  t h e  r e s u l t  o f  e x ces s iv e  B p r o t e i n  s y n t h e s i s  
i n to  Sf 2 0 - 6 0  V L D L  in  F H  s u b je c t s  3 a n d  4. T h e  
2 .9 - fo ld  i n c r e a s e  in  t h e  m a s s  o f  \  L D L 2 B p r o t e i n  in  t h e  
F H  s u b je c t s  d e r i v e d  p r i m a r i l y  f r o m  d e l a y e d  c l e a r a n c e .  
T h e  l a t t e r  a p p e a r e d  to  a r i s e  f r o m  tw o  a b n o r m a l i t i e s .  
F i r s t ,  t h e  r a t e  o f  t r a n s f e r  o f  B p r o t e i n  o u t  o f  \ L D L 2 in t o  
I D L  w a s  o n ly  31%  o f  n o r m a l  ( T a b le  3). S ec o n d ly ,  m o r e  
o f  t h e  V L D L 2 a p o B  w a s  d i v e r t e d  i n to  a  s low ly  m e t a b o ­
l i z e d  r e m n a n t  p o p u l a t i o n  (F ig .  1. c o m p a r t m e n t  6). I n  t h e  
c o n t r o l  g r o u p ,  o n l y  7 %  o f  th e  m a t e r i a l  in  c o m p a r t m e n t  
2 w a s  d i v e r t e d  f r o m  t h e  d e l i p i a a t i o n  c a s c a d e  i n to  r e m ­
n a n t s .  w h e r e a s  5 0 %  t o o k  th is  r o u t e  in  F H  s u b je c t s  1 to  
5. T h e  m e a n  c o m p u t e d  m a s s  o f  a p o B  in  t h e  r e m n a n t  
p o p u l a t i o n  was 23 2  m g  in  th e  F H  s u b je c t s  v e r s u s  2 4  m g  
in  t h e  n o r m a l s  ( T a b le  4, M 6). T h i s  e x p a n s i o n  w a s  n o t  d u e  
so le ly  to  i n c r e a s e d  r e m n a n t  f o r m a t i o n .  R e m n a n t  r e m o v a l  
w a s  a l s o  d e f e c t iv e  in  t h e  F H  g r o u p .  k 0.e b e i n g  r e d u c e d  b v  
5 0 %  in  t h e  la t te r .
F H  s u b je c t s  1 -4  s h o w e d  n o  r e q u i r e m e n t  fo r  d i r e c t  s y n ­
th e s is  o f  a p o B  i n to  I D L .  T h e y ,  as  d i d  t h e  c o n t r o l s ,  d e r i v e d  
th i s  f r a c t i o n  e n t i r e l v  b v  t r a n s f e r  f r o m  V L D L .  T h e  f lu x  o f
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F i g .  2.  A p o l i p o p r o t e i n  B r a d i o a c t i v i t y  d e c a y  c u r v e s  o f  13 lI - l a b e l e d  V L D L ,  (S f 6 0 - 4 0 0 )  a n d  123I - l a b e l e d  V L D L ?  
(S f 2 0 - 6 0 )  i n  c o n t r o l  s u b j e c t  N , .  V a l u e s  a r e  e x p r e s s e d  a s  p e r c e n t  o f  in i t i a l  d ose .  V L D L ,  ( • ) ,  S f 6 0 - 4 0 0 :  V L D L 2 
( ■ ) .  S f 2 0 - 6 0 ;  I D L  ( A ) .  S r 1 2 - 2 0 ;  L D L  (*),  S f 0 -1 2 .
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F i g .  3 .  A p o i i p o p r o t e i n  B r a d i o a c t i v i t y  d e c a y  c u rv e s  o f  13II - ! a b e l e d  V L D L !  (S r 6 0 - 4 0 0 )  a n d  i2;>I - l a b e l e d  V L D L  
( S :- 2 f i - 6 0 )  i n  s u b j e c t  F H 2. V a lu e s  a r e  e x p r e s s e d  as p e r c e n t  o f  i n i i i a i  d o s e .  V L D L .  ( • ' ) .  S f  5 0 - 4 0 0 ;  Y L D L >  ( S i .  
2 0 - 5 0 :  I D L  < A , / S f 1 2 -2 0 ;  L D L  ( " ) .  Sf 0 -1 2 .
B p r o t e i n  f r o m  s m a l l  V L D L  to  I D L  in  all  o f  t h e  F H  s u b ­
j e c t s  w as  e s s e n t i a l l y  n o r m a l .  So.  t h e  m a r k e d  ( 4 .9 - fo ld )  i n ­
c r e a s e  in  c i r c u l a t i n g  I D L  r e s u l t e d  f r o m  a  m a j o r  r e d u c t i o n  
in  its r a t e  o f  c a t a b o l i s m  in  F H .  T h e  f r a c t i o n a l  r a t e s  o f  
d i r e c t  r e m o v a l  a n d  t r a n s f e r  o f  th is  l i p o p r o t e i n  to  L D L  
w e re  s i g n i h c a n t l y  r e t a r d e d  (b y  7 2 % ,  P  <  0 .0 2 .  a n d  7 8 % , 
P <  0 .05 .  r e sp e c t iv e ly ) .  H o w e v e r ,  d e s p i t e  t h e  d e c r e a s e  in 
f r a c t i o n a l  t r a n s f e r ,  th e  f lux  o f  I D L  a p o B  in to  t h e  L D L  
d e n s i ty  i n t e r v a l  w as  n o r m a l  o r  e v e n  s l ig h t ly  i n c r e a s e d ,  a t  
a  m e a n  v a lu e  o f  503 m g - d ” \  I n  m o s t  F H  s u b je c t s ,  in 
a d d i t i o n  to B p r o t e i n  t r a n s f e r  f r o m  I D L .  it w as  n e c e s s a ry  
to sp e c i fy  d i r e c t  L D L  a p o B  i n p u t  to a c c o u n t  for  th e  o b ­
s e rv e d  c i r c u l a t i n g  m a s s  o f  L D L .  T o ta l  L D L  p r o d u c t i o n  
f ro m  b o t h  s o u rc e s  w as  i n c r e a s e d  to  700  ± 176 m g - d ” 1 in 
t h e  F H  g r o u p  c o m p a r e d  to 3 9 8  ± 116 m g - d " 1 in  th e  c o n ­
t ro ls  (P <  0 .02 ) .  H o w e v e r ,  d e c r e a s e d  B p r o t e i n  c a t a b o ­
l i s m  a lso  c o n t r i b u t e d  to th e  4 .1 - fo ld  e x p a n s i o n  o f  t h e  F H  
L D L  a p o B  p oo l .  T h e  f r a c t i o n a l  c a t a b o l i s m  o f  a p o B  f ro m  
th is  l i p o p r o t e i n  w as  0.11. v e r s u s  0.31 p o o ls  • d  1 in  t h e  c o n ­
t ro ls  (P <  0 .0 0 5 ) .
T h e  d a t a  f ro m  th e  tw o  p o r t a c a v a l  s h u n t  s u b j e c t s  F H 6 
a n d  F H -  w e re  h a n d l e d  s e p a r a t e l y  s in c e  t h e y  w e re  d i s ­
t in c t ly  d i f f e r e n t  f ro m  th e  o t h e r s  in t h e  g r o u p  (T a b le  3).
T ’n e v  s h o w e d  a  s u b s t a n t i a l  r e d u c t i o n  in the  r a t e  o f  l a rg e  
V L D L  a p o B  sy n th e s i s  c o m p a r e d  to b o t h  t h e  c o n t r o l s  a n d  
t h e  o t h e r  F H  p a t i e n t s .  M o r e o v e r ,  t h e  f r a c t i o n a l  c le a r a n c e  
r a t e  f r o m  th is  poo l  w a s  h i g h  a n d  so its p l a s m a  c o n c e n t r a ­
t i o n  w as  v e r y  low. T h i s  w a s  a lso  t r u e  for  s m a l l  V L D L  
a p o B  w h o s e  r a t e  o f  p r o d u c t i o n  e i t h e r  f ro m  la r g e  V L D L  
o r  bv  d i r e c t  s v n th e s i s  w a s  r e d u c e d .  S h u n t  su rgery ,  
h o w ev er ,  d i d  n o t  s e e m  to  a f fec t  t h e  d i s t r i b u t i o n  o f  B p r o ­
te in  w i t h i n  s m a l l  V L D L  in  t h a t  r e m n a n t s  a g a i n  a c c u m u ­
l a t e d  to a b o u t  4 5 %  o f  t h e  to t a l  m a s s  (c f  . \ L .  T a b le  4. w i th  
t h e  p o o l  o f  s m a l l  V L D L .  T a b le  3). I n t e re s t in g ly ,  t h e  ra te  
o f  r e m n a n t  r e m o v a l  ( K,> T t b l e  4) w as  n o t  a p p a r e n t l y  
a f fe c te d  b v  su rgerv .  w h e r e a s  th e  f r a c t io n a l  t r a n s f e r  o f  
V L D L 2 a p o B  to I D L  a p p e a r e d  to  be  h i g h e r  ( T a b le  3) even  
t h o u g h  th e  n e t  a m o u n t  t r a n s f e r r e d  w as  low. T h e  I D L  
a p o B  p o o ls  in  F H ^  a n d  F H 7 w e re  as  h ig h  as in  th e  o t h e r  
p a t i e n t s  in  th e  g r o u p .  A g a i n ,  d e f e c t iv e  c a t a b o l i s m  p la y e d  
a  m a j o r  r o le  in g e n e r a t i n g  th is  p h e n o m e n o n ,  a l t h o u g h  in 
b o t h  o f  t h e s e  su b je c t s  it w a s  n e c e s s a r y  to  invoke  d i r e c t  
I D L  s y n th e s i s  in o r d e r  to  a c c o u n t  for  th e  to ta l  m a s s  o f  
a p o B  in t h e  f ra c t io n .  T h e  p a t t e r n  w as  r e p e a t e d  in th e  
L D L  d e n s i t y  in te rv a l .  E x p a n s i o n  o f  th e  po o l  r e s u l t e d  
p r i m a r i l y  f ro m  d e fe c t iv e  c a t a b o l i s m  a l t h o u g h  i n c r e a s e d
James et al. A poB m etabolism  in fam ilia l hypercholestero lem ia  163
T
A
B
I.
K
 
4.
 
C
om
pu
te
d 
co
m
p
ar
tm
en
t 
m
as
se
s 
an
d 
ra
te
 
co
ns
ta
nt
s 
fo
r 
no
rm
al
 
an
d 
FH
 
su
bj
ec
ts
166 J o u rn a l o f L ip id  R esearch Volume 30, 1989
d i r e c t  s y n th e s i s  w as  a g a i n  c o n t r i b u to r y .  T h e  f ra c t i o n a l  
c a t a b o l i c  r a t e s  o f  a p o B  in I D L  a n d  L D L  d i d  n o t  a p p e a r  
to  b e  a f fe c te d  b y  s h u n t  s u r g e ry .
D I S C U S S I O N
V L D L  c o m p r i s e s  a  s t r u c t u r a l l y  h e t e r o g e n e o u s  s p e c ­
t r u m  o f  p a r t i c le s  w h o s e  p r o p e r t i e s  a r e  th e  s u b je c t  o f  c o n ­
t i n u i n g  r e s e a r c h .  I n  n o r m a l  i n d i v i d u a l s  m o s t  V L D L  is in 
t h e  d e n s e r  Sf 2 0 -6 0  i n t e r v a l  (18). F a m i l i a l  h y p e r t r i g ly c -  
e r i d e m i c  su b je c t s ,  o n  t h e  o t h e r  h a n d ,  po ss es s  i n c r e a s e d  
a m o u n t s  o f  l a r g e r  p a r t i c l e s  (14, 15, 18. 22)  w i t h  g r e a t e r  
t r i g l y c e r i d e  c o n t e n t ,  a n d  a  s i m i l a r  d i s t r i b u t i o n  c a n  b e  i n ­
d u c e d  in  n o r m a l  i n d i v i d u a l s  b y  c a r b o h y d r a t e  f e e d in g  
(2 3 ) .  T h e  size o f  th e  n a s c e n t  V L D L  m a v  g o v e rn  its s u b s e ­
q u e n t  m e t a b o l i c  b e h a v i o r  in  t h e  p l a s m a .  L a r g e  p a r t i c le s  
i n  t h e  f lo ta t i o n  r a n g e  S :- 1 0 0 - 4 0 0  u n d e r g o  r a p i d  h y d ro lv -  
sis v i a  l i p o p r o t e i n  l ip a se ,  a c q u i r i n g  in  t h e  p ro c e ss  
c h o le s t e ry l  e s t e r  b y  t r a n s f e r  f r o m  H D L .  S u c h  p a r t i c le s ,  in 
f ac t ,  a r e  t h e  f a v o re d  a c c e p to r s  o f  s t e ro l  e s t e r  (24 ) .  T h e  
r e m n a n t s  t h a t  c o m e  f r o m  t h e i r  I ipo lys is  r e m a i n  w i t h i n  the  
V L D L  s p e c t r a l  d i s t r i b u t i o n ,  a l t h o u g h  a t  its d e n s e r  e n d .  
H e r e  t h e y  res is t  f u r t h e r  h y d r o ly s i s  a n d  a r e  t h o u g h t  to be  
c a t a b o l i z e d  as a  u n i t  v ia  r e c e p t o r - m e d i a t e d  m e c h a n i s m s .  
T h e y  t h e r e f o r e  m a k e  l i t t le  c o n t r i b u t i o n  to  th e  p r o d u c t i o n  
o f  L D L .  T h e  l a t t e r  a p p e a r s  to  c o m e  f ro m  sm a l le r ,  d e n s e r  
V L D L  w h ic h  is s e c r e te d  d i r e c t l y  by  th e  l iv e r  (14. 15). T h e  
e x t e n t  to w h ic h  r e m n a n t s  c o n t r i b u t e  to t h e  t o ta l  V L D L  
p o p u l a t i o n  c a n  b e  a s s e s s e d  f r o m  th e  c h o le s t e ry l  ester ' '  
t r ig lv c e r id e  r a t i o  in t h a t  f r a c t i o n  (25).  W h e r e  t h e v  a re  
a b u n d a n t ,  as  in  T y p e  I I I  h y p e r l i p o p r o t e i n e m i a ,  t h e  r a t io  
is i n c r e a s e d .  T h i s  c o m p o s i t i o n a l  a b n o r m a l i t y  w a s  fo u n d  
in  th e  s m a l l  V L D L  a n d  I D L  o f  o u r  F H  p a t i e n t s ,  i n d i c a t ­
i n g  t h a t  B p r o t e i n  m e t a b o l i s m  w a s  g ro ss ly  p e r t u r b e d  in 
th is  g r o u p  o f  su b je c ts .
F H  s u b je c t s  1-5 p o s s e s se d  l a r g e  V L D L  t h a t  w as  e s s e n ­
t i a l ly  n o r m a l  b o t h  in t e r m s  o f  c o m p o s i t i o n  a n d  m e t a b ­
o l i s m .  In  p a r t i c u l a r ,  t h e  r a t e  o f  c o n v e r s io n  o f  l a rg e  to 
s m a l l  V L D L ,  m e d i a t e d  b y  l i p o p r o t e i n  l ip ase ,  w as  n o t  
i n f lu e n c e d  by  th e  r e c e p t o r  d e f e c t .  T h e  i m p a c t  o f  th e  d i s ­
e a s e  o n ly  b e c a m e  a p p a r e n t  a t  t h e  level  o f  sm a l l  V L D L .  A  
h i g h e r  p r o p o r t i o n  o f  B p r o t e i n  in  th is  f r a c t i o n  w as  c h a n ­
n e l l e d  in to  s low ly  m e t a b o l i z e d  r e m n a n t s ,  w h ic h  p r e s u m a ­
b ly  a c c o u n t e d  fo r  t h e  e le v a t e d  c h o le s t e ry l  e s t e r / t r i g ly c e r ­
id e  r a t i o  f o u n d  in F H  S ( 2 0 - 6 0  V L D L 2. T h e  m e c h a n i s m  
u n d e r l y i n g  th is  p h e n o m e n o n  is n o t  c lear ,  a l t h o u g h  it m a v  
b e  p o s t u l a t e d  t h a t  th e  p r o l o n g e d  p l a s m a  r e s i d e n c e  t im e  o f  
s m a l l  V L D L  w h ic h  fo llow ed f ro m  r e t a r d a t i o n  o f  th e  w h o le  
d e l i p i d a t i o n  p ro c e ss  m i g h t  e x p o s e  t h e  p a r t i c l e  to  i n ­
c r e a s e d  c h o le s te ry l  e s t e r  t r a n s f e r  f r o m  H D L ,  th e r e b v  
l i m i t i n g  its p o t e n t i a l  fo r  f u r t h e r  I ipolys is .  D e fe c t iv e  
c a t a b o l i s m  o f  th e  r e m n a n t s  ( k 0.s, T a b le  4) a lso  p la y e d  a  
p a r t  in t h e i r  a c c u m u l a t i o n  in  t h e s e  r e c e p t o r - d e f i c i e n t  p a ­
t i e n t s .  T h i s  o b s e r v a t i o n  s u g g e s t s  t h a t  t h e  L D L  r e c e p t o r  
m a y  b e  im p l i c a t e d  in  th is  p ro c e s s .  T h e  c a l c u l a t e d  10-Fold 
i n c r e a s e  in  the  c i r c u l a t i n g  V L D L  r e m n a n t  p o p u l a t i o n  in 
F H  (N T ,  T a b le  4) a c c o u n t e d  fo r  a b o u t  o n e - h a l f  o f  th e  e x ­
p a n d e d  Sf 2 0 - 6 0  V L D L  p o o l .  T h e  r e m a i n d e r  d e r iv e d  
f r o m  a n  i n c r e m e n t  in  d i r e c t  s y n th e s i s  o f  s m a l l  V L D L .  
p a r t i c u l a r ly  e v id e n t  in  s u b je c ts  F H 3 a n d  F H 4 (M=, Tab le  4).
A n  u n e x p e c t e d  f i n d in g  o f  th is  s tu d y ,  e v i d e n t  f ro m  th e  
d e c a y  p rofi les  t F ig. 3) , w a s  t h a t  th e  f r a c t i o n a l  r a te  o f  
t r a n s f e r  o f  B p r o t e i n  f r o m  s m a l l  V L D L 2 t h r o u g h  I D L  to 
L D L  w as  v e ry  slow. T h e s e  d e l i p i d a t i o n  s te p s  a r e  t h o u g h t  
to  b e  m e d i a t e d  by  l ip a se s ,  a n d  r e c e n t  r e s u l t s  f r o m  a n i m a l  
a n d  h u m a n  s tu d ie s  (26 .  2 7 ;  im p l i c a t e  h e p a t i c  l ip a se  in th e  
p ro c e s s .  I t  is n o t  i m m e d i a t e l y  o b v io u s  w h y  th e  V L D L -  
L D L  c o n v e r s io n  s h o u l d  b e  so slow in  th e s e  L D L  r e c e p to r -  
d e f i c i e n t  su b je c ts .  S e v e r a l  p o ss ib i l i t ie s  ex is t.  F i rs t ,  the  
d e l i p i d a t i o n  p a th w a y  m a v  be  s a t u r a t e d ,  l i m i t i n g  th e  
p r o c e s s i n g  o f  a p o B  to  a b o u t  5 0 0  m g  • d -1, a n d  r e d u c i n g  its 
f r a c t i o n a l  r a t e  o f  t r a n s f e r  t h r o u g h  th e  c a s c a d e .  H o w e v e r ,  
th i s  w o u l d  im p iy  ( T a b le  3) t h a t  t h e  c o n v e r s io n  p ro c e s s  is 
v i r t u a l l y  s a t u r a t e d  in  n o r m a l  s u b je c t s  also, a n d  w c u . d  n o t  
e x p l a i n  w h y  p a t i e n t s  F H 2, F H 3. a r . c  F H r e x h ib i t  s u c h  a 
low B p r o t e i n  f lux f r o m  V L D L  to L D L .  A  s e c o n d  a l t e r n a ­
t ive  is t h a t  t h e  g r e a t ly  i n c r e a s e d  I D L  a n d  L D L  p oo ls  ac t  
b v  p r o d u c t  i n h i b i t i o n  to  s u p p r e s s  h e p a t i c  l ip a se  activ i ty .  
O r  th i rd ly ,  it m a v  b e  p o s t u l a t e d  t h a t  L D L  r e c e p to r s  a n d  
l ip a s e  a c t  c o o p e r a t i v e ly  in  t h e  c o n v e r s io n  p ro c e ss .  It  is 
k n o w n  t h a t  th e  m a j o r i t y  o f  L D L  r e c e p t o r s  a r e  r o u n d  in 
t h e  l iv e r  (28  ' as is a l i p a se  w h i c h  e x p re s s e s  h ig h  a m m t v  to r  
s m a l l e r  V L D L  a n d  I D L  (2 9  u a n d  t r a n s h e p a t i c  m e a s u r e ­
m e n t s  i n d i c a t e  t h a t  th is  o r g a n  is t h e  m o s t  l ike ly  m e  of 
I D L - L D L  c o n v e r s io n  (30 ) .  H e p a t i c  l ip a s e  is r e p o r t e d  to 
b e  lo c a t e d  o n  the  s u r f a c e  o f  s in u s o id a l  ce lls (31 i .  w h ic h  
t h e m s e lv e s  a r e  a p a r t i c u l a r  v a r ie ty  o f  e n d o t h e l i a l  cells. 
T h e  l a t t e r  a r e  k n o w n  f r o m  t i s su e  c u l t u r e  s tu d i e s  to e x ­
p r e s s  L D L  r e c e p to r s  (3 2 ) .  a l t h o u g h  a t  c o n f lu e n c e  th e v  d o  
n o t  n e c e s s a r i l y  p a r t i c i p a t e  in  l i p o p r o t e i n  i n t e r n a l i z a t i o n  
a n d  d e g r a d a t i o n ,  b u t  m a y  m e r e l y  b i n d  a n d  re le a se  the  
p a r t i c l e s  (33).  It is t h e r e f o r e  p o ss ib le  t h a t  in  th e  l ive r  th ey  
a s s is t  l ipo lvs is .  b r i n g i n g  s m a l l  V L D L  a n d  I D L  in to  c o n ­
ta c t  w i th  h e p a t i c  l i p a s e  w h o s e  h y d r o ly t i c  a c t i o n s  le a d  to 
t h e  p r o d u c t i o n  o f  L D L .  S u b s e q u e n t  loss o f  a p o l i p o p r o t e in  
E  f ro m  th e  p a r t i c le  w o u ld  r e d u c e  its a f f in i ty  fo r  t h e  r e c e p ­
t o r  a n d  fac i l i ta te  its r e l e a s e  b a c k  in to  t h e  c i r c u l a t i o n .  S u c h  
a m e c h a n i s m  is. o f  c o u r s e ,  h i g h l y  s p e c u la t iv e  a l t h o u g h  it 
d o e s  e x p la in  th e  s low V L D L - L D L  c o n v e r s io n  t h a t  is seen  
in  d v s b e t a l i p o p r o t e i n e m i a .  in  f a m i l i a l  h y p e r c h o l e s t e r o l e ­
m ia ,  a n d  in h e p a t i c  l i p a s e  d e f ic ie n c y  (34).
A s  m i g h t  be  e x p e c t e d  in  F H  h o m o z y g o te s ,  d i r e c t  
c a t a b o l i s m  o f  a p o B - c o n t a i n i n g  p a r t i c l e s  w as  r e t a r d e d .  
L D L  w as  c l e a r e d  a t  o n e - t h i r d  o f  t h e  n o r m a l  r a te ,  p r e ­
s u m a b l y  by  r e c e p t o r - i n d e p e n d e n t  m e c h a n i s m s .  T.ne d a t a  
p r e s e n t e d  in T ab le  3 a n d  in  a n  e a r l i e r  p u b l i c a t i o n  by 
S o u t a r  a n d  h e r  c o l l e a g u e s  (9 )  s h o w  t h a t  I D L  c a t a b o l i s m
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is s i m i l a r l y  r e t a r d e d  a n d  i n d i c a t e  t h a t  r e c e p t o r s  m u s t  p lay  
a  ro le  in  t h e  p rocess .  VVe h a v e  a l r e a d y  s h o w n  (35)  t h a t  th is  
is l ik e ly  to  b e  the  c ase  in  a n  e x p e r i m e n t  in  w h i c h  t r e a t ­
m e n t  o f  V L D L  o r  I D L  w i t h  1,2 - c y c lo h e x a n e d io n e ,  a n  
a g e n t  t h a t  b lo ck s  p o t e n t i a l  i n t e r a c t i o n  o f  t h e  l i p o p r o t e i n  
w i t h  r e c e p to r s ,  s low ed  b o t h  t h e  d i r e c t  c a t a b o l i s m  o f  I D L  
a n d  its  c o n v e r s io n  to L D L .  T h u s  th e  c o n s e q u e n c e s  o f  
r e c e p t o r  d e f ic ie n c y  a r e  as  p r o f o u n d  fo r  I D L  as fo r  L D L .  
M o s t  o f  th e  d i f fe re n c e s  o b s e r v e d  b e t w e e n  th e  n o r m a l  a n d  
F H  h o m o z y g o t e s  a r e  so m a r k e d  t h a t  it is u n l ik e ly  t h e y  c a n  
b e  e x p l a i n e d  by  th e  n e c e s s a r y  v a r i a t i o n  in  a g e  a n d  b o d y  
w e i g h t  b e t w e e n  th e  tw o  g r o u p s .  T h e  in f lu e n c e s  o f  th ese  
f a c to r s ,  how ever ,  s h o u l d  b e  b o r n e  in  m i n d  w h e n  d i f fe r ­
e n c e s  b e t w e e n  th e  tw o  g r o u p s  a r e  sm a l l .
A  n u m b e r  o f  s tu d ie s  (3, 5)  h a v e  i n d i c a t e d  t h a t  h o m o z y ­
g o u s  F H  is a s s o c i a t e d  w i t h  o v e r p r o d u c t i o n  o f  L D L .  T a b le  
3 s h o w s  t h a t  th is  a lso  o c c u r r e d  in  F H  s u b je c t s  1 -5  in 
w h o m  to ta l  B p r o t e i n  s y n t h e s i s  w a s  o n  a v e r a g e  6 3 %  
h i g h e r  t h a n  in  c o n t r o l s  (P <  0 .0 2 5 ) .  T h e  m e c h a n i s m  
r e s p o n s i b l e  fo r  th is  effect  is u n k n o w n ,  a l t h o u g h  r e c e n t  in  
v i t r o  e x p e r i m e n t s  h a v e  l i n k e d  th e  c a t a b o l i s m  o f  L D L  w i th  
t h e  c o n t r o l  o f  a p o B  s y n th e s i s .  C u l t u r e d  h e p a t o m a  cells, 
s t a r v e d  o f  th e  l i p o p r o t e i n ,  s h o w  e n h a n c e d  a p o B  m R N A  
p r o d u c t i o n  w h ic h  is i n h i b i t e d  b y  a d d i t i o n  o f  L D L  to th e  
c u l t u r e  m e d i u m  (36).  E x t r a p o l a t i o n  to  t h e  in v iv o  s i t u a ­
t i o n  w o u l d  su g g e s t  t h a t  f a i l u r e  o f  L D L  to  b e  a s s i m i l a t e d  
by  th e  l iv e r  v ia  th e  r e c e p t o r  p a t h w a y  m a y  d e r e p r e s s  a p o B  
p r o d u c t i o n  in  t h a t  o r g a n .
W e  h a v e  a l r e a d y  c o m m e n t e d  o n  th e  v a r i a b i l i t y  in a p o B  
m e t a b o l i s m  w h ic h  w as  a p p a r e n t  in  o u r  se v e n  h o m o z v g o u s  
F H  s u b je c t s .  P a t i e n t  F H , ,  w h o  e x h i b i t e d  t h e  h ig h e s t  
p l a s m a  t r ig ly c e r id e  levels ,  s e c r e t e d  e x cess iv e  a m o u n t s  o f  
a p o B  in t o  V L D L  a n d  s h o w e d  n o  r e q u i r e m e n t  fo r  d i r e c t  
L D L  sy n th e s i s .  T h e s e  r e s u l t s  a r e  r e m i n i s c e n t  o f  t h e  s i t u a ­
t i o n  p r e v a l e n t  in W a t a n a b e  r a b b i t s  (7, 8) . H o w e v e r ,  in  o u r  
s u b j e c t s  w i th  lo w er  p l a s m a  t r i g l y c e r i d e  levels , a n  i n c r e a s ­
in g ly  h i g h e r  p r o p o r t i o n  o f  B p r o t e i n  w as  s e c r e t e d  d i r e c t ly  
in to  L D L .  C lea r ly ,  t h e  r a b b i t  m o d e l  is n o t  a p p l i c a b l e  
h e r e .
I f  we a s s u m e  th a t  p r i o r  to s h u n t  s u r g e r y  F H  s u b je c t s  6 
a n d  7 r e s e m b l e d  the  o t h e r  five in  th is  s tu d y ,  t h e n  it m ay­
be  s u r m i s e d  th a t  the  p o r t a c a v a l  a n a s t o m o s i s  p r i m a r i l y  i n ­
h ib i t s  t r ig ly c e r id e  sy n th e s i s ,  l i m i t i n g  s e c r e t i o n  o f  V L D L  
in to  t h e  p l a s m a .  In  th is  s i t u a t i o n ,  m o r e  a p o B  a p p e a r s  in 
th e  t r ig l v c e r i d e - d e p l e t e d  I D L  a n d  L D L  p a r t i c le s .  T h e  
p r o c e d u r e  i tse l f  se e m s  to m a k e  n o  i m p a c t  o n  th e  r a te s  o f  
c a t a b o l i s m  o f  V L D L  r e m n a n t s ,  I D L  or , a s  r e p o r t e d  
e a r l i e r ,  o f  L D L  (9).flfl
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APOLIPOPROTEIN B METABOLISM
James Shepherd, Thomas Demant and Christopher J Packard
University Department .of Pathological Biochemistry, Royal 
Infirmary, Glasgow
INTRODUCTION
Apolipoprotein B-100 (apo B) containing lipoproteins, 
isolated from plasma, constitute a spectrum ranging in density 
from 0.95 to 1.063 kg/L ie with Svedberg flotation coefficients of 
Sf0-400. The least dense particles are triglyceride rich with a 
low content of cholesterol and protein - the latter comprising apo 
B-100, apo C and apo E. With increasing density (decreasing
flotation rate) the lipoproteins become triglyceride depleted and 
enriched in cholesterol, cholesteryl ester and protein. The 
composition of the protein component alters so that apo C and apo 
E are lost while apo B becomes dominant. This spectrum can be 
viewed as a "delipidation cascade" in which the less dense Sf 100- 
400 VLDL are hydrolysed to form denser intermediate lipoproteins
(IDL) and then finally LDL. A number of enzymes participate in 
this remodelling process including lipoprotein lipase, hepatic 
lipase and lecithin:cholesterol acyl transfe.rase. Other protei*^ 
too such as cholesteryl ester transfer protein and the B/E 
receptor are important. In the following discussion we focus on
the quantitative aspects of this delipidation sequence and how it
differs in normal and hyperlipidaemic subjects.
METHODS
The approach used to investigate apo B metabolism involved 
the isolation of two subfractions of VLDL, VLDL-| (Sf 60-400) and 
V LDL2 (Sf 20-60) and their trace labelling with 131j and 125j 
respectively. Following re-injection into the donor, transit of 
apo B through VLDL-| , V L D L2 t IDL (Sf 12-20) and LDL (Sf 0-20) was 
followed by repeated purification of the B protein in these 
fractions at frequent time intervals and determination of its
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specific activity (1,2). Total radioactivities were calculated as 
the product of the specific activity and measured mass for each 
lipoprotein fraction. These data were then used in 
multicompartmental analyses using the SAAM program (3) to 
construct a metabolic model and to generate estimates for kinetic 
rate constants. The model employed is shown in Figure 1•
20 80
VLDL VLDL LDL
30
560 * 66 50 50 50 113 693
300300330 300 220
280 * 55 104 [865J
260 230
\
Unite
(5) Pool tizoa i mg 
(§ ) Fluxot * mg/d
Fig.1: Multicompartmental model describing the flux of
apolipoprotein B through the cascade system in^a normal 
subject.
RESULTS AND DISCUSSION
Early work in normolipaemic individuals suggested a rather 
simple precursor-product relationship between VLDL and LDL (4). 
However, recent studies from our laboratory and from other workers 
(5 ,6 ) have revealed a complex pathway with multiple inputs and 
exits. The flux of B protein through this system in normal
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individuals is quantified in Figure 1. It was necessary to 
postulate that there was direct synthesis of apo B into both large 
and small ^LDL. Two thirds of this material was transmitted 
through to IDL and LDL while the remainder generated a "remnant" 
pool which was cleared slowly from the circulation, probably via 
receptors. One important finding of these investigations was the 
requirement for subcompartmentalisation of IDL and LDL. This was 
needed to allow for the observation that apo B associated with the 
small VLDL tracer appeared more rapidly and in greater amount in 
IDL and LDL than apo B from large VLDL. That is, metabolic 
channels are present in the VLDL-LDL conversion process so that 
the fate of an apo B containing lipoprotein depends to a certain 
extent on its pedigree. Since VLDL is such an heterogeneous 
mixture of particles we ought to expect such metabolic 
heterogeneity in its products, IDL and LDL. The recognition of 
this phenomenon is an exciting development in our understanding of 
the structure and function of these lipoproteins (6 ).
Quantitative investigation of the rates of transport of apo B 
through the VLDL-IDL-LDL cascade reveal how much of each species 
is made and indicate its probable precursor. However, additional 
work is needed to elicit the mechanisms involved ~in these 
transformations. Further insight into the role of certain enzymes 
and receptors in the VLDL to LDL conversion comes from studies of 
human mutants.
VLDL apo B metabolism in familial hypercholesterolaemia (FH)
Familial hypercholesterolaemia results from partially or 
completely defective expression of the LDL or B/E receptor. This 
protein, present on the membranes of most cells in the body, is 
able to bind LDL and internalise it. Early studies of FH focused 
on the gross increase in LDL cholesterol that accompanies it and 
the impact that this had on atherosclerosis. More recently it has 
become appreciated that the B/E receptor has a much wider role in 
apolipoprotein B metabolism. Its absence affects not only LDL but 
also VLDL and IDL. Soutar et al (7) demonstrated a delayed 
clearance of IDL apo B in subjects homozygous for FH. We haveg| 
recently reexamined the situation in a group of seven FH
*
homozygotes in whom we investigated the metabolism of large VLDL-j 
and small VLDL 2 (Th Demant, J Shepherd, C J Packard, unpublished 
observations). A number of interesting findings emerged. First, 
the conversion of VLDL-j to V LDL2 was unimpaired by the lack of 
receptors. Small (Sf20— 60) VLDL metabolism, on the other hand, 
was grossly abnormal. Both the clearance of remnants from this 
density interval and the rate of delipidation to IDL and LDL were 
inhibited. Those FH subjects with the highest triglyceride levels 
oversynthesised apo B and derived most of their LDL from VLDL 
precursors. This process was inadequate in normotriglyceridaemic 
FH individuals who (like those studied by Soutar et a l . (8 ))
appeared to make and secrete LDL de novo.
VLDL apo B metabolism in lipase deficiencies
Two lipolytic enzymes - lipoprotein lipase and hepatic lipase 
- are believed to contribute to the delipidation of triglyceride 
rich particles. Recently we have had the opportunity of 
conducting VLDL apo B metabolic studies in these deficiency 
states. In the absence of lipoprotein lipase the conversion of 
VLDL-] to V LDL 2 is severely impaired as suggested from previously 
published work ‘f9>; The transfer of apo B between these two VLDL 
fractions occurs at only 10% of the normal rate and the VLDL-j apo 
B pool is greatly increased. Trace labelled VLDL2 however behaves 
in a different fashion. Its conversion to IDL and LDL is near 
normal, a finding that implies that lipoprotein lipase is not 
required for these steps (Th Demant, C 'J Packard, J Shepherd, 
unpublished). Rather, this component of the delipidation process 
seems to depend on the activity of hepatic lipase.
Studies in our laboratory of VLDL metabolism in a patient 
with hepatic lipase deficiency indicate that while the catabolism 
of VLDL-j to V L D L 2 is unimpaired, the transfer of apo B through 
V L D L 2 to IDL and LDL is diminished. In fact, normal LDL was 
virtually absent from the plasma of this individual in accord with 
animal experiments which showed that antibody-induced inhibition 
of HL leads to accumulation of small VLDL and IDL and a fall in 
LDL (10). If it is postulated that IDL-LDL conversion involves 
hepatic lipase then this activity must be located in the liver, a
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contention supported by examination of lipoprotein flux across the 
splanchnic bed. Turner et al. (11) found that while there was 
evidence for secretion of large (Sf100-400) VLDLi from the liver 
there was no detectable uptake of this lipoprotein fraction. On 
the other hand, radio-iodinated lipoproteins of Sf 12-60 (V LDL 2 
and IDL) were extracted from the circulation by the splanchnic bed 
and about half of the radioactivity reappeared in the hepatic vein 
as LDL (Sf 0-12). Therefore, this enzyme occupies a pivotal role 
in the transformation of apo B containing lipoproteins in the 
lower part of the delipidation cascade.
New perspectives in apolipoprotein B metabolism
Common genetic variations in apolipoproteins B and E 
contribute significantly to the variation in plasma cholesterol in 
a population, (12,13). Using the techniques of recombinant DNA 
technology, it is now possible to examine sub-sets of 
normolipaemic individuals to discover the genetic contribution to 
the wide diversity of blood lipid levels. One variation in the 
apo B gene is observed with the pABC cDNA probe following 
digestion with the Xbal endonuclease (12). A recent report (14) 
from our laboratory demonstrates that hypercholesterolaemic 
subjects who lack the cutting site (ie "X2X2" genotype) have a 
slower clearance of LDL from their circulation than those 
homozygous for the allele with the cutting site ("X1X1" genotype). 
The fractional catabolic rate for apo LDL in these groups was 0.22 
+ 0.03 pools/day and 0.27 + 0.02 pools/day respectively. We were 
careful to exclude subjects with FH and postulate that these 
differences are due to altered apo B in these individuals. 
Certainly this is associated with alterations in apo B 
conformation as detected by monoclonal antibodies (15). Further 
evidence to support this hypothesis comes from comparision studies 
performed in normal subjects (16).
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